City of Hope is advancing cancer treatment by utilizing our expertise in clinical research to develop lifesaving therapies. With over 1,000 patients treated with immune effector cells, including CAR T cell therapy, we continue to advance treatment possibilities to save the lives of more patients. Hope is here.

Visit us at Booth No. 949 to discover our leading-edge research and treatment options.
TABLE OF CONTENTS

1 Welcome Letter

2-25 Committees
2 AACR Annual Meeting 2023 Program Committee
2 AACR Scientific Program Subcommittee Members
5 AACR Education Committee
6 AACR Clinical Trials Committee
6 AACR Satellite Educational Symposia Committee
6 AACR Officers, Directors, and Foundation
7 AACR Standing Committees
9 AACR Specialty Award Committee
9 AACR Scientific Achievement Awards Committees
13 AACR Scientific Grant Review Committees
17 AACR Specialty Groups and Committees
19 AACR Scientific Task Forces
22 AACR Scientific Working Groups
24 AACR Constituency Groups
25 AACR 50-Year Members and Honorary Members

About the cover image:
The collaborative efforts of scientists and clinicians to prevent and cure cancer in all populations around world are at the center of the AACR’s mission.

Science images on front cover, left to right:
T cells, Getty Images; Molecular Cancer Therapeutics cover, March 2019; cancer cell division, Getty Images.

©2023 American Association for Cancer Research®
### TABLE OF CONTENTS (cont'd)

<table>
<thead>
<tr>
<th>Page Range</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>26-30</td>
<td>Supporters</td>
</tr>
<tr>
<td>26</td>
<td>AACR Annual Meeting 2023 Supporters</td>
</tr>
<tr>
<td>27</td>
<td>The Scientific Program</td>
</tr>
<tr>
<td>27</td>
<td>AACR Awards and Lectureships</td>
</tr>
<tr>
<td>27</td>
<td>AACR Runners for Research 5K Run/Walk Orlando</td>
</tr>
<tr>
<td>28</td>
<td>AACR Travel Grants and Scholar Awards</td>
</tr>
<tr>
<td>28</td>
<td>AACR Scientific Working Groups</td>
</tr>
<tr>
<td>28</td>
<td>AACR Annual Meeting 2023 Supporters</td>
</tr>
<tr>
<td>29</td>
<td>Research Grants and Fellowships</td>
</tr>
<tr>
<td>30</td>
<td>Special Conference Supporters for 2022-2023</td>
</tr>
<tr>
<td>30</td>
<td>Sustaining Members</td>
</tr>
<tr>
<td>31-46</td>
<td>General Information</td>
</tr>
<tr>
<td>47-59</td>
<td>Maps</td>
</tr>
<tr>
<td>47</td>
<td>Rosen Centre Hotel Level 1</td>
</tr>
<tr>
<td>48</td>
<td>Hyatt Regency Orlando Convention Level</td>
</tr>
<tr>
<td>50</td>
<td>Orange County Convention Center West Concourse Level 1</td>
</tr>
<tr>
<td>52</td>
<td>Orange County Convention Center West Concourse Level 2</td>
</tr>
<tr>
<td>54</td>
<td>Orange County Convention Center West Concourse Level 3 East</td>
</tr>
<tr>
<td>56</td>
<td>Orange County Convention Center West Concourse Level 3</td>
</tr>
<tr>
<td>58</td>
<td>Orange County Convention Center West Concourse Level 4</td>
</tr>
<tr>
<td>60-195</td>
<td>Program</td>
</tr>
<tr>
<td>60-65</td>
<td>FRIDAY, APRIL 14</td>
</tr>
<tr>
<td>66-83</td>
<td>SATURDAY, APRIL 15</td>
</tr>
<tr>
<td>84-111</td>
<td>SUNDAY, APRIL 16</td>
</tr>
<tr>
<td>112-149</td>
<td>MONDAY, APRIL 17</td>
</tr>
<tr>
<td>150-186</td>
<td>TUESDAY, APRIL 18</td>
</tr>
<tr>
<td>187-195</td>
<td>WEDNESDAY, APRIL 19</td>
</tr>
<tr>
<td>196-214</td>
<td>Travel Awards</td>
</tr>
<tr>
<td>196</td>
<td>AAC Scholar-in-Training Awards</td>
</tr>
<tr>
<td>207</td>
<td>AACR Global Scholar-in-Training Awards</td>
</tr>
<tr>
<td>209</td>
<td>AACR Minority and Minority-Serving Institution Faculty Scholar in Cancer Research Awards</td>
</tr>
<tr>
<td>210</td>
<td>AACR Minority Scholar in Cancer Research Awards</td>
</tr>
<tr>
<td>212</td>
<td>AACR Women in Cancer Research Scholar Awards</td>
</tr>
<tr>
<td>213</td>
<td>AACR-Undergraduate Scholar Awards</td>
</tr>
<tr>
<td>215-223</td>
<td>Exhibitors (Alphabetical)</td>
</tr>
<tr>
<td>224-232</td>
<td>Exhibitors (Booth Number)</td>
</tr>
</tbody>
</table>

AACR ANNUAL MEETING 2023
Expedite your cancer research

The Cancer Research Excellence Program (CREP) is a competitive research support program that provides select applicants that are performing research on solid tumors with **FREE access to Sysmex Inostics ultra-sensitive Plasma-Safe-SeqS (PSS) NGS tests.**

Stop by booth 1325 to discuss how the CREP program can enhance and expedite your research!

sysmex-inostics.com/CREP

**FUNDED BY SYSMEX INOSTICS**

We are a biotechnology firm and CLIA-certified lab offering biomarker testing to accelerate the development of personalized medicine.

Our world-class CLIA lab conducts blood-based biomarker analyses to detect, track, and monitor relevant mutations in ctDNA at levels between 0.03-0.05% with high specificity.
Thank you to our founders,

Margaret Foti, PhD, MD (hc);
Anna D. Barker, PhD, FAACR;

and to all of the patient advocates for their tireless efforts to support the AACR Scientist↔Survivor Program® for the past 25 years.

Thank you to our founding supporter

We would like to thank the following companies for their continued support.
Dear Members and Friends of the AACR,

We are excited to welcome you to the American Association for Cancer Research (AACR) Annual Meeting 2023 – the 114th Annual Meeting of the AACR! Whether you are joining us in person in Orlando or participating virtually, we look forward to a week of innovative science and synergistic collaborations.

Through the hard work and expert guidance from members of our Annual Meeting Program Committee, Education Committee, and Clinical Trials Committee, we have developed a multidisciplinary program that embodies the theme of this year’s meeting – “Advancing the Frontiers of Cancer Science and Medicine.” This theme reflects the critical role that the AACR and its Annual Meeting play in defining the research agenda for the cancer field and for the benefit of cancer patients.

A comprehensive slate of educational sessions and methods workshops, which present state-of-the-art concepts and technologies across the full spectrum of cancer science and medicine, begins at 3:00 p.m. on Friday, April 14, and run through Saturday, April 15. If you did not already purchase the Education Pass, please stop by the Registration desk and add it to your registration to ensure that you have access to these foundational sessions during and after the meeting.

The educational program is followed by a robust scientific program that showcases the latest advances in the etiology, biology, prevention, detection, diagnosis, and treatment of cancer. The Opening Plenary Session addresses the theme of the meeting and set the tone for a week of groundbreaking science. Daily plenary sessions address critical topics in the field, including the KRAS story, early detection and interception, immune ecosystems, and drug discovery and engineering. Major symposia present the latest discoveries from across the continuum of basic, translational, clinical, prevention, and population research. Advances sessions highlight the current state of the science and address emerging challenges in areas such as diagnosis and therapeutics, organ site research, population sciences, prevention research, and the science of cancer health disparities. And Forums offer the opportunity to engage in lively conversation with experts around provocative questions. Several of the major scientific sessions showcase the work of the 2023 AACR NextGen Stars. A total of 14 emerging early-career scientists have been selected as NextGen Stars through a highly competitive application process, and we look forward to their presentations.

During the meeting, we are excited to celebrate the 25th anniversary of the AACR Scientist®-Survivor Program® (SSP), which builds enduring partnerships among the leaders of the scientific, cancer survivor, and patient advocacy communities. By welcoming patient advocates to the meeting to attend sessions with science-mentors, SSP fosters an exchange in which patients and advocates explore the biology behind treatment decisions and scientists learn about the impact that their work has on the patient experience. The meeting program also features a number of special sessions on topics of interest to the various sectors of the cancer community. This year’s Presidential Select Symposium focuses on the critical issues that patients and families face when receiving a cancer diagnosis while pregnant or when considering a pregnancy, and the three-part series of New Drugs on the Horizon sessions offer first disclosures of the chemical structures of novel agents against emerging cancer targets. And in addition to the plenary session that showcases the “30-year overnight sensation” of recent successes in targeting RAS, a symposium celebrates the 25th anniversary of the discovery and preclinical and clinical development of trastuzumab, which established the current paradigm in personalized medicine and global drug discovery.

The scientific sessions are livestreamed to the virtual meeting platform for virtual and in-person meeting registrants. Microphones are available in the rooms for discussion periods, but both in-person and virtual attendees are also encouraged to submit questions to the speakers using the virtual platform or the meeting app.

We deeply appreciate the work done by members of the Scientific Program Committee who reviewed over 6,000 proffered papers that were submitted to the Annual Meeting and organized them into poster sessions and minisymposia. These proffered papers include nearly 250 clinical trials presented in Clinical Trials Plenary Sessions, minisymposia, and poster sessions. During the Clinical Trials Plenary Sessions, highly rated trials are paired with a presentation focusing on the science behind the trial and its implications for delivering improved care to patients.

Finally, we extend our gratitude to the corporations, organizations, and foundations that have provided generous support for AACR Annual Meeting 2023. These valued partners have enabled us to host this critically important scientific and clinical forum that lays the groundwork for fruitful collaborations and future advances against cancer. Their commitment also fosters the professional advancement of the next generation of leaders in cancer research through the support of numerous scientific sessions, research grants, scholar-in-training awards, and scientific merit awards.

Thank you for joining us! We look forward to an exciting week of spectacular scientific talks, stimulating discussions among colleagues, and innovative ideas about how to markedly decrease cancer incidence, morbidity, and mortality around the world. Please plan to attend the wrap-up Plenary Session on Wednesday, April 19, to hear about some of the highlights from the week. And if you miss anything on this huge program, recordings of the scientific and educational sessions may be viewed on our virtual meeting platform through July 19.

Robert H. Vonderheide, MD, DPhil
Chair, AACR Annual Meeting 2023
Program Committee

Lisa M. Coussens, PhD, FAACR
AACR President, 2022-2023

Margaret Foti, PhD, MD (hc)
Chief Executive Officer, AACR

Robert H. Vonderheide

Lisa M. Coussens, PhD, FAACR

Margaret Foti, PhD, MD (hc)
COMMITTEES

AACR Annual Meeting Program 2023 Committee

Chair
Robert H. Vonderheide

Vice Chairs
Lucile L. Adams-Campbell
Carlos M. Caldas
José R. Conejo-García
Benjamin L. Ebert
Peter Kuhn
Shivaani Kummar
Quynh-Thu Le
Christine M. Lovly
Sanjay V. Malhotra
Motomi Mori
Eileen M. O’Reilly
Seishi Ogawa
Anna Karolina Palucka
Sylvia K. Plevritis
Joachim Rudolph
John H. Stewart IV
Josep Tabernerro
Sarah K. Tasián
Matthew G. Vander Heiden
Judith A. Varner
Teresa A. Zimmers

Cochairs
Iannis Aifantis
Ido Amit
Andrew T. Chan
Alan D. D’Andrea
Matthew J. Ellis
Rebecca Fitzgerald
Kevin L. Gardner
Andrew K. Godwin
Jeremy Goecks
Romina Goldszmid
Carmen E. Guerra
Dawn L. Hershman
Trey Ideker
Jan Kitajewski
Harriett M. Kluger
Mignon Lee-Cheun Loh
Ruben A. Mesa
Kathleen N. Moore
Grzegorz S. Nowakowski
Taofeek K. Owonikoko
Marina Pasca di Magliano
Elizabeth A. Platz
Avery D. Posey, Jr.
Gabriel A. Rabinovich
Kimberly Stegmaier
Sheila A. Stewart
Chau Trinh-Shevvin
Mary Jo Turk
Cornelia M. Ulrich
Colonel James E. Williams
Bradly G. Wouters
Timothy A. Yap
Clayton C. Yates
Jinghui Zhang

AACR Scientific Program Subcommittee Members

BIOINFORMATICS, COMPUTATIONAL BIOLOGY, SYSTEMS BIOLOGY, AND CONVERGENT SCIENCE

Bioinformatics,
Computational Biology,
and Systems Biology
Shannon McWeeney, Chair
Ido Amit
Jay Gertz
Rafael A. Irizarry
Smita Krishnaswamy
Sylvia K. Plevritis
Trevor J. Pugh
Nidhi Sahni
Jiayang Yu

Convergent Science
Kristin R. Swanson, Chair
Andrea H. Bild
Heiko Enderling
Anang Shelat

CHEMISTRY

Drug Discovery, Design, and Delivery
Qiming Jane Wang, Chair
Karen S. Anderson
Angela N. Koehler
Zoran Rankovíc

Proteomics and Mass Spectrometry
Sanjay V. Malhotra, Chair
Thomas Kislinger

Structural and Chemical Biology
Xuedong Liu, Chair
Benjamin Brown

CLINICAL RESEARCH

Biomarkers
Nilofer S. Azad, Chair
Stefan Ambs
Alison Betof-Warner
JaeHyuk Choi
Diwakar Davar
Felix Y. Feng
D. Neil Hayes
Shivaani Kummar
Adana A.M. Llanos
John D. Minna
Everette J. Moding
Aung Naing
Nagireddy Putluri
Kurt A. Schalper
Jianjun Zhang

Biostatistics in Clinical Trials
Susan Halabi, Chair

Clinical Outcomes Research and Survivorship Research and Supportive Care
Smita Bhatia, Chair
Jennifer Ose
Clinical Research in the Elderly, and Clinical Research in Racial and Ethnic Minorities and Other Medically Underserved Populations
Christopher I. Li, Chair
Loudes A. Baezconde-Garbanati

Immuno-oncology
Helen E. Heslop, Chair
Juan A. Cubillos-Ruiz
Sawa Ito
Eduardo M. Sotomayor
Dmitry Zamarin

Pediatric Cancer – Clinical Investigations
Mignon Loh, Chair
Kelley M. Bailey
Jeff Klco

Precision Oncology and Real-World Data and Real-World Evidence
Christine M. Lovly, Chair
Vivek Subbiah
Shelley S. Tworoger

Radiation Science and Radiation Oncology
Quynh-Thu Le, Chair
Fei-Fei Liu
Marc S. Mendoca

Surgical Oncology
Nita Ahuja, Cochair
Stephen C. Rubin, Cochair

Translational Research – Molecular Biology in the Clinic
Taofeek K. Owonikoko, Chair
Tanios Bekali-Saab
Eric B. Haura

ENDOCRINOLOGY
Molecular, Preclinical, and Clinical Endocrinology
Rachel Schiff, Chair
Yosef Yarden

EXPERIMENTAL THERAPEUTICS
Biological Therapeutic Agents
Janice M. Mehnert, Chair
Amer Beg
Bin Zhang

Drug Discovery
John S. Lazo, Chair
Michelle R. Arkin
Jonathan R. Brody
Courtney W. Houchen
Christopher Nasveschuk
Mateusz Opyrchal
Sandip P. Patel
Rona Yaeger

Drug Resistance
James M. Cleary, Chair
Rene Bernards
Aaron N. Hata
Guang Peng
Jeff W. Tyner

Gene and Vector-Based Therapy
Alfred Garfall, Chair

Mechanisms of Drug Action
Hong Shen, Chair
Benjamin F. Cravatt

Molecular Targets
Naoko Takebe, Chair
Sheri L. Holmen
Marc Ladanyi
Donald Will Parsons
Chad V. Pecot
Joann B. Sweasy

Pharmacology, Pharmacogenetics, and Pharmacogenomics
Jordi Rodon, Chair
Todd C. Skaar
Jun Yang

Preclinical Radiotherapeutics
Sana D. Karam, Chair
Ranjit S. Bindra

Small Molecule Therapeutic Agents
Michelle A. Rudek, Chair
Jan H. Beumer
Jonathan Chernoff
Rachel N. Grisham
Erika P. Hamilton
Jung-Min Lee
Judith S. Leopold
John G. Moffat
Ganesh V. Raj

IMMUNOLOGY
Preclinical Immunotherapy
Jose R. Conejo Garcia, Chair
Daniel Abate Daga
Maria Casanova-Acebes
Marco L. Davila
Tanja D. de Grujil
Stephanie K. Dugan
Sylvia C. Formenti
Alexander Huang
Kelvin Lee
Gregory B. Lesinski
Roger Li
Yong Lu
Raphael A. Nemenoff
Anna Karolina Palucka
Yuliya Pelayeva-Gupta
Melissa Q. Reeves
Katayoun Rezvani
Pedro J. Romero
Mark P. Rubinstein
Megan Ruhland
Stephen P. Schoenberger
Ingunn M. Stromnes
Tumor Immunobiology
Ignacio Melero, Chair
José A. Guevara
Ping-chi Ho
Chengcheng Jin
David H. Munn
Mariana Salatino
Huda Salman
Cynthia L. Sears
Tanaya Shree
Jun Yan
Jelani C. Zarif

MOLECULAR/CELLULAR BIOLOGY AND GENETICS

Cell Cycle
Naoki Oshimori, Chair
Martine F. Roussel
Jean J. Zhao

Cell Death
Kay F. MacLeod, Chair
Suzanne Cory
Guido Kroemer

Cell Growth Signaling Pathways
David D. Schlaepfer, Chair
Barbara Fingleton
Carl-Henrik Heldin
Conor C. Lynch
David M. Virshup
Terese A. Zimmers

Cellular Stress Responses
Bradly G. Wouters, Chair
David A. Cheresh
Costas Koumenis

DNA Damage and Repair
Kathleen N. Moore, Chair
Sunil J. Advani
Catherine Ruffato Sears

Epigenetics
Eneda Toska, Chair
Scott A. Armstrong
Ellen L. Goode
Heather M. O’Hagan
Bing Ren

Gene Regulation and Transcription Factors
Jeremy N. Rich, Chair
Yonathan Lissau
Thomas Look
Harikrishna Nakshatri
Jorge S. Reis-Filho
Rosalie C. Sears

Genomics
Jinghui Zhang, Chair
Moray J. Campbell
Jeremy R. Chien
Adrian V. Lee
Eytan Ruppin
Peter A. Sims
Anders Jacobsen Skanderup
Mario L. Suva
Jianjun Zhang

Metabolism and Cancer
Michael Karin, Chair
Cosimo Commissio
Rushika M. Perera
Arun Sreekumar
Cullen M. Taniguchi
Elizabeth Wellberg

microRNAs and Other Noncoding RNAs
Jovanny Zabaleta, Chair
Sudarshan Anand

Oncogenes and Tumor Suppressor Genes
Qing Zhang, Chair
Lindsey D. Mayo

PREVENTION, EARLY DETECTION, AND INTERCEPTION (INCLUDING DIVERSITY, EQUITY, AND INCLUSION)

Clinical Prevention, Early Detection, and Interception
Ronald J. Chen, Cochair
Andrew K. Godwin, Cochair
Mark J. Gunter
Andreana N. Holowatyj
Fadlo R. Khuri

Preclinical Prevention, Early Detection, and Interception
Adriana Albini, Chair
J. Silvio Gutkind
Rama Khokha
Stephen Lam
Lecia V. Sequist

POPULATION SCIENCES (INCLUDING DIVERSITY, EQUITY, AND INCLUSION)

Population Sciences
Jennifer A. Doherty, Chair
Terry Hyslop
Marvin E. Langston
Marian L. Neuhouser
Jennifer B. Permuth
Jackilen Shannon
Melissa A. Simon
Aaron P. Thrift
Zhaoming Wang
REGULATORY SCIENCE AND POLICY

Regulatory Science and Policy
Gil S. Omenn, Chair

SCIENCE AND HEALTH POLICY

Science and Health Policy
Kenneth C. Anderson, Chair

TUMOR BIOLOGY

Angiogenesis
Howard C. Crawford, Chair
Luisa Iruela-Arispe

Carcinogenesis
Reginald Hill, Chair
Laurie E. Littlepage

In Vivo Imaging
Lacey R. McNally, Chair
Eugene J. Koay
Guillem Pratx

Metastasis
Adrienne Boire, Chair
Diana M. Cittely
Direna Alonso Curbelo
Sarah-Maria Fendt
Meenhard Herlyn
Laura A. Stabile
So häil Tavazoie
Wei Zhou

Pediatric Cancer - Basic Science
David Malkin, Chair
Maria G. Castro
Alejandro Sweet-Cordero

Stem Cell Biology
Ronald J. Buckanovich, Chair
Yoshiaki Ito
Qingfei Jiang

Tumor Adhesion
Lucia R. Languino, Chair
Johanna Ivaska

Tumor Evolution and Heterogeneity
Robert A. Gatenby, Chair
Andrew J. Aguirre

Tumor Microenvironment
Celeste Simon, Chair
Grace Y. Chen
Pilar De La Puente
Douglas T. Fearon
Robert L. Ferris
Eva M. Hernando
Alberto Mantovani
Florence McAllister
Aaron M. Newman
Michael C. Ostrowski
Paolo P. Provenzano
Mara H. Sherman
Sufi M. Thomas
Y. Alan Wang

AAPC Education Committee

Chairs
Carlos M. Caldas
Anna Karolina Palucka

Co-chairs
Elizabeth A. Platz
Sheila A. Stewart
Judith A. Varner

Members
Raza Ali
Olga A. Anczków-Camarda
Alberto Bardelli
Maria Casanova-Acebes
Robert Faccio
Stacey D. Finley
Claudia Fischbach
H. Courtney Hodges
Lilian Kabeche
Anusha Kalbasi
Leeat Keren
Christopher I. Li
Amanda W. Lund
Sandra S. McAllister
Dominique S. Michaud
Muhammad Murtaza
Erik Sahai
Maria S. Sosa
Eliezer M. Van Allen

Nonclinical Models of Cancer

Kwok-Kin Wong, Chair
Karen E. De Visser
David M. Langenau
Chien-Chi Lin
Trudy G. Oliver
Kwon-Sik Park
Gail P. Risbridger
Keisuke Sekine
AACR Clinical Trials Committee

Cochairs
Shivaani Kummar
Timothy A. Yap

Members
Nita Ahuja
Paolo A. Ascierto
Christian Blank
Erkut H. Borazanci
Margaret K. Callahan
Benedicto A. Carneiro
Ezra E.W. Cohen
William S. Dalton
Ruggero De Maria
Alexander E. Drilon
Ecaterina Ileana Dumbrava
Patrick M. Forde
Marcus DaSilva Goncalves
Susan Halabi
Roy S. Herbst
Alice Y. Ho
Virginia G. Kaklamani
Mustafa Khasraw
Steven K. Libutti
Jason J. Luke
Robert G. Maki
Ignacio Melero
Ruben A. Mesa
Pamela N. Munster
Natalie Ngoi
D. William Parsons
Akash Patnaik
Stephen C. Rubin
Howard I. Scher
Padmanee Sharma
Ryan J. Sullivan
Weijing Sun
Josep Tabernero
Beverly A. Teicher
Sara M. Tolaney
Nicholas C. Turner
Zev A. Wainberg
Colin D. Weekes

AACR Satellite Educational Symposia Committee

Cochairs
Sara A. Hurvitz
Steven T. Rosen
Evan Y. Yu

AACR Officers, Directors, and Foundation

OFFICERS AND DIRECTORS

President
Lisa M. Coussens

President-Elect
Philip D. Greenberg

Immediate Past President
David A. Tuveson

Treasurer
William N. Hait

Chief Executive Officer
Margaret Foti

Members
Nina Bharwaj
John D. Carpten
Christina Curtis
Luis A. Diaz, Jr.
Silvia Chiara Formenti
Elaine Fuchs
Susan M. Galbraith
Roy S. Herbst
Thomas J. Lynch, Jr.
Ira Mellman
Lisa A. Newman
William Pao
Kimberly Stegmaier
Suzanne Topalian
Robert H. Vonderheide

AACR FOUNDATION FOR THE PREVENTION AND CURE OF CANCER

Chair and President
Stephen D. Ryan

Secretary-Treasurer and Chief Executive Officer
Margaret Foti

Founding Chairman of the Board and President Emeritus
Bayard D. Clarkson

Trustees
Christiana Bardon
Thomas Bown II
James V. Buzzitta
Lauretta Chrys
Lisa M. Coussens
Nancy E. Davidson
Raymond N. DuBois
Faye Florence
Cathy Fraser
Philip D. Greenberg
William N. Hait
Tonya Hallett
Richard A. Heyman
Michael E. Jesanis
Eleanor D. Kress
John E. Leonard
Gladys H. Monroy
Anil K. Rustgi
Ajit Singh
Nancy Staisey
Gary Steele
David A. Tuveson
AACR Standing Committees

CONTINUING MEDICAL EDUCATION COMMITTEE

Chair
Steven T. Rosen

Members
Sarki A. Abdulkadir
Bishoy M. Faltas
Antonio T. Fojo
Karen A. Gelmon
Veronica C. Jones
Daniel A. Laheru
Bora Lim
Jennifer W. Mack
Jean L. Nakamura
Evan B. Shereck
Anita Villani
Evan Y. Yu

EXECUTIVE COMMITTEE

Lisa M. Coussens
Margaret Foti
Philip D. Greenberg
William N. Hait
David A. Tuveson

EDUCATION AND TRAINING COMMITTEE

Chair
Elaine R. Mardis

Members
Kimlin T. Ashing
Chetan Bettegowda
Nina Bhardwaj
Marcia R. Cruz-Correa
Chi Van Dang
Johann S. de Bono
Silvia C. Formenti
Obi Lee Griffith
Nada Jabado
Peter A. Jones
Yibin Kang
Michelle M. Le Beau
Massimo Loda
Patricia M. LoRusso
Scott W. Lowe
Hiroyuki Mano
Gabor T. Marth
Gerrit A. Meijer
Ira Mellman
Victoria M. Richon
Yu Shyr
Avrum Spira
José G. Treviño II
Daniel D. Von Hoff
Elizabeth M. Jaffee
(ex officio)

EXHIBITS COMMITTEE

Chair
Wafik S. El-Deiry

Members
Ana Luisa Correia
Laura M. Heiser
Amanda W. Lund
Esther A. Obeng
Feyruz V. Rassool
Rachel M. Syme
Ruoning Wang
Iain D. G. Watson

FINANCE AND AUDIT COMMITTEE

Chair
Cheryl L. Willman

Members
Anna D. Barker
Julie E. Bauman
Melissa B. Davis
H. Shelton Earp
Ruben A. Mesa
William Pao
Ben Ho Park

INTERNATIONAL AFFAIRS COMMITTEE

Chair
Elizabeth M. Jaffee

Members
John D. Carpten
Susan M. Galbraith
Ricky W. Johnstone
Edison T. Liu
Patricia M. LoRusso
Elaine R. Mardis
Martine Roussel
Yu Shyr
Lillian L. Siu

NOMINATING COMMITTEE

Chair
Michael A. Caligiuri

Members
Dafna Bar-Sagi
Levi A. Garraway
Patricia M. LoRusso
Guillermina Lozano
M. Celeste Simon
Pamela S. Ohashi
Valerie M. Weaver
PUBLICATIONS COMMITTEE

Chair
Victor E. Velculescu

Members
Adriana Albini
Laura Fejerman
Masanori Hatakeyama
Catriona H.M. Jamieson
Jos Jonkers
Virginia G. Kaklamani
Andrew Kung
Jonathan D. Licht
Ira Mellman
Gordon B. Mills
Kunle Odunsi
Kenneth J. Pienta
Joshua D. Rabinowitz
Timothy R. Rebbeck
David L. Rimm
Mack Roach III
Sheila K. Singh
Sheila A. Stewart
Miguel A. Villalona-Calero
Michael B. Yaffee

Ming Lei
Ruben A. Mesa
Quyen T. Nguyen
Maria Rescigno
Sandra W. Ryeom
José G. Treviño II
Lloyd C. Trotman

SCIENCE POLICY AND GOVERNMENT AFFAIRS COMMITTEE

Chair
Roy S. Herbst

Members
Kenneth C. Anderson
Anna D. Barker
Smita Bhatia
Michael A. Caligiuri
Gerardo Colón-Otero
Marcia R. Cruz-Correa
Nancy E. Davidson
David E. Fisher
Bianca N. Islam
Elizabeth M. Jaffee
Judith S. Kaur
Quynh-Thu Le
Peter F. Lebowitz
Mia A. Levy
Ruben A. Mesa
Stephen D. Nimer
Steven R. Patierno
Raphael E. Pollock
Anil K. Rustgi
Patricia Spears
Sheila A. Stewart
Cornelia M. Ulrich
Lisa M. Coussens (ex officio)
Philip D. Greenberg
(ex officio)
David A. Tuveson
(ex officio)

HEALTH POLICY SUBCOMMITTEE

Chair
Gilbert S. Omenn

Members
Karen H. Antman
William S. Dalton
Mark A. Israel
Richard E. Kouri
Thomas J. Lynch
Peter J. Neumann
Steven R. Patierno
Scott D. Ramsey
Mark E. Robson
Deborah Schrag
Ellen V. Sigal
Sean R. Tunis

SCIENCE EDUCATION AND CAREER ADVANCEMENT COMMITTEE

Chair
Brian M. Rivers

Immediate Past Chair
Kathleen W. Scotto

Members
Antonio T. Baines
Oliver Bögler
John M. Carethers
Edward Chu
Marcia R. Cruz-Correa
Johann S. de Bono
Lissette Delgado-Cruzata
Sandra Demaria
Nada Jabado

REGULATORY SCIENCE AND POLICY SUBCOMMITTEE

Chair
Kenneth C. Anderson

Members
Chris Boshoff
William S. Dalton
Raymond N. DuBois
Susan M. Galbraith
Judy E. Garber
Levi A. Garraway
Richard B. Gaynor
Eric B. Haura
Roy S. Herbst
Pasi A Jänne
Chitkala Kalidas
Peter F. Lebowitz
John E. Leonard
Thomas J. Lynch, Jr.
Elaine R. Mardis
David M. Reese
Eric H. Rubin
Charles L. Sawyers
Howard I. Scher
Ellen V. Sigal
Suzanne L. Topalian
Laura J. van’t Veer
Victor E. Velculescu

TOBACCO PRODUCTS AND CANCER SUBCOMMITTEE

Chair
Roy S. Herbst

Members
Christopher I. Amos
Barbara A. Burtner
Paul M. Cinciripini
Maciej L. Goniewicz
Dorothy K. Hatsukami
Suchitra Krishnan-Sarin
Scott J. Leischow
Timothy R. Rebbeck
Nancy A. Rigotti
Peter G. Shields
Avrum E. Spira
Benjamin A. Toll
Kasisomayajula Viswanath
Wendell Gray Yarbrough
Stephanie R. Land
(ex officio)

SPECIAL CONFERENCES COMMITTEE

Cochairs
Dafna Bar-Sagi
Roy S. Herbst

Members
Christina Curtis
Riccardo Dalla-Favera
Chi Van Dang
Johann S. de Bono
James V. DeGregori
Kevin L. Gardner
David Hyman
Quynh-Thu Le
Massimo Loda
William G. Nelson
Pamela S. Ohashi

AACR Specialty Award Committees

AACR JUNE L. BIEDLER PRIZE FOR CANCER JOURNALISM JUDGING PANEL

Chair
Clifton Leaf

Vice Chair
Ron Winslow

Members
David Boardman
Lecia Bushak
Antonio T. Fojo
Ellen L. Goode
Adam Hayden
Roy S. Herbst
Patrick Hwu
Donna M. Ludwinska
Adam Piore
Cynthia Ryan
Mariana Carla Stern

AACR Scientific Achievement Award Committees

AACR AWARD FOR LIFETIME ACHIEVEMENT IN CANCER RESEARCH COMMITTEE

Chair
Anil K. Rustgi

Members
Richard B. Gaynor
J. Jack Lee
Steven K. Libutti
Pamela S. Ohashi
Moshe Oren
William Pao
Jennifer A. Pietenpol
Brian M. Rivers
Martine F. Roussel
Michael M. Shen
Karen H. Vousden

Ashani Weeraratna
Kari L. Whitehead
Colonel James E. Williams

PELOTONIA-AACR WOMEN’S CANCER INITIATIVE SCIENTIFIC ADVISORY COMMITTEE

Members
Kimlin T. Ashing
Lisa A. Carey
Chad Creighton
Laura Fejerman
Brandy Heckman-Stoddard
Ann H. Klopp
Gordon B. Mills
Goli Samimi
Rulla M. Tamimi
Qi-En Wang
AACR AWARD FOR OUTSTANDING ACHIEVEMENT IN BLOOD CANCER RESEARCH

Chair
Mignon Lee-Cheun Loh

Members
Andy Chen
Rajesh Chopra
Faith E. Davies
Christopher R. Flowers
Larry W. Kwak
Ravi Majeti
Emmanuelle Passegué
Feyruz V. Rassool
Katayoun Rezvani
Kerry J. Savage
Christian Steidl
Andrei Thomas-Tikhonenko

AACR AWARD FOR OUTSTANDING ACHIEVEMENT IN CHEMISTRY IN CANCER RESEARCH COMMITTEE

Chair
Chudi O. Ndubaku

Members
Gunda I. Georg
Amanda B. Hummon
Katrina L. Jackson
Allan M. Jordan
Angela N. Koehler
Charles Lin
John E. Moses
Zaneta Nikolovska-Coleska
Stefani Thomas
Xiangshu Xiao

AACR CANCER EPIDEMIOLOGY AND PREVENTION AWARD COMMITTEE

Chair
Lorelei A. Mucci

Members
Yin Cao
Roger Chou
Andrea De Censi
Adana A.M. Llanos
Adam B. Murphy
Jesse Nodora
Megan Othus
Jong Y. Park
Sandi L. Pruitt
Laura S. Rozek
Rulla M. Tamimi

AACR AWARD FOR OUTSTANDING CONTRIBUTIONS TO EDUCATION AND TRAINING IN CANCER RESEARCH COMMITTEE

Chair
Johann S. de Bono

Members
Alex A. Adjei
Sara A. Byron
Edward Chu
Karyn A. Goodman
Manuel Hidalgo
Susan G. Hilsenbeck
Suwon Kim
Ming Lei
Vicki A. Morrison
W. Kimryn Rathmell
Meredith M. Regan
Yu Shyr
George W. Sledge
Charles R. Thomas, Jr.
Miguel A. Villalona-Calero

AACR CLINICAL CANCER RESEARCH AWARDS COMMITTEE

Chair
Dan Theodorescu

Members
Nadine J Barrett
Emily K. Bergsland
Alessandra Cesano
Lara E. Davis
Cathy Eng
David M. Hyman
Yelena Y. Janjigian
Kostas Kostarelos
Pamela Kunz
Gilberto De Lima Lopes
Christopher Nasveschuk
Manuel Alejandro Sepulveda
Anita Villani
Jennifer S. Yu

AACR DANIEL D. VON HOFF AWARD FOR OUTSTANDING CONTRIBUTIONS TO EDUCATION AND TRAINING IN CANCER RESEARCH COMMITTEE

Chair
Johann S. de Bono

Members
Alex A. Adjei
Sara A. Byron
Edward Chu
Karyn A. Goodman
Manuel Hidalgo
Susan G. Hilsenbeck
Suwon Kim
Ming Lei
Vicki A. Morrison
W. Kimryn Rathmell
Meredith M. Regan
Yu Shyr
George W. Sledge
Charles R. Thomas, Jr.
Miguel A. Villalona-Calero

AACR DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH COMMITTEE

Chair
Nancy E. Davidson

Members
Banu Arun
Roger A. Greenberg
Luisa Iruela-Arispe
Jos Jonkers
Kevin M. Kalinsky
Andrea S. Llera
Sibylle Loibl
Jorge S. Reis-Filho
Rebecca A. Shatsky
Naoto T. Ueno
Joanne B. Weidhaas
Dihua Yu  
Carlos L. Arteaga (ex officio)  

AACR DISTINGUISHED LECTURESHIP ON THE SCIENCE OF CANCER HEALTH DISPARITIES COMMITTEE  

Chair  
Gerardo Colón-Otero  

Members  
Jennifer Beebe-Dimmer  
Roshan Bastani  
Eloise Chapman-Davis  
Jorge E. Cortes  
Franklin W. Huang  
Steven R. Patierno  
Lewis R. Roberts  
Anne F. Rositch  
Claradina Soto  
Joseph A. Sparano  

AACR LABORATORY RESEARCH AWARDS COMMITTEE  

Chair  
Christine A. Iacobuzio-Donahue  

Members  
Donita C. Brady  
Hannah K. Carter  
Olivier Elemento  
Cyrus M. Ghajar  
Catherine Handy Marshall  
Shehnaz K. Hussain  
Chuan-Yuan Li  
Jeffrey M. Lipton  
Julia Maxson  
Sandra S. McAllister  
Lewis R. Roberts  
Takemasa Tsuji  
Bradly G. Wouters  

AACR JAMES S. EWING-THELMA B. DUNN AWARD FOR OUTSTANDING ACHIEVEMENT IN PATHOLOGY IN CANCER RESEARCH COMMITTEE  

Chair  
Roy A. Jensen  

Members  
Yuan Chang  
Kathleen R. Cho  
Jayanta Debnath  
Jennifer Dunlap  
Kojo Elenitoba-Johnson  
Celina G. Kleer  
Gerrit A. Meljer  
Anil Vasdev Parwani  
Andrea L. Richardson  
David L. Rimm  
Sabina Signoretti  

AACR MARGARET FOTI AWARD FOR LEADERSHIP AND EXTRAORDINARY ACHIEVEMENTS IN CANCER RESEARCH COMMITTEE  

Chair  
Patricia LoRusso  

Members  
Bruce A. Chabner  
Marcia R. Cruz-Correa  
Riccardo Dalla-Favera  
Edith P. Mitchell  
William Pao  
Brian M. Rivers  
Anil K. Rustgi  
Paul Workman  

AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH COMMITTEE  

Chair  
Ann H. Partridge  

Members  
Virginia F. Borges  
Abenaa M. Brewster  
Julie Dutil  
Joann G. Elmore  
Veronica C. Jones  
Maryam B. Lustberg  
Arpna M. Naik  
Melinda L. Telli  
Linda T. Vahdat  
Stephen T. Wong  
Carlos L. Arteaga (ex officio)  

AACR TEAM SCIENCE AWARD COMMITTEE  

Chair  
Jennifer Rubin Grandis  

Members  
Lara E. Davis  
Gianpietro Dotti  
Christopher J. Kemp  
Erin N. Kobetz  
Dung Thi Le  
Yanique Rattigan-Brown  
Olivia W. Rossanese  
Bryan P. Schneider  
Alex Sparreboom  
Zsofia Stadler  
Victor E. Velculescu
AACR-CANCER RESEARCH INSTITUTE LLOYD J. OLD AWARD IN CANCER IMMUNOLOGY COMMITTEE

Chair
Crystal L. Mackall

Members
Joshua Brody
Lawrence H. Fong
Ming Li
Gal Markel
Marcela V. Maus
Marcel R.M. van den Brink
Catherine J. Wu
Kai W. Wucherpfennig

AACR-PRINCESS TAKAMATSU MEMORIAL LECTURESHIP

Chair
Rakesh K. Jain

Members
Philippe L. Bedard
Paolo Boffetta
Mikala Egeblad
Hiroyuki Mano
Shigekazu Nagata
Rosalie C. Sears
Louis M. Staudt
Thea Dorothy Tlsty
Suzanne L. Topalian
Nikhil Wagle
Anna M. Wu
Takao Sekiya (ex officio)

AACR-MINORITIES IN CANCER RESEARCH JANE COOKE WRIGHT LECTURESHIP COMMITTEE

Chair
Lorna Rodriguez-Rust

Members
Sarki A. Abdulkadir
Nadine J. Barrett
Graham A. Colditz
Marvela Elizabeth Ford
Sophia H.L. George
Scarlett L. Gomez
William G. Nelson
Sorbarikor Piawah
Brian Ruffell
Eduardo Vilar-Sanchez

AACR-PRINCESS TAKAMATSU MEMORIAL LECTURESHIP

Chair
Rakesh K. Jain

Members
Philippe L. Bedard
Paolo Boffetta
Mikala Egeblad
Hiroyuki Mano
Shigekazu Nagata
Rosalie C. Sears
Louis M. Staudt
Thea Dorothy Tlsty
Suzanne L. Topalian
Nikhil Wagle
Anna M. Wu
Takao Sekiya (ex officio)

AACR-WAUN KI HONG AWARD FOR OUTSTANDING ACHIEVEMENT IN TRANSITIONAL AND CLINICAL CANCER RESEARCH COMMITTEE

Chair
Anne S. Tsao

Members
James L. Abbruzzese
Maura L. Gillison
Fadlo R. Khuri
Stephen Lam
Christopher I. Li
Nancy U. Lin
Roger S. Lo
David B. Solit
Margaret R. Spitz
Ignacio I. Wistuba
Jianda Yuan
Laurence Zitvogel

AACR-ST. BALDRICK’S FOUNDATION AWARD FOR OUTSTANDING ACHIEVEMENT IN PEDIATRIC CANCER RESEARCH COMMITTEE

Chair
Jason T. Yustein

Members
Lisa R. Diller
Maryam Fouladi
A. Lindsay Frazier
Julia L. Glade Bender
Elizabeth R. Lawlor
Stefan M. Pfister
Gilles Vassal
Alan S. Wayne

AACR-WOMEN IN CANCER RESEARCH CHARLOTTE FRIEND LECTURESHIP COMMITTEE

Chair
Sheila K. Singh

Members
Emily Bernstein
Heather R. Christofk
Carolyn Y. Fang
Karuna Ganesh
Beverly D. Lyn-Cook
Anirban Maitra
Shiva Malek
Polly A. Newcomb
Leslie L. Robison
Douglas Yee
PEZCOLLER FOUNDATION-AACR INTERNATIONAL AWARD FOR EXTRAORDINARY ACHIEVEMENT IN CANCER RESEARCH COMMITTEE

Chair
Anton J.M. Berns

Members
Dafna Bar-Sagi
Vincenzo Bronte
Francesca Demichelis
Johanna A. Joyce
Dana Pe’er
Nitzan Rosenfeld
Robert D. Schreiber
James A. Wells

Trevor J. Pugh
Lajos Pusztai
Jorge S. Reis-Filho
Hope S. Rugo
Violeta Serra
Christos Sotiriou

AACR BASIC CANCER RESEARCH GRANTS SCIENTIFIC REVIEW COMMITTEE

Chair
Kenneth J. Pienta

Members
Viktor A. Adalsteinsson
Ana Aparicio
Sandeep Burma
Janaí R. Carr-Ascher
Nicholas C. Denko
Dean W. Felsher
Hani Goodarzi
Matthew M. Gubin
Annie A. Huang
Sophia C. Kamran
Jan Karlseeder
Solange Landreville
Hui-Kuan Lin
Jun Luo
Nora M. Navone
Shyam Nyati
Bogdan Pasaniuc
Avery D. Posey
Nilay Shah
Mario L. Suvà
Edward William Tate
Anna Woloszynska
Binhua Peter Zhou

AACR-AORTIC-NCI BEGINNING INVESTIGATOR GRANTS FOR CATALYTIC RESEARCH (BIGCAT) SCIENTIFIC REVIEW COMMITTEE

Chair
Samuel Achilefu

Members
Francis Ali-Osman
Rebecca J. DeBoer
Pedro Fernandez
Elima E. Jedy-Agba
Johnan A.R. Kaleeba
Dinah M. Kassaman
Violet Kayamba
Cesaltina F. Lorenzoni
Michael M. Mwachiro
Thomas Odeny
Naomi Oyoe Ohene Oti
Feyruz V. Rassool
Adetunji T. Toriola
Katherine Van Loon

AACR-AORTIC-NCI BEGINNING INVESTIGATOR GRANTS FOR CATALYTIC RESEARCH (BIGCAT) STEERING COMMITTEE

Cochairs
James R. Alaro
Lisa A. Newman
Solomon O. Rotim

Members
Sam M. Mbulaiteye
Susan Citonje
Msadabwe-Chikuni
Yixian (John) Zhang

AACR Scientific Grant Review Committees

AACR-ASTRAZENECA CAREER DEVELOPMENT AWARD FOR PHYSICIAN-SCIENTISTS IN HONOR OF JOSÉ BASELGA SCIENTIFIC COMMITTEE

Chair
Luis A. Diaz

Members
Javier Cortés
Sara A. Hurvitz
Patrick Hwu
Cigall Kadoch
Anthony G. Letai
Roger S. Lo
Gordon B. Mills
Jorge J. Nieva

AACR-AORTIC-NCI BEGINNING INVESTIGATOR GRANTS FOR CATALYTIC RESEARCH (BIGCAT) STEERING COMMITTEE

Cochairs
James R. Alaro
Lisa A. Newman
Solomon O. Rotim

Members
Sam M. Mbulaiteye
Susan Citonje
Msadabwe-Chikuni
Yixian (John) Zhang
AACR BRAIN CANCER RESEARCH GRANTS SCIENTIFIC REVIEW COMMITTEE

Chair
Lisa M. DeAngelis

Members
Kenneth D. Aldape
Chetan Bettegowda
Priscilla K. Brastianos
Susan M. Chang
Sidi Chen
Peter B. Dirks
Yi Fan
Howard Alan Fine
Marco Gallo
Justin D. Lathia
Michael Lim
Elizabeth Maher
Donald M. O'Rourke
David R. Raleigh
Sriram Venneti
Derek A. Wainwright
Katherine E. Warren
Stephen Yip
Gelareh Zadeh
Yuan Zhu

Douglas Easton
Sarah-Maria Fendt
Patricia A. Ganz
Antonio Giordano
Christy R. Hagan
James B. Hicks
Jacqueline D. Jones
Benita S. Katzenellenbogen
Rama Khokha
Nancy U. Lin
Jennifer Keating Litton
Hui-Wen Lo
Gabriel Lopez-Berestein
Maryam B. Lustberg
Cynthia X. Ma
Dario Marchetti
Lucio Miele
Katherine L. Nathanson
Steffi Oesterreich
Nick Orr
Linda J.Z. Penn
Aleix Prat
Manjeet K. Rao
Violeta Serra
Qiang Shen
Daniel P. Silver
Jennifer Sims-Mourtada
Kalliopi P Siziopikou
Joseph A. Sparano
Daniel G. Stover
Saraswati Sukumar
Mylin A. Torres
Tiffany A. Traina
Linda T. Vahdat
Shizhen Emily Wang
Joanne B. Weidhaas
Jelle Wesseling
Jovanny Zabaleta
Siyuan Zhang

AACR CANCER DISPARITIES RESEARCH GRANTS SCIENTIFIC REVIEW COMMITTEE

Chair
Kevin L. Gardner

Members
Christina E. Bailey
Jennifer Beebe-Dimmer
Patricia Chalela
Jennifer A. Freedman
Theresa A. Hastert
Xavier Llor
Lorna Haughton McNeill
Khadijah A. Mitchell
Folakemi T. Odedina
Julie R. Palmer
Sandi L. Pruitt
Amelie G. Ramirez
Renee Reams
Melissa Troester
Joseph M. Unger

AACR BREAST CANCER RESEARCH GRANTS SCIENTIFIC REVIEW COMMITTEE

Chair
Virginia G. Kaklamani

Members
Banu Arun
Anne H. Blaes
Jose Javier Bravo-Cordero
Kristy A. Brown
Anuradha Chakravarthy
Justin A. Colacino
Chad Creighton
Bisrat G. Debe
Camila O. dos Santos

AACR CANCER DISPARITIES RESEARCH GRANTS SCIENTIFIC REVIEW COMMITTEE

Chair
Kevin L. Gardner

Members
Christina E. Bailey
Jennifer Beebe-Dimmer
Patricia Chalela
Jennifer A. Freedman
Theresa A. Hastert
Xavier Llor
Lorna Haughton McNeill
Khadijah A. Mitchell
Folakemi T. Odedina
Julie R. Palmer
Sandi L. Pruitt
Amelie G. Ramirez
Renee Reams
Melissa Troester
Joseph M. Unger

AACR CLINICAL ONCOLOGY RESEARCH (CORE) GRANTS SCIENTIFIC REVIEW COMMITTEE

Chair
Neil P. Shah

Members
Mariam Jamal-Hanjani
Ann H. Klopp
Jorge J. Nieva
AACR DIVERSITY, EQUITY, AND INCLUSION GRANTS SCIENTIFIC REVIEW COMMITTEE

Chair
Miguel A. Villalona-Calero

Members
Alex A. Adjei
Gabriele Bergers
John D. Carpten
Juan R. Cubillos-Ruiz
Carlos Gil M. Ferreira
Jane C. Figueiredo
Daniel J. George
Kent F. Hoskins
Lorna H. McNeill
Yamilé Molina
Steven R. Patierno
Anil K. Sood
Shobha Srinivasan
Stephen T. Wong

AACR GASTRIC CANCER RESEARCH GRANTS SCIENTIFIC REVIEW COMMITTEE

Chair
Sandra W. Ryeom

Members
Asfaneh Barzi
Barbara A. Burtness
Tamas A. Gonda
Haejin In
Jason C. Mills
Markus Moehler
Duane T. Smoot

AACR GERTRUDE B. ELION CANCER RESEARCH GRANTS SCIENTIFIC REVIEW COMMITTEE

Chair
Colin D. Weekes

Members
Nita Ahuja
Donita C. Brady
Kyle C. Cuneo
John Doench
Daniel Durocher
Rong Fan
Sunil R. Hingorani
Abner Louissaint
Leah E. Mechanic
Evan W. Newell
Trevor M. Penning
Daniel A. Pryma
Avraham Raz
Ran Reshef
Nima Sharifi
Koichi Takahashi
Tawee Tanvetyanon
Sophia S. Wang
Liqing Yang
Dihua Yu

AACR IMMUNO-ONCOLOGY RESEARCH GRANTS SCIENTIFIC REVIEW COMMITTEE

Chair
Jedd D. Wolchok

Members
Samuel E. Adunyah
Ido Amit
Djordje Atanackovic
Naomi S. Balzer-Haas
Ivan M. Borrello
Renier J. Brentjens
Yvonne Y. Chen
Christopher H. Contag
Leah M. Cook
Sandra P. D’Angelo
Daniel D. de Carvalho
Wendy S. Garbett
Sergei I. Grivennikov
Peixuan Guo
Kevin J. Harrington
Christian S. Hinrichs
Alex Yee-Chen Huang
Richard C. Koya
Peter P. Lee
Gerald P. Linette
Marcela V. Maus
Tara C. Mitchell
Pamela N. Munster
Jorge J. Nieva
Pierluigi Porcu
Nadeem Riaz
Andrea Schietinger
Stephen P. Schoenberger
Vivek Subbiah
Takemasa Tsuji
Jovanny Zabaleta

AACR HEMATOLOGIC MALIGNANCIES RESEARCH GRANTS SCIENTIFIC REVIEW COMMITTEE

Chair
John F. DiPersio

Members
Omar Abdel-Wahab
Lawrence H. Boise
Theodore P. Braun
John P. Chute
Lucy A. Godley
Yubin Kang
Larry W. Kwak

Eduardo Magalhães Rego
Hanna K.A. Mikkola
Sonali M. Smith
Amit K. Verma
AACR-JOHNSON & JOHNSON LUNG CANCER INITIATIVE
STIMULATING THERAPEUTIC ADVANCES THROUGH RESEARCH TRAINING (START) GRANTS
SCIENTIFIC REVIEW COMMITTEE

Chair
Christine M. Lovly

Members
Dennis O. Adeegbe
Daniel R. Gomez
Verline Justilien
William W. Lockwood
Terence M. Williams

AACR LUNG CANCER RESEARCH GRANTS
SCIENTIFIC REVIEW COMMITTEE

Chair
Katerina A. Politi

Members
Lauren A. Byers
Stephen G. Chun
Suzanne E. Dahlberg
Nathaniel R. Evans
Patrick Forde
Edward B. Garon
Nicolas Girard
Ramaswamy Govindan
H. Dean Hosgood
Natasha B Leighl
Stephen V. Liu
Patrick C. Ma
Erminia Massarelli
Patrick Nana-Sinkam
Joel W. Neal
Thales Papagiannakopoulos
Karen L. Reckamp
Rafael Rosell
Jill M. Siegfried
Laura Soucek
Nichole Tripician Tanner

AACR-LOBULAR BREAST CANCER ALLIANCE INVASIVE LOBULAR CARCINOMA RESEARCH GRANTS
SCIENTIFIC REVIEW COMMITTEE

Chair
Wendy A. Woodward

Members
Janice Axelrod
Christine Desmedt
Sophia H.L. George
Rinath M. Jeselsohn
Hans H. Kreipe
Megan L. Kruse
Sunil R. Lakhani
Christopher I. Li
Ingrid A. Mayer
Rita A. Mukhtar
Rita Nanda
Barbara Neilsen
Steffi Oesterreich
Ann H. Partridge
Roberto Salgado
Gabriele M. Zoppoli

AACR LUNG CANCER RESEARCH GRANTS
SCIENTIFIC REVIEW COMMITTEE

Chair
Katerina A. Politi

Members
Lauren A. Byers
Stephen G. Chun
Suzanne E. Dahlberg
Nathaniel R. Evans
Patrick Forde
Edward B. Garon
Nicolas Girard
Ramaswamy Govindan
H. Dean Hosgood
Natasha B Leighl
Stephen V. Liu
Patrick C. Ma
Erminia Massarelli
Patrick Nana-Sinkam
Joel W. Neal
Thales Papagiannakopoulos
Karen L. Reckamp
Rafael Rosell
Jill M. Siegfried
Laura Soucek
Nichole Tripician Tanner

AACR-MIRATI CHEMICAL BIOLOGY GRANTS SCIENTIFIC REVIEW COMMITTEE

Chair
Kevan M. Shokat

Members
Rima S. Al-awar
Michelle R. Arkin
Kimberly E. Beatty
Sara J. Buhrlage
Cosimo Commissio
Arvin Dar
Faith E. Davies
Michael A. Erb
Fleur M. Ferguson
Lyn H. Jones
Yamuna Krishnan
Piro Lito
Sanjay V. Malhotra
Elizabeth R. Sharlow

AACR MAXIMIZING OPPORTUNITY FOR NEW ADVANCEMENTS IN RESEARCH IN CANCER (MONARCA) GRANTS FOR LATIN AMERICA SCIENTIFIC REVIEW COMMITTEE

Chair
Marcia R. Cruz-Correa

Members
Isabel Alvarado-Cabrero
Daniel P. Bezerra
Roger Chammas
Henry L. Gomez
Sonia L. Hernandez-Lopez
Luis Alonso Herrera
Claudia Lanari
Vilma R. Martins
Jaime L. Matta
José Mordoh
Juan Carlo S. Roa
Eduardo M. Sotomayor
Luis Ubilollo
Luísa L. Villa
Additional appointments pending
AACR-NOVOCURE
RESEARCH GRANTS
SCIENTIFIC REVIEW
COMMITTEE

Chair
Appointment pending

Members
Alex A. Adjei
Erica Bell
Joseph F. Costello
Monika E. Hegi
Justin D. Lathia
Emil Lou
Chirag B. Patel
Zvi Ram
Michael D. Story
Eric T. Wong
Additional appointments pending

AACR PEDIATRIC
CANCER RESEARCH
GRANTS SCIENTIFIC REVIEW
COMMITTEE

Chair
Eugenie S. Kleinerman

Members
Claudia A. Benavente
Pablo Berlanga
Jonathan E. Con stance
Lara E. Davis
Klaus-Michael Debatin
Maria Kavallaris
Kara M. Kelly
Selene C. Koo
David Liebner
Troy A. McEachron
Rayne H. Rouce
David Solomon
Kai Tan
Brian Andrew Van Tine
Samuel L. Volchenboum
Gelareh Zadeh

AACR RENAL CELL
CARCINOMA GRANTS
SCIENTIFIC REVIEW
COMMITTEE

Chair
Brian I. Rini

Members
Elizabeth P. Henske
Payal Kapur
William Y. Kim
Rana R. McKay
Cora N. Sternberg
Javier F. Torres-Roca
Ulka N. Vaishampayan
Lily Wu

LUSTGARTEN
FOUNDATION-AACR
PANCREATIC CANCER
RESEARCH GRANTS
SCIENTIFIC REVIEW
COMMITTEE

Chair
Matthew G. Vander Heiden

Members
Andrew V. Biankin
Eric A. Collisson
Edna Cukierman
Kyle C. Cuneo
Channing J. Der
Michael G. Goggins
William G. Hawkins
Theodore S. Hong
Brian C. Lewis
Donghui Li
Gwen Lomberk
Scott W. Lowe
Peter J. O’Dwyer
Marina Pasca di Magliano
Rushika M. Perera
Mara H. Sherman
Julie L. Sutcliffe
Susan Tsai
Brian M. Wolpin
Laura DeLong Wood
Jen Jen Yeh

THE BOSARGE
FAMILY FOUNDATION-
WAUN KI HONG
SCHOLAR AWARD
FOR REGENERATIVE
CANCER MEDICINE
SCIENTIFIC REVIEW
COMMITTEE

Chair
Appointment pending

Members
Maria Grazia Roncarolo
Nagarajan Kannan
Additional appointments pending

AACR Specialty Groups and Committees

AACR AD HOC COMMITTEE ON
BYLAWS

Chair
Michael A. Caligiuri

Members
Dafna Bar-Sagi
Roy S. Herbst
Elizabeth A. Platz
Trevor J. Pugh
AACR CANCER DISPARITIES PROGRESS REPORT 2024

Steering Committee
Chair
Robert A. Winn

Advisory Committee
Appointments pending

AACR CANCER PROGRESS REPORT 2023 STEERING COMMITTEE

Chair
Philip D. Greenberg

Members
James L. Abbruzzese
Ezra E.W. Cohen
Susan M. Domcheck
Chyke A. Doubeni
Ivy Elkins
Silvia C. Formenti
Thomas J. Fuchs
John C. Kucharczuk
Ravindra Majeti
Paul S. Mischel
Lorelei A. Mucci
Padmanee Sharma
Melissa A. Simon
Alejandro Sweet-Cordero
Gita Thanarajasingam

William N. Hait
Elizabeth M. Jaffee
Peter A. Jones
Elaine R. Mardis
Olufunmilayo I. Olopade
Timothy R. Rebbeck
Daniel D. Von Hoff

AACR INTERNATIONAL-CANADA BOARD OF DIRECTORS

Chair
Lisa M. Coussens

Members
Margaret Foti
Philip D. Greenberg
Benjamin Haibe-Kains
William N. Hait
David G. Huntsman
Nada Jabado
Stephen M. Robbins
Lillian L. Siu
Bradly G. Wouters

AACR-MPM TRANSFORMATIVE CANCER RESEARCH GRANTS SCIENTIFIC ADVISORY BOARD

Chair
H. Robert Horvitz

Members
William C. Hahn
Helen E. Heslop
Yibin Kang
Elaine R. Mardis
David P. Ryan
Louis M. Weiner

FELLOWS OF THE AACR ACADEMY

Steering Committee
President
Charles L. Sawyers
Past-President
Judy E. Garber

Members
Suzanne Cory
Elaine Fuchs
Michael Kastan
Olufunmilayo I. Olopade
Martine J. Piccart
Geoffrey M. Wahl

Nomination and Election Oversight Committee
President
Charles L. Sawyers
Past-President
Judy E. Garber
Chair
Michael A. Caligiuri

Members
Judith Campisi
Suzanne Cory
Levi A. Garraway

President-Elect Nominating Committee
Chair
Mary C. Beckerle

Members
Joann S. Brugge
Riccardo Dalla-Favera
Tony Hunter
Kornelia Polyak

AACR HISTORY PROJECT ADVISORY COMMITTEE

Members
Anna D. Barker
Elizabeth H. Blackburn
Michael A. Caligiuri
Raymond N. DuBois
AACR PROJECT GENIE® STEERING COMMITTEE

Chair
Philippe Bedard

Founding Chair
Charles L. Sawyers

Executive Committee
Jeremy Segal
Alejandro Sweet-Cordero
Walter Urba
Zenta Walther

Steering Committee

Members
James L. Abbruzzese
Jean Abraham
Karen A. Pinilla Alba
Fabrice Andre
Alexander Baras
Lisa M. Coussens
Margaret Foti
Kevin Haigis
Brian Henick
Marilyn Li
Shannon Jones McCall
Gerrit Meijer
Christine Micheel
Ana Vivancos
Wei Zhang

AACR PROJECT GENIE® EXTERNAL ADVISORY BOARD

Chair
David R. Parkinson

Members
Samuel Aparicio
Paul R. Billings
Susan M. Domchek
Keith T. Flaherty
Patricia M. LoRusso
Louis M. Staudt

AACR Scientific Task Forces

AACR AGING AND CANCER: STRESS AND OTHER RISK FACTORS TASK FORCE

Chair
David A. Tuveson

Cochairs
Electra D. Paskett
Sheila A. Stewart

Members
Adriana Albini
Corina Amor Vegas
Lodovico Balducci
Dafna Bar-Sagi
Juan Carlos Izpisúa Belmonte
Kira Bona
Judith Campisi
Lewis C. Cantley
John D. Carpten
Andrew E Chapman
Harvey Jay Cohen
Alan D. ’Andrea
James V. DeGregori
Hariharan P. Easwaran
Mikala Egeblad
Martine Extermann
Lucy Godley
Marcia Haigis
Melissa M. Hudson
Michael R. Irwin
Scott W. Lowe
Lydia Lynch
Masashi Narita
Anna Karolina Palucka
Victoria L. Seewaldt
Manuel Serrano
Ned Sharpless
Cornelia M. Ulrich
Matthew G. Vander Heiden
Zhaoming Wang
Jennifer A. Wargo
Ashani Weeraratna
Robert A. Winn
E. John Wherry III

AACR EXPLORATORY IND/BIOMARKER DRIVEN CLINICAL TRIALS TASK FORCE

Chair
Patricia M. LoRusso

Vice Chair
David A. Tuveson

Members
Jaffer A. Ajani
Anna D. Barker
Nina Bhardwaj
Gideon M. Blumenthal
William S. Dalton
Johann S. de Bono
Caroline Dive
James H. Doroshow
Kojo Elenitoba-Johnson
Elena Elimova
Rebecca Fitzgerald
Keith T. Flaherty
James L. Gulley
Priti Hegde
David M. Hyman
Elizabeth M. Jaffee
Oliver Jonas
Shivaani Kummar
Anthony G. Letai
Ignacio Melero
Ira Mellman
Ruben A. Mesa
Nickolas Papadopoulos
Emanuel F. Petricoin III
Gary K. Schwartz
Mirat Shah
Padmanee Sharma
Yu Shyr
Lillian L. Siu
Jean-Charles Soria
Avrum Spira
Jeff L. Summers
Timothy A. Yap
Ying Yuan
AACR SCIENTIFIC COMMITTEES

AACR HEMATOLOGIC MALIGNANCIES TASK FORCE
Chair
Jonathan D. Licht

Members
Kenneth C. Anderson
Scott A. Armstrong
P. Leif Bergsagel
Michael A. Caligiuri
Rajesh Chopra
Riccardo Dalla-Favera
Faith E. Davies
John E. Dick
John D. DiPersio
Yusri Elsayed
Maria E. Figueroa
Steven D. Gore
Ricky W. Johnstone
Carl H. June
Thomas J. Kipps
Toshio Kitamura
Michelle M. Le Beau
Ronald Levy
Mignon Lee-Cheun Loh
Ravindra Majeti
Ali M. Melnick
Ruben A. Mesa
Phuong Khanh Morrow
Charles G. Mullighan
Bertrand Nadel
Lilli Petruzzelli
Stephen J. Schuster
Eduardo M. Sotomayor
Louis M. Staudt
Kimberly Stegmaier
Jeffrey W. Tyner
Nancy K. Valente
Cheryl L. Willman

AACR CANCER MOLECULAR IMAGING AND THERANOSTICS TASK FORCE
Co-chairs
Kayvan R. Keshari
David R. Piwnica-Worms
Julie Sutcliffe

Members
Eric O. Aboagye
Zaver M. Bhujwalla
Elisabeth de Vries
Ralph J. DeBerardinis
James R. Heath
Oluwatayo Iketun
David C. Lyden
David A. Mankoff
Florence McAllister
Jeffrey C. Rathmell
David A. Tuveson
Jeevan Virk

AACR PATHOLOGY IN CANCER RESEARCH TASK FORCE
Chair
Massimo Loda

Subcommittee Chairs
Robin G. Lorenz
(Communication and Education)
Anil V. Parwani (AI and Computational Pathology)
Jorge S. Reis-Filho
(Molecular Pathology and Precision Medicine)
Lawrence D. True
(Perspectives and Commentaries)

Members
Olusegun Isaac Alatise
Michael R. Angelo
Sunil S. Badve
Andrew H. Beck
Alexander S. Brodsky
Carolyn C. Compton
Suzana S. Couto
Jayanta Debnath
Angelo M. DeMarzo
Kojo Elenitoba-Johnson
Michelangelo Fiorentino
Chris A. French
Thomas J. Fuchs
Kevin L. Gardner
Felice Giangaspero
Jennifer M. Giltinan
Jiaoti Huang
A. John Iafrate
Michael M. Ittmann
Roy A. Jensen
Jakob N. Kather
Annette S. Kim
Michael Kluk
Tamara L. Lotan
Anirban Maitra
Diana Mandelker
Caterina Marchio
Gerrit A. Meijer
Richard N. Mitchell
Francesco Pezzella
Eli Pikarsky
Nicholas P. Reder
Andrea L. Richardson
David L. Rimm
Mark A. Rubin
Kalliopi P. Siziopikou
José G. van den Berg
Anne Vincent-Salomon
Britta Weigelt
Ignacio I. Wistuba
Laura D. Wood
AACR PRECISION COMBINATION THERAPIES TASK FORCE

Chair
Elizabeth M. Jaffee

Cochairs
Jennifer Rubin Grandis
Albert C. Koong
Patricia M. LoRusso
Antoni Ribas

Members
Alex A. Adjei
Kenneth C. Anderson
Anna D. Barker
Peter L. Choyke
Marcia R. Cruz-Correa
Sandra Demaria
James H. Doroshow
Laura J. Esserman
Katherine W. Ferrara
Silvia Formenti
Thomas J. Kipps
Massimo Loda
Crystal L. Mackall
Rita Nanda
Lisa A. Newman
Kunle Odunsi
Anil Vasdev Parwani
Mary W. Redman
Kurt A. Schalper
Yu Shyr
Louis M. Staudt
Charles Swanton
Marc R. Theoret
David A. Tuveson
Eliezer Van Allen
Jennifer A. Wargo
Timothy A. Yap

EDUCATION SUBCOMMITTEE

Cochairs
Albert C. Koong
Antoni Ribas

Members
Alex A. Adjei
Mary Redman
Eliezer Van Allen
Yu Shyr

PUBLICATION AND DISSEMINATION SUBCOMMITTEE

Cochairs
Elizabeth M. Jaffee
Kenneth C. Anderson

Members
Peter L. Choyke
James H. Doroshow
Silvia Formenti
Thomas J. Kipps
Rita Nanda
Mary Redman
Kurt A. Schalper
Timothy A. Yap

STANDARDIZATION SUBCOMMITTEE

Chair
Jennifer Rubin Grandis

Members
Alex A. Adjei
Kenneth C. Anderson
Anna D. Barker
Marcia R. Cruz-Correa

ELIMINATING RACIAL INEQUITIES IN CANCER RESEARCH

Cochairs
John M. Carethers
Melissa B. Davis

Members
Michael A. Caligiuri
Luis G. Carvajal-Carmona
Kevin D. Cassel
Gerardo Colon-Otero
Marcia R. Cruz-Correa
Lola A. Fashoyin-Aje
Rodney C. Haring
Christopher I. Li
Folasade P. May
Lisa A. Newman
Steven R. Patierno
Avery D. Posey Jr.
Antoni Ribas
Brian M. Rivers
Sanya A. Springfield
Mariana C. Stern
Karriem S. Watson
Ashani T. Weeraratna
Cheryl L. Willman
Robert A. Winn
Clayton C. Yates

COMMUNITY BUILDING SUBCOMMITTEE

Cochairs
Marcia R. Cruz-Correa
Lisa A. Newman

Members
Crystal L. Mackall
Eliezer Van Allen
Charles Swanton
David Tuveson

Sandra Demaria
James H. Doroshow
Katherine W. Ferrara
Silvia Formenti
Rita Nanda
Kunle Odunsi
Mary Redman
Kurt A. Schalper
AACR TRUST IN SCIENCE TASK FORCE

**Chair**
William S. Dalton

**Members**
Stacey J. Adam
Laleh Amiri-Kordestani
J. Carl Barrett
Arthur Caplan
John D. Carpten
Lisa M. Coussens
Marcia R. Cruz-Correa
Lee M. Ellis
Cimona V. Hinton
Melissa M. Hudson
Fabian McCartney Johnston
Edward Sanghyun Kim
Tamy Kim
James W. Lillard
Ira Mellman
Lisa A. Newman
Folakemi T. Odedina
Jesse Nodora
Debra Patt
Charles M. Perou
Martine J. Piccart
Eric H. Rubin
Patricia Spears
Javier F. Torres-Roca
David A. Tuveson
Robert A. Winn

AACR Scientific Working Groups

CANCER EVOLUTION WORKING GROUP (CEWG)

**Executive Committee**

**Cochairs**
Frank H. Laukien
Charles Swanton

**Cochairs-Elect**
Anna D. Barker
Jeffrey P. Townsend

**Members**
Denis Noble
Kenneth J. Pienta
George H. Poste
Susan M. Rosenberg
Jason A. Somarelli

**Steering Committee**

**Members**
M. William Audeh
Alberto Bardelli
Michael C. Campbell
Peter J. Campbell
Christina Curtis
James V. DeGregori
Robert A. Gatenby
Marco Gerlinger
Michael A. Gillette
Trevor Graham
Henry H.Q. Heng
Giulia C. Kennedy
Carlo C. Maley
Perry S. Marshall
Andriy Marusyk
Nicholas McGranahan
Franziska Michor
Paul S. Mischel
Nicholas E. Navin
Serena Nik-Zainal
Larry Norton
Elizabeth O’Day
Azra Raza
Andrea Sottoriva
Jonathan Weissman
Danny R. Welch

CANCER IMMUNOLOGY WORKING GROUP (CIMM)

**Steering Committee**

**Chair**
Kunle Odunsi

**Immediate Past Chair**
Sandra Demaria

**Members**
Djordje Atanackovic
Rostyslav Bilyy
Lisa H. Butterfield
Kavita Dhodapkar
Lawrence Fong
Helen E. Heslop
Richard C. Koya
Sherene Loi
Marcela V. Maus
Elizabeth A. Mittendorf
Marco Ruella
Eduardo M. Sotomayor
Takemasa Tsuji
Jennifer A. Wargo

CANCER PREVENTION WORKING GROUP (CPWG)

**Steering Committee**

**Chair**
Adriana Albini

**Members**
Melissa L. Bondy
Philip E. Castle
Andrea De Censi
Zigang Dong DrPH
G. Paolo Dotto
Raymond N. DuBois
Stephen S. Hecht
Lee W. Jones
Suchitra Krishnan-Sarin
Stephen Lam
J. Jack Lee
Christopher I. Li
Karen T. Liby
William G. Nelson
Klaus Pantel
Michael N. Pollak
Timothy R. Rebbeck
Leslie L. Robison
Anil K. Rustgi
Victoria L. Seewaldt
Melissa A. Simon
Avrum Spira
Mariana Carla Stern
Eva Szabo
Kenneth Kenji Tanabe
Cornelia M. Ulrich
Kala Visvanathan

CHEMISTRY IN CANCER RESEARCH WORKING GROUP (CICR)

Steering Committee

Chair
Mary M. Mader

Immediate Past Chair
Joachim R. Rudolph

Members
Rima Al-awar
Michelle Arkin
Sara J. Buhrlage
Laura Akullian D’Agostino
Danette L. Daniels
Benjamin L. Ebert
Adrian L. Gill
Ingo Hartung
David Millan
Christopher Nasveschuk
Daniel K. Nomura
Jennifer C. Petter
Zoran Rankovic
Hong Shen

AACR-CICR Award Nominating Subcommittee

Chair
Mary M. Mader

Members
James E. Audia
Laura D’Agostino
Benjamin L. Ebert
Ingo Hartung
Jennifer C. Petter

AACR-CICR Communications Subcommittee

Chair
Martin Swarbrick

Immediate Past Chair
Keith R. Hornberger

Members
Barbara Czako
Dennis X. Hu
Lyn Howard Jones
Milka Kostic
William Zuercher

AACR-CICR New Drugs on the Horizon Selection Subcommittee

Members
Sara J. Buhrlage
Adrian Gill
Mary M. Mader
David Millan
Zoran Rankovic
Joachim R. Rudolph

PEDiATRIC CANCER WORKING GROUP (PCWG)

Steering Committee

Chair
Katherine A. Janeway

Chair-Elect
E. Alejandro Sweet-Cordero

Members
Sam Behjati
Olivier Delattre
Maryam Fouladi
Elizabeth Fox
Julia L. Glade Bender
Alejandro Gutierrez
Douglas S. Hawkins
Meredith S. Irwin
Nada Jabado
Mark W. Kieran
Leona Knox
Corinne Linardic
Paul A. Northcott
Charles W.M. Roberts
Gudrun Schleiermacher

POPULATION SCIENCES WORKING GROUP (PSWG)

Steering Committee

Chair
Lorelei A. Mucci

Immediate Past Chair
Andrew T. Chan

Members
Peter T. Campbell
Iona C. Cheng
Michele L. Cote
Jason Diaz
Joanne W. Elena
Jane C. Figueiredo
Francesca Gany
Sophia H.L. George
Shehnaz K. Hussain
COMMITTEES | AACR Scientific Working Groups (cont’d)

RADIATION SCIENCE AND MEDICINE WORKING GROUP (RSM)

Steering Committee

Chair
Silvia C. Formenti

Chair-Elect
Fei-Fei Liu

Members
Maria G. Castro
Steven J. Chmura
Deborah Citrin
Theodore L. DeWeese
Daphne Haas-Kogan
Alice Y. Ho
Isabel Lauren Jackson
Billy W. Loo, Jr.
Marc Mendonca
Dorthe Schaue
Charles R. Thomas, Jr.
Phuoc Tran
Katherine A. Vallis
Joanne Weidhaas
David S. Yu

TUMOR MICROENVIRONMENT WORKING GROUP (TME)

Steering Committee

Chair
Mikala Egeblad

Immediate Past Chair
Theresa A. Guise

Members
Adrienne Boire
Paula D. Bos
Heather R. Christofk
Leah M. Cook
Karin E. de Visser
Neta Erez
Cyrus M. Ghajar
Sergei I. Grivennikov
Ilaria Malanchi
Florence McAllister
Erik Sahai
Mara H. Sherman
Ashani T. Weeraratna

AACR Constituency Groups

AACR ASSOCIATE MEMBER COUNCIL

Chair
Francesco Caiazza

Chair-Elect
Katie Campbell

Immediate Past Chair
Kristin G. Anderson

Members
Kristin A. Altwegg
Peter F. DelNero
Sunil K. Joshi
Wayne R. Lawrence
Russell J. Ledet
Safa Majeed
Margaret S. Pichardo
James SeongJun Han
Mathias Seviiri
Erica Tsang

AACR MINORITIES IN CANCER RESEARCH COUNCIL

Chair
Clayton C. Yates

Chair-Elect
Camille C.R. Ragin

Immediate Past Chair
Gerardo Colón-Otero

Members
Lourdes Baezconde-Garbanati
Melissa B. Davis
Luis A. Diaz, Jr.
Carmen E. Guerra
Folakemi T. Odedina
Dorothy A. Rhoades
Tiffany Wallace
Colin D. Weekes
Sanya A. Springfield (ex officio)

AACR WOMEN IN CANCER RESEARCH COUNCIL

Chair
Sheila K. Singh

Chair-Elect
Beverly D. Lyn-Cook

Immediate Past Chair
Amelie G. Ramirez

Members
Andrea A. Hayes-Dixon
Nada Jabado
Johanna A. Joyce
Christine M. Lovly
Shiva Malek
Claudia K. Petritsch
Victoria L. Seewaldt
Mariana C. Stern

COMMITTEES
It is the AACR’s privilege to honor those scientists who have reached the milestone of 50 years of AACR membership. The AACR Board of Directors would like to extend their sincere thanks and appreciation to these members for their dedication to cancer research and continued participation in and support of the AACR’s activities and programs.

Herbert T. Abelson
William F. Benedict
Darell D. Bigner
Robert E. Brooks
Charles P. Burns
Janet S. Butel
Ercole L. Cavalieri
Bruce A. Chabner
Tsann Ming Chu
John J. Costanzi
Thomas J. Cunningham
Rajendra G. Desai
Eugene R. DeSombre
George T. Diamandopoulos
Louis M. Fink
Thomas P. Fondy
Eiichi Furusawa
Phil Gold
Jordan U. Gutterman
Ingegerd Hellström
Susan Band Horwitz
Lucien Israel
George F. Kalf
David G. Kaufman
Philip Klubes

John M. Lehman
Maria C. Linder
Gerald Litwack
A. Macieira-Coelho
Henri Emile Maisin
J. Justin McCormick
Daniel Medina
Richard L. Momparler
Tetsuo Ono
Joseph S. Pagano
Beatriz G.T. Pogo
Aly A. Razek
Jerry M. Rice
Sheldon P. Rothenberg
D. S. R. Sarma
Hans Schreiber
Michael T. Shaw
Dilip Sinha
Chang W. Song
Gary S. Stein
Frej Stenback
John J. Stevens
James A. Swenberg
Glenn Tisman
Samuel Waxman
Samuel A. Wells
James L. Wittliff
Lauren G. Wolfe
Stuart H. Yuspa

The AACR is extremely pleased to recognize AACR’s Honorary Members. The AACR Board of Directors wish to convey their heartfelt thanks to the following individuals who have made extraordinary contributions to the advancement of cancer research, either through outstanding personal scientific activity or exceptional leadership in cancer research.

Hon. Joseph R. Biden, Jr.
HRH Princess Chulabhorn
Joseph F. Fraumeni, Jr.
Susan Band Horwitz
Hon. Connie Mack
James D. Watson
Harald zur Hausen
SUPPORTERS
Confirmed supporters as of March 15, 2023.

Special Thanks to
Distinguished Supporters of
AACR Annual Meeting 2023

AACR gratefully acknowledges the generous support of individuals and organizations whose funding has made the AACR Annual Meeting 2023 possible.

<table>
<thead>
<tr>
<th>CURE LEVEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Daiichi Sankyo, Inc.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PROGRESS LEVEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie Inc.</td>
</tr>
<tr>
<td>Loxo@Lilly</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PROMISE LEVEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACS Publications</td>
</tr>
<tr>
<td>American Brain Tumor Association</td>
</tr>
<tr>
<td>American Cancer Society</td>
</tr>
<tr>
<td>Amgen, Inc.</td>
</tr>
<tr>
<td>Astellas Pharma Inc.</td>
</tr>
<tr>
<td>Bayer</td>
</tr>
<tr>
<td>BeiGene</td>
</tr>
<tr>
<td>Breast Cancer Research Foundation</td>
</tr>
<tr>
<td>Cancer Research Institute</td>
</tr>
<tr>
<td>Change Our Future Fund</td>
</tr>
<tr>
<td>Chao Family Foundation</td>
</tr>
<tr>
<td>Doreen J. Putrah Cancer Research Foundation</td>
</tr>
<tr>
<td>Eisai Inc.</td>
</tr>
<tr>
<td>Exelixis, Inc.</td>
</tr>
<tr>
<td>Fondazione Pezcoller</td>
</tr>
<tr>
<td>Genentech, A Member of the Roche Group</td>
</tr>
<tr>
<td>Genmab</td>
</tr>
<tr>
<td>Gilead Oncology and Kite</td>
</tr>
<tr>
<td>GSK</td>
</tr>
<tr>
<td>Irving Weinstein Foundation</td>
</tr>
<tr>
<td>Janssen Pharmaceutical Companies of Johnson &amp; Johnson</td>
</tr>
<tr>
<td>Ludwig Cancer Research</td>
</tr>
<tr>
<td>Merck &amp; Co., Inc.</td>
</tr>
<tr>
<td>Novartis</td>
</tr>
<tr>
<td>Novocure</td>
</tr>
<tr>
<td>Pfizer, Inc.</td>
</tr>
<tr>
<td>Pharmacysclics, an AbbVie Company and Janssen Biotech, Inc.</td>
</tr>
<tr>
<td>Prostate Cancer Foundation</td>
</tr>
<tr>
<td>Regeneron</td>
</tr>
<tr>
<td>Sanofi</td>
</tr>
<tr>
<td>Science/AAAS</td>
</tr>
<tr>
<td>Seagen Inc.</td>
</tr>
<tr>
<td>St. Baldrick’s Foundation</td>
</tr>
<tr>
<td>Synature Discovery</td>
</tr>
<tr>
<td>Victoria’s Secret Global Fund for Women’s Cancers</td>
</tr>
</tbody>
</table>
The Scientific Program

FORUM
Dharma Master Jiantai Forum on Advances in Lung Cancer

MAJOR SYMPOSIA
AstraZeneca
Dharma Master Jiantai Symposium in Biomarkers
Dharma Master Jiantai Symposium in Targeted Therapy

REGULATORY SCIENCE AND POLICY TRACK
Bristol Myers Squibb

AACC Awards and Lectureships

AACC-AMERICAN CANCER SOCIETY AWARD FOR RESEARCH EXCELLENCE IN CANCER EPIDEMIOLOGY AND PREVENTION
American Cancer Society

AACC AWARD FOR OUTSTANDING ACHIEVEMENT IN BLOOD CANCER RESEARCH
Funding provided by an unrestricted educational grant from Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.

AACC-CANCER RESEARCH INSTITUTE LLOYD J. OLD AWARD IN CANCER IMMUNOLOGY
Cancer Research Institute

AACC GERTRUDE B. ELION CANCER RESEARCH AWARD
GSK

AACC-G.H.A. CLOWES AWARD FOR OUTSTANDING BASIC CANCER RESEARCH
Loxo@Lilly

AACC-IRVING WEINSTEIN FOUNDATION DISTINGUISHED LECTURESHIP
Irving Weinstein Foundation

AACC-JOSEPH H. BURCHENAL AWARD FOR OUTSTANDING ACHIEVEMENT IN CLINICAL CANCER RESEARCH
Bristol Myers Squibb

AACC-ST. BALDRICK'S FOUNDATION AWARD FOR OUTSTANDING ACHIEVEMENT IN PEDIATRIC CANCER RESEARCH
St. Baldrick’s Foundation

AACC TEAM SCIENCE AWARD
Loxo@Lilly

PEZCOLLER FOUNDATION-AACC INTERNATIONAL AWARD FOR EXTRAORDINARY ACHIEVEMENT IN CANCER RESEARCH
Fondazione Pezcoller

AACC OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH
Breast Cancer Research Foundation

AACC Runners for Research 5K Run/Walk Orlando

PRESENTING SPONSOR
AstraZeneca

INNOVATOR SPONSOR
Sidney Kimmel Cancer Center - Jefferson Health

ENTHUSIAST SPONSOR
Crown Bioscience
AACR Travel Grants and Scholar Awards

AACR MINORITY SCHOLAR IN CANCER RESEARCH AWARDS
Change Our Future Fund
Merck & Co., Inc.

THE MARGARET FOTI UNDERGRADUATE CANCER RESEARCH PRIZES
The Margaret Foti Foundation

AACR UNDERGRADUATE SCHOLAR AWARDS
American Association for Cancer Research Science/AAAS

Members of the AACR Science Education Committee
Brian M. Rivers, MPH, PhD
Kathleen W. Scotto, PhD
Beverly D. Lyn-Cook, PhD
John E. Leonard, MS, PhD
Sandra W. Ryeom, PhD
Jose G. Trevino, MD

AACR WOMEN IN CANCER RESEARCH SCHOLAR AWARDS
AstraZeneca
Victoria's Secret Global Fund for Women's Cancer

AACR SCHOLAR-IN-TRAINING AWARDS
AbbVie Inc.
American Association for Cancer Research
American Brain Tumor Association
Breast Cancer Research Foundation
Bristol Myers Squibb
Daiichi Sankyo, Inc.
Doreen J. Putrah Cancer Research Foundation
Fondazione Pezcoller
Ludwig Cancer Research
Prostate Cancer Foundation
Sanofi
Sygnature Discovery in Association with the CICR Working Group
The Estate of Dr. June L. Biedler
The Margaret Foti Foundation

AACR Scientific Working Groups

AACR CANCER IMMUNOLOGY WORKING GROUP
Bristol Myers Squibb

AACR CHEMISTRY IN CANCER RESEARCH WORKING GROUP
ACS Publications
Sygnature Discovery

AACR Annual Meeting 2023 Supporters

AACR ADVOCACY PARTNERS’ PAVILION
Pfizer, Inc.

AACR-G.H.A. CLOWES AWARD FOR OUTSTANDING BASIC CANCER RESEARCH RECEPTION
Loxo@Lilly

CHARGING STATIONS/LOUNGES
Daiichi Sankyo, Inc.

HOTEL KEY CARDS
AstraZeneca

ONLINE REGISTRATION
AstraZeneca
Daiichi Sankyo, Inc.
Genmab
Regeneron

PATIENT ADVOCACY POSTER SESSION
Pfizer, Inc.

POSTERS
Bristol Myers Squibb
Daiichi Sankyo, Inc.
PROFESSIONAL EDUCATIONAL GRANTS
AbbVie
Amgen
Astellas
AstraZeneca
Beigene
Daiichi- Sankyo
Eisai
Exelixis Inc.
Genentech
Gilead/Kite Pharma Inc.
GlaxoSmithKline
Incyte
Lilly
Merck
Novartis
Novocure
Pfizer
Seattle Genetics

AAcR SCIENTIST←SURVIVOR® PROGRAM
Bayer
Bristol Myers Squibb
Exelixis, Inc.
Genmab
Loxo@Lilly
Merck & Co., Inc.

SHUTTLE BUSES
Daiichi Sankyo, Inc.

SPECIAL PROGRAM FOR HIGH SCHOOL STUDENTS
Change Our Future Fund

AAcR WOMEN IN CANCER RESEARCH CONSTITUENCY GROUP (WICR)
AstraZeneca

Research Grants and Fellowships
AbbVie Inc.
Amgen, Inc.
AstraZeneca
Bayer
Breast Cancer Research Foundation
Bristol Myers Squibb
Conquer Cancer, the ASCO Foundation
Day One Biopharmaceuticals
Debbie’s Dream Foundation
Exelixis, Inc.
Genentech, A Member of the Roche Group
Genmab
GSK
Incyte Corporation
Johnson & Johnson
Lobular Breast Cancer Alliance
Lustgarten Foundation
Merck & Co., Inc.
Mirati Therapeutics, Inc.
MPM Oncology Charitable Foundation
Novocure
Ocular Melanoma Foundation
Party with a Purpose
Pelotonia
Pfizer, Inc.
Swim Across America
St. Baldrick’s Foundation
Takeda Pharmaceuticals, through their Center for Health Equity and Patient Affairs
The Bosarge Family Foundation
The John and Elizabeth Leonard Family Foundation
The QuadW Foundation
The Sontag Foundation
Triple Negative Breast Cancer Foundation
Victoria’s Secret Global Fund for Women’s Cancers
SUPPORTERS (cont’d)

Special Conference Supporters for 2022-2023
AbbVie Inc.
Adaptimmune Ltd.
Astellas Pharma Inc.
AstraZeneca
Daiichi Sankyo, Inc.
Delfi Diagnostics
Lobular Breast Cancer Alliance
Lustgarten Foundation
Mirati Therapeutics, Inc.
Novocure
Pancreatic Cancer Action Network
Pfizer, Inc.
Reaction Biology Corporation
Syros Pharmaceuticals
Verastem Oncology

Sustaining Members
LEADERSHIP SUSTAINING MEMBERS
AstraZeneca
Bayer
Boehringer Ingelheim International GmbH
Bristol Myers Squibb
Genentech, A Member of the Roche Group
Loxo@Lilly
Merck & Co., Inc.
Pfizer, Inc.
Takeda Pharmaceutical

STRATEGIC SUSTAINING MEMBERS
Amgen, Inc.
Eisai Inc.
Gilead Oncology and Kite
GSK
Incyte Corporation
Novocure
Pharmacyclics, an AbbVie Company

MAJOR SUSTAINING MEMBERS
Astex Pharmaceuticals, Inc.
Daiichi Sankyo, Inc.
Exelixis, Inc.
Fondazione Pezcoller
Genmab
Janssen Pharmaceutical Companies
of Johnson & Johnson
Jazz Pharmaceuticals
Novartis
Regeneron
Sanofi

ASSOCIATE SUSTAINING MEMBERS
Karyopharm
Mirati Therapeutics, Inc.
Qiagen
Servier
Verastem Oncology
Zai Lab
<table>
<thead>
<tr>
<th>Room Name</th>
<th>Location</th>
<th>Opens</th>
<th>Phone #</th>
</tr>
</thead>
<tbody>
<tr>
<td>AACR Office</td>
<td>Room W 222</td>
<td>Thursday, 6:00 a.m.</td>
<td>407-685-4005</td>
</tr>
<tr>
<td>AACR Exhibit Booth (AACR Central)</td>
<td>Exhibit Hall, Booth 443</td>
<td>Sunday, 1:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>AACR Amphitheater</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Associate Member Resource and Career Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Membership Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minorities in Cancer Research (MICR) Networking and Resource Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women in Cancer Research (WICR) Networking and Resource Center</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AACR Publications Booth</td>
<td>Exhibit Hall, Booth 2743</td>
<td>Sunday, 1:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>CancerCareers.org Center</td>
<td>West Lobby C</td>
<td>Sunday, 9:00 a.m.</td>
<td></td>
</tr>
<tr>
<td>CME Booth</td>
<td>West Lobby D</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>AACR Information Booth</td>
<td>West Lobby D</td>
<td>Friday, 12:00 p.m.</td>
<td>407-685-4006</td>
</tr>
<tr>
<td>Coat, Package, and Luggage Check</td>
<td>Level 1</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>West Lobby A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Child Care</td>
<td>Room W110A</td>
<td>Friday, 12:00 p.m.</td>
<td>407-685-4002</td>
</tr>
<tr>
<td>Exhibit Management Office</td>
<td>W Hall E</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>Exhibitor Lounge</td>
<td>W Hall B and W Hall E</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>Housing Booth (CMR)</td>
<td>West Lobby D</td>
<td>Friday, 12:00 p.m.</td>
<td>407-685-4007</td>
</tr>
<tr>
<td>First Aid Station</td>
<td>West Lobby C</td>
<td>Thursday, 7:00 a.m.</td>
<td></td>
</tr>
<tr>
<td>Membership Booth</td>
<td>West Lobby D</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>Membership Hub</td>
<td>West Lobby C</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>NCI/NIH Meeting Room</td>
<td>W314 B</td>
<td>Sunday, 9:00 a.m.</td>
<td></td>
</tr>
<tr>
<td>Nursing Suite</td>
<td>West Lobby B</td>
<td>Friday, 2:30 p.m.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>West Lobby C</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>West Lobby EF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prayer Room</td>
<td>Room W107</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>Press Office</td>
<td>Room W208</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>Registration</td>
<td>West Lobby D</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
<tr>
<td>AACR Scientist-Survivor Program® Room</td>
<td>Room W 308 CD</td>
<td>Sunday, 6:30 a.m.</td>
<td></td>
</tr>
<tr>
<td>Speaker Preparation Room</td>
<td>Room W221</td>
<td>Friday, 12:00 p.m.</td>
<td></td>
</tr>
</tbody>
</table>
Registration

Registration will be located in West Lobby D on the following schedule:

- **Friday, April 14**: 12:00 p.m.-7:00 p.m.
- **Saturday, April 15**: 7:00 a.m.-6:00 p.m.
- **Sunday, April 16**: 7:00 a.m.-6:00 p.m.
- **Monday, April 17**: 7:00 a.m.-6:00 p.m.
- **Tuesday, April 18**: 7:00 a.m.-6:00 p.m.
- **Wednesday, April 19**: 7:00 a.m.-12:00 p.m.

Exhibit Hall

The Exhibit Hall is located in Halls B-E1. Exhibit hours are:

- **Sunday, April 16**: 1:00 p.m.-5:00 p.m.
- **Monday, April 17**: 9:00 a.m.-5:00 p.m.
- **Tuesday, April 18**: 9:00 a.m.-5:00 p.m.
- **Wednesday, April 19**: 9:00 a.m.-12:30 p.m.

Housing

The AACR Housing Desk (CMR) will be available in the West Lobby D for individuals who need assistance with their accommodations. The Housing Desk will be open during the following hours:

- **Friday, April 14**: 12:00 p.m.-6:00 p.m.
- **Saturday, April 15**: 7:00 a.m.-6:00 p.m.
- **Sunday, April 16**: 7:00 a.m.-6:00 p.m.
- **Monday, April 17**: 7:00 a.m.-6:00 p.m.
- **Tuesday, April 18**: 7:00 a.m.-6:00 p.m.
- **Wednesday, April 19**: 7:00 a.m.-12:00 p.m.

Shuttle Bus Transporation

There is shuttle bus service between a number of hotels in the AACR block and the Orange County Convention Center (OCCC) outside Halls D-F. Shuttle bus service will operate on the following schedule in 10-15 minutes intervals until 10:00 a.m. and after 4:00 p.m. and in 30-minute intervals during mid-day hours unless otherwise noted:

- **Friday, April 14**: 11:30 a.m.-6:30 p.m. (30-minute intervals all day)
- **Saturday, April 15**: 6:30 a.m.-7:00 p.m.
- **Extended Saturday service**: 7:00 p.m. - 9:30 p.m. (30-minute intervals from OCCC to hotels only)
- **Sunday, April 16**: 6:30 a.m.-7:00 p.m. (15-minute intervals until 1:00 p.m.)
- **Extended Sunday service**: 7:00 p.m.-11:59 p.m. (Annual Reception return shuttle to hotels)
- **Monday, April 17**: 6:30 a.m.-7:00 p.m.
- **Extended Monday service**: 7:00 p.m. - 9:30 p.m. (30-minute intervals from OCCC to hotels only)
- **Tuesday, April 18**: 6:30 a.m.-7:00 p.m.
- **Extended Tuesday service**: 7:00 p.m. - 9:30 p.m. (30-minute intervals from OCCC to hotels only)
- **Wednesday, April 19**: 6:30 a.m.-7:00 p.m.
Please note that all shuttles depart from and arrive at the Orange County Convention Center outside Halls D-F. Attendees of events at the headquarters hotels must return to the Orange County Convention Center to obtain shuttle service. Shuttle schedules will be available at AACR block hotels and the Information Desk at the Convention Center in West Lobby D.

Membership

With over 54,000 members in over 130 countries and territories, the AACR comprises leaders and future leaders focused on every aspect of high-quality innovative cancer research. We firmly believe that our members play an integral part in achieving our mission.

Annual Meeting participants are invited to visit the Membership Hub (West Lobby C), the Membership Center (located in AACR Central), and the Membership Booth (Registration) to learn more about membership and the exclusive benefits available to members, join one or more association groups within the AACR, update contact information, pay membership dues, and more. AACR Dedicated Member emblems are also available on a first-come, first-served basis.

MEMBERSHIP HUB

The Membership Hub is a home base for AACR members to refresh, connect, and learn more about AACR’s events, programs, and activities, during the meeting. Attendees are encouraged to engage with colleagues from around the world, join Association Groups, become more involved in AACR programs and activities, and share member experiences. Not a member? Stop by the Hub and join!

MEMBERSHIP FOR EARLY-CAREER TRAINEES AND STUDENTS

The AACR is committed to the education, training, and professional development of early-career researchers, trainees, and students. Membership is FREE for graduate students, medical students, residents, postdoctoral or clinical fellows, undergraduate students, and high school students who are enrolled in education or training programs that could lead to a career in cancer research. Visit the Membership Hub, Membership Center at AACR Central, or Membership Booth (Registration) to learn more about this amazing opportunity to join our esteemed association.

AACR NEW MEMBER NETWORKING MIXER

The AACR is extremely pleased to host a New Member Networking Mixer each year to welcome newly elected members into the association and provide them with an opportunity to meet and interact with the AACR leadership, network with colleagues, and forge new relationships, and learn more about exclusive member benefits and how to get involved in the association. Visit the Membership Hub for more information.
MEMBER APPRECIATION BREAKFAST: CELEBRATING AACR LONG-TERM MEMBERS

The AACR is extremely pleased to recognize those scientists who have been long-term members of the association for 25 years and more. The AACR board of directors extends its sincere and heartfelt thanks to these members for their devotion to cancer research and long participation in and support of the AACR. Visit the Membership Hub for more information.

MEET THE 2023-2024 AACR PRESIDENT, PHILIP D. GREENBERG, MD, FAACR

The Meet the 2023-2024 AACR President event provides an opportunity for AACR members and Annual Meeting attendees to meet informally with the 2023-2024 AACR President, Dr. Philip D. Greenberg, to congratulate him on his presidency and ask general questions. Join us Tuesday, April 18, 1:30-2:30 p.m. in the AACR Central Amphitheater (Exhibit Booth 443).

AACR Annual Meeting Information Booth

The AACR Annual Meeting Information Booth is located in West Lobby D. It will be open during session hours to provide information about the AACR, the AACR Annual Meeting, and the city of Orlando. Staff members will be available to assist you with city and convention center maps, shuttle bus schedules, and information on AACR’s programs.

Professional Advancement Series

Professional Advancement Series of sessions are organized to provide important skills to investigators at all levels, from junior faculty to high school students. These sessions are an exclusive benefit for AACR members. For all Professional Advancement Sessions, attendance is free for members with your Annual Meeting registration. The Professional Advancement Series of sessions are organized in a collaborative effort between the Associate Member Council (AMC), Minorities in Cancer Research (MICR) Council, Women in Cancer Research (WICR) Council, and the AACR Science Education and Career Advancement Committee.

Space is limited, and participation by AACR members for all sessions is available on a first-come, first-served basis, except for the Personalized Career Conversations and Productive Peer Review sessions which require advance registration.

Speaker Preparation Room

Speakers should visit the Speaker Preparation Room located in Room W221 of the Convention Center at least four hours before their sessions begin to test their presentations. The Speaker Preparation Room will be open on Friday, April 14, from 12:00 p.m. to 6:30 p.m., daily during the meeting from 6:30 a.m. to 6:30 p.m., and will close on Wednesday, April 19, at 12:00 p.m. Please note: Speakers in sessions located in hotels should not check in at the Speaker Preparation Room. Speakers in hotel sessions should arrive at the session room 30 minutes prior to the start of the session and check in with the AV technician...
to upload and test presentations. Speakers cannot use personal laptops in any session rooms.

**Press Relations**

The AACR Press Office is located in Room W208 of the Convention Center. It will be open from 12:00 p.m. to 6:00 p.m., Friday, April 14; 7:30 a.m. to 6:00 p.m., Saturday, April 15 through Tuesday, April 18; and 7:30 a.m. to 12:00 p.m., Wednesday, April 19. The AACR’s press contacts are Kathleen Venango, Manager of Public Relations, 215-290-5408, kathleen.venango@aacr.org; Julia Gunther, Director of Public Relations, 770-403-7690, julia.gunther@aacr.org; and Rick Buck, Chief Communications Officer, 856-562-5668, rick.buck@aacr.org.

**Child Care**

Professional childcare services, administered by KiddieCorp, will be in Room W110A of the Convention Center on the following schedule:

- **Friday, April 14**: 12:00 p.m.-6:30 p.m.
- **Saturday, April 15**: 7:00 a.m.-6:30 p.m.
- **Sunday, April 16**: 6:30 a.m.-7:00 p.m.
- **Monday, April 17**: 6:30 a.m.-7:00 p.m.
- **Tuesday, April 18**: 6:30 a.m.-7:00 p.m.
- **Wednesday, April 19**: 6:30 a.m.-1:30 p.m.

As a convenience for registrants, the AACR will cover the cost of this service. Snacks and beverages are included, but meals must be provided by parents/guardians. Medication will NOT be administered by KiddieCorp. To ensure a safe and fun-filled environment, any child who is ill will not be admitted to the children’s program, and the AACR will follow all CDC recommendations for our COVID-19 policies at the AACR Annual Meeting. Advance registration was recommended. On-site registration will be permitted as space allows.

**Nursing Mothers Suites**

Annual Meeting participants who are also nursing mothers will find the built-in Wellness Rooms at the Orange County Convention Center to be a private, comfortable, and secure environment. AACR-Women in Cancer Research (WICR) is pleased to sponsor this important service again in 2023. There are three Wellness Rooms in the Convention Center, one located in the West Lobby B area on Level One, one in West Lobby C, and one in West Lobby EF, both of which are on level 2. Hours for the Nursing Mothers Suites are as follows:

- **Friday, April 14**: 12:00 p.m.-7:00 p.m.
- **Saturday, April 15**: 7:00 a.m.-6:00 p.m.
- **Sunday, April 16**: 6:30 a.m.-6:00 p.m.
- **Monday, April 17**: 6:30 a.m.-6:00 p.m.
- **Tuesday, April 18**: 6:30 a.m.-6:00 p.m.
- **Wednesday, April 19**: 6:30 a.m.-12:00 p.m.
Satellite Educational Symposia

The Satellite Educational Symposia will be held in conjunction with the AACR Annual Meeting. These CME-accredited events are supported by parties other than AACR and are not part of the official program of the AACR Annual Meeting. Symposia are evaluated by the Satellite Educational Symposia Committee to ensure that the educational content will enhance that provided by the official AACR scientific program. Additional information can be found at the specially marked counter located in the Registration area.

To view more information or register for any of these symposia, visit AACR.org/satellite23.

A New Era of Early-Stage Cancer Care: A Think Tank Discussion on the Clinical Impact of Pathologic Response to Immunotherapy
Saturday, April 15 | 6:30 p.m.-9:00 p.m.
Grand Ballroom B, Rosen Centre Hotel

Designing and Using Antibody-Drug Conjugates to Treat Solid Tumors
Saturday, April 15 | 6:30 p.m.-8:15 p.m.
Grand Ballroom A, Rosen Centre Hotel

The Advancing Role of PARP Inhibitor Combination Therapies to Improve Outcomes for Patients with mCRPC
Sunday, April 16 | 6:30 p.m.-8:30 p.m.
Grand Ballroom A, Rosen Centre Hotel

Targeting TROP2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors
Sunday, April 16 | 6:30 p.m.-9:00 p.m.
Grand Ballroom B, Rosen Centre Hotel

Exhibitor Spotlight Theaters

Located in the Exhibit Hall, W Hall D, the Exhibitor Spotlight Theaters have been reserved by exhibiting companies to present special one-hour sessions during exhibit hours. For a full list of presentations taking place in Spotlight Theaters A, B, C, D, and E, please refer to the Annual Meeting App.

Explore!

Explore! is a fun way attendees can interact with exhibitors while entering a drawing for $250 Amazon gift cards. Download the AACR Annual Meeting App. Scan the QR codes when visiting participating exhibitors and special locations for a chance to win, courtesy of the AACR. Get out there, visit the exhibitors, and Explore! Winners will be notified after the meeting and prizes will be mailed shortly thereafter.

Headshot Lounge

Need a new headshot? Don’t forget to stop by the Headshot Lounge, supported by AstraZeneca, located in the Exhibit Hall, Booth 2875. Professional photographers will be available to provide you with the perfect headshot for your next business card, resume, etc. Receive access to your digital headshot and share on social media.
Charging Stations/Lounges

Located in the Exhibit Hall and Convention Center lobby, these charging lounges, supported by Daiichi Sankyo, provide attendees ample opportunity to charge their devices and take a well-deserved break during the meeting. Bring your cords, grab a snack, sit and relax.

Wellness Lounge

Stop by our Wellness Lounge Supported by AstraZeneca in the Exhibit Hall, Booth 3379 to relax, sit back and take a much need respite. Therapy Dogs provided by Orlando Health will be available in the afternoons Sunday through Tuesday from 1:00 p.m.-5:00 p.m. Seated hand or neck massages will be available during Exhibit Show hours. Make this lounge a must visit while visiting with exhibitors.

Enhanced Refreshment Breaks

Don’t miss the Refreshment Breaks in the Exhibit Hall on Monday, April 17 and Tuesday, April 18, starting at 1:30 p.m. Light snacks and coffee will be available. Strategically located food and beverage stations are the ideal platform for interaction between attendees and exhibitors.

Food Court and Coffee Breaks

Coffee breaks are located throughout the Exhibit Hall. Grab a cup while you walk the aisles and engage with exhibitors. Additionally, in the back of the exhibit hall, you will find two food courts, with ample seating. Take a break for lunch in the Exhibit Hall. A variety of food outlets will be available. All food and beverage outlets in the Orange County Convention Center are credit card only. No cash is accepted.

AACR Shop

Located in W Hall B1 Lobby

Stop by the AACR Shop, located just outside of the Exhibit Hall. Shop new items for yourself or souvenirs for loved ones.

**Operational Hours:**
- Saturday, April 15: 1:00 p.m.-5:00 p.m.
- Sunday, April 16: 1:00 p.m.-5:00 p.m.
- Monday, April 17: 9:00 a.m.-5:00 p.m.
- Tuesday, April 18: 9:00 a.m.-5:00 p.m.
- Wednesday, April 19: 9:00 a.m.-12:00 p.m.

AACR Central

AACR Central serves as a hub for information and services for attendees and also as an event space for various programs. Open during Exhibit Hall hours, AACR Central is located centrally in the Exhibit Hall and is home to the Amphitheater, Membership Center, MICR Networking and Resource Center, WICR Networking and Resource Center, and information kiosks covering: Scientific Meetings and Workshops; AACR Foundation; AACR Publications; Scientific Review and Grants Administration; Science Policy and Advocacy; and much more.
At AACR Central, attendees can:

- Apply for AACR membership, learn more about AACR member benefits, and check on the status of membership.

- Participate in events organized by the Associate Member Council (AMC), Minorities in Cancer Research (MICR), Women in Cancer Research (WICR), the Science Education and Career Advancement Committee, and others.

- Find additional information on AACR’s conferences, award programs, advocacy efforts, and the AACR Foundation.

- Pick up copies of Cancer Today, AACR’s peer-reviewed journals, the AARC Cancer Progress Report, the AARC Cancer Disparities Progress Report, and Leading Discoveries magazine.

Cancer and Biomedical Research Career Fair

The 2023 Cancer and Biomedical Research Career Fair is coming to Orlando, on Saturday, April 15, from 9:00 a.m. to 3:00 p.m. in W Hall C of the Orange County Convention Center. Building upon the success of AACR’s previous Career Fairs, the 2023 Career Fair will provide many opportunities for both job seekers and employers. The Career Fair will once again bring job seekers with highly specialized scientific skills (basic and translational researchers, clinicians, and epidemiologists) together with recruiters and potential employers representing academia, cancer centers, government, and industry. Employers will be able to speak with early-career scientists as well as more experienced scientists during the Career Fair and throughout the Annual Meeting inside the CancerCareers.org Center, located on level 1, West Lobby C of the Convention Center. Registration for the Career Fair is free to job seekers. Upload your CV/ resume on CancerCareers.org (https://www.cancercareers.org/profiles/sign_up) and search and apply for positions.

Annual Reception

All Annual Meeting registrants are invited to attend the Annual Reception on Sunday evening, April 16, from 8:30 p.m. to 11:30 p.m. in the Regency Ballroom of the Hyatt Regency Orlando. Complimentary light refreshments will be served, and a live band will provide music for dancing. Each registrant will receive a voucher for a complimentary beverage at the Annual Reception with their registration materials. On Sunday evening, shuttle buses will run extended hours from 8:30 p.m. to 11:30 p.m. At the conclusion of the reception, attendees must walk to the Convention Center to ride the shuttle to the AACR Hotels. Shuttle schedules will be posted in each hotel.

Associate Member Meet and Greet

Sunday, April 16 | 8:00 p.m.-9:30 p.m.
Orlando L, Hyatt Regency

Hosted by the AACR Associate Member Council (AMC), join fellow Associate members for an informal meet and greet and network with other early-career attendees; obtain information about programs, events, and initiatives specifically
for Associate members both at the conference and throughout the year; and meet with those representatives who are advocating to the AACR on behalf of the needs and concerns of graduate students, medical students and residents, and clinical and postdoctoral fellows. Take advantage of some exciting promotions that will be available only for those who stop by this informal pop-up space and connect with other early-career attendees throughout the reception!

**NCI/NIH Meeting Room**

The NCI/NIH Meeting Room, located in Room W314 B of the Convention Center, provides researchers with the opportunity to interact with NCI and NIH Program Staff. Program and Review staff from the NCI as well as Review staff from CSR attend the Annual Meeting and can be available at the Meeting Room for discussions and consultation throughout the conference.

Researchers interested in speaking with their Program Directors were encouraged to contact them ahead of the AACR Annual Meeting to arrange a time to meet at the NCI Meeting Room and discuss individual grant/review questions. New investigators are especially encouraged to meet with Program staff handling grant portfolios in their area of scientific interest.

The Meeting Room will be open from 9:00 a.m. to 5:00 p.m. Sunday through Tuesday and from 9:00 a.m. until 12:00 p.m. on Wednesday.

**AACR Scientist↔Survivor Program®**

Now celebrating its 25th Anniversary, the AACR Scientist↔Survivor Program® (SSP) is an education program for patient advocates. Led admirably since its inception by Anna D. Barker, PhD, FAACR, of the Lawrence J. Ellison Institute for Transformative Medicine, SSP is designed to build enduring partnerships among the leaders of the scientific, cancer survivor, and patient advocacy communities worldwide.

The unique AACR Annual Meeting SSP provides an opportunity for patient advocates and researchers to discuss the latest findings in cancer research, foster collaborative interdisciplinary partnerships, and promote progress in new research areas in the cancer field. Advocates benefit from special scientific lectures; stimulating small group discussions; and other opportunities to exchange information on key aspects of cancer research, survivorship, advocacy, and public policy.

To learn more about patient advocacy in cancer research, please visit the AACR Scientist↔Survivor Program® Poster Sessions on Monday, April 17, from 1:30 p.m. to 5:00 p.m. and Tuesday, April 18, from 9:00 a.m. to 12:30 p.m. in the Poster and Exhibit Hall. To learn more about the AACR Scientist↔Survivor Program®, please visit [AACR.org/SSP2023](http://AACR.org/SSP2023) or email advocacy@aacr.org.
AACR Advocacy Partners’ Pavilion

Visit the Advocacy Partners’ Pavilion, supported by Pfizer, Inc., located in the front of Exhibit Hall (W Hall B-E1), to learn more about nonprofit patient advocacy organizations focused on supporting patients with cancer and meet patient advocates who are leading the fight against cancer.

AACR Foundation

Join us for the 2023 AACR Runners for Research 5K Run/Walk on Saturday, April 15. Each year, our signature event kicks-off the AACR Annual Meeting, bringing together a community of scientists, patient advocates, healthcare professionals, and others to support the AACR’s mission to prevent and cure cancer. We hope that you will join us with your friends, family, and colleagues; it is a great way to engage in a healthy lifestyle activity while supporting cancer research.

This year’s 5K Run/Walk will start and finish at the Orange County Convention Center South Concourse.

To register and learn more about this event, visit AACR.org/5K.

To learn about all the AACR Foundation activities and how you can get involved, stop by the AACR Foundation kiosk located in AACR Central in the Exhibit Hall.

ONLINE ITINERARY PLANNER AND AACR ANNUAL MEETING APP

The Annual Meeting program is subject to change. Updates will be available in the online Itinerary Planner and the Annual Meeting App, along with full session details, including complete titles, author listings, and text for abstracts in poster sessions and minisymposia. To access the Itinerary Planner and download the Annual Meeting App, visit AACR.org/AACR2023.

Virtual Meeting Platform

Both in-person and virtual registration packages for the AACR Annual Meeting 2023 include access to live sessions, Q&A, networking, CME/MOC credits, and more. In-person registrants also receive complimentary access to the virtual meeting platform. Access to the Educational Sessions and Methods Workshops scheduled for Friday and Saturday, April 14 and 15, require the separate purchase of an AACR Educational Program Pass. Sessions that take place in hotels will not be included on the virtual meeting platform. Access to the virtual meeting will begin on April 14, 2023, and will run through July 19, 2023. For more information and to access the virtual meeting platform, visit AACR.org/AACR2023.
Coat and Luggage Check

Coat, package, and luggage check service will be available in Level 1, West Lobby A on the following schedule:

- Friday, April 14: 12:00 p.m.-7:00 p.m.
- Saturday, April 15: 6:30 a.m.-7:00 p.m.
- Sunday, April 16: 6:30 a.m.-8:30 p.m.
- Monday, April 17: 6:30 a.m.-7:00 p.m.
- Tuesday, April 18: 6:30 a.m.-7:00 p.m.
- Wednesday, April 19: 6:30 a.m.-3:00 p.m.

SPECIAL ACCOMMODATIONS FOR ATTENDEES

The American Association for Cancer Research recognizes the importance of making its educational activities available to all interested participants of the professional medical community. This AACR educational activity is designed to accommodate all attendees and fully complies with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Registrants in need of auxiliary learning aids or special requirements for hotel accommodations, transportation, or other facilities connected with this meeting should contact the AACR Office in Room W222 of the Convention Center.

Code of Conduct, Policies, and Procedures

The AACR Annual Meeting 2023 will bring together academics, scientists, pharmaceutical industry representatives, and others from across the globe. In order for all participants to have the opportunity to gain the most benefit from this conference, the AACR is committed to providing a safe and secure environment. Please review the following policies and procedures for conference participants. By registering for the AACR Annual Meeting 2023, you agree to the following terms:

- The AACR prohibits intimidating, threatening, or harassing conduct of any kind during this program. This applies to all participants—attendees, presenters, exhibitors, staff, vendors, etc.
- The AACR is committed to a safe, hospitable, and productive environment for all participants of this program, regardless of age, disability, ethnicity, gender, religion, or sexual orientation.
- The AACR expects all participants to communicate professionally and constructively, handling dissent and disagreement with courtesy, dignity, and an open mind, being respectful when providing feedback and being open to alternate points of view.
- Children under 12 years of age are not permitted in any scientific session, poster session, the Exhibit Hall, or any official event taking place at this program at any time. Children cannot be left unattended or unsupervised in the Convention Center.
- Cell phones and other electronic devices must be turned off or placed on “silent” mode before entering a session. Participants should step out of session rooms to make calls or send emails or...
texts as the back lighting on electronic devices is distracting to other participants.

- The AACR expects participants to share information about this program responsibly and clearly distinguish individual opinion from fact.

- Participants must obey all applicable laws and regulations of the relevant government authorities while attending this program. Participants must comply with all applicable safety guidelines related to the conference venue.

- If a session room becomes too crowded, the AACR asks you to follow instructions provided by the AACR staff, Convention Center staff, or security. Instructions may include not standing against the walls, not blocking the aisles or doors, or being denied entry if the room becomes too crowded. The AACR and all participants are obligated to abide by the guidelines established by the Fire Marshal in the Convention Center. If a room reaches full capacity and there is not full cooperation, the Fire Marshal has the authority to delay or terminate the conference.

- The AACR encourages responsible drinking for those drinking alcohol. Beer and wine will be offered at some official events throughout this program. Alcohol will not be served to anyone under the age of 21. Alcoholic beverages are allowed in specific areas and must not be taken out of these areas.

COVID POLICY

The health and safety of AACR Annual Meeting participants, as well as the patients and communities we serve, are among AACR’s highest priorities. By attending the AACR Annual Meeting 2023, you agree to abide by the AACR Annual Meeting COVID-19 policy, which is posted on the AACR website. Please visit AACR.org/AACR2023 for details.

Photography and Social Media Policies

Photography. Conference attendees may take photographs during oral or poster presentations provided that the photographs are strictly for personal, noncommercial use and are not to be published in any form. Attendees are prohibited from using flash photography or otherwise distracting the presenters or members of the audience.

Social Media. Conference attendees may share information from presentations on social media provided that they respect the wishes of presenters. Oral presenters may label any or all slides in their presentations with “DO NOT POST.” Similarly, poster presenters may label their posters with “DO NOT POST.” Attendees must respect the presenters’ requests in these instances and refrain from posting any images from these designated slides or posters on social media.
Emergency Response Procedures

There is a first aid office located in West Lobby C of the Orange County Convention Center.

If an emergency occurs, immediately call the Orange County Convention Center Security at 407-685-1119 (or 5-1119 from a house phone). They will contact the Orange County Police Department at the 9-1-1 Center via their direct line. Do not contact 9-1-1 yourself.

No Smoking Regulation

Smoking is prohibited in all areas of the Convention Center and at sessions and social events held in other venues.

Notice of Photographer and Videographer on Premises

A professional photographer and videographer may be on-site to document AACR Annual Meeting events and activities between April 14 and 19, 2023. Photographs and video footage are the sole property of AACR. By registering for and attending these events, attendees understand that AACR may use their likenesses for future promotional purposes. If you do not wish to be photographed, please notify the photographer and/or videographer on site.

Continuing Medical Education (CME)

ACCREDITATION STATEMENT

The American Association for Cancer Research® (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

CREDIT DESIGNATION STATEMENT

AACR has designated the AACR Annual Meeting 2023 live activity for a maximum of 402.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

CLAIMING CME CREDIT

Credit Survey

All individuals requesting continuing medical education credits must complete a CME Request for Credit Survey by Thursday, June 1, 2023. The Request for Credit Survey will be accessible by logging into the AACR Annual Meeting 2023 Program Planner and via email. Registrants log on using their registration number and last name.

General instructions for claiming CME/CE credit

If you built a “My Itinerary” schedule, from “My Itinerary” click on “Add all eligible Sessions to Credit Cart”.
GENERAL INFORMATION (cont’d)

If you did not build a “My Itinerary” schedule, add the sessions you attended by browsing sessions by day, by session category, or by session. Click the “Add to Cart” icon to the right of each CME eligible session. (Note: non-CME sessions will not have this “Add to Cart” option.)

Print CME Certificate
Print your CME Certificate by clicking “CME Certificates” on the menu at right.

ABIM MOC STATEMENT

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 402.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive ABIM MOC, participants must complete all questions in the CME Request for Credit Survey and claim CME credit hours. Please then select “Request MOC Points Here” on the bottom right side of the screen. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

STATEMENT OF EDUCATIONAL NEED, TARGET AUDIENCE, AND LEARNING OBJECTIVES

The fight against cancer is rapidly progressing with the accelerating pace of discoveries in the basic, translational, and clinical sciences. This is due in large part to the advent of new technologies, such as advanced live imaging techniques and liquid biopsies, and our increased understanding of the importance of harnessing the power of the immune system to develop new immunotherapies. However, understanding and combating the processes of cancer initiation, progression, and response to treatment require a convergence of various disciplines. The AACR Annual Meeting brings together cancer biologists, clinical oncologists, and population scientists with engineers, computational biologists, and physical scientists to develop quantitative approaches and ask new questions to develop better strategies for curing cancer. By bridging the gap between what physicians understand about cancer biology and the clinical applications, this meeting aids basic researchers, physicians, and clinician-scientists in obtaining, synthesizing, and integrating the most current molecular-based tests to aid in the diagnosis, treatment, and prevention of cancer. Further, facilitating the interface between physicians and scientists increases the contributions of laboratory research to drug development as well as patient care, transforms the design and conduct of clinical research protocols, and creates an avenue for the rapid translation of laboratory research findings from “bench-to-bedside” for the benefit of improving patient outcomes. This meeting also acts as a forum to discuss cancer disparities and help ensure that all patients benefit from emerging breakthroughs in research and cancer treatment.
Despite the tremendous progress in the field, cancer continues to be a global public health challenge, accounting for about 1,670 deaths per day around the world. In the United States (U.S.) alone, it is predicted that 609,360 people will die from some form of cancer in 2022, making it the second most common cause of death after heart disease. One of the challenges we face is that cancer comprises more than 200 different diseases. For many of the most common cancers in the U.S.—including lung, thyroid, bladder, ovarian, and colorectal cancer—incidence has been declining for more than a decade. However, incidence of other forms of cancer—including breast, renal, pancreatic, endometrial, liver, and melanoma—has been on the rise. Incidence, diagnosis, access to treatment, and survival rates are also impacted by the cancer disparities that exist in certain segments of the U.S. population, with older and underprivileged populations often witnessing higher incidences of cancer and mortality.

The AACR Annual Meeting historically brings together over 22,000 investigators from the basic, translational, and clinical disciplines and provides them with a venue to discuss their recent advances, test new hypotheses, and establish new collaborations. To provide the most advanced technologies and treatments, it is critical to bridge the gap between physicians who are answering fundamental questions about cancer biology, clinicians who are applying the latest diagnostics and treatment strategies to patient care and the basic, translational, population and computational scientists who are striving to recognize and eliminate cancer disparities. As the incidence of cancer continues to increase, the fields of cancer prevention, advanced detection, and early interception offer unprecedented opportunities to decrease the worldwide burden of cancer.

After participating in this CME activity, participants will be able to:

1. Assess the technological advances and tools, such as liquid biopsies and single-cell techniques, being used to accelerate progress in cancer research and improve early detection and early interception, with the ultimate goal of extending patients’ lives and improving their quality of life.

2. Articulate how real-world evidence is informing precision cancer medicine and leading to improved patient outcomes.

3. Incorporate the latest research findings regarding therapies and treatment options, including immunotherapy and combination therapies, in a variety of cancer types to improve patient outcomes.

4. Evaluate the impact of tumor evolution in developing resistance to therapy and exploit tumor heterogeneity to design improved strategies for cancer prevention, interception, and treatment.

5. Identify factors that impact the diagnosis, treatment, and prevention of various forms of cancers in patients from diverse populations and contribute to reducing cancer disparities.

6. Develop collaborations among physicians, researchers, and clinician-scientists to advance approaches for cancer treatment and prevention and support survivors.
DISCLOSURE STATEMENT

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about their financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated.

ACKNOWLEDGMENT OF FINANCIAL OR OTHER SUPPORT

This activity is supported by Professional Educational Grants and will be disclosed at the activity.

QUESTIONS ABOUT CME?

Please contact the Office of CME at 215-440-9300 or cme@aacr.org.
Hyatt Regency Orlando
CONVENTION LEVEL

MAPS (cont’d)
SCAN HERE TO ACCESS THE EXHIBITOR DIRECTORY
Orange County Convention Center
WEST CONCOURSE LEVEL 3 EAST
Orange County Convention Center
WEST CONCOURSE LEVEL 3
Orange County Convention Center
WEST CONCOURSE LEVEL 4
FRIDAY, APRIL 14*

Professional Advancement Session • 12:00 p.m.–4:00 p.m.
NOT ELIGIBLE FOR CME CREDIT

W Hall E2, Convention Center
GRANT WRITING WORKSHOP:
TIPS FOR SUCCESS FROM EXPERIENCED SCIENTISTS

Cochairs: Oliver Bogler, Bethesda, MD; Victoria L. Seewaldt, Duarte, CA; Sanya A. Springfield, Rockville, MD; Kristin G. Anderson, Seattle, WA

Educational Sessions • 3:00 p.m.–4:30 p.m.

Room W311 E-H, Convention Center
FROM THE PATIENT VOICE TO THE FDA, EARLY PHASE CLINICAL TRIALS

Chair: Amylou Dueck, Scottsdale, AZ
3:00 p.m. What item banks and item libraries contribute to gathering patient experience in early phase trials. David Cella, Evanston, IL
3:30 p.m. Incorporating patient reported outcomes in dose-finding clinical trials. Shing M. Lee, New York, NY
4:00 p.m. Statistical analysis and visualization of patient-reported outcomes in early phase trials. Amylou Dueck, Scottsdale, AZ

Room W312, Convention Center
HOW CAN WE REALIZE THE PROMISE OF NOVEL TECHNOLOGIES FOR EARLY CANCER DETECTION?

Chair: Timothy R. Rebbeck, Boston, MA
3:00 p.m. Developing realistic expectations for new cancer screening tests. Ruth D. Etzioni, Seattle, WA
3:30 p.m. Can novel cancer early detection tests achieve equity in benefit for all? Timothy R. Rebbeck, Boston, MA
4:00 p.m. Policy and guideline needs for effective cancer detection test impact. Robert A. Smith, Atlanta, GA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
LOOKING FOR THE ACHILLES HEEL: PHENOTYPIC SCREENING AS AN ENGINE IN CANCER DRUG DISCOVERY

**Chair:** Mathew Garnett, Cambridge, United Kingdom

3:00 p.m. **Phenotypic screening: Why, when, and how?** Fabien Vincent, Groton, CT

3:30 p.m. **High content phenotypic and pathway profiling identifies novel drug mechanisms-of-action tailored towards cancers of unmet need.** Neil Carragher, Edinburgh, United Kingdom

4:00 p.m. **Functional genomics as an enabling tool for phenotypic screening.** Mathew Garnett, Cambridge, United Kingdom

SEX-BIASED ACTION OF TARGETED AGENTS

**Chair:** Joshua B. Rubin, St. Louis, MO

3:00 p.m. **Translation of cancer sex differences into clinical practice.** Joshua B. Rubin, St. Louis, MO

3:30 p.m. **Impact of sex-based differences on the efficacy of immune checkpoint inhibitors: Critical analysis of data available, missing evidence, and misinterpretations.** Fabio Conforti, Bergamo BG, Italy

4:00 p.m. **Sex hormone signaling in melanoma.** Todd W. Ridky, Philadelphia, PA

THE BACTERIAL-CANCER AXIS: WHAT DOES IT MEAN?

**Chair:** Dominique S. Michaud, Boston, MA

3:00 p.m. **Using population studies to address the role of bacterial dysbiosis and immunity in cancer risk.** Dominique S. Michaud, Boston, MA

3:30 p.m. **Microbiota mediated anti-cancer immunity.** June L. Round, Salt Lake City, UT

4:00 p.m. **Monitoring and modulating the microbiome in the setting of cancer therapy.** Carrie R. Daniel-MacDougall, Houston, TX
THE DARK SIDE OF OUR TREATMENTS: THERAPY-INDUCED COMORBIDITIES

Chair: Stefanie Geisler, St. Louis, MO

3:00 p.m. Clinical aspects of chemotherapy-induced neurotoxicity. Nathan P. Staff, Rochester, MN

3:30 p.m. Chemotherapy-induced neuropathy: From bedside to bench and back. Stefanie Geisler, St. Louis, MO

4:00 p.m. Tri-glia dysregulation of cancer therapy-related cognitive impairment. Erin Gibson, Stanford, CA

TUMOR CELL ADAPTABILITY AND STRESS RESPONSE

Chair: Nadine Hempel, Pittsburgh, PA

3:00 p.m. Oxidative stress adaptations during metastasis: Focus on antioxidant enzyme function and regulation. Nadine Hempel, Pittsburgh, PA

3:30 p.m. Sensitizing quasi-mesenchymal breast cancer cells to immune checkpoint blockade therapy by targeting hypoxia-adenosinergic signaling. Anushka Dongre, Ithaca, NY

4:00 p.m. Tumor cell adaptation to nutrient stress. Gina M. DeNicola, Tampa, FL

Methods Workshops • 3:00 p.m.–4:30 p.m.

AI/ML APPROACHES IN TRANSLATIONAL RESEARCH

Chair: Carlos M. Caldas, Cambridge, United Kingdom

3:00 p.m. Building a mind for cancer. Trey Ideker, La Jolla, CA

3:30 p.m. Adventures and misadventures in ML for molecular oncology: Selected case studies. Ash A. Alizadeh, Stanford, CA

4:00 p.m. Machine learning and multi-omics to deliver precision cancer medicine 2.0. Carlos M. Caldas, Cambridge, United Kingdom

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Room W311 A-D, Convention Center

ENGINEERED MODEL SYSTEMS FOR CANCER RESEARCH:
A FOCUS ON FLUID FLOWS AND MATRIX ORGANIZATION

Chair: Stephanie Irene Fraley, La Jolla, CA

3:00 p.m. Collagen architecture drives collective invasion by impinging on iron regulation. Stephanie Irene Fraley, La Jolla, CA

3:30 p.m. Engineering patient-informed cellular models of glioblastoma for therapeutic testing. Jennifer Munson, Roanoke, VA

4:00 p.m. Engineered systems for disease modeling enable next-generation approaches in cancer immunotherapy. Susan N. Thomas, Atlanta, GA

Educational Sessions • 4:45 p.m.–6:15 p.m.

Room W224, Convention Center

CHEMISTRY TO THE CLINIC: PART 1 OF 3: THE NEXT GENERATION OF ANTIBODY DRUG CONJUGATES

Chair: Peter S. Dragovich, South San Francisco, CA

4:45 p.m. Recent progress in the optimization of antibody-drug conjugates as novel cancer therapies. Peter S. Dragovich, South San Francisco, CA

5:15 p.m. Immunostimulatory payloads and novel technologies for antibody-drug conjugates. Marc I. Damelin, Cambridge, MA

5:45 p.m. Considerations for non-oncology antibody-drug conjugates. Adrian D. Hobson, Worcester, MA

Room W311 A-D, Convention Center

EMERGING VULNERABILITIES OF TUMOR-SPECIFIC CELL DEATH PATHWAYS

Chair: Daisuke Nakada, Houston, TX

4:45 p.m. Targeting ferroptosis vulnerability in cancer. Boyi Gan, Houston, TX

5:15 p.m. Lighting a fire: Can activating pyroptosis and other innate immune pathways ignite tumor immunity? Judy Lieberman, Boston, MA

5:45 p.m. Emerging metabolic vulnerability of cancer. Daisuke Nakada, Houston, TX
FRIDAY, APRIL 14* | Educational Sessions (cont’d)

Tangerine Ballroom 1 (WF1), Convention Center
FOLLOW THE LEADER: TUMOR CELLS DRIVE INVASION AND METASTASIS THROUGH COLLABORATION

Chair: Huiping Liu, Chicago, IL

4:45 p.m. Solo or orchestra: Machine learning-assisted elucidation of circulating tumor stem cells in metastasis. Huiping Liu, Chicago, IL

5:15 p.m. Studying tumor dormancy and metastasis in immune-competent settings. Cyrus M. Ghajar, Seattle, WA

5:45 p.m. Collaboration between tumor cells and the inflammatory environment of distant organ drives metastasis by impairing effector immune cell deployment. Erwei Song, Guangzhou, China

Room W331, Convention Center
HOLD THAT SQUAT: EXERCISING TO BETTER CANCER OUTCOMES

Chair: Lindsay L. Peterson, St. Louis, MO

4:45 p.m. Metabolism to microenvironment: Mechanisms of exercise in cancer outcomes. Lindsay L. Peterson, St. Louis, MO

5:15 p.m. Resistance exercise is medicine: Application to improve health and cancer outcomes. Christina M. Dieli-Conwright, Boston, MA

5:45 p.m. Impact of aerobic exercise on cancer outcomes. Kristin Campbell, Vancouver, BC, Canada

Tangerine Ballroom 2 (WF2), Convention Center
LIQUID BIOPSIES FOR DETECTION AND MONITORING: CHALLENGES AND OPPORTUNITIES

Chair: Muhammed Murtaza, Madison, WI

4:45 p.m. Early cancer detection by liquid biopsy. Allen K.C. Chan, Hong Kong

5:15 p.m. Liquid biopsies for molecular characterization and the study of clonal evolution in pediatric solid tumors. Gudrun Schleiermacher, Paris, France

5:45 p.m. Liquid biopsies for minimal residual disease detection. Muhammed Murtaza, Madison, WI

Room W311 E-H, Convention Center
MODELS FOR AGING AND CANCER

Chair: Lan G. Coffman, Pittsburgh, PA

4:45 p.m. Age-dependent evolution of cancers: Leveraging computational, mouse and human models. James V. DeGregori, Aurora, CO

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
5:15 p.m.  Studying the impact of the aging stromal microenvironment on cancer initiation. Lan G. Coffman, Pittsburgh, PA

5:45 p.m.  Evaluation of aging mechanisms in the pre-malignant population. Megan Weivoda, Rochester, MN

Room W312, Convention Center

NEXT GENERATION CANCER EPIDEMIOLOGIC COHORTS

Chair: Scarlett L. Gomez, San Francisco, CA

4:45 p.m.  Next generation cancer epidemiologic cohorts: Gaps and opportunities. Scarlett L. Gomez, San Francisco, CA

5:15 p.m.  Survivorship and Access to care for Latinos to Understand and address Disparities (SALUD): Closing the gap in childhood cancer outcomes. Maria M. Gramatges, Houston, TX

5:45 p.m.  Cohorts for Environmental Exposures and Cancer Risk (CEECR): From cohort inception to future opportunities. Shaneda W. Andersen, Madison, WI

Chapin Theater, Convention Center

T CELL THERAPIES IN IMMUNOLOGICALLY COLD MALIGNANCIES

Chair: Hélène Salmon, Paris, France

4:45 p.m.  Specific cancer-associated fibroblasts to target to overcome T cell exclusion in solid tumors. Hélène Salmon, Paris, France

5:15 p.m.  Exploiting T cell receptors to access new categories of cancer immunotherapy targets. Johanna Olweus, Olso, Norway

5:45 p.m.  Targeting cancer-associated fibroblasts to overcome immunotherapy resistance. Gareth Thomas, Southampton, United Kingdom

Tangerine Ballroom 3-4 (WF3-4), Convention Center

THE EVOLVING METABOLOME OF CANCER

Chair: Gary Patti, St. Louis, MO

4:45 p.m.  Cell-intrinsic and cell-extrinsic metabolic drivers of oncogenesis. Gary Patti, St. Louis, MO

5:15 p.m.  Targeting metabolic liabilities in cancer metastasis. Alpaslan Tasdogan, Essen, Germany

5:45 p.m.  Metabolic adaptations to the tumor microenvironment. Nada Y. Kalaany, Boston, MA
SATURDAY, APRIL 15*

**CME Educational Sessions • 8:00 a.m.–9:30 a.m.**

Tangerine Ballroom 3-4 (WF3-4), Convention Center

**ANTIGEN PRESENTATION: THE MACROPHAGE-DENDRITIC CELL DEBATE**

Chair: Brian Ruffell, Tampa, FL

8:00 a.m. **Competing for attention: Myeloid and T cell spatial interactions.** Brian Ruffell, Tampa, FL

8:30 a.m. **Macrophages rule in cancer.** Judith A. Varner, La Jolla, CA

9:00 a.m. **Dendritic cells and macrophages in the tumor: Dr. Jekyll and Mr. Hyde.** Karolina Palucka, Farmington, CT

Tangerine Ballroom 2 (WF2), Convention Center

**EPIGENETICS AND 3D GENOME IN CANCER INITIATION AND EVOLUTION**

Chair: Sheng Li, West Hartford, CT

8:00 a.m. **Detection and characterization of enhancer hijacking in cancer.** Feng Yue, Chicago, IL

8:30 a.m. **Epigenetic dysregulation in AML.** Yali Dou, Los Angeles, CA

9:00 a.m. **Inferring cellular epigenome heterogeneity and evolution in cancer.** Sheng Li, West Hartford, CT

Chapin Theater, Convention Center

**EVOLUTION OF DRUG RESISTANCE**

Chair: Sydney Shaffer, Philadelphia, PA

8:00 a.m. **Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions.** Amy Brock, Austin, TX

8:30 a.m. **Cancer cell states and plasticity in drug-induced adaptation.** Gustavo Starvaggi França, New York, NY

9:00 a.m. **Tracking resistance evolution across multiple therapies.** Sydney Shaffer, Philadelphia, PA

Room W331, Convention Center

**EXTRACELLULAR VESICLES AND PARTICLES (EVPS) FROM THE SMALL TO THE LARGE: SCIENCE IN THE ABSENCE OF A NUCLEUS**

Chair: David C. Lyden, New York, NY

8:00 a.m. **Extracellular vesicles, particles, cancer, and immunity.** Edit Buzás, Budapest, Hungary

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers
8:30 a.m.   Extracellular vesicles and particles in cancer progression and metastasis. Lucia R. Languino, Philadelphia, PA
9:00 a.m.   Tumor-derived extracellular vesicles and particles promote liver dysregulation and drug metabolizing defects. David C. Lyden, New York, NY

Room W315, Convention Center

FOSTERING ENTREPRENEURSHIP I: COMMERCIALIZING INNOVATIVE IDEAS – WHERE TO START?

NOT ELIGIBLE FOR CME CREDIT

Moderator: Michael A. Caligiuri, Duarte, CA
Panelists: C. Casey Cunningham, Boston, MA
Elizabeth M. Jaffee, Baltimore, MD
Ferran Prat, Houston, TX
Antoni Ribas, Los Angeles, CA

Valencia D, Convention Center

MAKING BETTER PRECLINICAL MODELS OF CANCER

Chair: Cedric Blanpain, Bruxelles, Belgium

8:00 a.m.   Deciphering the mechanisms of tumor initiation at the single cell resolution in living mice. Cedric Blanpain, Bruxelles, Belgium
8:30 a.m.   Exploring tumor-host interactions and mechanisms of immunosuppression using small and large animal models of cancer. Dieter Saur, Munich, Germany
9:00 a.m.   Patient-derived models of breast cancer for discovery science and precision medicine. Alana L. Welm, Salt Lake City, UT

Valencia A, Convention Center

NEW WAYS TO SKIN A CAT: EMERGING TECHNOLOGIES TO TARGET PROTEIN DEGRADATION

Chair: Danette L. Daniels, Cambridge, MA

8:00 a.m.   Considerations for heterobifunctional degraders and translation to clinic. Danette L. Daniels, Cambridge, MA
8:30 a.m.   Molecular glue degraders: Access to new mechanisms and disease targets. Christopher Nasveschuk, Stoneham, MA
9:00 a.m.   Interrogating the druggable proteome with proximity-mediated pharmacology. Fleur Ferguson, LaJolla, CA
SENESCENCE IN THE DRIVER’S SEAT: MANIPULATING THE HOST IMMUNE RESPONSE TO CANCER

Chair: Makoto Nakanishi, Tokyo, Japan

8:00 a.m. Cellular senescence as a gain-of-function phenotype. Masashi Narita, Cambridge, United Kingdom

8:30 a.m. Emerging role of stromal senescent cells in cancer progression. Makoto Nakanishi, Tokyo, Japan

9:00 a.m. Immunogenicity, plasticity, immune escalation, and evasion in cellular senescence. Clemens A. Schmitt, Berlin, Germany

SENITEL LYMPH NODES: WHAT DO THEY TELL US ABOUT PROGRESSION AND RESPONSE TO THERAPY

Chair: Timothy P. Padera, Boston, MA

8:00 a.m. The lymph node microenvironment induces cancer cell plasticity and evasion of anticancer immunity. Timothy P. Padera, Boston, MA

8:30 a.m. The lymph-borne melanoma proteome conditions lymph nodes for metastasis. Amanda W. Lund, New York, NY

9:00 a.m. Lymph node metastases provide a roadmap for the development of cold tumors. Dennis Jones, Boston, MA

SYSTEMIC MULTI-ORGAN COMMUNICATION DURING CANCER PROGRESSION

Chair: Florent Elefteriou, Houston, TX

8:01 a.m. Brain, seeds and soil: How do sympathetic nerves contribute to skeletal metastasis? Florent Elefteriou, Houston, TX

8:30 a.m. Regulation of anti-tumoral immunity via brain-bone interactions. Serkin Park, Seoul, Korea, Republic of

9:00 a.m. Local and distal control of tumor immunity. Kyunghee Choi, St. Louis, MO

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers
Methods Workshops • 8:00 a.m.–9:30 a.m.

Room W224, Convention Center
ACCESSIBLE COMPUTATIONAL PLATFORMS FOR LARGE-SCALE CANCER DATA ANALYSES

Chair: Jeremy Goecks, Portland, OR

8:00 a.m.   The Galaxy software workbench for reproducible and collaborative cancer data analyses. Jeremy Goecks, Portland, OR

8:30 a.m.   Analytical tools for precision oncology: The cBioPortal for cancer genomics and OncoKB. Nikolaus Schultz, New York, NY

9:00 a.m.   UCSC Xena for cancer multiomics data visualization and analysis. Jingchun Zhu, Santa Cruz, CA

Room W312, Convention Center
MICROFLUIDIC DEVICES TO TRACK LEADER CELL MOVEMENT

Chair: Priscilla Hwang, Richmond, VA

8:00 a.m.   Leader cell biomechanics regulating collective migration. Priscilla Hwang, Richmond, VA

8:30 a.m.   Image-guided genomics to isolate phenotypically distinct cellular sub-populations. Adam I. Marcus, Atlanta, GA

9:00 a.m.   Extracellular matrix composition and stromal fibroblasts regulate breast cancer invasion. Suzanne M. Ponik, Madison, WI

Room W414, Convention Center
PATHOLOGY FOR CANCER RESEARCHERS

Chair: Laura Delong Wood, Baltimore, MD

8:00 a.m.   Applications of artificial intelligence in histopathology-based prognosis. Toby Cornish, Aurora, CO

8:30 a.m.   Lighting up the tumor microenvironment: Multiplexed spatial analysis for research and clinic. Kurt Alex Schalper, New Haven, CT

9:00 a.m.   Pathology of precancers in two and three dimensions. Laura Delong Wood, Baltimore, MD
Room W311 A-D, Convention Center

**UTILIZING ACR PROJECT GENIE REAL-WORLD CLINICO-GENOMIC DATA**

**Cochairs:** Alexander S. Baras, Baltimore, MD; Tali Mazor, Boston, MA

8:00 a.m. **Cochair Introduction.** Tali Mazor, Boston, MA

8:05 a.m. **Leveraging ACR Project GENIE to flag putative assay artifacts and calibrate estimates of exomic mutation burden.** Alexander S. Baras, Baltimore, MD

8:25 a.m. **Using GENIE data to aid in ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.** Amin H. Nassar, New Haven, CT

8:45 a.m. **Exploring the BPC CRC 2.0-public dataset using cBioPortal.** Tali Mazor, Boston, MA

9:05 a.m. **General Discussion.** Alexander S. Baras, Baltimore, MD

---

**Professional Advancement Session • 9:00 a.m.–4:00 p.m.**

**NOT ELIGIBLE FOR CME CREDIT**

W Hall E2, Convention Center

**18TH ANNUAL ACR UNDERGRADUATE STUDENT CAUCUS AND POSTER COMPETITION**

**Chair:** Brian M. Rivers, Atlanta, GA

---

**CME Educational Sessions • 10:00 a.m.–11:30 a.m.**

Room W224, Convention Center

**CHEMISTRY TO THE CLINIC: PART 2 OF 3: LEVERAGING INDUCED PROXIMITY: BEYOND TARGETED PROTEIN DEGRADATION**

**Chair:** Lyn H. Jones, Boston, MA

10:00 a.m. **Emerging opportunities for non-degrading molecular superglues.** Lyn H. Jones, Boston, MA

10:30 a.m. **Sequence-based design of small molecule RNA degraders.** Matthew D. Disney, Juniper, FL

11:00 a.m. **Mechanism of action of velcrin small molecules.** Heidi Greulich, Cambridge, MA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers*
Tangerine Ballroom 2 (WF2), Convention Center

CHROMOSOMAL INSTABILITY IN CANCER EVOLUTION AND TREATMENT

Chair: Florian M. Markowetz, Cambridge, United Kingdom

10:00 a.m. The 17 deadly CINs: A pan-cancer compendium of chromosomal instability. Florian M. Markowetz, Cambridge, United Kingdom

10:30 a.m. Chromothripsis in cancer: Context of occurrence, mechanistic basis, and implications for patients. Aurelie Ernst, Heidelberg, Germany

11:00 a.m. Evolutionary dynamics and mutational processes in genome instable tumors. Christina Curtis, Stanford, CA

Room W315, Convention Center

FOSTERING ENTREPRENEURSHIP II: BIOTECH 101

NOT ELIGIBLE FOR CME CREDIT

Moderator: Alan Colowick, Waltham, MA

Panelist: Melissa McCracken, Boston, MA

Additional panelists to be announced.

Room W311 E-H, Convention Center

THE GUT MICROBIOTA AND COLORECTAL CANCER

Chair: Wendy Sarah Garrett, Boston, MA

10:00 a.m. The facts in the case of bacteria potentiating colorectal carcinogenesis, with a focus on fusobacteria. Wendy Sarah Garrett, Boston, MA

10:30 a.m. Driver pathogens and microbe: Microbe community interactions in CRC. Julia Lynn Drewes, Baltimore, MD

11:00 a.m. Clinical translation of the gut microbiome for colorectal cancer prevention. Andrew T. Chan, Boston, MA

Valencia A, Convention Center

HOW DOES THE NICHE REGULATE DISSEMINATED TUMOR CELL DORMANCY AND METASTASIS?

Chair: Ana Luisa Correia, Lisbon, Portugal

10:01 a.m. Understanding site-specific immunity to maintain disseminated tumor cell dormancy. Ana Luisa Correia, Lisbon, Portugal

10:30 a.m. Epigenetic control of dormancy. Ana P. Da Silva Gomes, Tampa, FL

11:00 a.m. How aging promotes reactivation from metastatic melanoma dormancy. Mitchell Fane, Baltimore, MD
Room W312, Convention Center
INNOVATIONS IN METHODS FOR ADAPTING AND PERSONALIZING INTERVENTIONS FOR CANCER CONTROL

Chair: Inbal Nahum-Shani, Ann Arbor, MI

10:01 a.m. Introduction to adaptive interventions and just-in-time adaptive interventions. Inbal Nahum-Shani, Ann Arbor, MI

10:30 a.m. Innovations in adaptive intervention development for cancer control: The QuitSMART Utah study. David W. Wetter, Salt Lake City, UT

11:00 a.m. Innovations in JITAI development for cancer control: The Sense2stop study. Susan A. Murphy, Cambridge, MA

Tangerine Ballroom 1 (WF1), Convention Center
IT’S MORE THAN THE ECM: PHYSICAL ONCOLOGY

Chair: Ovijit Chaudhuri, Stanford, CA

10:00 a.m. Changes in the extracellular matrix and their impact on cancer progression. Ovijit Chaudhuri, Stanford, CA

10:20 a.m. Dynamic interplay between cellular and non-cellular tissue stroma, tissue tension and tumor progression. Valerie M. Weaver, San Francisco, CA

10:40 a.m. Mechanical and structural regulation of T cell behavior in solid tumor microenvironments. Paolo P. Provenzano, Minneapolis, MN

11:00 a.m. Panel Discussion

Tangerine Ballroom 3-4 (WF3-4), Convention Center
RNA BIOGENESIS IN CANCER: WHAT DO WE KNOW?

Chair: Marisol Soengas, Madrid, Spain

10:00 a.m. dsRNA binding proteins modulating immune suppression in melanoma. Marisol Soengas, Madrid, Spain

10:30 a.m. The roles of RNA splicing in cancer initiation and progression, and its modulation for cancer therapy. Rotem Karni, Jerusalem, Israel

11:00 a.m. The CPEB family of RNA-binding proteins in the translational control of tumor-niche chronic stress response. Raul Mendez, Barcelona, Spain

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers
Chapin Theater, Convention Center
TUMOR IMMUNOLOGY AND IMMUNOTHERAPY FOR NONIMMUNOLOGISTS: ENHANCING RESPONSIVENESS TO CANCER IMMUNOTHERAPY

Chair: Kunle Odunsi, Chicago, IL

10:00 a.m. The broad applicability of T cell therapies to treat cancer. Catherine Bollard, Washington, DC
10:30 a.m. Tertiary lymphoid structures in cancer. Jose R. Conejo-Garcia, Durham, NC
11:00 a.m. The role of tissue resident T cells and cancer immunotherapy. Kunle Odunsi, Chicago, IL

Valencia BC, Convention Center
UNDERSTANDING NEUTROPHIL DYNAMICS IN CANCER: MOUSE TO HUMAN AND BACK AGAIN

Chair: Mikala Egeblad, Cold Spring Harbor, NY

10:00 a.m. A tumor-induced neutrophil subpopulation drives vascular occlusion, pleomorphic necrosis, and metastasis. Mikala Egeblad, Cold Spring Harbor, NY
10:30 a.m. Microbiota licenses neutrophils to respond to chemotherapy. Romina Goldszmid, Bethesda, MD
11:00 a.m. Immunotherapies trigger neutrophil activation to eliminate tumor antigen escape variants. Taha Merghoub, New York, NY

CME Methods Workshops • 10:00 a.m.–11:30 a.m.

Valencia D, Convention Center
CLINICAL TRIAL DESIGN IN A DIVERSE WORLD, PART 1: ALIGNING THE NEEDS OF A CLINICAL TRIAL WITH THE MOST APPROPRIATE DESIGN

Cochairs: Ezra E.W. Cohen, San Diego, CA; Wendy B. London, Boston, MA

10:00 a.m. Chair Introduction. Wendy B. London, Boston, MA
10:05 a.m. Making phase I trials relevant: Aligning need with design. Thomas M. Braun, Ann Arbor, MI
10:25 a.m. Trial designs for answering phase II questions. Elizabeth Garrett-Mayer, Alexandria, VA
10:45 a.m. Clinical trials in the post-PD1 immunotherapy era. Ezra E.W. Cohen, San Diego, CA
11:05 a.m. Panel Discussion
Room W414, Convention Center

HTAN DATA IN THE WILD: ACCESSING AND ANALYZING SINGLE-CELL SEQUENCING AND HIGHLY MULTIPLEXED SPATIAL-PROTEOMICS USING THE HTAN DATA PORTAL AND NCI’S CLOUD RESOURCES

Chair: Vésteinn Thorsson, Seattle, WA

10:00 a.m. Accessing and visualizing Human Tumor Atlas Network (HTAN) data through the HTAN data portal and associated resources. Vésteinn Thorsson, Seattle, WA

10:30 a.m. HTAN data in the NCI cancer research data commons. Erika Kim, Bethesda, MD

11:00 a.m. Spatial proteomics analysis of highly multiplexed tissue imaging. Allison L. Creason, Portland, OR

Career Development Forum • 11:45 a.m.-3:45 p.m.

NOT ELIGIBLE FOR CME CREDIT

WOMEN AND POWER WORKSHOP: ADVANCING AND SECURING YOUR CAREER IN SCIENCE

11:00 a.m. Lunch

11:45 a.m. Workshop

Educational Sessions • 12:30 p.m.–2:00 p.m.

Room W331, Convention Center

DISTILLING DATA FROM SINGLE CELL AND SPATIAL RNA-SEQ: A NEW PERSPECTIVE, A NEW APPROACH

Chair: Jeffrey H. Chuang, Farmington, CT

12:30 p.m. Developing approaches for single cell and spatial expression analysis in tumors. Jeffrey H. Chuang, Farmington, CT

1:00 p.m. Single-cell RNA-Seq analysis of cancer therapy resistance. Kai Tan, Philadelphia, PA

1:30 p.m. Delineating intra-tumor heterogeneity with spatial multi-omics. Elana Judith Fertig, Baltimore, MD

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers
Valencia A, Convention Center

EXPLOITING THE DNA DAMAGE RESPONSE IN NOVEL THERAPY APPROACHES

Chair: Alan D. D’Andrea, Boston, MA

12:30 p.m. Overcoming PARP inhibitor resistance by targeting POLQ or USP1.
Alan D. D’Andrea, Boston, MA

1:00 p.m. The radiation-induced DNA damage response modulates cancer cell immunogenicity and response to immunotherapy. Sandra Demaria, New York, NY

1:30 p.m. Exploiting the synthetic lethality interaction: A hit for new therapeutics.
Stephanie Lheureux, Toronto, ON, Canada

Room W315, Convention Center

FOSTERING ENTREPRENEURSHIP III: FINANCING OPTIONS

NOT ELIGIBLE FOR CME CREDIT

Moderator: Christiana Bardon, Boston, MA

Panelists: Tom Cirrito, Walnut, CA
Christina M. Coughlin, Monrovia, CA
Jeffrey A. Engelman, Cambridge, MA
Susan M. Galbraith, Cambridge, United Kingdom
William N. Hait, New Brunswick, NJ

Tangerine Ballroom 3-4 (WF3-4), Convention Center

MULTIPLEX, SPATIALLY RESOLVED IMAGING: READY FOR PRIMETIME?

Chair: Leeat Keren, Rehovot, Israel

12:30 p.m. Unravelling the tumor microenvironment in metastatic melanoma using multiplexed imaging. Leeat Keren, Rehovot, Israel

1:00 p.m. Introduction to MCMICRO, histoCAT and other tools tailored for spatial omics analysis. Denis Schapiro, Heidelberg, Germany

1:30 p.m. Is it spillover, a doublet, or a tissue slicing effect? Understanding the consequences of experimental and analytic choices on spatial omics data interpretation. Kieran Campbell, Toronto, ON, Canada

Tangerine Ballroom 2 (WF2), Convention Center

TARGETING THE TME

Chair: Edna Cukierman, Philadelphia, PA

12:30 p.m. Establishment and regulation of the pancreatic cancer microenvironment. Marina Pasca Di Magliano, Ann Arbor, MI

1:00 p.m. Epithelial and stromal complicity in pancreas cancer. Sunil R. Hingorani, Seattle, WA

1:30 p.m. The fibroblastic ECM as a functional unit. Edna Cukierman, Philadelphia, PA
SATURDAY, APRIL 15* | Educational Sessions (cont’d)

Room W311 E-H, Convention Center
TERTIARY LYMPHOID STRUCTURES: WHAT THEY ARE AND HOW THEY INFLUENCE IMMUNOTHERAPY RESPONSES

Chair: Wolf Hervé Fridman, Paris, France

12:30 p.m.   The definition of tertiary lymphoid structures: The knowns and the knowledge gap. Tullia C. Bruno, Pittsburgh, PA

1:00 p.m.   The effect of tertiary lymphoid structures on immunotherapy response. Göran B. Jönsson, Lund, Sweden

1:30 p.m.   The role of plasma cells and antibodies generated in TLS in immunotherapy responses. Wolf Hervé Fridman, Paris, France

Chapin Theater, Convention Center
TUMOR ANTIGENS FOR CANCER IMMUNOTHERAPY

Chair: Sacha Gnjatic, New York, NY

12:30 p.m.   What contributes to a good tumor antigen? Sacha Gnjatic, New York, NY

1:00 p.m.   Involvement of host immune integrity in the immunogenicity of tumor antigens. Yoshihiro Ohue, New York, NY

1:30 p.m.   Making way for tumor associated antigen targeted therapies in pancreatic cancer. Ellen Puré, Philadelphia, PA

Tangerine Ballroom 1 (WF1), Convention Center
TUMOR-INFILTRATING B CELLS AND TERTIARY LYMPHOID STRUCTURES: MECHANISTIC INSIGHTS AND THERAPEUTIC OPPORTUNITIES

Chair: Brad Nelson, Victoria, BC, Canada

12:30 p.m.   The multi-faceted roles of effector B cells in anti-tumor immunity. Brad Nelson, Victoria, BC, Canada

1:00 p.m.   Regulatory B cells in cancer. Yuliya Pylayeva-Gupta, Chapel Hill, NC

1:30 p.m.   Tertiary lymphoid structures: From structure and function towards the next generation of immunotherapy. Marie-Caroline Dieu-Nosjean, Paris, France

Room W311 A-D, Convention Center
USING BIG DATA IN POPULATION SCIENCE

Chair: Nicola J. Camp, Salt Lake City, UT

12:30 p.m.   The Utah population database: A unique resource for cancer research. Nicola J. Camp, Salt Lake City, UT

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers
1:00 p.m.  Harnessing real-world data in oncology: Insights and applications. Tina Hernandez-Boussard, Stanford, CA

1:30 p.m.  #DataMatter: Leveraging NCI datasets for cancer discovery and impact. Jill S. Barnholtz-Sloan, Rockville, MD

Room W312, Convention Center
WASTE NOT, WANT NOT: DISCOVERY IN CANCER CACHEXIA
Chair: Teresa A. Zimmers, Portland, OR
12:30 p.m. Modeling cancer cachexia: From flies to rodents to organoids. Teresa A. Zimmers, Portland, OR
1:00 p.m. Bench to bedside and back in cancer cachexia. Andrew R. Judge, Gainesville, FL
1:30 p.m. Precision approaches to clinical interrogation of cancer cachexia. Mariam Jamal-Hanjani, London, United Kingdom

CME Methods Workshops • 12:30 p.m.–2:00 p.m.
Valencia D, Convention Center
CLINICAL TRIAL DESIGN IN A DIVERSE WORLD, PART 2: CHALLENGES IN CLINICAL TRIAL ENROLLMENT
Cochairs: Ezra E.W. Cohen, San Diego, CA; Wendy B. London, Boston, MA
12:30 p.m. Introduction. Ezra E.W. Cohen, San Diego, CA; Wendy B. London, Boston, MA
12:35 p.m. An overview of barriers to patient enrollment and diversity plans to improve enrollment in cancer clinical trials. Katherine Panageas, New York, NY
12:50 p.m. Increasing clinical trial accrual of under-represented patients by shifting the power differential in the patient-provider relationship. Maria Elena Martinez, San Diego, CA
1:05 p.m. Innovative strategies to address enrollment barriers and enhance participation among disparity populations. Chanita Hughes-Halbert, Los Angeles, CA
1:20 p.m. How can technology and decentralized clinical trials processes modernize your next protocol? Muhammad Shaalan Beg, Dallas, TX
1:35 p.m. Panel Discussion
EMERGING PLATFORMS FOR CANCER IMMUNOTHERAPY

**Chair:** Omid Veiseh, Houston, TX

**12:30 p.m.** Developing clinically translatable cytokine factories for cancer immunotherapy. Omid Veiseh, Houston, TX

**1:00 p.m.** Tumor-selective delivery of immunostimulatory cytokine/antibody fusion proteins. Jamie B. Spangler, Baltimore, MD

**1:30 p.m.** Delivery technologies for cancer immunotherapy. Michael John Mitchell, Philadelphia, PA

INTERCEPTING MOLECULAR RESIDUAL DISEASE IN THE CLINIC

**Chair:** Nicholas Turner, London, United Kingdom

**12:30 p.m.** Sensitive methods to detect ctDNA and MRD in patients with solid tumors. Nitzan Rosenfeld, Cambridge, United Kingdom

**1:00 p.m.** MRD evaluation and interception in head and neck cancer. Lillian L. Siu, Toronto, ON, Canada

**1:30 p.m.** MRD detection and clonal evolution in breast cancer. Nicholas Turner, London, United Kingdom

ORGANOIDS FOR DISEASE MODELING AND PRECISION MEDICINE

**Chair:** Vincenzo Corbo, Verona, Italy

**12:30 p.m.** Patient derived organoids to study genetic heterogeneity in pancreatic cancer. Vincenzo Corbo, Verona, Italy

**1:00 p.m.** Patient-derived tumor organoids for precision medicine. Alice Soragni, Los Angeles, CA

**1:30 p.m.** Single-cell signaling analysis of tumor microenvironment organoids. Chris Tape, London, United Kingdom

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers*
Educational Sessions • 2:30 p.m.–4:00 p.m.

Room W311 A-D, Convention Center

A ROAD LESS TRAVELED: WHERE DO CAFS COME FROM AND WHERE DO THEY GO?

Chair: Ruth Scherz-Shouval, Rehovot, Israel

2:30 p.m.  Accelerators, brakes, and instructors: The many roles of CAFs in the microenvironment. Claus Jorgensen, Manchester, United Kingdom

3:00 p.m.  Cancer-CAF coevolution. Ruth Scherz-Shouval, Rehovot, Israel

3:30 p.m.  Stromal plasticity shapes the metastatic microenvironment. Neta Erez, Tel Aviv, Israel

Tangerine Ballroom 2 (WF2), Convention Center

AI IS HERE TO STAY: ITS IMPACT IN CANCER RESEARCH

Chair: Jakob Nikolas Kather, Dresden, Germany

2:30 p.m.  Artificial Intelligence-based biomarkers in precision oncology. Jakob Nickolas Kather, Dresden, Germany

3:00 p.m.  Under the scope: The current landscape of AI for oncologic histopathology. Jeanne Shen, Stanford, CA

3:30 p.m.  Towards robust and equitable AI for cancer diagnostics and treatment. Regina Barzilay, Cambridge, MA

Room W224, Convention Center

CHEMISTRY TO THE CLINIC: PART 3 OF 3: COVALENCY AND TARGET VALIDATION

Chair: Daniel K. Nomura, Berkeley, CA

2:30 p.m.  Covalent small-molecule protein degraders. Ekaterina V. Vinogradova, New York, NY

3:00 p.m.  Recent advances in covalent therapeutics: Expanding the druggable proteome. Patrick T. Gunning, Mississauga, ON, Canada

3:30 p.m.  Reimagining druggability using chemoproteomic platforms. Daniel K. Nomura, Berkeley, CA
Room W314 A, Convention Center

**FOSTERING ENTREPRENEURSHIP IV: INTERACTING WITH REGULATORY AGENCIES**

*NOT ELIGIBLE FOR CME CREDIT*

**Moderator:** Jeff Summers, Silver Spring, MD

**Panelists:**
- Julian Adams, Boston, MA
- Omer Butt, Duarte, CA
- Elaine R. Mardis, Columbus, OH
- David R. Parkinson, San Francisco, CA
- Eric H. Rubin, North Wales, PA

Room W315, Convention Center

**PROJECT LIVIN’ LABEL: FAM-TRASTUZUMAB DERUXTECAN-NXKI IN BREAST CANCER — REDEFINING HER2 STATUS**

**Moderator:** Preeti Narayan, Silver Spring, MD

**Panelists:**
- Asma Dilawari, Silver Spring, MD
- Deborah Geary, Miami, FL
- Kasey Hoggatt, Coffeyville, KS
- Neha Mangini, Salt Lake City, UT
- Naoto Ueno, Honolulu, HI

Tangerine Ballroom 3-4 (WF3-4), Convention Center

**RECENT ADVANCES AND FUTURE DIRECTIONS IN IMMUNOTHERAPEUTIC APPROACHES TO CHILDHOOD SOLID MALIGNANCIES**

**Chair:** John M. Maris, Philadelphia, PA

2:30 p.m.  **Leveraging developmental biology to identify optimal immunotherapeutic targets for childhood cancers.**  John M. Maris, Philadelphia, PA

3:00 p.m.  **Bispecific therapeutic that converts PD-L1 from a defense mechanism to a cancer cell vulnerability.**  James M. Olson, Seattle, WA

3:30 p.m.  **CAR T cells for children’s cancers.**  Crystal L. Mackall, Stanford, CA

Tangerine Ballroom 1 (WF1), Convention Center

**T RESIDENT MEMORY CELLS**

**Chair:** Ananda W. Goldrath, La Jolla, CA

2:30 p.m.  **Resident memory T cell development in tissues and tumors.**  Laura Mackay, Victoria, Australia

3:00 p.m.  **Lessons from studying T cells in human tumors.**  Pandurangan Vijayanand, La Jolla, CA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers*
3:30 p.m.  Leveraging transcriptional programming tissue resident memory T cells to
enhance anti-tumor immunity. Ananda W. Goldrath, La Jolla, CA

Room W331, Convention Center
TUMOR HETEROGENEITY: RAPID AUTOPSY TO LONGITUDINAL BIOPSIES:
WHAT CAN WE LEARN?
Chair: Charles Swanton, London, United Kingdom
2:30 p.m.  Chair Introduction. Charles Swanton, London, United Kingdom
2:32 p.m.  Lung cancer evolution during immune predation: Insights from TRACERx
and the PEACE Autopsy Program. Charles Swanton, London, United Kingdom
2:54 p.m.  Insights and resources from longitudinal sampling and rapid autopsy of
pancreatic cancer patients. Michael A. Hollingsworth, Omaha, NE
3:16 p.m.  Intra and inter-tumor heterogeneity across cancer metastases: A reality
check for targeted therapeutics and the utility of non-invasive biomarkers.
Peter S. Nelson, Seattle, WA
3:38 p.m.  Title to be announced. Jody E. Hooper, Stanford, CA

Room W312, Convention Center
UNDERSTANDING THE DISEASE BIOLOGY OF ALL:
INSIGHTS FROM GENOMIC AND TRANSLATIONAL STUDIES
Chair: Caner Saygin, Chicago, IL
2:30 p.m.  B-cell acute lymphoblastic leukemia genomics: Biological and clinical
implications. Ilaria Iacobucci, Memphis, TN
3:00 p.m.  Novel transcriptional regulation and therapeutic targets in T cell acute
lymphoblastic leukemia. Daniel Herranz, New Brunswick, NJ
3:30 p.m.  New insights into the pathogenesis of ALL in older adults. Caner Saygin,
Chicago, IL

Valencia BC, Convention Center
YIN AND YANG OF INFLAMMASOMES IN CANCER
Chair: Gabriel Mbalaviele, St. Louis, MO
2:30 p.m.  Pyroptosis: A programmed form of cell death. Gabriel Mbalaviele, St. Louis, MO
3:00 p.m.  Cancer-associated pyroptosis: A new license to kill tumors. Zhibin Zhang,
Houston, TX
3:30 p.m.  Activation of antitumor immunity by bacteria-derived signals: Pyroptosis
and beyond. Feng Shao, Beijing, China
Methods Workshops • 2:30 p.m.–4:00 p.m.

Room W311 E-H, Convention Center

ADVANCING OUR UNDERSTANDING OF CANCER BURDEN THROUGH GEOSPATIAL DATA

Chair: Trang VoPham, Seattle, WA

2:30 p.m. Chair Introduction. Trang VoPham, Seattle, WA

2:35 p.m. A geospatial guide for integrating location into cancer population sciences research. Trang VoPham, Seattle, WA

3:05 p.m. Leveraging geospatial data and methods for studies of environment and cancer. Rena R. Jones, Bethesda, MD

3:35 p.m. The role of outdoor air pollutant mixtures in breast cancer risk: An application of geospatial data in a prospective cohort. Alexandra J. White, Research Triangle Park, NC

4:05 p.m. Panel Discussion

Valencia D, Convention Center

CLINICAL TRIAL DESIGN IN A DIVERSE WORLD, PART 3: BIOMARKERS IN CLINICAL TRIALS

Cochairs: Ezra E.W. Cohen, San Diego, CA; Wendy B. London, Boston, MA

2:00 p.m. Introduction. Ezra E.W. Cohen, San Diego, CA

2:35 p.m. Standardization, prioritization, and optimal use of advanced molecular studies in clinical cancer research. Kurt Alex Schalper, Branford, CT

2:55 p.m. Incorporation of proof-of-mechanism pharmacodynamic biomarkers and predictive biomarkers of response in early phase clinical trials. Timothy A. Yap, Houston, TX

3:15 p.m. Statistical and practical guidance for biomarker studies. Wendy B. London, Boston, MA

3:35 p.m. Panel Discussion

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers
Valencia A, Convention Center
NEW METHODS IN SPATIAL IMAGING

**Chair:** Peter K. Sorger, Winchester, MA

**2:30 p.m.**  Applying spatial functional genomics to identify drivers of the tumor microenvironment. Brian Brown, New York City, NY

**3:00 p.m.**  The molecular architecture of immunoediting and immunosuppression in solid cancers. Peter K. Sorger, Winchester, MA

**3:30 p.m.**  Investigating metabolites in the tumor microenvironment. Marcia Haigis, Boston, MA

Chapin Theater, Convention Center
THE SPATIAL REVOLUTION: APPLYING SINGLE-CELL SPATIAL TECHNOLOGIES TO CANCER RESEARCH

**Chair:** Martin Guilliams, Ghent, Belgium

**2:30 p.m.**  Developing spatial single-cell pipelines in cancer. Martin Guilliams, Ghent, Belgium

**3:00 p.m.**  Exploring the tumor microenvironment from the point of view of cell-cell communication at the single-cell level. Merav Cohen, Tel Aviv, Israel

**3:30 p.m.**  Single-cell spatial transcriptomic analyses of tumor immune responses during checkpoint immunotherapy. Diether Lambrechts, Leuven, Belgium

---

**CME**  **Plenary Session • 4:15 p.m.–6:15 p.m.**

W Hall A2-3, Convention Center
BEATING KRAS: A 30-YEAR OVERNIGHT SENSATION

**Chair:** Dafna Bar-Sagi, New York, NY

**4:15 p.m.**  Introduction. Dafna Bar-Sagi, New York, NY

**4:19 p.m.**  The race to kill Ras. Frank McCormick, San Francisco, CA

**4:46 p.m.**  Disruption of immune homeostasis circuits in mutant Ras tumors: Who is the culprit? Dafna Bar-Sagi, New York, NY

**5:13 p.m.**  Progress in the treatment of KRAS mutant cancers. Pasi A. Jänne, Boston, MA

**5:40 p.m.**  KRAS is personal: Just ask the immune system. Beatriz M. Carreno, Philadelphia, PA

**6:07 p.m.**  Wrap-up and opportunities for the future. Dafna Bar-Sagi, New York, NY
Opening Ceremony • 8:00 a.m.–9:30 a.m.
NOT ELIGIBLE FOR CME CREDIT

W Hall A2-3, Convention Center

Join us on Sunday for the Annual Meeting Opening Ceremony, a yearly tradition marking the start of four days filled with outstanding and innovative science.

Highlights of this year’s Opening Ceremony include:

• Remarks from AACR CEO Margaret Foti and AACR President Lisa M. Coussens
• AACR Award for Lifetime Achievement in Cancer Research
• AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
• AACR Team Science Award
• AACR June L. Biedler Prizes for Cancer Journalism
• Remarks from NCI Director Monica M. Bertagnolli
• Recognition of the 25th Anniversary of the AACR Scientist↔Survivor Program
• AACR Distinguished Public Service Awards

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Opening Plenary Session • 9:30 a.m.–11:30 a.m.
W Hall A2-3, Convention Center

OPENING PLENARY SESSION:
ADVANCING THE FRONTIERS OF CANCER SCIENCE AND MEDICINE

Chair: Robert H. Vonderheide, Philadelphia, PA

9:30 a.m. Introduction. Robert H. Vonderheide, Philadelphia, PA
9:35 a.m. Translating knowledge from panels to practice to population health. Deborah Schrag, New York, NY
9:57 a.m. Learning tumor immunology from immunotherapy success and failures. David G. Denardo, St. Louis, MO
10:19 a.m. Cancer cachexia: Out of intense complexities, intense simplicities emerge. Teresa A. Zimmers, Portland, OR
10:41 a.m. Malignancies in people with HIV: Successes and challenges at the intersection of virology, immunology, and oncology. Robert Yarchoan, Bethesda, MD
11:03 a.m. To the moon and back: Centering equity at the frontiers of cancer care. Tomi Akinyemiju, Durham, NC
11:25 a.m. Wrap-up and opportunities for the future. Robert H. Vonderheide, Philadelphia, PA

NCI-NIH-Sponsored Session • 11:45 p.m.–12:45 p.m.
NOT ELIGIBLE FOR CME CREDIT
Room W314 A, Convention Center

NCI FUNDING OPPORTUNITIES FOR DIVERSITY TRAINING AND DISPARITIES RESEARCH IN CANCER TO PROMOTE HEALTH EQUITY

Moderator: Sanya A. Springfield, Rockville, MD
Presenters: Behrous Davani, Bethesda, MD
LeeAnn O. Bailey, Bethesda, MD
Tiffany A. Wallace, Rockville, MD

Awards and Lectures • 12:00 p.m.–12:45 p.m.
Room W414, Convention Center

PEZCOLLER FOUNDATION-AACR INTERNATIONAL AWARD FOR EXTRAORDINARY ACHIEVEMENT IN CANCER RESEARCH

Chair: Anton J.M. Berns, Amsterdam, Netherlands
12:05 p.m. Funder Remarks. Enzo Galligioni, Trento, Italy
12:10 p.m. Award Lecture. Tak W. Mak, Toronto, ON, Canada
Clinical Trials Plenary Session • 12:45 p.m.–3:15 p.m.
Chapin Theater, Convention Center
HARNESSING THE IMMUNE SYSTEM IN THE CLINIC

Cochairs: Shivaani Kummar, Portland, OR; Timothy Yap, Houston, TX

Introduction

12:45 p.m.  CT001 A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial. Jeffrey S. Weber, New York, NY

1:00 p.m.  Discussant. Margaret Callahan, New York, NY

1:10 p.m.  Discussion

1:15 p.m.  CT002 KEYMAKER-U02 substudy 02C: Neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma. Reinhard Dummer, Zurich, Switzerland

1:30 p.m.  Discussant. Ryan J. Sullivan, Boston, MA

1:40 p.m.  Discussion

1:45 p.m.  CT003 IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation. Ahmed O. Kaseb, Houston, TX

2:00 p.m.  Discussant. Stephen Lam Chan, Shatin, Hong Kong

2:10 p.m.  Discussion

2:15 p.m.  CT004 Intratumoral (IT) MEDI1191 + durvalumab (D): Update on the first-in-human study in advanced solid tumors. Eduardo Castañón, Pamplona, Spain

2:30 p.m.  Discussant. Tara Mitchell, Philadelphia, PA

2:40 p.m.  Discussion

2:45 p.m.  CT005 AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. John V. Heymach, Houston, TX

3:00 p.m.  Discussant. Roy S. Herbst, New Haven, CT

3:10 p.m.  Discussion

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
NCI-NIH-Sponsored Session • 1:00 p.m.–2:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Room W314 A, Convention Center
NIH FINAL POLICY FOR DATA MANAGEMENT AND SHARING EXPLAINED

Moderator: Emily S. Boja, Bethesda, MD

Presenters: Heather Basehore, Bethesda, MD
Brandon Wright, Bethesda, MD
Nathan Boyd, Bethesda, MD

CME

Major Symposium • 1:00 p.m.–2:15 p.m.

Room W330, Convention Center
Science Policy Session
PRESIDENT BIDEN’S CANCER MOONSHOT REIGNITED

Moderator: Cheryl L. Willman, Rochester, MN

1:15 p.m. Nancy G. Brinker, Palm Beach, FL
1:25 p.m. Danielle Carnival, Washington, DC
1:35 p.m. Phyllis Pettit Nassi, Salt Lake City, UT
1:45 p.m. Ricki Fairley, Annapolis, MD
1:55 p.m. Panel Discussion

CME

Advances in Diagnostics and Therapeutics
1:00 p.m.–2:30 p.m.

Room W307, Convention Center
FLASH RADIOTHERAPY: FROM ANIMAL MODELS TO THE CLINIC

Chair: Constantinos Koumenis, Philadelphia, PA

1:00 p.m. Chair Introduction. Constantinos Koumenis, Philadelphia, PA
1:05 p.m. Preclinical studies with proton FLASH radiation in mouse models and canine patients. Constantinos Koumenis, Philadelphia, PA
1:30 p.m. Abdominal FLASH irradiation: Molecular mechanisms and therapeutic potential. Erinn Rankin, Stanford, CA
1:55 p.m. Flash radiotherapy: Linking dosimetry, radiochemistry, and radiobiology. Brian W. Pogue, Madison, WI
**INTRAOPERATIVE MOLECULAR IMAGING: NEW CLINICAL INSIGHTS**

**Chair:** Eben L. Rosenthal, Nashville, TN

1:00 p.m. **Chair Introduction.** Eben L. Rosenthal, Nashville, TN

1:05 p.m. **Practical implications of fluorescent guided surgery in primary tumor and regional metastasis.** Eben L. Rosenthal, Nashville, TN

1:30 p.m. **Use of fluorescent guided surgery and theranostic applications in neurosurgery.** Constantinos G. Hadjipanayis, New York, NY

1:55 p.m. **Intraoperative molecular imaging of lung cancer: The road to FDA approval.** Sunil Singhal, Philadelphia, PA

**THE BIOLOGY OF EARLY CANCERS, PRECISION PREVENTION AND EARLY CANCER DETECTION**

**Chair:** Caroline Dive, Manchester, United Kingdom

1:00 p.m. **Chair Introduction.** Caroline Dive, Manchester, United Kingdom

1:05 p.m. **The genomic landscape of human precancer.** Ludmil B. Alexandrov, La Jolla, CA

1:30 p.m. **Models and mechanisms to aid precision prevention in colorectal cancer.** Philip Dunne, Belfast, Ireland

1:55 p.m. **Development of a multimodal liquid biopsy to augment low dose-CT screening for lung cancer early detection.** Caroline Dive, Manchester, United Kingdom

**COLORECTAL CANCER INITIATION, PROGRESSION, AND THERAPEUTIC RESISTANCE**

**Chair:** Jacco Van Rheenen, Amsterdam, Netherlands

1:00 p.m. **Chair Introduction.** Jacco Van Rheenen, Amsterdam, Netherlands

1:05 p.m. **Features and susceptibility to environmentally induced colorectal carcinogenesis.** Marios Giannakis, Boston, MA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
1:33 p.m. Intravital imaging of the fate of mutant intestinal cells reveals cellular mechanisms that minimize mutation accumulation. Jacco Van Rheenen, Amsterdam, Netherlands

2:01 p.m. Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells. Eduard Batlle Gomez, Barcelona, Spain

[CME] Advances in Population Sciences • 1:00 p.m.–2:30 p.m.

Room W311 E-H, Convention Center
IMMUNOLOGY, IMMUNOGENICITY, AND EFFICACY OF COVID-19 VACCINATION IN PATIENTS WITH CANCER

Chair: Sjoukje Oosting, Ruinerwold, Netherlands

1:00 p.m. Chair Introduction. Sjoukje Oosting, Ruinerwold, Netherlands

1:05 p.m. Immune memory to SARS-CoV-2 and COVID-19 vaccination. Shane Crotty, La Jolla, CA

1:30 p.m. Immunogenicity and safety of COVID-19 vaccination during cancer treatment. Sjoukje Oosting, Ruinerwold, Netherlands

1:55 p.m. Real-world evidence for risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer. Jing Su, Indianapolis, IN

[CME] Advances in the Science of Cancer Disparities
1:00 p.m.–2:30 p.m.

Room W304 A-D, Convention Center
DISPARITIES AND CANCER OUTCOMES

Chair: Lucile L. Adams-Campbell, Washington, DC

1:00 p.m. Chair Introduction. Lucile L. Adams-Campbell, Washington, DC

1:05 p.m. Exercise and allostatic load in Black women at increased risk for breast cancer. Lucile L. Adams-Campbell, Washington, DC

1:30 p.m. Measures of pre-diagnostic allostatic load and breast cancer outcomes in Black women. Adana A.M. Llanos, New York, NY

SUNDAY, APRIL 16* (cont’d)

Major Symposia • 1:00 p.m.–2:30 p.m.
Tangerine Ballroom 1 (WF1), Convention Center
B CELL RESPONSES AND TERTIARY LYMPHOID STRUCTURES IN CANCER

Chair: Yuliya Pylayeva-Gupta, Chapel Hill, NC

1:00 p.m.  Chair Introduction. Yuliya Pylayeva-Gupta, Chapel Hill, NC
1:05 p.m.  Determinants of B cell function in cancer. Yuliya Pylayeva-Gupta, Chapel Hill, NC
1:30 p.m.  Generation of B cell immunity in tertiary lymphoid structures supports response to immunotherapy. Wolf Hervé Fridman, Paris, France
1:55 p.m.  Integrative single-cell and spatial profiling of B cells and tertiary lymphoid structures in cancer. Linghua Wang, Houston, TX

Room W224, Convention Center
CONTRIBUTIONS OF THE TUMOR GLYCOME TO IMMUNE SUPPRESSION AND IMMUNOTHERAPY RESISTANCE AND OPPORTUNITIES FOR THERAPEUTIC INTERVENTION

Chair: Avery D. Posey, Philadelphia, PA

1:00 p.m.  Chair Introduction. Avery D. Posey, Philadelphia, PA
1:05 p.m.  Reprogramming the tumor-immune microenvironment by targeting galectin-glycan interactions. Gabriel A. Rabinovich, Ciudad de Buenos Aires, Argentina
1:30 p.m.  The glyco-code in cancer, novel immune checkpoints. Yvette Van Kooyk, Amsterdam, Netherlands
1:55 p.m.  Interactions between truncated O-glycans and the immune system, and opportunities for intervention. Avery D. Posey, Philadelphia, PA

Valencia D, Convention Center
EMERGING CLINICAL STRATEGIES FOR MYELOID CELL MODULATION IN CANCER

Chair: Karin E. de Visser, Amsterdam, Netherlands

1:00 p.m.  Chair Introduction. Karin E. de Visser, Amsterdam, Netherlands
1:01 p.m.  Tumor agnostic dendritic cell vaccines. Michele De Palma, Lausanne, Switzerland
1:25 p.m.  Dendritic cell intrinsic androgen receptor signaling reduces dendritic cell function and anti-tumor immunity. Megan Ruhland, Portland, OR [AACR NextGen Star]

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
1:43 p.m.  **Interleukin-8, neutrophils and NETs in a druggable collusion against cancer immunotherapy.** Ignacio Melero, Pamplona, Spain

2:07 p.m.  **Crosstalk between eosinophils and adaptive immune cells: A new avenue for immune checkpoint blockade in breast cancer.** Karin E. de Visser, Amsterdam, Netherlands

Room W315, Convention Center
**Regulatory Science and Policy Session**

**MODERNIZING CLINICAL TRIAL CONDUCT AND EVIDENCE GENERATION: ADVANCING DECENTRALIZED ONCOLOGY TRIALS**

**Moderator:** Paul G. Kluetz, Silver Spring, MD

**Panelists:** Muhammad Shaalan Beg, Durham, NC
Hassan Kadhim, New York, NY
Craig Lipset, New York, NY
Timil Patel, Silver Spring, MD
Alicia C. Staley, Charlestown, MA
Ramya Thota, Murray, UT

Valencia BC, Convention Center
**NEW INSIGHTS INTO CANCER INITIATION, EVOLUTION, THERAPY, AND SURVIVORSHIP THROUGH BIG DATA ANALYSIS**

**Chair:** Jinghui Zhang, Memphis, TN

1:00 p.m.  **Chair Introduction.** Jinghui Zhang, Memphis, TN

1:05 p.m.  **Landscape of mutagenesis in over 12,000 whole genome sequenced cancers of UK NHS patients.** Serena Nik-Zainal, Cambridge, United Kingdom

1:25 p.m.  **Ordered and selective patterns of cancer genome evolution revealed by lineage tracing of sporadic p53 loss.** Timour Baslan, New York, NY

1:40 p.m.  **Dynamics of age- versus therapy-related clonal hematopoiesis in 2,860 long-term survivors of pediatric cancer.** Jinghui Zhang, Memphis, TN

2:00 p.m.  **Big data approaches to study intercellular signaling during tumor immune evasion.** Peng Jiang, Bethesda, MD

2:20 p.m.  **Panel Discussion**
Room W304 E-H, Convention Center
PATHOGENESIS OF CHILDHOOD CANCERS AND OPPORTUNITIES FOR NEW THERAPEUTIC APPROACHES

Chair: Sarah K. Tasian, Philadelphia, PA

1:00 p.m. Chair Introduction. Sarah K. Tasian, Philadelphia, PA
1:05 p.m. Philadelphia chromosome-like ALL: Biology informs targeted therapies. Sarah K. Tasian, Philadelphia, PA
1:30 p.m. Mechanistic insights of brain tumor relapse. Jezabel Rodriguez-Blanco, Charleston, SC
1:55 p.m. Rhabdomyosarcoma: New research tools for precision medicine. Corinne Mary Linardic, Durham, NC

Room W414, Convention Center
ROLE OF AGING IN CANCER

Chair: Sandra S. McAllister, Boston, MA

1:00 p.m. Chair Introduction. Sandra S. McAllister, Boston, MA
1:05 p.m. Integrating noise from random damages into signals that presage breast cancer susceptibility. Mark A. Labarge, Duarte, CA
1:30 p.m. Metabolic reprogramming: A bridge between aging and tumor progression. Ana P. Da Silva Gomes, Tampa, FL
1:55 p.m. Impact of immune age on cancer progression and therapeutic response. Sandra S. McAllister, Boston, MA

Tangerine Ballroom 3-4 (WF3-4), Convention Center
TARGETING RNA SPlicing IN CANCER AND THE IMMUNE SYSTEM

Chair: Olga A. Anczukow, Farmington, CT

1:00 p.m. Chair Introduction. Olga A. Anczukow, Farmington, CT
1:05 p.m. Understanding and targeting RNA splicing in breast cancer. Olga A. Anczukow, Farmington, CT
1:30 p.m. RNA splicing in cancer: From synthetic lethality to immuno-oncology and beyond. Thomas (Trey) Westbrook, Houston, TX
1:55 p.m. From splicing to polyadenylation in tumor immunity. Robert Bradley, Seattle, WA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
SUNDAY

**Special Session • 1:00 p.m.–2:30 p.m.**

Tangerine Ballroom 2 (WF2), Convention Center

NEW DRUGS ON THE HORIZON: PART 1

**Cochairs:** Mary M. Mader, Indianapolis, IN; David Millan, Cambridge, MA

**1:00 p.m.**  Introduction. Mary M. Mader, Indianapolis, IN

**1:05 p.m.**  ND01 ABBV-319: A first-in-class Glucocorticoid Receptor Modulator (GRM) agonist ADC for the treatment of B-cell malignancies. James W. Purcell, South San Francisco, CA

**1:25 p.m.**  ND02 CTX112 and CTX131: Next-generation CRISPR/Cas9-engineered allogeneic (allo) CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors. Jonathan A. Terrett, Cambridge, MA

**1:45 p.m.**  ND03 Discovery of ARV-766, an androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer. Larry Snyder, New Haven, CT

**2:05 p.m.**  ND04 BAY 2965501: A highly selective DGK-ζ inhibitor for cancer immunotherapy with first-in-class potential. Dennis Kirchhoff, Berlin, Germany

**2:25 p.m.**  Closing remarks. David Millan, Cambridge, MA

---

**MEET AND GREET • 1:15 p.m.–2:45 p.m.**

NOT ELIGIBLE FOR CME

W Halls B-E1, AACR Central, Convention Center

MINORITIES IN CANCER RESEARCH (MICR) MEET AND GREET

**Chair:** Clayton C. Yates, Baltimore, MD

---

**MEET AND GREET 1:30 p.m.–3:00 p.m.**

NOT ELIGIBLE FOR CME

W Halls B-E1, AACR Central, Convention Center

WOMEN IN CANCER RESEARCH (WICR) MEET AND GREET

**Chair:** Sheila Kumari Singh, Hamilton, ON, Canada
POSTER SESSIONS • 1:30 p.m.-5:00 p.m.

W Halls B-E1, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

TUMOR BIOLOGY

Section 1  Mouse Models of Human Cancer
Section 2  Novel Models of Human Cancer
Section 3  Tumor Dormancy and Metastasis
Section 4  Tumor Heterogeneity 1
Section 5  Tumor Heterogeneity 2
Section 6  Tumor Organoids for Cancer Research
Section 7  Tumor Organoids for Therapeutic Testing

MOLECULAR/CELLULAR BIOLOGY AND GENETICS

Section 8  Innovative Approaches for Tumor Profiling and Data Analysis 1
Section 9  Innovative Approaches for Tumor Profiling and Data Analysis 2
Section 10  Signaling Pathways in Cancer Metabolism
Section 11  Targeting Replication Stress and the Immune Microenvironment
Section 12  Tumor Signaling

MULTIDISCIPLINARY

Section 13  Cancer Cachexia

EXPERIMENTAL AND MOLECULAR THERAPEUTICS

Section 14  Drug Resistance in Molecular Targeted Therapies 1
Section 15  Drug Resistance in Molecular Targeted Therapies 2
Section 16  New Drug Targets
Section 17  Novel Antitumor Agents 1
Section 18  Novel Antitumor Agents 2
Section 19  Oncogenes and Tumor Suppressor Genes as Targets for Therapy 1
Section 20  Targeting the Tumor Microenvironment
Section 35  Late-Breaking Research: Experimental and Molecular Therapeutics 1

IMMUNOLOGY

Section 21  Adaptive Immunity to Tumors
Section 22  Cancer-associated Inflammation and Microbiome
Section 23  Innate Immunity to Tumors
Section 24  Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
SCIENCE AND HEALTH POLICY
Section 26  Science and Health Policy / Regulatory Science and Policy

POPULATION SCIENCES
Section 27  Cancer Survivorship

PREVENTION / EARLY DETECTION / INTERCEPTION
Section 28  Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment

COVID-19 AND CANCER
Section 29  COVID-19 and Cancer

CHEMISTRY
Section 30  Basic and Applied Nanotechnology and Nano-based Therapeutics and Drug Delivery
Section 34  Late-Breaking Research: Chemistry

BIOINFORMATICS / COMPUTATIONAL BIOLOGY / SYSTEMS BIOLOGY / CONVERGENT SCIENCE
Section 31  Mathematical Modeling of Tumor Growth and Treatment Response
Section 32  Molecular Modeling, Sequence, and Integrative Analysis

MOLECULAR/CELLULAR BIOLOGY AND GENETICS
Section 36  Late-Breaking Research: Molecular/Cellular Biology and Genetics 1

CLINICAL RESEARCH EXCLUDING TRIALS
Section 37  Adoptive Cell Therapy 1
Section 38  Analyses Using Clinical and Genomic Databases
Section 39  Biomarkers of Therapeutic Benefit 1
Section 40  Biostatistics in Clinical Trials / Surgical Oncology
Section 41  Diagnostic and Prognostic Biomarkers 1
Section 42  Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1
Section 43  Precision Molecular Subtyping and Therapeutic Development
Section 44  Radiation Oncology / Radiation Science
Meet and Greet • 2:00 p.m.–3:00 p.m.
NOT ELIGIBLE FOR CME CREDIT
Publications Booth 2743, W Halls B-E1
MEET THE EDITORS-IN-CHIEF OF CANCER DISCOVERY:
LEWIS C. CANTLEY, PhD AND LUIS A. DIAZ JR., MD

Awards and Lectures • 3:00 p.m.–3:45 p.m.
Room W311 E-H, Convention Center
AACR-G.H.A. CLOWES AWARD FOR OUTSTANDING
BASIC CANCER RESEARCH
Chair: Christine A. Iacobuzio-Donahue
3:00 p.m. Introduction. Christine A. Iacobuzio-Donahue
3:05 p.m. Award Lecture. M. Celeste Simon, Philadelphia, PA

Room W312, Convention Center
AACR-MINORITIES IN CANCER RESEARCH
JANE COOKE WRIGHT LECTURESHP
Chair: Lorna Rodriguez-Rust, Duarte, CA
3:00 p.m. Introduction. Lorna Rodriguez-Rust, Duarte, CA
3:05 p.m. Award Lecture. Selwyn M. Vickers, Birmingham, AL

Meet and Greet • 3:00 p.m.–4:00 p.m.
NOT ELIGIBLE FOR CME CREDIT
Publications Booth 2743, W Halls B-E1
MEET THE EDITOR-IN-CHIEF OF CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION: ELIZABETH A. PLATZ, SCD, MPH

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Forum • 3:00 p.m.–4:30 p.m.
Room W315, Convention Center
Science Policy Session
MAKING YOUR VOICES HEARD: AACR’S ADVOCACY EFFORTS WITH POLICY MAKERS-DEDICATED TO THE MEMORY OF CHAIRMAN JOHN EDWARD PORTER
Moderator: Roy S. Herbst, New Haven, CT
Panelists: John DeMuro, Tampa, FL
Dana Acton, Washington, DC

Special Session • 3:00 p.m.–4:30 p.m.
Tangerine Ballroom 2 (WF2), Convention Center
NEW DRUGS ON THE HORIZON: PART 2
Cochairs: Joachim Rudolph, South San Francisco, CA; Sara J. Buhrlage, Boston, MA

3:00 p.m. Introduction. Joachim Rudolph, South San Francisco, CA

3:05 p.m. ND05 The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers. Yanke Liang, Watertown, MA

3:25 p.m. ND06 AMG 305, a dual targeting BiTE® molecule with selective activity for solid tumors that co-express CDH3 and MSLN. Elizabeth Pham, South San Francisco, CA

3:45 p.m. ND07 Discovery of RMC-6291, a tri-complex KRASG12C(ON) inhibitor. Jim Cregg, Belmont, CA

4:05 p.m. ND08 Discovery of FX-909, a first-in-class inverse agonist of the peroxisome proliferator-activated receptor gamma (PPARG) lineage transcription factor, to treat patients with the luminal subtype of advanced urothelial cancer (UC). Robert Sims, Cambridge, MA

4:25 p.m. Closing remarks. Sara J. Buhrlage, Boston, MA
Clinical Trials Minisymposium • 3:00 p.m.–5:00 p.m.

Valencia A, Convention Center

NOVEL CLINICAL TRIALS FOR HEMATOLOGICAL MALIGNANCIES

Cochairs: Dorothy A. Sipkins, Durham, NC; Clifton C. Mo, Boston, MA

3:00 p.m. **Introduction**

3:05 p.m. **CT021** Assessing clinical and pharmacodynamic (PD) profiles of patients (pts) with chronic lymphocytic leukemia (CLL) on ianalumab (VAY736) + ibrutinib. Janghee Woo, Cambridge, MA

3:30 p.m. **CT022** Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study. Johannes Duell, Würzburg, Germany

3:35 p.m. **CT023** Phase 1 trial of CD19/CD20 bispecific chimeric antigen receptor-engineered naïve/memory T cells for relapsed or refractory non-Hodgkin lymphoma. Benjamin R. Puliafito, Los Angeles, CA

3:50 p.m. **CT024** REDIRECT: A Phase 2 study of AFM13 in patients with CD30positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL). Won Seog Kim, Seoul, Korea, Republic of

4:05 p.m. **CT025** NMS-03592088, a novel, potent FLT3, KIT and CSF1R inhibitor with activity in FLT3 positive acute myeloid leukemia patients with prior FLT3 inhibitor experience. Antonio Curti, Bologna, Italy

4:20 p.m **CT026** A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies. Courtney D. DiNardo, Houston, TX

4:35 p.m. **Discussant.** William S. Dalton, Tampa, FL

4:50 p.m. **Closing remarks**

Minisymposia • 3:00 p.m.–5:00 p.m.

Room W240, Convention Center

Bioinformatics / Computational Biology / Systems Biology / Convergent Science

CUTTING-EDGE COMPUTATIONAL APPROACHES FOR PRECISION ONCOLOGY AND CANCER BIOLOGY

Cochairs: Sylvia K. Plevritis, Stanford, CA; Jiyang Yu, Memphis, TN

3:00 p.m. **Introduction**

3:05 p.m. **1116** Identifying neuroendocrine prostate cancer drivers using in vivo forward genetics. Alessandro Vasciaveo, New York, NY

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
3:20 p.m.  1117  Rapid label-free imaging-based evaluation of cancer dependencies in zero-passage primary cells. Csaba Molnar, Cambridge, MA

3:35 p.m.  1118  High-dimensional deconstruction of pancreatic cancer identifies co-occurring TME features associated with survival. Erik Storrs, St. Louis, MO

3:50 p.m.  1119  Systems pharmacology approaches to study tumor drug mechanism of action. Lucas Zhongming Hu, New York, NY

4:05 p.m.  1120  Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomics. Shreya Johri, Boston, MA

4:20 p.m.  1121  Patient-centric Discovery by Active Learning (PeDAL) platform to predict drug response in a heterogeneous patient population. Arlette H. Uihlein, Pittsburgh, PA

4:35 p.m.  1122  Pan-cancer analysis reveals roles of retrotransposon-fusion RNAs. E. Alice Lee, Boston, MA

4:50 p.m.  Closing remarks

Room W414, Convention Center
Clinical Research Excluding Trials
IMMUNOTHERAPY

Cochairs: Juan R. Cubillos-Ruiz, New York, NY; Pedro J. Romero, Epalinges, Switzerland

3:00 p.m.  Introduction

3:05 p.m.  1124  PTEN loss confers resistance to anti-PD-1 therapy in NSCLC by increasing tumor infiltration of T regulatory cells. Francisco Exposito, Pamplona, Spain / New Haven, CT

3:20 p.m.  1125  Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab. Tyler Joseph Alban, Cleveland, OH

3:35 p.m.  1126  Disease monitoring with comprehensive genomics provides evidence of mechanism of action and immune evasion in patients receiving an individualized neoantigen cancer vaccine. Matthew Davis, Emeryville, CA

3:50 p.m.  1127  Preclinical development of safe and effective T cell receptors specific for mutant KRAS G12D peptide. Loic Vincent, Watertown, MA

4:05 p.m.  1128  Lineage tracing of CAR T cells in patients with B cell malignancies. Zinaida Good, Stanford, CA

4:20 p.m.  1129  Targeting tissue-resident macrophage progenitors restores anti-tumor immunity and suppresses tumor growth. Hui Chen, San Diego, CA

4:35 p.m.  1130  A phase 1 dose escalation study of GCC19CART - a novel CoupledCAR therapy for subjects with metastatic colorectal cancer. Lei Xiao, Rockville, MD

4:50 p.m.  Closing remarks
Room W331, Convention Center
Experimental and Molecular Therapeutics
INNOVATIVE THERAPEUTIC APPROACHES

Cochairs: Mateusz Opyrchal, St. Louis, MO; Jonathan R. Brody, Portland, OR

3:00 p.m. Introduction

3:05 p.m. 1132 Exploiting MGMT loss using a new class of DNA modifiers which selectively target tumor DNA and overcome therapy resistance mechanisms across multiple tumor types. Kyle Tarantino, New Haven, CT

3:20 p.m. 1133 A B7-H4 targeting antibody-drug conjugate shows anti-tumor activity in PARPi and platinum resistant cancers with B7-H4 expression. Sarah B. Gitto, Philadelphia, PA

3:35 p.m. 1134 Therapeutic potential of an antibody-drug conjugate directed against a tumor-specific epitope on podocalyxin. Pamela M. Austin Dean, Vancouver, BC, Canada

3:50 p.m. 1135 TP317, a first-in-class resolvin E1 small molecule, potentiates the efficacy of immune checkpoint (ICI) inhibitors in ICI-resistant and ICI-sensitive tumors. Franciele C. Kipper, Boston, MA

4:05 p.m. 1136 Targeting DHX9 inhibition as a novel therapeutic modality in microsatellite instable colorectal cancer. Jennifer Castro, Lexington, MA

4:20 p.m. 1137 Identification of a high selective SMARCA2 degrader which effectively suppresses the SMARCA4-deficient tumors in vitro and in vivo. Renhong Tang, Nanjing, China

4:35 p.m. 1138 Novel SMARCA2 degrading bifunctional molecules as therapeutics in SMARCA4 mutant lung cancer. Yonathan Lissanu, Houston, TX

4:50 p.m. Closing remarks

Room W224, Convention Center
Experimental and Molecular Therapeutics
SMALL MOLECULE THERAPEUTIC AGENTS

Cochairs: Rachel N. Grisham, New York, NY; Judy Leopold, Ann Arbor, MI

3:00 p.m. Introduction

3:05 p.m. 1140 Pre-clinical efficacy of targeting BAF complexes through inhibition of the dual ATPases BRG1 and BRM by FHD-286 in cellular models of AML. Warren C. Fiskus, Houston, TX

3:20 p.m. 1141 The CoREST complex as a novel target to disrupt AT/RT’s abnormal epigenetic landscape. Anupa Geethadevi, Baltimore, MD

3:35 p.m. 1142 Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C. Kevin R. Webster, Boston, MA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
3:50 p.m.  1143  Development of a CDK2-selective small molecule inhibitor INCB123667 for the treatment of CCNE1hi breast cancers. Saswati Chand, Wilmington, DE

4:05 p.m.  1144  Dynamic changes in circulating tumor DNA (ctDNA) in patients treated with sotorasib for KRAS G12C mutant non-small cell lung cancer. Yonina R. Murciano-Goroff, New York, NY

4:20 p.m.  1145  PH020-803: an MTA-cooperative and brain-penetrable PRMT5 inhibitor that selectively targets MTAP-deleted tumors. Feng Gao, Beijing, China

4:35 p.m.  1146  Tepotinib treatment inhibits tumor growth and affects tumor permeability in an intracranial PDX model of MET-amplified NSCLC brain metastasis. Joachim Albers, Darmstadt, Germany

4:50 p.m.  Closing remarks

Valencia BC, Convention Center
Immunology
GENETICALLY ENGINEERED ANTICANCER T CELLS

Chair: Nabil Ahmed, Houston, TX; Jose-Alejandro Guevara, Tampa, FL

3:00 p.m.  Introduction

3:05 p.m.  1148  1XX mutations slow CAR T cell signaling and increase in vivo persistence. Cynthia C. Bamdad, Waltham, MA

3:20 p.m.  1149  Universal redirection of chimeric antigen receptor T cells against solid tumors via tumor cell membrane-inserting CAR ligands. Angela Zhang, Cambridge, MA

3:35 p.m.  1150  CD70 HIT T cells overcome tumor antigen heterogeneity in renal cell carcinoma. Sophie A. Hanina, New York, NY

3:50 p.m.  1151  CD6 isoforms improve CAR T cell fitness. Jessica S. Morris, Houston, TX

4:05 p.m.  1152  NKTR-255, a polymer-conjugated IL-15, dramatically improves ROR1 CAR-T cell persistence and anti-tumor efficacy in an autochthonous model of ROR1+ lung cancer. W. Sam Nutt, Seattle, WA

4:20 p.m.  1153  IL-4 depletion leads to the improvement of CART cell therapy. Carli Stewart, Rochester, MN

4:35 p.m.  1154  Investigating the functional role of GPNMB in glioblastoma and the tumor immune microenvironment and its targeted elimination using CAR-Ts. Neil Savage, Hamilton, ON, Canada

4:50 p.m.  Closing remarks
ROOM W304 A-D, CONVENTION CENTER
MOLECULAR/CYTOLOGIC BIOLOGY AND GENETICS
METABOLISM AND CANCER

Co-chairs: Nissim Hay, Chicago, IL; Jorge Moscat, New York, NY

3:00 p.m. Introduction

3:05 p.m. 1156 GUK1 is a novel metabolic liability in oncogene-driven lung cancer. Jaime Laurel Schneider, Boston, MA

3:20 p.m. 1157 Uncovering a novel role of peroxisomal β-oxidation in advanced, treatment-resistant prostate cancer. Chui Yan Mah, Adelaide, Australia

3:35 p.m. 1158 Inosine endows CAR T cells with features of increased stemness and anti-tumor potency. Dorota Klysz, Palo Alto, CA

3:50 p.m. 1159 BRAF-mediated PHGDH induction establishes a metabolic vulnerability in melanoma. Neel Jasani, Tampa, FL

4:05 p.m. 1160 A machine learning-based method for in-vivo metabolic flux analysis of patient tumors. Anjali Mittal, Ann Arbor, MI

4:20 p.m. 1161 Primary and metastatic tumors exhibit systems-level differences in dependence on mitochondrial respiratory function. Neal K. Bennett, San Francisco, CA

4:35 p.m. 1162 Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia. Miriam Ferrer, Cold Spring Harbor, NY

4:50 p.m. Closing remarks

TANGERINE BALLROOM 1 (WF1), CONVENTION CENTER
MOLECULAR/CYTOLOGIC BIOLOGY AND GENETICS
TUMOR HETEROGENEITY AT SINGLE-CELL RESOLUTION IN SPACE AND TIME

Co-chairs: Jinghui Zhang, Memphis, TN

3:00 p.m. Introduction

3:05 p.m. 1164 Spatiotemporal profiling defines persister and resistance signatures in targeted treatment of melanoma. Jill Carol Rubinstein, Farmington, CT

3:20 p.m. 1165 Mechanisms of therapeutic resistance in pancreatic cancer identified by single-cell spatial transcriptomics and genetically-engineered stromal tumoroids. Carina Shiau, Boston, MA

3:35 p.m. 1166 APOBEC deaminases compete with tobacco smoking mutagenesis and affect age at onset of lung cancer. Tongwu Zhang, Bethesda, MD

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
3:50 p.m.  1167  Single-cell transcriptomic profiling of SCLC transformation reveals increased intratumoral diversity of variant and non-neuroendocrine subtypes. Joseph Minhow Chan, New York, NY

4:05 p.m.  1168  Mutational processes in tumor-adjacent normal kidneys across countries with varying cancer incidence rates. Yichen Wang, Cambridge, United Kingdom

4:20 p.m.  1169  Genomic evolution of pancreatic cancer at single-cell resolution. Haochen Zhang, New York, NY

4:35 p.m.  1170  Scalable co-sequencing of RNA and DNA from individual nuclei. Timothy R. Olsen, New York, NY

4:50 p.m.  Closing remarks

Room W230, Convention Center
Multidisciplinary
ADVANCING CANCER RESEARCH THROUGH AN INTERNATIONAL CANCER REGISTRY: AACR PROJECT GENIE USE CASES

Chair: Shannon McWeeney, Portland, OR

3:00 p.m.  Introduction Shannon McWeeney, Portland, OR

3:05 p.m.  1172  Oncogenic context shapes the fitness landscape of tumor suppression. Lily M. Blair, Mountain View, CA

3:20 p.m.  1173  Landscape of 4,506 pan-cancer samples harboring BRAFV600E mutations, and NTRK/RET Fusions from 137,401 adult patients with cancer: Clinical implications for tissue agnostic therapies. Mohamed A. Gouda, Houston, TX

3:35 p.m.  1174  Enhancing the utilization of deep learning to predict patient response in small immunotherapy cohorts using real-world data. Gustavo Arango-Argoty, Waltham, MA

3:50 p.m.  1175  Systematic profiling of conditional pathway activation as a new class of cancer dependency. Liang Chang, Cambridge, MA

4:05 p.m.  1176  Quantitative integration of PIK3CA hotspots and paralogy identifies occult oncogenic mutants in PIK3CD. Aphrothiti J. Hanrahan, New York, NY

4:20 p.m.  1177  Genomic characteristics and clinical outcomes of early onset colorectal cancer (EOCRC): Findings from AACR Project GENIE Biopharma Collaborative registry. Enrique Sanz Garcia, Toronto, ON, Canada

4:35 p.m.  LB056  Crowdsourcing rare cancer research in the Hack4NF GENIE-NF tumor identification and classification challenge. Robert J. Allaway, Seattle, WA

4:50 p.m.  Closing remarks. Shannon McWeeney, Portland, OR
Room W304 E-H, Convention Center
Population Sciences
BEYOND GWAS: UNDERSTANDING ETIOLOGIC HETEROGENEITY

Chair: Joellen Schildkraut, Atlanta, GA; Jirong Long, Nashville, TN

3:00 p.m. Introduction

3:05 p.m. 1180 Identification of target proteins for breast cancer genetic risk loci and blood risk biomarkers in a large study by integrating genomic and proteomic data. Guochong Jia, Nashville, TN

3:20 p.m. 1181 Etiologic heterogeneity of genetic risk for DLBCL cell-of-origin molecular subtypes. Rosalie Griffin Waller, Rochester, MN

3:35 p.m. 1182 Association of prostate cancer candidate genes with overall and aggressive prostate cancer in men of African ancestry. Fei Chen, Los Angeles, CA

3:50 p.m. 1183 Mutation type and location in breast cancer susceptibility genes are associated with differential risk in the general population. Mwangala P. Akamandisa, Philadelphia, PA

4:05 p.m. 1184 Impact of individual level uncertainty of lung cancer polygenic risk score on risk stratification and prediction. Xinan Wang, Boston, MA

4:20 p.m. 1185 Mosaic chromosomal alterations are independent predictors of chronic lymphocytic leukemia risk. Aubrey K. Hubbard, Rockville, MD

4:35 p.m. 1186 Contraception and ovarian cancer risk by tumor immune profiles. Jennifer Mongiovi, Boston, MA

4:50 p.m. Closing remarks

Room W311 A-D, Convention Center
Tumor Biology
INTERACTIONS BETWEEN TUMOR CELLS AND IMMUNE CELLS, NEURONS, AND FIBROBLASTS IN THE TUMOR MICROENVIRONMENT

Cochairs: Sandra W. Ryeom, New York, NY; Florencia McAllister, Houston, TX

3:00 p.m. Introduction

3:05 p.m. 1188 L-17/IL-17RA signaling in the pancreatic epithelium upregulates B7-H4 to promote tumorigenesis. Susana Castro Pando, Houston, TX

3:20 p.m. 1189 MERTK is a target in the microenvironment of osteolytic bone metastasis. Janik Engelmann, Hamburg, Germany

3:35 p.m. 1190 Mimicking CAFs, pial cells support leptomeningeal metastasis. Jenna Snyder, New York, NY

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
3:50 p.m.  1191  Targeting the tumor extracellular matrix to enhance therapeutic interventions in glioblastoma. Sara Pedron-Haba, Urbana, IL

4:05 p.m.  1192  Branched-chain keto acids exert an immune-suppressive and neurodegenerative microenvironment in CNS leptomeningeal lymphoma. Mariam Lotfy Khaled, Tampa, FL

4:20 p.m.  1193  Sensory innervation directly promotes gastric cancer and modulates the tumor microenvironment. Xiaofei Zhi, New York, NY

4:35 p.m.  1194  Evolution of immune and stromal cell states during the gastric cancer continuum. Ruiping Wang, Houston, TX

4:50 p.m.  Closing remarks

Room W307, Convention Center

Tumor Biology

PEDIATRIC CANCER 1: GENOMICS AND BIOLOGY INFORM INNOVATIVE DIAGNOSTIC AND TREATMENT APPROACHES

Cochairs: Mignon L. Loh, Seattle, WA; David Malkin, Toronto, ON, Canada

3:00 p.m.  Introduction

3:05 p.m.  1196  The epigenetic impact and therapeutic opportunity of AR-directed therapy for DSRCT. Danh Truong, Houston, TX

3:20 p.m.  1197  B7-H3-CAR T cells for the treatment of pediatric adrenocortical carcinoma. Rebecca Epperly, Memphis, TN

3:35 p.m.  1198  T cell receptor (TCR) landscape of childhood brain tumors. Itay Raphael, Pittsburgh, PA

3:50 p.m.  1199  Discovery of subtype-specific and therapy associated effects on the tumor immune microenvironment in pediatric neuroblastoma. Katherine E. Masih, Bethesda, MD

4:05 p.m.  1200  Aurora kinase A is a potential therapeutic target regulated by the MYCN oncogene in human retinoblastoma. Naheed Arfin Borah, Bhubaneswar, India

4:20 p.m.  1201  ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma. Anne-Florence Blandin, Boston, MA

4:35 p.m.  1202  Targeting cell adhesion molecule 1 (CADM1) with an antibody drug conjugate for the treatment of osteosarcoma. Yifei Wang, Houston, TX

4:50 p.m.  Closing remarks
Clinical Trials Plenary Session • 3:30 p.m.–5:30 p.m.
W Hall A2-3, Convention Center
HOPE FOR RARE CANCERS: NOVEL TARGETED AND IMMUNOTHERAPY AGENTS
Cochairs: Hedy Kindler, Chicago, IL; Brian A. Van Tine, St. Louis, MO

3:30 p.m.  CT006  First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. Timothy A. Yap, Houston, TX

3:45 p.m.  Discussant. Dean A. Fennell, Leicester, United Kingdom
3:55 p.m.  Discussion

4:00 p.m.  CT007  Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma. Peter W. Szlosarek, London, United Kingdom
4:15 p.m.  Discussant. Patrick M. Forde, Baltimore, MD
4:25 p.m.  Discussion

4:30 p.m.  CT008  Pembrolizumab (pembro) in combination with gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC): Phase 3 KEYNOTE-966 study. Robin Kate Kelley, San Francisco, CA
4:45 p.m.  Discussant. Rachna T. Shroff, Tucson, AZ
4:55 p.m.  Discussion

5:00 p.m.  CT009  S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma. Kari Kendra, Columbus, OH
5:15 p.m.  Discussant. Zeynep Eroglu, Tampa, FL
5:25 p.m.  Discussion

Awards and Lectures • 4:00 p.m.–4:45 p.m.
Room W311 E-H, Convention Center
AACR-WAUN KI HONG AWARD FOR OUTSTANDING ACHIEVEMENT IN TRANSLATIONAL AND CLINICAL CANCER RESEARCH
Chair: Anne S. Tsao, Houston, TX

4:00 p.m.  Introduction. Anne S. Tsao, Houston, TX
4:05 p.m.  Award Lecture. Jun J. Yang, Memphis, TN

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Room W312, Convention Center

AACR-WOMEN IN CANCER RESEARCH
CHARLOTTE FRIEND LECTURESHIP

Chair: Sheila Kumari Singh, Dundas, ON, Canada

4:00 p.m. Introduction. Sheila Kumari Singh, Dundas, ON, Canada

4:05 p.m. Paying it forward — a path to a successful career in cancer research.
Cory Abate-Shen, New York, NY

Meet and Greet • 4:00 p.m.–5:00 p.m.
NOT ELIGIBLE FOR CME CREDIT

Publications Booth 2743, W Halls B-E1
MEET THE EDITOR-IN-CHIEF OF CANCER RESEARCH:
CHRISTINE A. IACOBUZIO-DONAHUE, MD, PHD

NCI-NIH-Sponsored Session • 4:00 p.m.–5:00 p.m.
NOT ELIGIBLE FOR CME CREDIT

Room W314 A, Convention Center

NCI FUNDING OPPORTUNITIES IN CANCER IMMUNOPREVENTION
AND CHEMOPREVENTION

Moderator: Robert H. Shoemaker, Bethesda, MD

4:00 p.m. Beyond immunotherapy, towards immunoprevention: NCI journey so far.
Robert H. Shoemaker, Bethesda, MD

4:15 p.m. Overview of Cancer Immunoprevention Network (CIP-Net).
Altarf Mohammed, Rockville, MD

4:30 p.m. HTAN Pre-Cancer Atlases: Immune targeting opportunities.
Sharmistha Ghosh-Janjigian, Rockville, MD

4:45 p.m. Overview of PREVENT drug development program.
Mark Steven Miller, Rockville, MD
Special Session • 4:00 p.m.–5:00 p.m.
Room W330, Convention Center
**Science Policy Session**
PATIENT AND COMMUNITY ADVOCATE PARTNERS IN CANCER RESEARCH:
DEDICATED TO THE MEMORY OF MARY (DICEY) JACKSON SCROGGINS

Moderator: Patricia Spears, Chapel Hill, NC
Speakers: To be announced

---

**Awards and Lectures • 4:30 p.m.–5:15 p.m.**
Valencia D, Convention Center

**AACR AWARD FOR LIFETIME ACHIEVEMENT IN CANCER RESEARCH**

Chair: To be announced
4:00 p.m. Introduction. To be announced
4:35 p.m. Award Lecture. Carl H. June, Philadelphia, PA

Tangerine Ballroom 3-4 (WF3-4), Convention Center

**AACR AWARD FOR OUTSTANDING ACHIEVEMENT IN CHEMISTRY IN CANCER RESEARCH**

Chair: Chudi Ndubaku, Montreal, QC, Canada
4:30 p.m. Introduction. Chudi Ndubaku, Montreal, QC, Canada
4:35 p.m. Award Lecture. Carolyn R. Bertozzi, Stanford, CA

---

**Professional Advancement Sessions • 5:00 p.m.–6:30 p.m.**
Junior Ballroom F, Rosen Centre Hotel

HOW TO DESIGN A SUCCESSFUL CAREER PATH IN CANCER RESEARCH:
THE DO’S AND DON’TS FOR EARLY-STAGE INVESTIGATORS

Cochairs: Jose G. Trevino, Richmond, VA; Folakemi T. Odedina, Jacksonville, FL; Mariana C. Stern, Los Angeles, CA; Peter DelNero, Little Rock, AR

---

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Executive H-I, Rosen Centre Hotel

PERSONALIZED CAREER CONVERSATIONS

Co-chairs: Antonio T. Baines, Greensboro, NC; Melissa B. Davis, New York, NY; Shiva Malek, South San Francisco, CA; Erica S. Tsang, Vancouver, BC, Canada

Awards and Lectures • 5:30 p.m.–6:15 p.m.

Chapin Theater, Convention Center

PRESIDENTIAL ADDRESS: IDENTIFYING IMMUNE VULNERABILITIES IN SOLID TUMORS - LEUKOCYTE COMMUNICATION NETWORKS REGULATE NEOPLASTIC PROGRESSION AND RESPONSE TO THERAPY

Chair: William N. Hait, New Brunswick, NJ

5:30 p.m.  Introduction. William N. Hait, New Brunswick, NJ

5:35 p.m.  Identifying immune vulnerabilities in solid tumors: Leukocyte communication networks regulate neoplastic progression and response to therapy. Lisa M. Coussens, Portland, OR

Town Meetings • 6:00 p.m.–8:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Windermere W, Hyatt Regency

CELL-OF-ORIGIN AND TUMOR HETEROGENEITY IN CHILDHOOD CANCERS: A PEDIATRIC CANCER WORKING GROUP TOWN HALL MEETING AND NETWORKING RECEPTION

Chair: Katherine A. Janeway, Boston, MA

6:00 p.m.  Networking Reception

6:30 p.m.  PCWG Working Group Overview. E. Alejandro Sweet-Cordero, San Francisco, CA; Katherine A. Janeway, Boston, MA

6:40 p.m.  Title to be announced. Sam Behjati, Cambridgeshire, United Kingdom

6:50 p.m.  Title to be announced. Mariella G. Filbin, Boston, MA

7:00 p.m.  Title to be announced. Frank Westermann, Heidelberg, Germany

7:10 p.m.  Panel Discussion

7:30 p.m.  Networking Reception
Windermere Y, Hyatt Regency
POSITIONING THE AACR AT THE FOREFRONT OF RADIATION SCIENCE AND MEDICINE INNOVATION: A RADIATION SCIENCE AND MEDICINE WORKING GROUP TOWN HALL MEETING AND NETWORKING RECEPTION

Chair: Silvia C. Formenti, New York, NY

6:00 p.m.  Networking Reception
6:30 p.m.  RSM Working Group Overview. Silvia C. Formenti, New York, NY; Fei-Fei Liu, Toronto, ON, Canada
6:40 p.m.  Title to be announced. Mekhail Anwwar, San Francisco, CA
6:50 p.m.  Targeting DNA repair in cancer therapy. Alan D. D’Andrea, Boston, MA
7:00 p.m.  Title to be announced. Jennifer S. Yu, Cleveland, OH
7:10 p.m.  Panel Discussion
7:30 p.m.  Networking Reception

Windermere X, Hyatt Regency
TUMOR-BODY INTERACTIONS: EMERGING INSIGHTS INTO THE INTERPLAY BETWEEN TUMOR MICRO- AND MACROENVIRONMENTS: A TUMOR MICROENVIRONMENT WORKING GROUP TOWN HALL MEETING AND NETWORKING RECEPTION

Chair: Mikala Egeblad, Cold Spring Harbor, NY

6:00 p.m.  Networking Reception
6:30 p.m.  TME Working Group Overview. Mikala Egeblad, Cold Spring Harbor, NY
6:40 p.m.  Untangling the connection between chronic stress and breast cancer metastasis. Xue-Yan He, Cold Spring Harbor, NY
6:50 p.m.  The aged pancreatic microenvironment promotes pancreatic cancer progression. Daniel J. Zabransky, Baltimore, MD
7:00 p.m.  Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Joseph Tintelnot, Hamburg, Germany
7:10 p.m.  Panel Discussion
7:30 p.m.  Networking Reception

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Special Session • 6:30 p.m.–8:00 p.m.
NOT ELIGIBLE FOR CME CREDIT
West Lobby B - Convention Center

NETWORKING HUBS

Networking Hubs:
Cancercareers: Scientific Careers’ Resource Center
Digital Technologies for Research and Trials
Entrepreneurship
Hematologic Malignancies
Interception, Early Detection, and Prevention
Resiliency and Survivorship
MONDAY, APRIL 17*

Meet-the-Expert Sessions • 7:00 a.m.–7:45 a.m.

Room W240, Convention Center
AGING BIOMARKERS AND ACCELERATED AGING AS A NEW PARADIGM FOR CLINICAL RESEARCH IN SURVIVORS OF CHILDHOOD CANCER
Zhaoming Wang, Memphis, TN

Room W331, Convention Center
BIOLOGY, GENETICS, AND NOVEL THERAPIES FOR METASTATIC DISEASE
Sohail Tavazoie, New York, NY

Room W311 A-D, Convention Center
COLLABORATING ACROSS DISCIPLINES – INCLUDING EPIDEMIOLOGY – FOR CANCER DISCOVERY AND TRANSLATION
Elizabeth A. Platz, Baltimore, MD

Room W312, Convention Center
CONTROL OF TELOMERASE IN CANCER
Steven E. Artandi, Stanford, CA

Room W330, Convention Center
CONTROVERSIES IN FRONT LINE THERAPY OF DIFFUSE LARGE B-CELL LYMPHOMA: IS RCHOP STILL A STANDARD?
Grzegorz S. Nowakowski, Rochester, MN

Room W311 E-H, Convention Center
EMERGING INTERDISCIPLINARY OPPORTUNITIES IN COMPUTATIONAL ONCOLOGY
Eliezer M. Van Allen, Boston, MA

Chapin Theater, Convention Center
IMMUNE SURVEILLANCE: WHAT’S NEW IN RESPONDING CELLS AND REGULATION
Pamela S. Ohashi, Toronto, ON, Canada

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Room W304 E-H, Convention Center
**JOS JONKERS: TITLE TO BE ANNOUNCED**
Jos Jonkers, Amsterdam, Netherlands

Room W315, Convention Center
**PREDICTION AND PREVENTION: SEEKING THE HOLY GRAIL FOR CANCER PREDISPOSITION**
David Malkin, Toronto, ON, Canada

Room W304 A-D, Convention Center
**RESISTANCE TO ENDOCRINE THERAPY IN BREAST CANCER**
Carlos L. Arteaga, Dallas, TX

Room W307, Convention Center
**SMALL MOLECULE TARGETING OF TRANSCRIPTION-REPLICATION CONFLICT FOR SELECTIVE CHEMOTHERAPY**
Linda H. Malkas, Duarte, CA

Room W314 A, Convention Center
**SO YOU WANT TO JOIN A HOT BAND CALLED CLINICAL IMPACT, PLEASE COME AND JOIN! SPECIFICALLY WANTED/NEEDED ARE CLINICIANS AND BASIC/TRANSLATIONAL SCIENTISTS**
Jonathan R. Brody, Portland, OR

Room W230, Convention Center
**UNDERSTANDING LUNG CANCER DISPARITIES THROUGH MULTIENTHNIC STUDIES**
Loic Le Marchand, Honolulu, HI
**MONDAY, APRIL 17* (cont’d)**

**Plenary Session • 8:00 a.m.–10:00 a.m.**

W Hall A2-3, Convention Center

**EARLY DETECTION AND INTERCEPTION OF CANCER**

Chair: Peter Kuhn, Los Angeles, CA

- **8:00 a.m.**  
  Introduction. Peter Kuhn, Los Angeles, CA

- **8:05 a.m.**  
  New insights into carcinogenesis from normal esophagus.  
  Phil H. Jones, Cambridge, United Kingdom

- **8:27 a.m.**  
  When to intervene along the breast cancer continuum?  
  E. Shelley Hwang, Durham, NC

- **8:49 a.m.**  
  Improving cancer outcomes through equitable access to cfDNA tests.  
  Phillip G. Febbo, San Diego, CA

- **9:11 a.m.**  
  Forecasting pancreatic carcinogenesis through spatial multi-omics.  
  Elana Judith Fertig, Baltimore, MD

- **9:33 a.m.**  
  Early engagement equals early detection.  
  Karriem S. Watson, Bethesda, MD

- **9:55 a.m.**  
  Wrap-up and opportunities for the future.  
  Peter Kuhn, Los Angeles, CA

**Poster Sessions • 9:00 a.m.-12:30 p.m.**

**NOT ELIGIBLE FOR CME CREDIT**

W Halls B-E1, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

**TUMOR BIOLOGY**

- Section 1: Carcinogenesis and Mutagenesis
- Section 2: EMT and Plasticity
- Section 3: Metabolic Influences on the Tumor Microenvironment
- Section 4: Metastasis Promoting and Suppressing Genes
- Section 5: Metastatic and Premetastatic Microenvironments
- Section 6: Tumor Cell Interactions with Fibroblasts, Neuronal Cells, and Immune Cells

---

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
MOLECULAR/CELLULAR BIOLOGY AND GENETICS
Section 8  Autophagy, Mitochondrial Function, and Ferroptosis
Section 9  Biomarker Discovery
Section 10  Cell Cycle Progression, Checkpoint, and Telomeres
Section 11  Gene Regulation in Hormonal and Pediatric Cancers
Section 12  Gene Regulation in Solid Tumors
Section 13  Tumor Heterogeneity and Clonal Evolution

EXPERIMENTAL AND MOLECULAR THERAPEUTICS
Section 14  Antibody Drug Conjugates
Section 15  Cell Cycle/Cell Proliferation Inhibitors for Cancer Therapy
Section 16  New Therapeutic Targeted Agents
Section 17  Novel Antitumor Agents 3
Section 18  Novel Antitumor Agents 4
Section 19  Novel Mechanisms / Drug Transport and Metabolism
Section 20  Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2
Section 21  Reversal of Drug Resistance

IMMUNOLOGY
Section 22  CAR T-cell Therapy 1
Section 23  Immunomodulatory Agents and Interventions 1
Section 24  Immunomodulatory Agents and Interventions 2
Section 25  Therapeutic Antibodies 1
Section 35  Late-Breaking Research: Immunology 1

POPULATION SCIENCES
Section 26  Cancer Disparities 1
Section 27  Cancer Disparities 2

PREVENTION / EARLY DETECTION / INTERCEPTION
Section 28  Cancer Disparities Research
Section 36  Late-Breaking Research: Prevention, Early Detection, and Interception

CHEMISTRY
Section 30  Drug Delivery
Section 31  Proteomics and Biomarker Discovery
BIOINFORMATICS / COMPUTATIONAL BIOLOGY / SYSTEMS BIOLOGY / CONVERGENT SCIENCE

Section 32  Bioinformatics Applications in Cancer Biology 1
Section 33  New Analysis Tools
Section 34  Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1

CLINICAL RESEARCH EXCLUDING TRIALS

Section 38  Biomarkers for Elucidation of Tumor Biology and Metastasis
Section 39  Biomarkers of Therapeutic Benefit 2
Section 40  Biomarkers of Therapeutic Benefit 3
Section 41  Diagnostic and Prognostic Biomarkers 2
Section 42  Genomic and Epigenomic Profiles for Response Prediction
Section 43  Immune Response to Therapies
Section 44  Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 2
Section 45  Modifiers of the Tumor Microenvironment

CLINICAL TRIALS

Section 46  Phase II and Phase III Clinical Trials in Progress
Section 47  Phase III and Pediatric Clinical Trials

Meet and Greet • 9:30 a.m.–10:30 a.m.

NOT ELIGIBLE FOR CME CREDIT

Publications Booth 2743, W Halls B-E1

MEET THE EDITORS-IN-CHIEF OF CANCER IMMUNOLOGY RESEARCH:
ROBERT D. SCHREIBER, PhD AND PHILIP D. GREENBERG, MD

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
**Awards and Lectures • 10:15 a.m.–11:00 a.m.**

Chapin Theater, Convention Center

**Science Policy Session**

**NCI DIRECTOR’S ADDRESS AND FIRESIDE CHAT**

10:15 a.m.  **Introduction.** Lisa M. Coussens, Portland, OR
10:20 a.m.  **NCI Director’s Address.** Monica Marie Bertagnolli, Bethesda, MD
10:30 a.m.  **Fireside Chat**

**Advances in Organ Site Research • 10:15 a.m.–11:45 a.m.**

Valencia BC, Convention Center

**INFORMING FUTURE PRECISION MEDICINE**

**TRIALS FOR PANCREATIC CANCER**

Chair: Jennifer J. Knox, Toronto, ON, Canada

10:15 a.m.  **Introduction.** Jennifer J. Knox, Toronto, ON, Canada
10:20 a.m.  **The necessity, the challenge and tangible hope of precision trials in pancreatic cancer.** Jennifer J. Knox, Toronto, ON, Canada
10:45 a.m.  **The cellular heterogeneity of pancreatic cancer drives local and systemic immune responses and leads to opportunities for patient stratification and trial design.** Marina Pasca Di Magliano, Ann Arbor, MI
11:10 a.m.  **Clonal architecture and tumor heterogeneity during treatment response and dissemination: Lessons from barcoding.** Andrea Viale, Houston, TX
11:35 a.m.  **Panel Discussion**

Room W304 E-H, Convention Center

**THE OVARIAN CANCER MICROENVIRONMENT: PROMISE FOR NEW THERAPIES**

Chair: Kathleen N. Moore, Oklahoma City, OK

10:20 a.m.  **Building human ovarian cancer microenvironment models.** Frances R. Balkwill, London, United Kingdom
10:45 a.m.  **Preclinical evidence for targeting the microenvironment.** Katherine C. Fuh, St. Louis, MO
11:10 a.m.  **Targeting the microenvironment: Moving bench findings to the bedside in ovarian cancer.** Kathleen N. Moore, Oklahoma City, OK
**Advances in Population Sciences • 10:15 a.m.–11:45 a.m.**

Room W307, Convention Center

**BEHAVIORAL ECONOMICS AND NUDGES TO IMPROVE CANCER CARE**

**Chair:** Shivan J. Mehta, Philadelphia, PA

10:20 a.m.  Behavioral economic approaches for population-based cancer screening.  
Shivan J. Mehta, Philadelphia, PA

10:45 a.m.  From biomarker testing to targeted therapy: Leveraging behavioral nudges to optimize precision oncology care.  
Kelsey S. Lau-Min, Boston, MA

11:10 a.m.  Nudging our way to better end-of-life care for patients with cancer.  
Christopher Manz, Boston, MA

**Advances in the Science of Cancer Disparities  
10:15 a.m.–11:45 a.m.**

Tangerine Ballroom 1 (WF1), Convention Center

**STRUCTURE VS. BIOLOGY AND THE IMPACT ON OUR COMMUNITIES**

**Chair:** Robert A. Winn, Richmond, VA

10:15 a.m.  Chair Introduction.  
Robert A. Winn, Richmond, VA

10:20 a.m.  The missing omics in the structure vs. biology.  
Robert A. Winn, Richmond, VA

10:35 a.m.  Molecular markers of CRC in African Americans and Caucasians: Immunity and mutations.  
Jovanny Zabaleta, New Orleans, LA

10:50 a.m.  Ancestry and the DARC-immune response in cancer disparities.  
Melissa B. Davis, New York, NY

11:05 a.m.  Multiomics in disparities research: Identifying African ancestry-specific mechanisms in the triple negative breast cancer tumor microenvironment.  
Rachel Martini, New York, NY  
[AACR NextGen Star]

11:20 a.m.  Panel Discussion

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
**Major Symposia • 10:15 a.m.–11:45 a.m.**

Room W304 A-D, Convention Center

**25TH ANNIVERSARY OF TRASTUZUMAB: IMPACT AND FUTURE DIRECTIONS**

**Chair:** H. Michael Shepard, Springfield, OR

- **10:15 a.m.**  **Chair Introduction.** H. Michael Shepard, Springfield, OR
- **10:20 a.m.**  **Development of trastuzumab: A journey through the early days.** Gail D. Lewis, San Francisco, CA
- **10:45 a.m.**  **New approaches to the treatment of HER2-positive breast cancer: Lessons learned.** Dennis J. Slamon, Los Angeles, CA
- **11:10 a.m.**  **Can cellular therapy provide another arrow in the quiver for HER2 positive malignancies?** Gregory I. Frost, West Palm Beach, FL

Room W311 E-H, Convention Center

**ADVANCES IN QUANTITATIVE SCIENCES IN CANCER: FROM ATOMIC SCALE TO PATIENTS**

**Chair:** Nagarajan Vaidehi, Duarte, CA

- **10:15 a.m.**  **Chair Introduction.** Nagarajan Vaidehi, Duarte, CA
- **10:20 a.m.**  **Harnessing allostery and disordered proteins in designing the next generation targeted therapeutics.** Nagarajan Vaidehi, Duarte, CA
- **10:45 a.m.**  **Oncosomes in the early stages of breast cancer.** Peter Kuhn, Los Angeles, CA
- **11:10 a.m.**  **Composing each patient's equation: Unraveling brain tumor complexity by integrating multi-regional image-localized biopsies.** Kristin R. Swanson, Phoenix, AZ

Room W311 A-D, Convention Center

**CLONAL HEMATOPOIESIS**

**Chair:** Benjamin L. Ebert, Boston, MA

- **10:15 a.m.**  **Chair Introduction.** Benjamin L. Ebert, Boston, MA
- **10:20 a.m.**  **Determinants of clonal expansion rate in CHIP.** Siddhartha Jaiswal, Stanford, CA
- **10:45 a.m.**  **The bone marrow microenvironment as a driver of clonal hematopoiesis and leukemic transformation.** Jennifer Trowbridge, Bar Harbor, ME
- **11:10 a.m.**  **Clonal hematopoiesis and inflammation.** Benjamin L. Ebert, Boston, MA
Room W224, Convention Center
HISTONE ALTERATIONS AND EPIGENETICS AS CANCER DRIVERS

Chair: Liling Wan, Philadelphia, PA

10:15 a.m.   Chair Introduction. Liling Wan, Philadelphia, PA
10:20 a.m.   Modeling and targeting epigenetic cancer drivers. Bradley E. Bernstein, Boston, MA
10:45 a.m.   Oncohistones and disrupted development in diffuse glioma. Suzanne J. Baker, Memphis, TN
11:10 a.m.   Reading epigenetic landscape: New mechanisms and therapeutic opportunities. Liling Wan, Philadelphia, PA

Room W315, Convention Center
Regulatory Science and Policy Session
IMPORTANCE OF OVERALL SURVIVAL IN ASSESSING RISK/BENEFIT: THE PARP AND PI3K INHIBITOR STORIES

Moderator: Mirat Shah, Silver Spring, MD

Panelists: Laleh Amiri-Kordestani, Silver Spring, MD
          George D. Demetri, Boston, MA
          Mallorie Fiero, Silver Spring, MD
          Nicole J. Gormley, Silver Spring, MD
          Abigail Johnston, Orlando, FL
          Nicholas Richardson, Silver Spring, MD
          Mikkael A. Sekeres, Miami, FL

Tangerine Ballroom 3-4 (WF3-4), Convention Center
INNATE LYMPHOID CELLS IN CANCER

Chair: Tobias Bald, Bonn, Germany

10:15 a.m.   Chair Introduction. Tobias Bald, Bonn, Germany
10:20 a.m.   Mouse models to study natural killer cells and innate lymphoid cells in cancer. Tobias Bald, Bonn, Germany
10:45 a.m.   Human natural killer cell and innate lymphoid cell differentiation in cancer. Aharon Gideon Freud, Columbus, OH
11:10 a.m.   Reverse engineering tumor escape to increase persistence of allogeneic iPSC-NK cell therapy. Karl-Johan Malmberg, Oslo, Norway

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Room W414, Convention Center

ORGAN SPECIFIC REGULATION OF METASTASIS

Chair: Mikala Egeblad, Cold Spring Harbor, NY

10:15 a.m.  Chair Introduction. Mikala Egeblad, Cold Spring Harbor, NY
10:20 a.m.  Chronic stress causes metastasis via neutrophil-mediated changes to the microenvironment. Mikala Egeblad, Cold Spring Harbor, NY
10:45 a.m.  Systemic instigation of neuroinflammation facilitates brain metastasis. Neta Erez, Tel Aviv, Israel
11:10 a.m.  Organ-specific responses to targeted and immunotherapies. Erik Sahai, London, United Kingdom

Valencia D, Convention Center

SPATIAL TECHNOLOGIES FOR MAPPING CANCER CELL ARCHITECTURE

Chair: Emma Lundberg, Stanford, CA

10:15 a.m.  Chair Introduction. Emma Lundberg, Stanford, CA
10:20 a.m.  Mapping stromal-immune cellular communities in breast cancer. Alexander Swarbrick, Darlinghurst, Australia
10:45 a.m.  Mapping cellular plasticity in tumor progression and drug resistance. Itai Yanai, New York, NY
11:10 a.m.  Mapping the spatiotemporal proteome architecture of human cells. Emma Lundberg, Stanford, CA

Valencia A, Convention Center

T CELLS AND THE TUMOR

Chair: Stephanie K. Dougan, Boston, MA

10:15 a.m.  Chair Introduction. Stephanie K. Dougan, Boston, MA
10:16 a.m.  Epigenetic reprogramming of T cell exhaustion: Lessons from chronic viral infection. Debattama Sen, Cambridge, MA
10:36 p.m.  Title to be announced. Nathan Reticker-Flynn, Stanford, CA
10:56 a.m.  Agonistic anti-CD40 converts regulatory T cells into Type 1 effector cells within the tumor microenvironment. Katelyn T. Byrne, Portland, OR [AACR NextGen Star]
11:16 a.m.  Lowering the TCR signaling threshold with a DGKa/z dual inhibitor potentiates anti-tumor immunity. Stephanie K. Dougan, Boston, MA
11:35 a.m.  Panel Discussion
MONDAY, APRIL 17*  (cont’d)

**Special Session • 10:15 a.m.–11:45 a.m.**
Tangerine Ballroom 2 (WF2), Convention Center
NEW DRUGS ON THE HORIZON: PART 3
Cochairs: Zoran Rankovic, Memphis, TN; Adrian L. Gill, Redwood City, CA

10:15 a.m.  **Introduction.** Zoran Rankovic, Memphis, TN

10:20 a.m.  ND09  M3913 induces the maladaptive unfolded protein response through a novel mechanism resulting in strong anti-tumor activity. Ralph Lindemann, Darmstadt, Germany

10:40 a.m.  ND10  Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers. Owen B. Wallace, Boston, MA

11:00 a.m.  ND11  EO-3021: An antibody drug conjugate targeting CLDN18.2 expressing cancers. David Dornan, New York, NY

11:20 a.m.  ND12  TNG260: A novel, orally active, CoREST-selective deacetylase inhibitor for the treatment of STK11-mutant cancers. Leanne G. Ahronian, Boston, MA

11:40 a.m.  **Closing remarks.** Adrian L. Gill, Redwood City, CA

---

**Clinical Trials Plenary Session • 10:15 a.m.–12:15 p.m.**
W Hall A2-3, Convention Center
PROMISING NOVEL ANTITUMOR STRATEGIES IN EARLY PHASE CLINICAL TRIALS
Cochairs: Nilofer S. Azad, Baltimore, MD; Susanna V. Ulahannan, Oklahoma City, OK

**Introduction**

10:15 a.m.  CT011  A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC). Samer Srour, Houston, TX

10:30 a.m.  **Discussant.** John B.A.G. Haanen, Amsterdam, Netherlands

10:40 a.m.  **Discussion**

10:45 a.m.  CT012  Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC). Ezra E. Cohen, San Diego, CA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
11:00 a.m.  
Discussant. Lillian L. Siu, Toronto, ON, Canada

11:10 a.m.  
Discussion

11:15 a.m.  
**CT013**  
Safety and efficacy from the phase 1/2 first-in-human study of REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity, in patients with relapsed/refractory multiple myeloma. Attaya Suvannasankha, Indianapolis, IN

11:30 a.m.  
Discussant. Kenneth C. Anderson, Boston, MA

11:40 a.m.  
Discussion

11:45 a.m.  
**CT014**  
Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer. Jones T. Nauseef, New York, NY

12:00 p.m.  
Discussant. Howard I. Scher, New York, NY

12:10 p.m.  
Discussion

---

**Meet and Greet • 11:30 a.m.–12:30 p.m.**

NOT ELIGIBLE FOR CME CREDIT

Publications Booth 2743, W Halls B-E1

MEET THE EDITOR-IN-CHIEF OF *MOLECULAR CANCER RESEARCH*: MASSIMO LODA, MD
**Major Symposium • 11:45 a.m.–1:00 p.m.**

Chapin Theater, Convention Center  
**PRESIDENTIAL SELECT SYMPOSIUM: PREGNANCY AND CANCER**

**Chair:** Ann H. Partridge, Boston, MA  

11:45 a.m.  **Introductory Remarks from AACR President.** Lisa M. Coussens, Portland, OR  

11:48 a.m.  **Chair Introduction.** Ann H. Partridge, Boston, MA  

11:50 a.m.  **A patient-centered, evidence-based approach to cancer during pregnancy.** Ann H. Partridge, Boston, MA  

12:05 p.m.  **The importance of reproductive rights for pregnant women facing cancer: Difficult choices at a difficult time.** Virginia F. Borges, Denver, CO  

12:20 p.m.  **Helping patients with hematologic malignancies manage issues of fertility preservation and pregnancy.** Brandon M. Hayes-Lattin, Portland, OR  

12:35 p.m.  **Panel Discussion**  
Ann H. Partridge, Boston, MA  
Virginia F. Borges, Denver, CO  
Brandon M. Hayes-Lattin, Portland, OR  
Julia Maues, Baltimore, MD

---

**Meet and Greet • 12:30 p.m.–1:30 p.m.**

**NOT ELIGIBLE FOR CME CREDIT**  
Publications Booth 2743, W Halls B-E1  
**MEET THE EDITORS-IN-CHIEF OF BLOOD CANCER DISCOVERY: RICCARDO DALLA-FAVERA, MD AND KENNETH C. ANDERSON, MD**

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
NCI-NIH-Sponsored Session • 12:30 p.m.–1:30 p.m.
NOT ELIGIBLE FOR CME CREDIT

Room W330, Convention Center
YOU CAN CHOOSE BOTH: STRATEGIES FOR COMPANIES SEEKING BOTH NCI PARTNERSHIP AND FUNDING OPPORTUNITIES FOR TECHNOLOGY DEVELOPMENT AND COMMERCIALIZATION

Moderator: Michael Salgaller, Bethesda, MD
Presenters: Michael Pollack, Bethesda, MD
Patricia Weber, Bethesda, MD
Lauren V. Wood, Bethesda, MD

Advances in Diagnostics and Therapeutics
12:30 p.m.–2:00 p.m.

Room W414, Convention Center
MULTIOMICS IN DIAGNOSIS AND CARE MANAGEMENT

Chair: Raza Ali, London, United Kingdom

12:30 p.m. Chair Introduction. Raza Ali, London, United Kingdom
12:35 p.m. Multi-omic approaches to study the role of plasticity in therapy resistance and metastasis in lung cancer. Alvaro Quintanal-Villalonga, New York, NY [AACR NextGen Star]
1:15 p.m. Deciphering cancer evolution and ecology and their association with cancer prognosis. Wenyi Wang, Houston, TX
1:35 p.m. Circulating tumor DNA analysis for detection and molecular characterization of cancers. Maximilian Diehn, Stanford, CA
Advances in Organ Site Research • 12:30 p.m.–2:00 p.m.
Room W311 E-H, Convention Center
ALTERNATIVE STRATEGIES TO TRADITIONAL CHEMOTHERAPY TO TREAT ACUTE LEUKEMIA

Chair: David N. Wald, Cleveland, OH

12:30 p.m.   **Chair Introduction.** David N. Wald, Cleveland, OH
12:35 p.m.   **AML differentiation therapy.** David N. Wald, Cleveland, OH
12:55 p.m.   **Targeting apoptosis in leukemia: Lessons and challenges.** Marina Y. Konopleva, Houston, TX
1:25 p.m.   **Dissecting immune microenvironment of T-cell acute lymphoblastic leukemia.** Anastasia Tikhonova, Toronto, ON, Canada
1:10 p.m.   **Training NK cells for enhanced cellular therapy of leukemia.** Todd A. Fehniger, St. Louis, MO

Small Cell Lung Cancer: Moving Biology to the Clinic

Chair: Taofeek Kunle Owonikoko, Pittsburgh, PA

12:30 p.m.   **Chair Introduction.** Taofeek Kunle Owonikoko, Pittsburgh, PA
12:35 p.m.   **Putting SCLC in context using emerging clinical and translational insights.** Taofeek Kunle Owonikoko, Pittsburgh, PA
1:00 p.m.   **Measuring and modulating SCLC transcriptional heterogeneity from murine models to clinical trials.** Joseph Hiatt, Seattle, WA
1:25 p.m.   **Understanding SCLC biology and plasticity to define therapeutic vulnerabilities.** Alvaro Quintanal-Villalonga, New York, NY

Advances in Population Sciences • 12:30 p.m.–2:00 p.m.
Room W304 E-H, Convention Center
POPULATION SCIENCES IN THE ERA OF OMICS

Chair: Andrew T. Chan, Boston, MA

12:35 p.m.   **Interrogating cancer risk with germline genetics and other multi-omic data.** Burcu F. Darst, Seattle, WA
1:00 p.m.   **Surveying non-malignant tissues to identify genomic markers of risk.** Paul A. Scheet, Houston, TX
1:25 p.m.   **Leveraging omic data to bridge association to causation.** Andrew T. Chan, Boston, MA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
**CME** Advances in Prevention Research • 12:30 p.m.–2:00 p.m.

Tangerine Ballroom 3-4 (WF3-4), Convention Center

**DIAGNOSIS AND MANAGEMENT OF HEREDITARY CANCERS**

**Chair:** Violeta Serra Elizalde, Barcelona, Spain

- **12:35 p.m.**   **Personalized cancer surveillance, immunotherapy, and immunoprevention in Lynch syndrome.** Matthew Yurgelun, Boston, MA
- **1:00 p.m.**   **Prostate cancer genetic testing and management of genetic carriers.** Kara N. Maxwell, Philadelphia, PA
- **1:25 p.m.**   **Using functional HRD to identify PARP inhibitor sensitive tumors.** Violeta Serra Elizalde, Barcelona, Spain

**CME** Advances in the Science of Cancer Disparities  
**12:30 p.m.–2:00 p.m.**

Tangerine Ballroom 1 (WF1), Convention Center

**NOVEL APPROACHES TO PERSONALIZED CANCER HEALTH EQUITY**

**Chair:** John H. Stewart, New Orleans, LA

- **12:35 p.m.**   **Cancer health equity in 2023: Now is the time for a personalized approach.** John H. Stewart, New Orleans, LA
- **1:00 p.m.**   **Harnessing the power of authentic community engagement to overcome the cancer inequity conundrum.** Charles R. Rogers, Milwaukee, WI
- **1:25 p.m.**   **Strategies for equitable access to cancer clinical trials.** Carmen E. Guerra, Philadelphia, PA

**CME** Major Symposia • 12:30 p.m.–2:00 p.m.

Room W224, Convention Center

**AACR-BAYARD D. CLARKSON SYMPOSIUM ON CANCER AND METASTATIC STEM CELLS: RESISTANCE TO THERAPY AND IMMUNE EVASION**

**Chair:** Judith Agudo, Boston, MA

- **12:30 p.m.**   **Chair Introduction.** Judith Agudo, Boston, MA
- **12:35 p.m.**   **Progressive plasticity during colorectal cancer metastasis.** Karuna Ganesh, New York, NY
- **1:00 p.m.**   **Mechanisms regulating tumor transition states.** Cedric Blanpain, Bruxelles, Belgium
- **1:25 p.m.**   **Dissecting mechanisms of escape from T cell attack in cancer stem cells.** Judith Agudo, Boston, MA
IMMUNOMETABOLISM AND THE TUMOR MICROENVIRONMENT

Chair: Greg M. Delgoffe, Pittsburgh, PA

12:30 p.m.   Chair Introduction. Greg M. Delgoffe, Pittsburgh, PA
12:35 p.m.   Targeting glutamine in immune-suppressive tumor associated macrophages to overcome tumor immunity in mCRPC. Jelani C. Zarif, Baltimore, MD
1:00 p.m.   Dissecting the role of metabolites in the tumor microenvironment. Marcia Haigis, Boston, MA
1:25 p.m.   Leveraging metabolism to improve cancer immunotherapy. Greg M. Delgoffe, Pittsburgh, PA

Room W315, Convention Center
Regulatory Science and Policy Session
IMPLEMENTING DIVERSITY ACTION PLANS FOR CLINICAL TRIALS

Moderator: Lola A. Fashoyin-Aje, Silver Spring, MD

Opening Remarks: Jon G. Retzlaff, Washington, DC

Panelists: Sandra Amaro, Groton, CT
           Chitkala Kalidas, Whippany, NJ
           Bea Lavery, San Francisco, CA
           Craig L. Tendler, Raritan, NJ

MOLECULAR MECHANISMS OF KRAS PATHWAY INHIBITORS

Chair: Ryan B. Corcoran, Boston, MA

12:30 p.m.   Chair Introduction. Ryan B. Corcoran, Boston, MA
12:35 p.m.   Progress on development of KRAS allele-specific inhibitors and contribution of cell autonomous and pro-immunogenic activity to anti-tumor activity. James G. Christensen, San Diego, CA
1:00 p.m.   Targeting KRAS for pancreatic cancer treatment. Channing J. Der, Chapel Hill, NC
1:25 p.m.   Overcoming resistance to KRAS inhibition. Ryan B. Corcoran, Boston, MA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Tangerine Ballroom 2 (WF2), Convention Center

NEW HORIZONS FOR T CELL IMMUNITY AND CHECKPOINTS

Chair: Mary Jo Turk, Lebanon, NH

12:30 p.m.  Chair Introduction. Mary Jo Turk, Lebanon, NH

12:35 p.m.  A structural blueprint for understanding LAG3 agonism and antagonism. Vince Luca, Tampa, FL

1:00 p.m.   IFN addiction in cancer immunotherapy. Weiping Zou, Ann Arbor, MI

1:25 p.m.   Resident memory T cells in tissue-localized immunity to cancer. Mary Jo Turk, Lebanon, NH

Room W304 A-D, Convention Center

RADIATION THERAPY, DNA DAMAGE, AND IMMUNE RESPONSE

Chair: Quynh-Thu Le, Palo Alto, CA

12:30 p.m.  Chair Introduction. Quynh-Thu Le, Palo Alto, CA

12:35 p.m.  Determinants of hypoxia in pancreatic cancer and identification of ULK1 as a potential therapeutic target. Bradly G. Wouters, Toronto, ON, Canada

1:00 p.m.   Targeting galectin-1 with radiation therapy. Quynh-Thu Le, Palo Alto, CA

1:25 p.m.   Exploiting DNA damage response pathways to stimulate immunotherapy response in glioma. Ranjit S. Bindra, New Haven, CT

Valencia A, Convention Center

UNDERSTANDING AND INTERCEPTING TUMOR INTRINSIC AND EXTRINSIC MECHANISMS OF DRUG RESISTANCE

Chair: Valsamo K. Anagnostou, Baltimore, MD

12:30 p.m.  Chair Introduction. Valsamo K. Anagnostou, Baltimore, MD

12:35 p.m.  Genomic landscape of response and resistance to immune checkpoint blockade. Valsamo K. Anagnostou, Baltimore, MD

1:00 p.m.   Polymerase theta inhibition: A multifaceted strategy to reverse PARP inhibitor and immunotherapy resistance in homologous recombination-repair deficient cancers. Geoffrey I. Shapiro, Boston, MA

1:25 p.m.   Overcoming PARP inhibitor resistance through rational combinations in the clinic. Timothy A. Yap, Houston, TX
MONDAY, APRIL 17* (cont’d)

Special Session • 1:15 p.m.–2:30 p.m.
NOT ELIGIBLE FOR CME CREDIT
Room W 314A, Convention Center
AACR ANNUAL BUSINESS MEETING OF MEMBERS
AACR Chief Executive Officer: Margaret Foti, Philadelphia, PA
AACR President: Lisa M. Coussens, Portland, OR
AACR President-Elect: Philip D. Greenberg, Seattle, WA
AACR Immediate Past President: David A. Tuveson, Cold Spring Harbor, NY
AACR Treasurer: William N. Hait, New Brunswick, NJ

Meet and Greet • 1:30 p.m.–2:30 p.m.
NOT ELIGIBLE FOR CME CREDIT
Publications Booth 2743, W Halls B-E1
MEET THE EDITOR-IN-CHIEF OF CLINICAL CANCER RESEARCH:
KEITH T. FLAHERTY, MD

Poster Sessions • 1:30 p.m.-5:00 p.m.
NOT ELIGIBLE FOR CME CREDIT
W Halls B-E1, Convention Center
Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

TUMOR BIOLOGY
Section 1 Fibrosis, the Extracellular Matrix, and Therapeutic Impact on Cancer Progression
Section 2 Photoacoustic, Ultrasound, and Fluorescence Imaging
Section 3 Radiation Sciences
Section 4 Regulation of Stemness: Transformation, Differentiation, and Plasticity
Section 5 Translational Metastasis Research
Section 6 Tumor-Host Interactions and Disease Progression
Section 36 Late-Breaking Research: Tumor Biology 1

MOLECULAR/CELLULAR BIOLOGY AND GENETICS
Section 7 Apoptosis and Bcl-2 Family Members
Section 8 Kinase Signaling
Section 9 Oncogene and Tumor Suppressor Signaling in Cancer 1
Section 10 Oncogene and Tumor Suppressor Signaling in Cancer 2
Section 11 Ras-related Signaling

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
EXPERIMENTAL AND MOLECULAR THERAPEUTICS
Section 13 Antibody Technologies
Section 14 Chemotherapeutic Combinations
Section 15 Drug Delivery Systems
Section 16 Gene and Vector-based Therapy
Section 17 Innovative Assay Technologies
Section 18 Pharmacokinetics, Pharmacodynamics, and Molecular Pharmacology
Section 19 Radiosensitizers and Radio-immunomodulators
Section 20 Strategies for Reversal of Drug Resistance

IMMUNOLOGY
Section 21 Cancer-associated Immunosuppression
Section 22 Natural Killer and Natural Killer T Cell-based Cellular Therapies
Section 23 Therapeutic Antibodies 2
Section 24 Therapeutic Antibodies 3
Section 25 Tumor Antigens and Antigen Presentation

SURVIVORSHIP
Section 26 Advocates Poster Session 1

POPULATION SCIENCES
Section 27 Aging, Immune Factors, and Metabolomics
Section 35 Late-Breaking Research: Population Sciences

PREVENTION / EARLY DETECTION / INTERCEPTION
Section 28 Biological and Behavioral Factors in Cancer Surveillance, Prevention, and Survivorship

ENDOCRINOLOGY
Section 29 Endocrine-related Cancers: Treatment Resistance and Novel Targets and Therapeutics
Section 34 Late-Breaking Research: Clinical Research 1 / Endocrinology

CHEMISTRY
Section 31 Targeted Drug Design and Development for Cancer Therapy
MONDAY, APRIL 17* | Poster Sessions (cont’d)

**BIOINFORMATICS / COMPUTATIONAL BIOLOGY / SYSTEMS BIOLOGY / CONVERGENT SCIENCE**

Section 32  Bioinformatics Applications in Cancer Biology 2
Section 33  Integrative Computational Approaches and Analyses

**CLINICAL RESEARCH EXCLUDING TRIALS**

Section 34  Late-Breaking Research: Clinical Research 1 / Endocrinology
Section 37  Adoptive Cell Therapy 2
Section 38  Cancer Outcomes 1
Section 39  Combination Immunotherapies 1
Section 40  Combination Immunotherapies 2
Section 41  Diagnostic and Prognostic Biomarkers 3
Section 42  Early Detection Biomarkers
Section 43  Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 3
Section 44  Molecular Targeted Therapies 1

**CLINICAL TRIALS**

Section 45  First-in-Human Phase I Clinical Trials 1
Section 46  Phase I Clinical Trials in Progress
Section 47  Phase II Clinical Trials 1

**Meet and Greet • 2:30 p.m.–3:15 p.m.**

*NOT ELIGIBLE FOR CME CREDIT*

AACR Central, W Halls B-E1

MEET THE RESEARCH GRANT REVIEWERS

2:30 p.m.  **AACR Grant Reviewer.** James V. DeGregori, Aurora, CO

**CME  Major Symposium • 2:30 p.m.–4:00 p.m.**

Room W330, Convention Center

Science Policy Session

FDA CENTER FOR TOBACCO PRODUCTS’ PRIORITIES TO ADDRESS TOBACCO USE AND SUPPORT THE CANCER MOONSHOT

**Moderators:** Christine M. Lovly, Nashville, TN
Suchitra Krishnan-Sarin, New Haven, CT

**Speaker:** Brian A. King, Silver Spring, MD

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
ROOM W315, CONVENTION CENTER

REGULATORY SCIENCE AND POLICY SESSION

USING REAL-WORLD EVIDENCE TO ADVANCE PEDIATRIC CANCER DRUG DEVELOPMENT

**Cochairs:** Katherine A. Janeway, Boston, MA; E. Alejandro Sweet-Cordero, San Francisco, CA

**2:50 p.m. Introduction.** Martha Donoghue, Silver Spring, MD

Additional speakers to be announced

---

**CME Clinical Trials Minisymposium • 2:30 p.m.–4:30 p.m.**

CHAPIN THEATER, CONVENTION CENTER

TARGETING THE KRAS PATHWAY IN THE CLINIC

**Cochairs:** Trever G. Bivona, San Francisco, CA; Natalie Ngoi, Singapore

**2:30 p.m.** Introduction

**2:35 p.m.** Discussant. Ryan B. Corcoran, Boston, MA

**2:50 p.m.** CT028 A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors. Yonina R. Murciano-Goroff, New York, NY

**3:05 p.m.** CT029 Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation. Jayesh Desai, Melbourne, Australia

**3:20 p.m.** CT030 Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study. Qing Zhou, Guangzhou, China

**3:35 p.m.** CT031 A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors. Alison M. Schram, New York, NY

**3:50 p.m.** CT032 Trials in progress: a global phase 1/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma. Alexander Spira, Fairfax, VA

**4:05 p.m.** CT033 Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors. Benjamin Solomon, East Melbourne, Australia

**4:20 p.m.** Closing remarks
**MONDAY, APRIL 17**

### Late-Breaking Minisymposium • 2:30 p.m.–4:30 p.m.

**MINISYMPOSIUM: LATE-BREAKING RESEARCH**

Chair: Robert H. Vonderheide, Philadelphia, PA

- **2:30 p.m.** Introduction
- **2:35 p.m.** LB357 CRISPR-Cas9 targeting of somatic mutations selectively kills cancer cells. Kirsten Bowland, Baltimore, MD
- **2:50 p.m.** LB358 Efficacy of a functional precision medicine approach in relapsed/refractory pediatric cancer patients: Results from a prospective clinical study. Diana J. Azzam, Miami, FL
- **3:05 p.m.** LB360 Type-1 interferon sensing is critical for CD8+ resident memory (TRM) cell generation in tumor-draining lymph nodes. Nikhil Khatwani, Lebanon, NH
- **3:20 p.m.** LB361 Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death. Joshua H. Choe, New York, NY
- **3:35 p.m.** LB362 Epigenome-wide DNA methylation alterations precede diagnosis since birth and affect prognosis of pediatric B-cell acute lymphoblastic leukemia. Zdenko Herceg, Lyon, France
- **3:50 p.m.** LB363 Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukemia. Eirini Papapetrou, New York, NY
- **4:05 p.m.** 3520 Single cell-derived spheroids capture functional and genetic heterogeneity of head and neck cancer. Rana P. Singh, New Delhi, India
- **4:20 p.m.** Closing remarks

### Minisymposia • 2:30 p.m.–4:30 p.m.

**NEW TARGETED PROTEIN DEGRADERS: DISCOVERY AND NOVEL DESIGN STRATEGIES**

**Cochairs:** Qiming Jane Wang, Pittsburgh, PA; Zoran Rankovic, Memphis, TN

- **2:30 p.m.** Introduction
- **2:35 p.m.** 3423 NX-2127: A first-in-class clinical stage degrader of BTK and IKZF1/3 for the treatment of patients with B cell malignancies. Jeffrey T. Mihalic, San Francisco, CA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
2:50 p.m.  3424  Template-assisted covalent modification of DCAF16 enables BRD4 molecular glue degraders. Yen-Der Li, Cambridge, MA

3:05 p.m.  3425  The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers. Yanke Liang, Watertown, MA

3:20 p.m.  3426  Catalytic degraders effectively address kinase site mutations in EML-ALK oncogenic fusions. Jianwei Che, Boston, MA

3:35 p.m.  3427  ICP-490 is a highly potent and selective IKZF1/3 degrader with robust anti-tumor activities against multiple myeloma and non-Hodgkin’s lymphoma. Davy Xuesong Ouyang, Beijing, China

3:50 p.m.  3428  Discovery of a highly potent and selective dual PROTAC degrader of CDK12 and CDK13. Yu Chang, Ann Arbor, MI

4:05 p.m.  3429  Beyond cereblon IMIDs - biophysics-based discovery of novel molecular glue chemotypes. Roland Hjerpe, Nottingham, United Kingdom

4:20 p.m.  Closing remarks

Room W414, Convention Center
Clinical Research Excluding Trials
BIOMARKERS OF RESPONSE IN NOVEL MOLECULAR THERAPEUTICS

Co-chairs: Nilofer S. Azad, Baltimore, MD; Rona Yaeger, New York, NY

2:30 p.m.  Introduction

2:35 p.m.  3431  Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC. Ferdinandos Skoulidis, Houston, TX

2:50 p.m.  3432  Ataxia-telangiectasia mutated loss of function displays variant and tissue specific differences across tumor types. Patrick G. Pilie, Houston, TX

3:05 p.m.  3433  Global proteomic analysis of urine using a label-free LC-MS/MS approach identifies potential biomarkers of metastatic breast cancer. Roopali Roy, Boston, MA

3:20 p.m.  3434  Selective glucocorticoid receptor modulation reveals a new role for CLEC10A in patients with solid tumors. Erkut H. Borazanci, Scottsdale, AZ

3:35 pm.  3435  Identification of potential biomarkers of response to OMO-103, a first-in-modality pan-MYC inhibitor, in patients with advanced solid tumors. Laura Soucek, Barcelona, Spain

3:50 p.m.  3436  Reduced p63 expression is linked to a low density of regulatory T-cells and unfavorable prognosis in muscle-invasive urothelial carcinoma of the bladder. Elena Bady, Hamburg, Germany

4:05 p.m.  3437  Whole genome and transcriptome sequencing of a pan-cancer cohort unearths novel therapeutic avenues. Majd Al Assaad, New York, NY

4:20 p.m.  Closing remarks
MONDAY, APRIL 17* | Minisymposia (cont’d)

Room W311 E-H, Convention Center

Endocrinology

NUCLEAR RECEPTORS AND ENDOCRINE RELATED CANCERS: NEW INSIGHTS INTO TREATMENT RESISTANCE AND THERAPEUTICS DEVELOPMENT

Cochairs: Rachel Schiff, Houston, TX; Clodia Osipo, Maywood, IL

2:30 p.m. Introduction
2:35 p.m. 3439 Evaluating nuclear receptor heterodimerization using live cell proximity assays: Implications for novel therapeutic approaches for hormone driven cancers. Amira Ishag-Osman, Boston, MA
2:50 p.m. 3440 Targeting the mutant estrogen receptor in metastatic breast cancer. Karla Parra, Dallas, TX
3:05 p.m. 3441 A multivalent peptoid conjugate that inhibits therapy-resistant prostate cancer cell proliferation by modulating androgen receptor transcriptional activity. Justine Habault, New York, NY
3:20 p.m. 3442 FXR mediates macrophage intrinsic responses to suppress colon cancer progression. Ting Fu, Madison, WI
3:35 p.m. 3443 Aryl hydrocarbon receptor and its ligands influence the formation of colonic tertiary lymphoid tissues. Kimberly F. Allred, Greensboro, NC
3:50 p.m. 3444 Role of AKR1C3 in converting reservoirs of DHEA-S into potent androgens that drive prostate cancer cell growth. Andrea J. Detlefsen, Philadelphia, PA
4:05 p.m. 3445 Immune cells infiltration and activation are higher in breast cancers resistant to antiestrogen therapy. Fabiana Napolitano, Dallas, TX
4:20 p.m. Closing remarks

Room W331, Convention Center

Experimental and Molecular Therapeutics

NOVEL ANTITUMOR AGENTS AND TARGETS

Cochairs: Jan H. Beumer, Pittsburgh, PA; Ganesh V. Raj, Dallas, TX

2:30 p.m. Introduction
2:35 p.m. 3447 NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer. Tejaswini P. Reddy, Houston, TX
2:50 p.m. 3448 Discovery of HYP-2A, a 2nd-generation KRASG12C inhibitor exhibits potent in vivo efficacy in drug resistant tumor models. Shoujun Chen, Chengdu, China

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
3:05 p.m.  3449  Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction. Gerald Gavory, Basel, Switzerland

3:20 p.m.  3450  Discovery and preclinical study of novel BTK degrader HZ-Q1070. Xingguo Liu, Hangzhou, China

3:35 p.m.  3451  XS-04: A first-in-class dual IRAK4/BTK inhibitor for the treatment of hematological malignancies. Xiaohong Yu, Shanghai, China

3:50 p.m.  3452  TNG908, a brain-penetrant MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical glioblastoma models. Minjie Zhang, Boston, MA

4:05 p.m.  3453  First disclosure of a highly potent and selective HPK1 inhibitor that rescues T cell exhaustion. Deanna A. Mele, Waltham, MA

4:20 p.m.  Closing remarks

Valencia BC, Convention Center
Experimental and Molecular Therapeutics
OVERCOMING RESISTANCE SECONDARY TO GENOMIC ALTERATIONS AND TUMOR HETEROGENEITY WITH NOVEL STRATEGIES AND COMBINATORIAL APPROACHES

Cochairs: James M. Cleary, Boston, MA; Daniela E. Matei, Chicago, IL

2:30 p.m.  Introduction

2:35 p.m.  3455  Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance. Vakul Mohanty, Houston, TX

2:50 p.m.  3456  Synergistic drug combinations promote the development of resistance in acute myeloid leukemia. Emily Mason-Osann, Waltham, MA

3:05 p.m.  3457  Characterization of acquired resistance mutations to menin inhibitors. Florian Perner, Boston, MA

3:20 p.m.  3458  Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer. Francesco Facchinetti, Paris, France

3:35 p.m.  3459  Drug persistence pathways in ovarian cancer identified by single-cell analysis of patient samples and cell line models. Elizaveta Leshchiner, Cambridge, MA

3:50 p.m.  3460  Targeting the MIF-CD74 axis to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Motohiro Izumi, Boston, MA

4:05 p.m.  3461  Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS mutated non-small cell lung cancer. Uday Banerji, London, United Kingdom

4:20 p.m.  Closing remarks
Valencia A, Convention Center

Immunology

FROM CANCER IMMUNOLOGY TO IMMUNOTHERAPY

Cochairs: Taha Merghoub, New York, NY; Ignacio Melero, Pamplona, Spain

2:30 p.m. Introduction

2:35 p.m. 3463 Longitudinal microbiome-immune dynamics in melanoma patients treated with immune checkpoint inhibitor immunotherapy. Rebecca C. Simpson, Sydney, Australia

2:50 p.m. 3464 Dynamics of resident memory (Trm) cell responses between skin and draining lymph nodes during primary and recall responses to melanoma. Cameron Messier, Hanover, NH

3:05 p.m. 3465 HDAC8 regulates immune escape in melanoma through increased transcription of inhibitory cytokines that increase accumulation of myeloid-derived suppressor cells (MDSCs). Chao Zhang, Tampa, FL

3:20 p.m. 3466 Microbial neoantigen vectors for cancer immunotherapy. Nicholas Arpaia, New York, NY

3:35 p.m. 3467 GRWD5769: A first-in-class inhibitor of ERAP1, generating novel cancer antigens to drive de novo anti-tumor T cell responses. Peter I. Joyce, Oxford, United Kingdom

3:50 p.m. 3468 Immunoproteasome expression and checkpoint blockade response in advanced non-small cell lung cancer. Vivek Naranbhai, Boston, MA

4:05 p.m. 3469 Lymph node colonization promotes distant tumor metastasis through the induction of tumor-specific immune tolerance. Nathan E. Reticker-Flynn, Stanford, CA

4:20 p.m. Closing remarks

Valencia D, Convention Center

Immunology

IMMUNE CHECKPOINTS AT TUMOR BEDS

Cochairs: Jonathan Villena-Vargas, New York, NY; Ingunn M. Stromnes, Minneapolis, MN

2:30 p.m. Introduction

2:35 p.m. 3471 A function-based high-throughput discovery platform, myeloid iOTarg, identifies novel immune checkpoints of the tumor microenvironment. Tillmann Michels, Martinsried/Munich, Germany

2:50 p.m. 3472 A tumor draining lymph node CD8 T cell memory response is pivotal for a decrease in recurrence after neoadjuvant anti PD-1 therapy for NSCLC. Tatiana Delgado Cruz, New York, NY

3:05 p.m. 3473 High throughput screening of combination therapies to improve response to checkpoint inhibitors in solid tumors using a myelomonocytic and T cell co-culture assay. Sushil Kumar, Portland, OR

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
3:20 p.m.  3474 Identification of the selective CBL-b inhibitors which effectively prevent T cells from exhaustion and demonstrate synergistic anti-tumor activity in combination with an anti-PD1 antibody. Renhong Tang, Nanjing, China

3:35 p.m.  3475 RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models. Marie J. Menard, Redwood City, CA

3:50 p.m.  3476 TAK-243 increases tumor immunogenicity enhancing systemic anti-tumor immune response and tumor regression in combination with immune checkpoint inhibition in a syngeneic model of lymphoma. Richard Klinghoffer, Seattle, WA

4:05 p.m.  3477 Maximizing the outcome of CD226 stimulation through targeting beyond TIGIT signaling with combination and multi-specific approaches for cancer immunotherapy. Tom Li Stephen, Cambridge, MA

4:20 p.m.  Closing remarks

Tangerine Ballroom 3-4 (WF3-4), Convention Center
Molecular/Cellular Biology and Genetics
EPIGENETICS MECHANISMS IN CANCER

Cochairs: Eneda Toska, Baltimore, MD; Ellen L. Goode, Rochester, MN

2:30 p.m.  Introduction

2:35 p.m.  3481 A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma. Royce Zhou, New York, NY

2:50 p.m.  3479 Modeling epigenetic lesions that cause gliomas. Gilbert J. Rahme, Boston, MA

3:05 p.m.  3480 Modulating DNA and histone methylation as a therapeutic target for non-small cell lung cancer by shifting the composition of immune cells. Ying-Yu Chen, Baltimore, MD

3:20 p.m.  3482 METTL3-mediated m6A modification controls splicing factor abundance and contributes to CLL progression. Yiming Wu, Monrovia, CA

3:35 p.m.  3483 Epigenome-wide association study of lung cancer among never-smokers in two prospective cohorts in Shanghai. Mohammad L. Rahman, Rockville, MD

3:50 p.m.  3484 Oncohistone H2B-E76K alters gene expression & cellular phenotype in a bronchial epithelial cell line. Kimberly Espinoza Pereira, Gainesville, FL

4:05 p.m.  3485 Intrinsically disordered regions of the ARID1A/B tumor suppressors encode an interaction network within biomolecular condensates that directs mSWI/SNF chromatin remodeler complex activity. Ajinkya Patil, Boston, MA

4:20 p.m.  Closing remarks
MONDAY, APRIL 17* | Minisymposia (cont’d)

Room W304 E-H, Convention Center
**Molecular/Cellular Biology and Genetics**
**TYROSINE KINASE AND RAS SIGNALING**

**Cochairs:** David D. Schlaepfer, La Jolla, CA; Donita C. Brady, Philadelphia, PA

2:30 p.m.  **Introduction**

2:35 p.m.  **3487**  An atlas of substrate specificities for the human tyrosine kinome. Jared L. Johnson, New York, NY

2:50 p.m.  **3488**  Truncated FGFR2 - a clinically actionable oncogene in multiple cancers. Daniel Kaspar Zingg, Amsterdam, Netherlands

3:05 p.m.  **3489**  TNK1 is a ubiquitin sensing kinase that can be targeted in vivo to block tumor growth. Joshua Lyon Andersen, Provo, UT

3:20 p.m.  **3490**  IGFBP1 mediates musculoskeletal defects in colorectal cancer. Andrea Bonetto, Aurora, CO

3:35 p.m.  **3491**  Designed sensors reveal normal and oncogenic Ras signaling in endomembranes and condensates. Jason Z. Zhang, Seattle, WA

3:50 p.m.  **3492**  The small GTPase ARF6 augments BRAFV600E-MAPK signaling in melanomagenesis. Allie Grossmann, Salt Lake City, UT

4:05 p.m.  **3493**  Drug targeting of KRAS accumulation on the cilium inhibits its stemness driving activity. Daniel Abankwa, Esch-sur-Alzette, Luxembourg

4:20 p.m.  **Closing remarks**

Room W304 A-D, Convention Center
**Multidisciplinary**
**MOLECULAR PATHWAY DISCOVERY AND TRANSLATION IN SOLID TUMORS**

**Chair:** John L. Cleveland, Tampa, FL

2:30 p.m.  **Introduction.** John L. Cleveland, Tampa, FL

2:35 p.m.  **3495**  A kinome-wide CRISPR screen identifies CK1α as a novel target to overcome enzalutamide resistance of prostate cancer. Jinhui Liu, Lexington, KY

2:50 p.m.  **3496**  p53 mutation biases SCJ progenitor cells towards dysplasia rather than metaplasia in Barrett’s esophagus. Guodong Lian, New York, NY

3:05 p.m.  **3497**  The polyclonal path to malignant transformation in familial adenomatous polyposis. Ryan O. Schenck, Palo Alto, CA

3:20 p.m.  **3498**  GTP-dependent signaling links metabolism, non-homologous end joining and treatment responses in cancer and normal tissues. Weihua Zhou, Ann Arbor, MI

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
3:35 p.m. 3499 Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC. Shilpi Khare, San Diego, CA

3:50 p.m. 3500 A noncatalytic role for mettl1 in oncogenic translation in soft tissue sarcoma. Raja Hussain Ali, Boston, MA

4:05 p.m. 3501 A genome-wide screen for determinants of radioresistance in head and neck cancer. Jacqueline H. Law, Toronto, ON, Canada

4:20 p.m. Closing remarks. John L. Cleveland, Tampa, FL

Room W240, Convention Center
Population Sciences
MOLECULAR, SOMATIC, SOCIAL, AND GEOSPATIAL FACTORS AND CANCER DISPARITIES

Cochairs: Iona C. Cheng, Honolulu, HI; Michele L. Cote, Indianapolis, IN

2:30 p.m. Introduction

2:35 p.m. 3503 Racial disparity and roles of social determinants of health in epigenetic age acceleration among survivors of childhood cancer. Noel-Marie Plonski, Memphis, TN

2:50 p.m. 3504 Evaluating the molecular determinants of PDAC racial health disparities. Anthony E. Johansen-Sallee, Omaha, NE

3:05 p.m. 3505 Cancer disparities in race exposed through geospatial analysis of mutational signatures and environmental exposure. Judy Bai, Albuquerque, NM

3:20 p.m. 3506 High-grade serous ovarian cancer somatic mutational signatures in Black and White individuals. Katherine A. Lawson-Michod, Salt Lake City, UT

3:35 p.m. 3507 Mosaic chromosomal alterations in blood across ancestries via whole-genome sequencing. Yasminka A. Jakubek, Lexington, KY

3:50 p.m. 3508 Association between clonal hematopoiesis and risk of prostate cancer in a large sample of African ancestry men. Anqi Wang, Los Angeles, CA

4:05 p.m. 3509 1,25-dihydroxyvitamin D3-mediated suppression of genes associated with cell cycle regulation and actin organization in a non-malignant African American prostate cell line. Jabril R. Johnson, Smyrna, GA

4:20 p.m. Closing remarks
Room W311 A-D, Convention Center
Tumor Biology
THE METASTATIC NICHE

Cochairs: Adrienne Boire, New York, NY; Neta Erez, Tel Aviv, Israel

2:30 p.m. Introduction

2:35 p.m. 3511 Melanoma-shed, lymph-borne CSPG4 conditions the pre-metastatic lymph node niche. Haley du Bois, New York, NY

2:50 p.m. 3512 Organ-specific effects of Smad4 in metastatic pancreatic cancer. Kaloyan M. Tsanov, New York, NY

3:05 p.m. 3513 Developing a 3D biomimetic liver metastatic niche model for pancreatic cancer. Mahsa Pahlavanneshan, Los Angeles, CA

3:20 p.m. 3514 A genetic-metabolic circuit of liver-specific metastatic organotropism. Meri Rogava, New York, NY

3:35 p.m. 3515 Histone demethylase KDM5D drives sex-specific differences in colorectal cancer. Jiexi Li, Houston, TX

3:50 p.m. 3516 Metastatic colonization requires a proliferative pause linked to vascular co-option. Pedro García-Gómez, Madrid, Spain

4:05 p.m. 3517 Multi-modal single-cell and spatial genomics reveals genomic, adaptive and microenvironmental features of human non-small cell lung cancer brain metastasis. Somnath Tagore, New York, NY

4:20 p.m. Closing remarks

---

Special Session • 2:30 p.m.–4:30 p.m.

Tangerine Ballroom 1 (WF1), Convention Center
AACR-JCA JOINT SESSION: REAL-WORLD EVIDENCE IN CANCER GENOMICS RESEARCH

Cochairs: Hiroyuki Mano, Tokyo, Japan; Kenneth L. Kehl, Boston, MA

2:30 p.m. Introduction. Kenneth L. Kehl, Boston, MA

2:36 p.m. C-CAT: The national datacenter for cancer genomic medicine. Hiroyuki Mano, Tokyo, Japan

3:03 p.m. Informative cohort entry in clinico-genomic real-world data. Kim Van Naarden Braun, New York, NY

3:30 p.m. Clinico-genomic data from AACR Project GENIE. Kenneth L. Kehl, Boston, MA

3:57 p.m. A nationwide framework of genomic medicine for pediatric cancer. Motohiro Kato, Tokyo, Japan

4:24 p.m. Closing remarks. Hiroyuki Mano, Tokyo, Japan

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
NCI-NIH-Sponsored Session • 2:45 p.m.–3:45 p.m.
NOT ELIGIBLE FOR CME CREDIT

Room W314 A, Convention Center
THE NCI’S INVESTMENT IN CANCER-RELATED TELEHEALTH RESEARCH

Moderator: Robin Vanderpool, Bethesda, MD

2:45 p.m. Advancing a telehealth research agenda. Robin Vanderpool, Bethesda, MD
2:50 p.m. NCI telehealth funding trends. Roxanne Jensen, Bethesda, MD
2:58 p.m. Telehealth Research and Innovation for Veterans with Cancer (THRIVE). Scott Sherman, New York, NY
3:06 p.m. University of Pennsylvania Telehealth Research Center of Excellence (Penn TRACE). Justin Bekelman, Philadelphia, PA
3:14 p.m. Scalable TELehealLth Cancer cARE (STELLAR). Bonnie Spring, Chicago, IL
3:22 p.m. Making Telehealth Delivery of Cancer Care at Home Effective and Safe (MATCHES). Michael J. Morris, New York, NY

---

Awards and Lectures • 3:00 p.m.–3:45 p.m.

Room W312, Convention Center
AACR-JOSEPH H. BURCHENAL AWARD FOR OUTSTANDING ACHIEVEMENT IN CLINICAL CANCER RESEARCH

Chair: Dan Theodorescu, Los Angeles, CA
3:00 p.m. Introduction. Dan Theodorescu, Los Angeles, CA
3:05 p.m. Award Lecture. Melissa M. Hudson, Memphis, TN

---

Awards and Lectures • 3:30 p.m.–4:15 p.m.

Tangerine Ballroom 2 (WF2), Convention Center
AACR-CANCER RESEARCH INSTITUTE LLOYD J. OLD AWARD IN CANCER IMMUNOLOGY

Chair: Crystal L. Mackall, Stanford, CA
3:00 p.m. Introduction. Crystal L. Mackall, Stanford, CA
3:35 p.m. Award Lecture. E. John Wherry, Philadelphia, PA
NCI-NIH-Sponsored Session • 4:00 p.m.–5:00 p.m.

Room W314 A, Convention Center

NIH GRANTS SESSION: UPDATES ON FUNDING POLICIES AND REVIEW OF NCI APPLICATIONS

Moderator: Daniel L. Gallahan, Bethesda, MD

4:00 p.m.  Introduction. Daniel L. Gallahan, Bethesda, MD
4:05 p.m.  Overview of NCI grants. Shannon Hughes, Rockville, MD
4:20 p.m.  Peer review at NIH. Amy Rubinstein, Bethesda, MD
4:35 p.m.  Panel Discussion

Awards and Lectures • 4:15 p.m.–5:00 p.m.

Room W312, Convention Center

AACR-AMERICAN CANCER SOCIETY AWARD FOR RESEARCH EXCELLENCE IN CANCER EPIDEMIOLOGY AND PREVENTION

Chair: Lorelei A. Mucci, Boston, MA

4:15 p.m.  Introduction. Lorelei A. Mucci, Boston, MA
4:20 p.m.  Award Lecture. Patricia A. Ganz, Los Angeles, CA

Awards and Lectures • 4:45 p.m.–5:30 p.m.

Tangerine Ballroom 2 (WF2), Convention Center

AACR MARGARET FOTI AWARD FOR LEADERSHIP AND EXTRAORDINARY ACHIEVEMENTS IN CANCER RESEARCH

Chair: Patricia M. LoRusso, New Haven, CT

4:45 p.m.  Introduction. Patricia M. LoRusso, New Haven, CT
4:50 p.m.  Award Lecture. Elizabeth M. Jaffee, Baltimore, MD

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
**Special Session • 4:45 p.m.–6:15 p.m.**
Room W315, Convention Center
**AACR-ASCO JOINT SESSION: MYELOID-TARGETED AGENTS FOR SOLID TUMORS**

_Cochairs:_ Lisa M. Coussens, Portland, OR; Eric P. Winer, New Haven, CT

**4:45 p.m.**  
Welcome and introductory remarks from the AACR President. Lisa M. Coussens, Portland, OR

**4:48 p.m.**  
Welcome and introductory remarks from the ASCO President. Eric P. Winer, New Haven, CT

**Speakers:** Karin E. de Visser, Amsterdam, Netherlands
Pablo Martinez Rodriguez, Tampa, FL
Padmanee Sharma, Houston, TX

**6:10 p.m.**  
Closing remarks

**Forums • 5:00 p.m.–6:30 p.m.**
Chapin Theater, Convention Center
**CAR CELLS: WHICH CAR TO DRIVE?**

_Cochair:_ Saar Gill, Philadelphia, PA

**5:10 p.m.**  
Synthetic biology for CAR protein engineering. Yvonne Y. Chen, Los Angeles, CA

**5:25 p.m.**  
CAR protein engineering: Practical considerations and functional implications. Christine E. Brown, Duarte, CA

Room W311 A-D, Convention Center
**HOW CAN WE MAKE CANCER CARE AT HOME THE NORM AND NOT THE EXCEPTION?**

_Cochair:_ Kathi Mooney, Salt Lake City, UT

**5:00 p.m.**  
Introduction. Kathi Mooney, Salt Lake City, UT

**5:05 p.m.**  
Why cancer care is moving to the home: The broader context. Susan Dentzer, Washington, DC

**5:20 p.m.**  
Where we are and where we are going: Cancer drugs in the home. Justin Bekelman, Philadelphia, PA

**5:35 p.m.**  
Where we are and where we are going: Hospital care in the home. Kathi Mooney, Salt Lake City, UT
Room W311 E-H, Convention Center
WHAT ARE THE CHALLENGES AND SOLUTIONS IN ADOLESCENT AND YOUNG ADULT CANCERS?

**Moderator:** Mark Lewis, Murray, UT

5:00 p.m. **Moderator Introduction.** Mark Lewis, Murray, UT

5:10 p.m. **Salient differences in AYA vs. older adult population regarding health literacy, insurance insecurity, and perceived vs. actual comfort levels as digital natives.** Anne Kirchhoff, Salt Lake City, UT

5:25 p.m. **Inherited susceptibility to cancer in the AYA population.** Katherine L. Nathanson, Philadelphia, PA

Tangerine Ballroom 1 (WF1), Convention Center
WHAT IS THE UTILITY OF PDX AND ORGANOID MODELS IN THE ERA OF IMMUNO-ONCOCOLOGY?

**Moderator:** Alana L. Welm, Salt Lake City, UT

5:10 p.m. **Using humanized mice to study interactions between human cancer and the immune system.** Karolina Palucka, Farmington, CT

5:25 p.m. **What’s new in organoid-immune co-cultures?** Calvin J. Kuo, Stanford, CA

Room W331, Convention Center
WHY SHARE DATA AND HOW TO DO IT BETTER?: A SWOT ANALYSIS

**Moderator:** Michael J. Becich, Pittsburgh, PA

5:00 p.m. **Moderator Introduction.** Michael J. Becich, Pittsburgh, PA

5:10 p.m. **Data sharing is the key to discovery.** Sylvia K. Plevritis, Stanford, CA

5:25 p.m. **Data sharing is a moral obligation. (But still allow for opt out.).** Jessie Tenenbaum, Raleigh, NC

5:40 p.m. **Data sharing leads to more citations, accelerated path to promotion and higher impact of your innovation.** Michael J. Becich, Pittsburgh, PA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Awards and Lectures • 5:15 p.m.–6:00 p.m.
Room W312, Convention Center
AACR AWARD FOR OUTSTANDING ACHIEVEMENT IN BASIC CANCER RESEARCH
Chair: Donita C. Brady, Philadelphia, PA
5:15 p.m. Introduction. Donita C. Brady, Philadelphia, PA
5:20 p.m. Award Lecture. Kathryn E. Wellen, Philadelphia, PA

Awards and Lectures • 5:30 p.m.–6:15 p.m.
Tangerine Ballroom 3-4 (WF3-4), Convention Center
AACR-PRINCESS TAKAMATSU MEMORIAL LECTURESHP
Chair: Rakesh K. Jain, Boston, MA
5:30 p.m. Introduction. Rakesh K. Jain, Boston, MA
5:35 p.m. Funder Remarks. Yoshinori Murakami, Tokyo, Japan
5:40 p.m. Award Lecture. Robert D. Schreiber, St. Louis, MO

Professional Advancement Session • 5:30 p.m.–7:00 p.m.
NOT ELIGIBLE FOR CME CREDIT
Signature 2, Rosen Centre Hotel
PRODUCTIVE PEER REVIEW: IMPROVING SCIENCE WHILE AVOIDING PITFALLS
Moderators: New Editor-in-Chief of Cancer Research
Christine A. Iacobuzio-Donahue, New York, NY
Cancer Discovery Scientific Editor
Christine M. Lovly, Nashville, TN

Town Meeting • 5:30 p.m.–7:00 p.m.
NOT ELIGIBLE FOR CME CREDIT
Junior Ballroom G, Rosen Centre Hotel
MINORITIES IN CANCER RESEARCH (MICR) TOWN HALL MEETING
Cochairs: Clayton Yates, Baltimore, MD; Gerardo Colon-Otero, Jacksonville, FL; Camille C.R. Ragin, Philadelphia, PA
MONDAY, APRIL 17* (cont’d)

Town Meetings • 6:00 p.m.–8:00 p.m.
NOT ELIGIBLE FOR CME CREDIT

Windermere X, Hyatt Regency
CANCER IMMUNOPREVENTION: A CANCER IMMUNOLOGY WORKING GROUP
TOWN HALL MEETING AND NETWORKING RECEPTION

Chair: Kunle Odunsi, Chicago, IL

6:00 p.m. Networking Reception

6:40 p.m. Immunoprevention of NF-1 associated malignant peripheral nerve sheath tumor. David A. Largaespada, Minneapolis, MN

6:50 p.m. Resolving an immune tolerogenic niche at the earliest phase of cancer initiation. Yu Leo Lei, Ann Harbor, MI

7:00 p.m. NCI infrastructure and programs in cancer immunoprevention. Philip E. Castle, Rockville, MD

7:10 p.m. Panel Discussion

7:30 p.m. Networking Reception

Windermere Y, Hyatt Regency
LINKING EPIDEMIOLOGY AND IMPLEMENTATION SCIENCES:
A POPULATION SCIENCES WORKING GROUP TOWN HALL MEETING
AND NETWORKING RECEPTION

Chair: Lorelei A. Mucci, Boston, MA

6:00 p.m. Networking Reception

6:30 p.m. PSWG Working Group Overview. Lorelei A. Mucci, Boston, MA; Andrew T. Chan, Boston, MA

6:40 p.m. Title to be announced. Katrina A.B. Goddard, Rockville, MD

6:50 p.m. Panel: Linking epidemiology and implementation science

Moderator: Maria Elena Martinez, San Diego, CA

Panelists: Graham A. Colditz, St. Louis, MO
Katrina A.B. Goddard, Rockville, MD
Gila Neta, Rockville, MD

7:40 p.m. Networking Reception

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
STICKING IT TO CANCER WITH MOLECULAR GLUES: A CHEMISTRY IN CANCER RESEARCH WORKING GROUP TOWN HALL MEETING AND NETWORKING RECEPTION

Chair: Mary M. Mader, Indianapolis, IN

6:00 p.m. Networking Reception

6:30 p.m. CICR Working Group Overview. Mary M. Mader, Indianapolis, IN; Joachim Rudolph, South San Francisco, CA

Moderator: Benjamin L. Ebert, Boston, MA

6:40 p.m. Title to be announced. Mary Matyskiela, San Diego, CA

6:50 p.m. Title to be announced. Michael Rapé, Berkeley, CA

7:00 p.m. Title to be announced. Riccardo Sabatini, Waltham, MA

7:10 p.m. Panel Discussion

7:30 p.m. Networking Reception

Professional Advancement Session • 7:00 p.m.–9:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Junior Ballroom F, Rosen Centre Hotel

NAVIGATING THE PATH TO A SUCCESSFUL CAREER IN CANCER RESEARCH

Cochairs: Beverly D. Lyn-Cook, Little Rock, AR; Brian M. Rivers, Atlanta, GA; Camille C.R. Ragin, Philadelphia, PA; Katie M. Campbell, Los Angeles, CA
TUESDAY, APRIL 18*

Meet-the-Expert Sessions • 7:00 a.m.–7:45 a.m.

Tangerine Ballroom 3-4 (WF3-4), Convention Center

THE BONE MARROW NICHE FOR STEM CELLS AND METASTASIS

Sean J. Morrison, Dallas, TX

Room W230, Convention Center

COLORECTAL CANCER: HOW SIGNATURE MUTATIONS DRIVE PROGRESSION, SHAPE TUMOR BIOLOGY, AND INFORM TREATMENT STRATEGIES

Ronald A. DePinho, Houston, TX

Room W224, Convention Center

COMBINATION OF RADIATION AND IMMUNOTHERAPY: BEYOND THE MICROENVIRONMENT

Sana D. Karam, Aurora, CO

Room W315, Convention Center

A ROAD MAP TO DEFEAT PANCREATIC CANCER

David A. Tuveson, Cold Spring Harbor, NY

Room W311 E-H, Convention Center

EPITRANSCRIPTOMICS AND TUMOR METABOLISM

Jeremy N. Rich, Pittsburgh, PA

Chapin Theater, Convention Center

GENETIC ENGINEERING MEETS TUMOR IMMUNOLOGY: LESSONS FROM MOUSE MODELS OF CANCER

Tyler Jacks, Cambridge, MA

Room W314 A, Convention Center

HEALTH EQUITY APPROACHES TO CANCER PREVENTION AND CONTROL

Chau Trinh-Shevrin, New York, NY

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Room W331, Convention Center

**LOSS OF HETEROZYGOSITY IN CANCER EVOLUTION**
Francesca Demichelis, Trento, Italy

Room W311 A-D, Convention Center

**NEIGHBORHOODS MATTER: WHAT’S LURKING IN THE TUMOR MICROENVIRONMENT?**
Sylvia K. Plevritis, Stanford, CA

Room W304 E-H, Convention Center

**NEW CANCER INSIGHTS FROM FUNCTIONAL GENOMIC APPROACHES**
Kimberly Stegmaier, Boston, MA

Room W240, Convention Center

**NON-GENETIC MECHANISMS OF CANCER THERAPY RESISTANCE**
Joan S. Brugge, Boston, MA

Tangerine Ballroom 1 (WF1), Convention Center

**NOVEL APPROACHES TO OVERCOME ACQUIRED RESISTANCE IN EGFR MUTANT LUNG CANCER**
Suresh S. Ramalingam, Atlanta, GA

Room W304 A-D, Convention Center

**PLAN TO ENHANCE DIVERSITY: OPPORTUNITIES, CHALLENGES, BEST PRACTICES, AND INNOVATIVE STRATEGIES TO ADVANCE A CULTURE OF INCLUSIVE EXCELLENCE AT CANCER CENTERS**
Christopher I. Li, Seattle, WA

Room W330, Convention Center

**PREVENTION, DIAGNOSIS, AND TREATMENT OF GYNECOLOGIC CANCERS: HOW CAN WE OVERCOME THE CURRENT DISPARITIES?**
Eloise Chapman-Davis, New York, NY
Valencia BC, Convention Center
STRATEGIES FOR DEVELOPING COMBINATORIAL THERAPIES FOR RAS-DRIVEN CANCERS
Karen M. Cichowski, Boston, MA

Room W312, Convention Center
TARGETING KRAS: LIGHT AT THE END OF THE TUNNEL
Mariano Barbacid, Madrid, Spain

Room W307, Convention Center
TUMOR ADAPTATION AND PLASTICITY
Dario C. Altieri, Philadelphia, PA

CME Plenary Session • 8:00 a.m.–10:00 a.m.
W Hall A2-3, Convention Center
EMBRACING IMMUNE ECOSYSTEMS
Chair: Judith A. Varner, La Jolla, CA
8:00 a.m.  Chair Introduction. Judith A. Varner, La Jolla, CA
8:05 a.m.  Targeting myeloid cells in cancer. Miriam Merad, New York, NY
8:27 a.m.  Tumor macrophage heterogeneity. Florent Ginhoux, Villejuif, France
8:49 a.m.  LAG3: The third checkpoint inhibitor. Dario A. Vignali, Pittsburgh, PA
9:11 a.m.  CAR-T cells: Next generation. Gianpietro Dotti, Chapel Hill, NC
9:33 a.m.  Understanding spontaneous IgA responses at tumor beds provides a rationale for novel immunotherapeutic approaches. Jose R. Conejo-Garcia, Durham, NC
9:55 a.m.  Wrap-up and opportunities for the future. Judith A. Varner, La Jolla, CA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Professional Advancement Session • 8:30 a.m.–2:00 p.m.
NOT ELIGIBLE FOR CME CREDIT

W Hall E2, Convention Center

SPECIAL PROGRAM FOR HIGH SCHOOL STUDENTS, “THE CONQUEST OF CANCER AND THE NEXT GENERATION OF CANCER RESEARCHERS”

Chair: Brian M. Rivers, Atlanta, GA

Poster Sessions • 9:00 a.m.-12:30 p.m.
NOT ELIGIBLE FOR CME CREDIT

W Halls B-E1, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

TUMOR BIOLOGY
Section 1  Pediatric Cancer 2: Biology and Therapeutics
Section 2  Pediatric Cancer 3: Genomes and Novel Tumor Models
Section 3  PET, MRI, and CT Imaging
Section 4  Regulation of Invasion and Migration
Section 5  Signaling Pathways That Impact the Tumor Microenvironment
Section 6  Stem Cells and the Microenvironment

MOLECULAR/CELLULAR BIOLOGY AND GENETICS
Section 7  Cancer and Metabolism 1
Section 8  Cancer and Metabolism 2
Section 9  Gene Regulation in Cancer
Section 10  Non-coding RNAs in Brain, Melanoma, Lung, and Head/Neck
Section 11  Non-coding RNAs in Breast and Gynecological/Urinary Tract Cancers and New Techniques/Technologies
Section 12  Non-coding RNAs in Gastrointestinal, Blood, and Bone Marrow Cancers

CHEMISTRY
Section 13  Natural Products
Section 14  Structural and Chemical Biology
**EXPERIMENTAL AND MOLECULAR THERAPEUTICS**

Section 15 Drug Resistance in Molecular Targeted Therapies 3
Section 16 Drug Resistance in Molecular Targeted Therapies 4 / Regulation of Gene Expression in Drug Resistance
Section 17 Identification of Molecular Targets 1
Section 18 Identification of Molecular Targets 2 / New Nonclinical Models for Targets
Section 19 Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3
Section 20 Tyrosine Kinase and Phosphatase Inhibitors 1
Section 21 Tyrosine Kinase and Phosphatase Inhibitors 2

**IMMUNOLOGY**

Section 22 Adoptive Cell and Natural Killer Cell Therapy
Section 23 CAR T-cell Therapy 2
Section 24 Determinants of Immunotherapeutic Effectiveness
Section 25 Developments in Anticancer Immunotherapy
Section 26 Advocates Poster Session 2

**SURVIVORSHIP**

Section 26 Advocates Poster Session 2

**POPULATION SCIENCES**

Section 28 Cancer Screening and Health Equity
Section 29 Descriptive Epidemiology and Environmental Risk Factors

**PREVENTION / EARLY DETECTION / INTERCEPTION**

Section 30 Diet, Nutrition, Lifestyle, and Environment and Cancer Prevention

**MULTIDISCIPLINARY**

Section 31 AACR Project GENIE Use Cases

**BIOINFORMATICS / COMPUTATIONAL BIOLOGY / SYSTEMS BIOLOGY / CONVERGENT SCIENCE**

Section 32 Algorithms and Statistical Methods
Section 33 Integrative Cancer Systems Biology
Section 34 Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
CLINICAL RESEARCH EXCLUDING TRIALS
Section 35  Late-Breaking Research: Clinical Research 2
Section 37  Biomarkers of Therapeutic Benefit 4
Section 38  Cancer Outcomes 2
Section 39  Clinical Informatics and Data Science / Retrospective Clinical Analyses 1
Section 40  Immunomodulatory Agents and Interventions
Section 41  Inflammation, Immunity, and Cancer
Section 42  Molecular Targeted Therapies 2
Section 43  Precision Oncology in Pediatric Cancer: From Genomics to Databases to Real World Evidence
Section 44  Spatial Profiling, Tumor Classification, and Response Assessment

CLINICAL TRIALS
Section 45  First-in-Human Phase I Clinical Trials 2
Section 46  Phase I Clinical Trials 1
Section 47  Phase II Clinical Trials 2

Meet and Greet • 9:30 a.m.–10:30 a.m.
NOT ELIGIBLE FOR CME CREDIT
Publications Booth 2743, W Halls B-E1
MEET THE EDITOR-IN-CHIEF OF MOLECULAR CANCER THERAPEUTICS: BEVERLY A. TEICHER, PHD

NCI-NIH-Sponsored Session • 10:15 a.m.–11:15 a.m.
NOT ELIGIBLE FOR CME CREDIT
Room W314 A, Convention Center
INTRAMURAL AND EXTRAMURAL TRAINING AND CANCER DEVELOPMENT AWARDS AND OPPORTUNITIES
Moderator: Nastaran Zahir, Bethesda, MD

10:15 a.m.  Introduction: Nastaran Zahir, Bethesda, MD
10:25 a.m.  Overview of NCI intramural training programs. Erika Ginsburg, Bethesda, MD
10:35 a.m.  NCI fellowship funding opportunities for predocs and postdocs. Mariam Eljanne, Bethesda, MD,
10:45 a.m.  NCI career development award funding opportunities: Tips for early-career-stage investigators. Sonia B. Jakowlew, Bethesda, MD
10:55 a.m.  Panel Discussion
Advances in Diagnostics and Therapeutics
10:15 a.m.–11:45 a.m.

Tangerine Ballroom 3-4 (WF3-4), Convention Center

CANCER VACCINES: BACK TO THE FUTURE

Chair: Vinod P. Balachandran, New York, NY

10:15 a.m.  Chair Introduction. Vinod P. Balachandran, New York, NY
10:20 a.m.  Title to be announced. Catherine J. Wu, Boston, MA
11:05 a.m.  A pentavalent prophylactic Epstein-Barr virus elicits high titers of neutralizing antibodies that prevents EBV infection in humanized mice. Javier G. Ogembo, Duarte, CA
10:40 a.m.  Individualized mRNA neoantigen vaccines for pancreatic cancer. Vinod P. Balachandran, New York, NY

Dharma Master Jiantai Advances in Biomarkers Session: Next Generation Technologies and Biomarkers for the Early Detection of Cancer

Chair: Andrew K. Godwin, Kansas City, KS

10:15 a.m.  Chair Introduction. Andrew K. Godwin, Kansas City, KS
10:45 a.m.  Urinary assessment of response and resistance to checkpoint blockade immunotherapy via activity-based synthetic biomarkers. Gabe Kwong, Atlanta, GA
11:10 a.m.  Tiny packages, enormous potential: Exploiting extracellular vesicles for early detection and disease monitoring of cancer. Andrew K. Godwin, Kansas City, KS

Functional Precision Medicine in Oncology

Chair: Anthony Letai, Boston, MA

10:15 a.m.  Chair Introduction. Anthony Letai, Boston, MA
10:20 a.m.  Utilization of functional precision medicine for clinical trials in acute leukemia and multiple myeloma: Correlation with molecular data. Pamela Becker, Duarte, CA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
10:45 a.m.  Feasibility of using patient-derived models for functional precision medicine in breast cancer trials. Alana L. Welm, Salt Lake City, UT

11:10 a.m.  Single cell functional testing to guide treatment in aggressive hematologic malignancies. Philipp Staber, Vienna, Austria

Valencia A, Convention Center

NOVEL FRONTIERS IN DRUG DISCOVERY

Chair: Eric S. Fischer, Boston, MA

10:15 a.m.  Chair Introduction. Eric S. Fischer, Boston, MA

10:20 a.m.  Molecular glues for protein degradation and beyond. Eric S. Fischer, Boston, MA

10:45 a.m.  Targeting autophagy in cancer. Christina G. Towers, La Jolla, CA

11:10 a.m.  Drugging GBP1 as a therapeutic strategy for cancer. Sanjay V. Malhotra, Portland, OR

CME Advances in Organ Site Research • 10:15 a.m.–11:45 a.m.

Room W224, Convention Center

DECODING THE ORIGINS OF DRUG RESISTANCE PHENOTYPES IN CANCER

Chair: Samuel Aparicio, Vancouver, BC, Canada

10:15 a.m.  Chair Introduction. Samuel Aparicio, Vancouver, BC, Canada

10:20 a.m.  Investigating biological mediators of social and environmental risk factors on cancer health disparities. Brittany D. Lord, Bethesda, MD [AACR NextGen Star]

11:00 a.m.  Non-genetic mechanisms of emergent drug resistant states in cancer. Celine Vallot, Paris, France

10:40 a.m.  Quantifying the role of copy number-structural mutation in resistance to chemotherapeutic agents in cancer. Samuel Aparicio, Vancouver, BC, Canada

11:20 a.m.  Emerging mechanisms of CDK4/6 resistance in ER+ breast cancers. David W. Cescon, Toronto, ON, Canada
Room W307, Convention Center
INTEGRATING GENOMICS INTO CLINICAL ADVANCES IN LYMPHOMA

Chair: Christopher R. Flowers, Houston, TX

10:15 a.m.  Chair Introduction. Christopher R. Flowers, Houston, TX
10:20 a.m.  Next generation sequencing in aggressive B-cell lymphomas. Anne J. Novak, Rochester, MN
10:40 a.m.  Integrating genomic subtyping into lymphoma clinical trials and care. Christopher R. Flowers, Houston, TX
11:00 a.m.  Towards a genomic classification of T cell lymphoma. Megan S. Lim, Philadelphia, PA
11:20 a.m.  Panel Discussion

Advances in Prevention Research • 10:15 a.m.–11:45 a.m.

Room W311 A-D, Convention Center
INCREASING THE REACH AND EFFICACY OF EVIDENCE-BASED INTERVENTIONS FOR TOBACCO DEPENDENCE

Chair: David W. Wetter, Salt Lake City, UT

10:15 a.m.  Chair Introduction. David W. Wetter, Salt Lake City, UT
10:20 a.m.  Increasing the reach of evidence-based interventions for tobacco use. David W. Wetter, Salt Lake City, UT
10:45 a.m.  Improving the use and effectiveness of treatments for tobacco use in clinical settings. Robert A. Schnoll, Philadelphia, PA
11:10 a.m.  Personalizing medication treatment for tobacco cessation. Paul M. Cinciripini, Houston, TX
11:35 a.m.  Panel Discussion

Major Symposia • 10:15 a.m.–11:45 a.m.

Room W312, Convention Center
ADVANCES IN SUPPORTIVE CARE

Chair: Alicia Morgans, Boston, MA

10:15 a.m.  Chair Introduction. Alicia Morgans, Boston, MA
10:20 a.m.  Living longer and better: Advances in cancer survivorship care. Alicia Morgans, Boston, MA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
10:45 a.m.  **Advances in cardio-oncology clinical science and patient care.** Bonnie Ky, Philadelphia, PA

11:10 a.m.  **Bad to the bone: Effects of pathologic bone destruction on muscle.** Theresa A. Guise, Houston, TX

11:35 a.m.  **Panel Discussion**

Valencia BC, Convention Center

**THE CONNECTION BETWEEN AUTOIMMUNITY AND IMMUNOTHERAPY IN CANCER**

Chair: David V. Serreze, Bar Harbor, ME

10:15 a.m.  **Chair Introduction.** David V. Serreze, Bar Harbor, ME

10:20 a.m.  **Title to be announced.** Ana L. Perdigoto, New Haven, CT

10:45 a.m.  **Clinical advances in irAE diagnosis and management.** Jarushka Naidoo, Baltimore, MD

11:10 a.m.  **Use of humanized mice to identify genes contributing to checkpoint blockade induced irAEs.** David V. Serreze, Bar Harbor, ME

11:45 a.m.  **Discussion**

Room W414, Convention Center

**DIETARY REGULATION OF CANCER PROGRESSION**

Chair: Lydia Lynch, Boston, MA

10:15 a.m.  **Chair Introduction.** Lydia Lynch, Boston, MA

10:20 a.m.  **The impact of dietary lipids fueling anti-tumor immunity.** Lydia Lynch, Boston, MA

10:45 a.m.  **Stress granules at the crossroads of obesity-induced cellular stress and pancreatic cancer.** Elda Grabocka, Philadelphia, PA

11:10 a.m.  **Fasting mimicking diet cycles in cancer treatment.** Valter D. Longo, Los Angeles, CA

11:35 a.m.  **Panel Discussion**
**Room W311 E-H, Convention Center**

**ELECTRONIC HEALTH RECORDS AND CANCER LEARNING HEALTH SYSTEMS**

**Chair:** Tina Hernandez-Boussard, Stanford, CA

10:15 a.m.  **Chair Introduction.** Tina Hernandez-Boussard, Stanford, CA

10:20 a.m.  **A learning system for personalized breast cancer risk management.** Mia A. Levy, Cambridge, MA

10:45 a.m.  **Deploying, sustaining, and learning from PROS: Lessons from the SIMPRO consortium.** Michael Hassett, Boston, MA

11:10 a.m.  **Developing accurate risk models for cancer care: Addressing biases, uncertainty, and clinical utility.** Tina Hernandez-Boussard, Stanford, CA

11:35 a.m.  **Panel Discussion**

**Room W304 E-H, Convention Center**

**MINORITIES IN CANCER RESEARCH SCIENTIFIC SYMPOSIUM ON INNOVATION TO ADDRESS DISPARITIES IN ONCOLOGY CLINICAL TRIALS**

**Cochairs:** Luis Diaz, New York, NY; Folakemi T. Odedina, Jacksonville, FL

10:15 a.m.  **Introduction.** Luis A. Diaz, New York, NY

10:25 a.m.  **Innovation through decentralization: Meeting participants where they are.** Folakemi T. Odedina, Jacksonville, FL

10:45 a.m.  **The role of the FDA in addressing disparities in oncology clinical trials.** Lola A. Fashoyin-Aje, Silver Spring, MD

10:55 a.m.  **Discussion**

**Valencia D, Convention Center**

**NEXT GENERATION OF MYELOID CHECKPOINTS IN CANCER**

**Chair:** Ido Amit, Rehovot, Israel

10:15 a.m.  **Chair Introduction.** Ido Amit, Rehovot, Israel

10:20 a.m.  **Basic and clinical impacts of targeting myeloid cells in tumors.** Judith A. Varner, La Jolla, CA

10:45 a.m.  **Regulation of macrophage and dendritic cell differentiation in the tumor microenvironment.** Malay Haldar, Philadelphia, PA

11:10 a.m.  **The power of One: Immuno-oncology in the age of single cell genomics.** Ido Amit, Rehovot, Israel

11:35 a.m.  **Panel Discussion**

Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Room W315, Convention Center

Regulatory Science and Policy Session

PROJECT SITE SELECTOR: NAVIGATING ONCOLOGY DRUG DEVELOPMENT THROUGH TROUBLED WATERS

Moderator: Harpreet Singh, Silver Spring, MD

Panelists: Ladi Akinboro, Silver Spring, MD
Jhanelle E. Gray, Tampa, FL
Bea Lavery, San Francisco, CA
Carrie Lee, Chapel Hill, NC
Ke Liu, Boston, MA
Leigh Marcus, Silver Spring, MD
Meg Valnoski, Princeton, NJ

Room W304 A-D, Convention Center

STRESS, STEMNESS, AND DRUG RESISTANCE

Chair: Hua Yu, Duarte, CA

10:15 a.m.  Chair Introduction. Hua Yu, Duarte, CA

10:20 a.m.  Landscape of single-cell developmental states across human malignancies.
Aaron M. Newman, Stanford, CA

10:40 a.m.  Targeting polyamines metabolism in acute myeloid leukemia stem cells.
Courtney Jones, Toronto, ON, Canada
[AACR NextGen Star]

11:00 a.m.  Therapy resistance induced by reprogrammed lipid metabolism. Hua Yu,
Duarte, CA

11:20 a.m.  Therapy-induced stress adaptations driving tumor evolution during
molecular therapy in human NSCLC. Trever G. Bivona, San Francisco, CA

11:40 a.m.  Discussion
Clinical Trials Plenary Session • 10:15 a.m.–12:15 p.m.

Location to be announced

NOVEL BIOMARKER-DRIVEN MOLECULARLY TARGETED THERAPY TRIALS

Cochairs: Bridgitte C. Widemann, Bethesda, MD; Mustafa Khasraw, Durham, NC

Introduction

10:15 a.m.  CT016  Clinical and translational findings of pemigatinib in previously treated solid tumors with activating FGFR1-3 alterations in the FIGHT-207 study. Jordi Rodon, Houston, TX

10:30 a.m.  Discussant. Alexander Drilon, New York, NY

10:40 a.m.  Discussion

10:45 a.m.  CT017  Pan-mutant and isoform selective PI3Kα inhibitor, RLY-2608, demonstrates selective targeting in a first-in-human study of PIK3CA-mutant solid tumor patients, ReDiscover trial. Andreas Varkaris, Boston, MA

11:00 a.m.  Discussant. Fabrice Andre, Villejuif, France

11:10 a.m.  Discussion

11:15 a.m.  CT018  Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations. Timothy A. Yap, Houston, TX

11:30 a.m.  Discussant. Fiona Simpkins, Philadelphia, PA

11:40 a.m.  Discussion

11:45 a.m.  CT019  Phase I/II study of the PARP inhibitor olaparib and ATR inhibitor ceralasertib in children with advanced malignancies: Arm N of the AcSé-ESMART trial. Susanne A. Gatz, Birmingham, United Kingdom

12:00 p.m.  Discussant. Julia L. Glade Bender, New York, NY

12:10 p.m.  Discussion

Meet and Greet • 11:30 a.m.–12:30 p.m.

NOT ELIGIBLE FOR CME CREDIT

Publications Booth 2743, W Halls B-E1

MEET THE EDITORS-IN-CHIEF OF CANCER PREVENTION RESEARCH:
RAYMOND N. DUBOIS, MD, PhD AND MICHAEL N. POLLAK, MD

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
**Awards and Lectures • 12:00 p.m.–12:30 p.m.**  
Room W240, Convention Center  
**AACR GERTRUDE B. ELION CANCER RESEARCH AWARD LECTURE**

12:00 p.m.  **Unravel the root of cancer immune resistance.** Yuxuan Phoenix Miao, Chicago, IL

---

**NCI-NIH-Sponsored Session • 12:30 p.m.–1:30 p.m. NOT ELIGIBLE FOR CME CREDIT**  
Room W314 A, Convention Center  
**HELPING EXTRAMURAL INNOVATORS REACH THE CLINIC: NCI DEVELOPMENTAL THERAPEUTICS PROGRAM**

**Moderator:** Rosemarie Aurigemma, Rockville, MD

12:30 p.m.  **Funding opportunities.** Sundar Venkatachalam, Bethesda, MD
12:40 p.m.  **New drug development resources.** Rosemarie Aurigemma, Bethesda, MD
12:50 p.m.  **Stepping Stones program.** Sharad K. Verma, Bethesda, MD
1:00 p.m.  **Immuno-oncology initiatives and services.** Marc S. Ernstoff, Bethesda, MD
1:10 p.m.  **Panel Discussion**

---

**CME Advances in Diagnostics and Therapeutics  
12:30 p.m.–2:00 p.m.**  
Room W224, Convention Center  
**HOW CAN WE LEVERAGE EMERGING SINGLE-CELL AND SPATIAL PROFILING METHODS TO UNDERSTAND THE FUNCTIONAL PROPERTIES OF CANCERS?**

**Chair:** Alex K. Shalek, Cambridge, MA

12:30 p.m.  **Chair Introduction.** Alex K. Shalek, Cambridge, MA
12:35 p.m.  **Charting human pre-cancer to cancer transitions with single-cell and spatial data.** Ken S. Lau, Nashville, TN
1:00 p.m.  **Tracking the clonal origins of metaplasia and cancer.** Sydney Shaffer, Philadelphia, PA
1:25 p.m.  **Does cell state matter in cancer?** Alex K. Shalek, Cambridge, MA
1:50 p.m.  **Panel Discussion**
TANGERINE BALLROOM 3-4 (WF3-4), CONVENTION CENTER

**IMMUNE PROFILING AND IMMUNE HEALTH IN CANCER**

**Chair:** Trevor J. Pugh, Toronto, ON, Canada

12:30 p.m.  **Chair Introduction.** Trevor J. Pugh, Toronto, ON, Canada

12:35 p.m.  Immune cells as ‘biosensors’ and the basis for immune health profiling of cancer and beyond. E. John Wherry, Philadelphia, PA

1:00 p.m.   **Immune-driven evolution in cancer.** Marta Luksza, New York, NY

1:25 p.m.   Understanding immunotherapy response through immune repertoire sequencing. Trevor J. Pugh, Toronto, ON, Canada

1:50 p.m.   **Panel Discussion**

---

**CME**  
**Advances in Organ Site Research • 12:30 p.m.–2:00 p.m.**

Room W307, Convention Center

**ADVANCES IN BRAIN TUMOR RESEARCH AND TREATMENT**

**Chair:** Samuel K. McBrayer, Dallas, TX

12:30 p.m.  **Chair introduction.** Samuel K. McBrayer, Dallas, TX

12:35 p.m.  **ONC201 in H3K27M-mutant diffuse midline gliomas: Clinical biomarkers and mechanisms of response.** Carl Koschmann, Ann Arbor, MI

1:00 p.m.   Improving treatment of adult and pediatric brain tumors: Emerging strategies. Rakesh K. Jain, Boston, MA

1:25 p.m.   Targeting metabolic vulnerabilities in IDH mutant glioma. Samuel K. McBrayer, Dallas, TX

1:50 p.m.   **Panel Discussion**

---

Room W312, Convention Center

**CHALLENGES AND ADVANCES IN SARCOMA TRANSLATIONAL RESEARCH**

**Chair:** Judith V.M.G. Bovee, Leiden, Netherlands

12:30 p.m.  **Chair Introduction.** Judith V.M.G. Bovee, Leiden, Netherlands

12:35 p.m.  **Methylation profiling and NGS in sarcoma diagnostics.** Daniel Baumhoer, Basel, Switzerland

1:00 p.m.   On the importance of the microenvironment of pediatric sarcoma. Troy A. McEachron, Bethesda, MD

---

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
1:25 p.m.  On the development of sarcoma models for patient tailored therapy.  
Judith V.M.G. Bovee, Leiden, Netherlands

1:50 p.m.  Panel Discussion

---

**CME**  Advances in Prevention Research • 12:30 p.m.–2:00 p.m.

Room W311 A-D, Convention Center

COMMUNITY ENGAGEMENT TO REDUCE CANCER DISPARITIES

Chair: Francisco Cartujano, Rochester, NY

12:30 p.m.  Chair Introduction

12:35 p.m.  Addressing tobacco-related disparities among Latinos via community-based participatory research. Francisco Cartujano, Rochester, NY

1:00 p.m.  Engaging the transgender community: Best practices for cancer prevention and control. Inés Aristegui, Buenos Aires, Argentina

1:25 p.m.  Examination of barriers and facilitators for breast and cervical cancer screening among Latinx trans and non-binary individuals. Alixida Ramos-Pibernus, Ponce, PR

1:50 p.m.  Panel Discussion

---

**CME**  Major Symposia • 12:30 p.m.–2:00 p.m.

Room W304 A-D, Convention Center

BIOLOGICAL BASIS OF NOVEL TARGETS FOR SOLID TUMORS

Chair: Carlos Caulin, Tucson, AZ

12:30 p.m.  Chair Introduction. Carlos Caulin, Tucson, AZ

12:35 p.m.  Oncogenic activities that promote and sustain adenoid cystic carcinoma development. Carlos Caulin, Tucson, AZ

1:00 p.m.  Novel molecular mechanisms of lung cancer plasticity and targeting lung squamous cell carcinoma. Cecil Han, Washington, DC

1:25 p.m.  Targeting the metabolic vulnerabilities of cancer cells by phosphoinositide kinase inhibition. Brooke M. Emerling, La Jolla, CA

1:50 p.m.  Panel Discussion
Tangerine Ballroom 2 (WF2), Convention Center

**DHARMA MASTER JIANTAI SYMPOSIUM IN TARGETED THERAPY:**
**CELLULAR THERAPIES FOR CANCER**

**Chair:** Christopher A. Klebanoff, New York, NY

12:30 p.m.  **Chair Introduction.** Christopher A. Klebanoff, New York, NY

12:35 p.m.  **Immunogenicity and therapeutic targeting of recurrently mutated ‘public’ neoantigens.** Christopher A. Klebanoff, New York, NY

1:00 p.m.  **CRISPR-based engineering of key gene targets to enhance T cell therapies.**
Julia Carnevale, Burlingame, CA

1:25 p.m.  **In depth analysis of TIL in melanoma and correlations with outcome.**
John B.A.G. Haanen, Amsterdam, Netherlands

1:50 p.m.  **Panel Discussion**

Room W414, Convention Center

**DNA DAMAGE AND THERAPEUTIC STRATEGIES**

**Chair:** Peng Mao, Albuquerque, NM

12:30 p.m.  **Chair Introduction.** Peng Mao, Albuquerque, NM

12:35 p.m.  **A new role of transcription-coupled DNA repair in affecting temozolomide adducts and mutations.** Peng Mao, Albuquerque, NM

1:00 p.m.  **Novel strategies for homologous recombination deficient pancreatic cancer.**
Kim A. Reiss, Philadelphia, PA

1:25 p.m.  **MMEJ targeting for treating HR deficient tumors.** Agnel J. Sfeir, New York, NY

1:50 p.m.  **Panel Discussion**

Room W311 E-H, Convention Center

**FUTURE OF PHASE I CLINICAL TRIALS**

**Chair:** Shivaani Kummar, Portland, OR

12:30 p.m.  **Chair Introduction.** Shivaani Kummar, Portland, OR

12:35 p.m.  **Revolution in the precision medicine paradigm in phase 1 trials: The future is now.** Vivek Subbiah, Houston, TX

1:00 p.m.  **Antibody drug conjugates: Selection, drug resistance, and combinations.**
Patricia M. LoRusso, Hamden, CT

1:25 p.m.  **Immunotherapies: Where do we go next?** Shivaani Kummar, Portland, OR

1:50 p.m.  **Panel Discussion**

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Valencia A, Convention Center

LIQUID BIOPSY: OPPORTUNITIES AND CHALLENGES OF CELL-FREE DNA

Chair: Aadel A. Chaudhuri, St. Louis, MO

12:30 p.m. Chair Introduction. Aadel A. Chaudhuri, St. Louis, MO

12:35 p.m. Translating fragmentomics discoveries into impacts in liquid biopsies. Dennis Lo, Hong Kong, China

1:00 p.m. Leveraging genomic and epigenomic cell-free DNA features for clinical translation. Sarah-Jane Dawson, Melbourne, Australia

1:25 p.m. Proximal and systemic cell-free DNA analysis for detection of adult and pediatric malignancies. Aadel A. Chaudhuri, St. Louis, MO

1:50 p.m. Panel Discussion

Tangerine Ballroom 1 (WF1), Convention Center

METABOLIC INFLUENCE ON THE CANCER CELL STATE

Chair: Matthew G. Vander Heiden, Cambridge, MA

12:30 p.m. Mechanisms of epigenetic regulation and therapeutic response in hormone-driven tumors. Eneda Toska, Baltimore, MD

12:50 p.m. Transcriptional and metabolic dynamics of cancer cells under nutrient deprivation. Alvin P. Makohon-Moore, Nutley, NJ [AACR NextGen Star]

1:05 p.m. Metabolic rewiring during tumor suppression. Lydia WS Finley, New York, NY

1:25 p.m. Relationship between nucleotide metabolism and cell state regulation. Matthew G. Vander Heiden, Cambridge, MA

1:50 p.m. Panel Discussion
Valencia BC, Convention Center
MICROBIOME AND CANCER IMMUNOTHERAPY

Chair: Florencia McAllister, Houston, TX

12:30 p.m.  Chair Introduction. Florencia McAllister, Houston, TX

12:35 p.m.  Mechanisms employed by the tumor microbiome to mediate responses to immunotherapy. Florencia McAllister, Houston, TX

12:55 p.m.  A biobank of Fecal Immunochemical Tests (FIT) for gut microbiome measurement: A paradigm for studying the microbiome and cancer. Doratha A. Byrd, Tampa, FL [AACR NextGen Star]

1:10 p.m.  The impact of gut microbial amino acid metabolism on immunity in the solid tumor microenvironment. Tracy L. McGaha, Toronto, ON, Canada

1:30 p.m.  Molecular pathways activated by the gut microbiota to improve cancer immunotherapy. Maria Rescigno, Milan, Italy

1:50 p.m.  Panel Discussion

Room W315, Convention Center
Regulatory Science and Policy Session
MULTI-CANCER EARLY DETECTION (MCED) ASSAYS:
EARLY DETECTION VERSUS EARLY DISTRACTION

Moderators: Jamie Brewer, Silver Spring, MD

Panelists: Angela R. Bradbury, Merion Station, PA
Philip E. Castle, Rockville, MD
Luis A. Diaz, New York, NY
Kimberly Lynn Newcomer, Milton, WI
Marie E. Wood, Aurora, CO

Room W304 E-H, Convention Center
SEX HORMONES AND CANCER

Chair: Amy Moran, Portland, OR

12:30 p.m.  Chair Introduction. Amy Moran, Portland, OR

12:35 p.m.  Sex steroid hormones in breast cancer heterogeneity and endocrine resistance. Carol A. Sartorius, Aurora, CO

1:00 p.m.  Androgens and Immunotherapy-a novel mechanism of immunotherapy resistance. Amy Moran, Portland, OR

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
1:25 p.m.  Sex differences in severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in Cancer clinical trials: An evidentiary perspective. Joseph M. Unger, Seattle, WA

1:50 p.m.  Panel Discussion

The Dulicitous Tumor Microenvironment

Chair: Amanda W. Lund, New York, NY

12:30 p.m.  Chair Introduction. Amanda W. Lund, New York, NY

12:35 p.m.  The complexities of tumor associated macrophages and the key to effective targeting for anti-cancer therapy. Jennifer L. Guerriero, Boston, MA

1:00 p.m.  Tumor-associated lymphatic vessels and T cell transit through the tumor microenvironment. Amanda W. Lund, New York, NY

1:25 p.m.  Age-related changes in the tumor microenvironment drive tumor progression. Sheila A. Stewart, St. Louis, MO

1:50 p.m.  Panel Discussion

Meet and Greet • 1:30 p.m.–2:30 p.m.

Meet the Editors-in-Chief of Cancer Research Communications: Elaine R. Mardis, PhD and Lillian L. Siu, MD
Poster Sessions • 1:30 p.m.-5:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

W Halls B-E1, Convention Center

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

**TUMOR BIOLOGY**

- **Section 2** 3D and Tissue Recombinant Models
- **Section 3** Advances in Angiogenesis
- **Section 4** Evaluating Tumor Progression via 3D and Spatial Approaches
- **Section 5** Inflammation and Tumor Progression
- **Section 6** Patient-Derived Xenograft Models
- **Section 7** Single Cell and Spatial Considerations of the Tumor Microenvironment
- **Section 36** Late-Breaking Research: Tumor Biology 2

**MOLECULAR/CELLULAR BIOLOGY AND GENETICS**

- **Section 8** Chromatin Structure and Function in Cancer
- **Section 9** Epigenetic Mechanisms as Drivers of Tumorigenesis
- **Section 10** Oxidative Stress, Metabolism, and Cell Senescence
- **Section 11** Responses to Hypoxic, Proteotoxic, and Other Novel Forms of Cell Stress
- **Section 12** Role of Mitochondria and Signaling Pathways in Cancer
- **Section 35** Late-Breaking Research: Molecular/Cellular Biology and Genetics 2

**EXPERIMENTAL AND MOLECULAR THERAPEUTICS**

- **Section 13** Anticancer Approaches Targeting Signal Transduction Pathways
- **Section 14** Anticancer Approaches: Antibody-Drug Conjugates, Epigenetics, and Tumor Environment
- **Section 15** Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerasers
- **Section 16** Novel Targets and Pathways
- **Section 17** Targeting Protein Kinases and Phosphatases for Therapy 1
- **Section 18** Targeting Protein Kinases and Phosphatases for Therapy 2
- **Section 19** Theranostics and Radionuclides / Pharmacologic Approaches
- **Section 34** Late-Breaking Research: Experimental and Molecular Therapeutics 2

**IMMUNOLOGY**

- **Section 21** Combination Immunotherapies 1
- **Section 22** Combination Immunotherapies 2
- **Section 23** Inflammation and Immunity in the Tumor Microenvironment
- **Section 24** Modifiers of the Tumor Microenvironment
- **Section 25** Novel Preclinical Models for Cancer Immunotherapy

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
POPULATION SCIENCES
Section 26  GWAS/Post-GWAS

PREVENTION / EARLY DETECTION / INTERCEPTION
Section 27  Dietary Derivatives and Repurposed and New Drugs for Cancer Prevention

ENDOCRINOLOGY
Section 28  Endocrine-related Cancers and Nuclear Receptors: Molecular Biology, Biomarkers, and Genomics

CHEMISTRY
Section 29  Biological Mass Spectrometry and Systems Biology
Section 30  High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery

BIOINFORMATICS / COMPUTATIONAL BIOLOGY / SYSTEMS BIOLOGY / CONVERGENT SCIENCE
Section 31  Artificial Intelligence and Machine/Deep Learning 1
Section 32  Artificial Intelligence and Machine/Deep Learning 2
Section 33  Artificial Intelligence: From Pathomics to Radiomics

CLINICAL RESEARCH EXCLUDING TRIALS
Section 37  Biomarkers of Therapeutic Benefit 5
Section 38  Combination Therapies for Cancer
Section 39  Community-based Research and Biobanking Research
Section 40  Diagnostic and Prognostic Biomarkers 4
Section 41  Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 4
Section 42  New Approaches in Radiodiagnostics and Theranostics
Section 43  Spatial Proteomics and Transcriptomics 1
Section 44  Therapeutic Antibodies, Including Engineered Antibodies

CLINICAL TRIALS
Section 46  Phase I and First-in-Human Clinical Trials in Progress
Section 47  Phase I Clinical Trials 2
NCI-NIH-Sponsored Session • 2:30 p.m.–3:30 p.m.  
NOT ELIGIBLE FOR CME CREDIT

Room W314 A, Convention Center  
HUMAN CANCER MODELS INITIATIVE: A RESOURCE OF NEXT-GENERATION CANCER MODELS AND DATA

Moderator: Cindy Kyi, Bethesda, MD

2:30 p.m.  Introduction. Cindy Kyi, Bethesda, MD

2:36 p.m.  Human Cancer Models Initiative (HCMI): An overview. Julyann Perez-Mayoral, Bethesda, MD

2:54 p.m.  Navigating the HCMI searchable catalog and program resources. Eva Tonsing-Carter, Bethesda, MD

3:12 p.m.  Title to be announced. James Clinton, Gaithersburg, MD

Major Symposium • 2:30 p.m.–4:00 p.m.

Room W315, Convention Center  
Regulatory Science and Policy Session  
LIQUID BIOPSIES FOR CURATIVE-INTENT SOLID TUMOR DRUG DEVELOPMENT

Moderators: Reena Philip, Silver Spring, MD; Paz Joan Vellanki, Silver Spring, MD

Panelists: Christopher Abbosh, London, United Kingdom  
Valsamo K. Anagnostou, Baltimore, MD  
Jonathan Baden, Princeton, NJ  
David R. Gandara, Sacramento, CA  
Anand Pathak, Silver Spring, MD  
Patricia Spears, Raleigh, NC

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Clinical Trials Minisymposium • 2:30 p.m.–4:30 p.m.

Chapin Theater, Convention Center

NOVEL IMMUNOTHERAPY COMBINATION CLINICAL TRIALS

Cochairs: Ecaterina Elena Dumbrava, Houston, TX; Collin D. Weekes, Aurora, CO

2:30 p.m.   Introduction

2:35 p.m.   CT034  GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors. Jason J. Luke, Pittsburgh, PA

2:50 p.m.   CT035  Addition of Salmonella-IL2 to FOLFIRINOX for metastatic stage 4 pancreatic cancer nearly doubles median survival. Daniel A. Saltzman, Cambridge, MA

3:05 p.m.   CT036  Safety and immunogenicity of a first-in-human mutant KRAS long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer: Preliminary analysis from a phase I study. Saurav D. Haldar, Baltimore, MD

3:20 p.m.   CT037  Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses. Yelena Y. Janjigian, New York, NY

3:35 p.m.   CT038  Comprehensive molecular characterization of clinical response to durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: A phase 2 clinical trial. Hyo Song Kim, Seoul, Korea, Republic of

3:50 p.m.   CT039  Immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617). Sonia Iyer, Boston, MA

4:05 p.m.   CT040  A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors: Dose escalation study. Luke Chung, Palo Alto, CA

4:20 p.m.   Closing remarks
Minisymposia • 2:30 p.m.–4:30 p.m.

Valencia BC, Convention Center
Bioinformatics / Computational Biology / Systems Biology / Convergent Science
CLINICAL APPLICATIONS OF ARTIFICIAL INTELLIGENCE AND MATHEMATICAL ONCOLOGY

Cochairs: Kristin R. Swanson, Phoenix, AZ; Heiko Enderling, Tampa, FL

2:30 pm. Introduction

2:35 p.m. 5693 Cancer cells subvert fibroblast function to promote a growth factor enriched tumor microenvironment in endocrine therapy resistant ER+ breast cancer. Jason I. Griffiths, Duarte, CA

2:50 p.m. 5694 Adaptive treatment scheduling of PARP inhibitors in ovarian cancer: Using mathematical modeling to assess clinical feasibility and estimate potential benefits. Maximilian A. Strobl, Tampa, FL

3:05 p.m. 5695 Deep learning risk prediction model of distant recurrence from H&E endometrial cancer slides. Sarah Fremond, Leiden, Netherlands

3:20 p.m. 5696 A prognostic machine learning model for early breast cancer which combines clinical and genetic data in patients treated with neo/adjuvant chemotherapy. Aidan (Amanzhol) Kubeyev, Cambridge, United Kingdom

3:35 p.m. 5697 Predicting response to PD-L1 inhibition in NSCLC using a quantitative systems pharmacology model guided by immunogenomic data. Hanwen Wang, Baltimore, MD

3:50 p.m. 5698 A multicenter study validated an integrated deep learning model for precision malignancy risk assessment and reducing unnecessary biopsies in BI-RADS 4 cases. Chika F. Ezeana, Houston, TX

4:05 p.m. 5699 Development and validation of a quantitative systems pharmacology model for prediction of preclinical efficacy of PARP inhibitors rucaparib and talazoparib combined with the ATR inhibitor gartisertib (M4344). Nathalie Dupuy, Oxford, United Kingdom

4:20 p.m. Closing remarks

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
Valencia A, Convention Center
Clinical Research Excluding Trials
IMMUNE-BASED BIOMARKERS FOR PROGNOSTIC AND PREDICTIVE BENEFIT

Cochairs: Stephanie K. Dougan, Boston, MA; Hao Wang, Baltimore, MD

2:30 pm. Introduction

2:35 p.m.  5701 Predictive biomarker models of immunotherapy response in patients with metastatic melanoma: genomic, transcriptomic, and immune profiles from the Personalised Immunotherapy Program (PIP). James S. Wilmott, Camperdown, Australia

2:50 p.m.  5702 Ovarian cancer tumor microenvironment and atezolizumab (atezo) clinical activity: IMagyn050 sub-study. Venkatesh Krishnan, South San Francisco, CA

3:05 p.m.  5703 The immune cell state atlas analysis predicts therapeutic benefits with immune checkpoint inhibitors. Tingyi Li, Tampa, FL

3:20 p.m.  5704 An integrated immune signature predictive of adjuvant immunotherapeutic benefits for high-risk melanoma. Ahmad A. Tahrini, Tampa, FL

3:35 p.m.  5705 Digital pathology based prognostic & predictive biomarkers in metastatic non-small cell lung cancer. Assaf Amitai, South San Francisco, CA

3:50 p.m.  5706 ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies. James Lindsay, Boston, MA

4:05 p.m.  5707 Tumor and immune determinants of response to anti-BCMA CAR T-cell therapy in multiple myeloma using cell-free DNA. Mia Carleton, Stanford, CA

4:20 p.m. Closing remarks
Valencia D, Convention Center
Clinical Research Excluding Trials
INCREASING THE CLINICAL UTILITY OF CELL-FREE DNA TESTING

Cochairs: Luis A. Diaz, New York, NY; Muhammed Murtaza, Madison, WI

2:30 p.m.  Introduction

2:35 p.m.  5709  Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoring. Alexandre P. Cheng, New York, NY

2:50 p.m.  5710  Detection and monitoring of t(11;14) in liquid biopsies from patients with relapsed/refractory multiple myeloma treated with venetoclax-based regimens. Jeremy A. Ross, North Chicago, IL

3:05 p.m.  5711  Blood-based early detection of non-small cell lung cancer using orphan noncoding RNAs. Mehran Karimzadeh, Palo Alto, CA

3:20 p.m.  5712  Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade. Namrata S. Patil, South San Francisco, CA

3:35 p.m.  5713  Assessing the real-world utility of cell-free microbial DNA in diagnosing early-stage lung cancer. Gregory D. Sepich-Poore, San Diego, CA

3:50 p.m.  5714  Cell-free DNA fragmentation profiling for monitoring therapeutic response in metastatic colorectal cancer. Bahar Alipanahi, Baltimore, MD

4:05 p.m.  5715  Circulating tumor DNA in colorectal cancer patients with resectable liver metastases: Preliminary results of the MIRACLE study. Lissa Wullaert, Rotterdam, Netherlands

4:20 p.m.  Closing remarks

Room W414, Convention Center
Clinical Research Excluding Trials
THE NEXT WAVE OF PRECISION ONCOLOGY: NEW DRUGS, DATABASES, AND ANALYTICS TO REFINE CARE

Cochairs: Christine M. Lovly, Nashville, TN; Shelley S. Tworoger, Tampa, FL

2:30 pm.  Introduction

2:35 p.m.  5717  Bridging the gap between clinical-omics and machine learning to improve cancer treatment. Chang In Moon, Houston, TX

2:50 p.m.  5718  Additivity predicts the clinical efficacy of most approved combination therapies for advanced cancer. Adam C. Palmer, Chapel Hill, NC

3:05 p.m.  5719  Clinical response to the PDGFRα inhibitor avapritinib in high-grade glioma patients. Kallen Schwark, Ann Arbor, MI

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
3:20 p.m.  5720  Combination therapies in matched 3D in vitro and in vivo preclinical models of rare and recalcitrant cancers from the National Cancer Institute’s Patient-Derived Models Repository. Thomas S. Dexheimer, Frederick, MD

3:35 p.m.  5721  Automated annotation for large-scale clinicogenomic models of lung cancer treatment response and overall survival. Justin Jee, New York, NY

3:50 p.m.  5722  The mutational signatures of 100,477 targeted sequenced tumors. Bin Zhu, Bethesda, MD

4:05 p.m.  5723  An in vivo pharmacogenomics platform replicates and extends biomarkers of therapy response identified via causal inference analysis of clinical data. Michael J. Rosen, Mountain View, CA

4:20 p.m.  Closing remarks

Tangerine Ballroom 3-4 (WF3-4), Convention Center
Experimental and Molecular Therapeutics
MOLECULAR TARGETS

Cochairs: Naoko Takebe, Bethesda, MD; Joann B. Sweasy, Tucson, AZ

2:30 pm.  Introduction

2:35 p.m.  5725  The USP1 inhibitor I-138 kills BRCA1-deficient tumor cells and overcomes PARP inhibitor resistance. Alexandre Andre B. A. Da Costa, Cambridge, MA

2:50 p.m.  5726  Pan-cancer proteogenomics expands the landscape of therapeutic targets. Jonathan T. Lei, Houston, TX

3:05 p.m.  5727  Identification of synthetic lethal vulnerabilities in cancers with loss of function mutations in NOTCH. Deli Hong, Boston, MA

3:20 p.m.  5728  Inhibition of TACC3 blocks the growth of highly aggressive breast cancers with centrosome amplification. Ozge Saatci, Charleston, SC

3:35 p.m.  5729  Imiqualines for pancreatic cancer: first-in-class potent and synergistic inhibitors of microtubule polymerisation. Kevin Bigot, Montpellier, France

3:50 p.m.  5730  Targeting intrinsically disordered protein βII-spectrin prevents metabolic syndrome and hepatocellular carcinoma on a sex-based bias. Xiaochun Yang, New York, NY

4:05 p.m.  5731  Apoptosis Inducing Agent 1 enhances cancer therapy-induced apoptosis by direct interaction with BAX and BAK. Xingping Qin, Boston, MA

4:20 p.m.  Closing remarks
NEW TRICKS FOR KNOWN TARGETS: NOVEL APPROACHES TO INHIBIT ONCOGENIC SIGNALING

**Room W224, Convention Center**

**Experimental and Molecular Therapeutics**

**NEW TRICKS FOR KNOWN TARGETS: NOVEL APPROACHES TO INHIBIT ONCOGENIC SIGNALING**

**Cochairs:** Janice M. Mehnert, New York, NY; Ryan J. Sullivan, Boston, MA

**2:30 pm.** Introduction

**2:35 p.m.** 5733 Combining KRASG12C(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer. Miriam Molina-Arcas, London, United Kingdom

**2:50 p.m.** 5734 Designing RAF and MEK inhibitor combinations based on their biochemical properties to effectively target MAPK-driven cancers. Ana Orive-Ramos, New York, NY

**3:05 p.m.** 5735 Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models. Takeyuki Nagashima, Tsukuba-shi, Japan

**3:20 p.m.** 5736 AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond. Frank Comer, Gaithersburg, MD

**3:35 p.m.** 5737 Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate. Lara McGrath, Waltham, MA

**3:50 p.m.** 5738 A pan-ras mRNA vaccine elicits specific immune responses and inhibits tumor growth in the mouse model of colon cancer. Dong Shen, Germantown, MD

**4:05 p.m.** 5739 Targeting WEE1 to improve the therapy of KRAS G12C mutant non-small cell lung cancer. Gaku Yamamoto, Kashiwa, Chiba, Japan

**4:20 p.m.** Closing remarks

Tangerine Ballroom 2 (WF2), Convention Center

**Immunology**

**NEW OPPORTUNITIES FOR COMBINATORIAL IMMUNOTHERAPIES**

**Cochairs:** Melissa Q. Reeves, Salt Lake City, UT; Crystal L. Mackall, Stanford, CA

**2:30 pm.** Introduction

**2:35 p.m.** 5741 Harnessing macrophages, while protecting T cells, enhances anti-tumor efficacy. Sean A. Yamada-Hunter, Stanford, CA

**2:50 p.m.** 5742 Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. James D. Thomas, Seattle, WA

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
3:05 p.m.  5743  Reprogramming myeloid cells by JAK inhibition to enhance checkpoint blockade immunotherapy. Jaroslav Zak, La Jolla, CA

3:20 p.m.  5744  Decreasing toxicity of immunocytokines by transient and selective inhibition of their intracellular signaling activation. Giulia Rotta, Otelfingen, Switzerland

3:35 p.m.  5745  Proposing the best MET inhibitor to improve anti-PD-1 efficacy in HCC. Ricardo A. de Azevedo, Houston, TX

3:50 p.m.  5746  Flexible tumor-specific cytokine and antigen delivery through the T-SIGn vector platform enables effective CAR-T cell therapy against solid tumors. Maria Stella Sasso, Abingdon, United Kingdom

4:05 p.m.  5747  A novel combination therapy of arenavirus vectors and PD1-IL2v strongly potentiates tumor specific T cell responses resulting in synergistic anti-tumor efficacy. Judith Strauss, New York, NY

4:20 p.m.  Closing remarks

Room W311 A-D, Convention Center
Molecular/Cellular Biology and Genetics
GENE REGULATION AND TRANSCRIPTION FACTORS IN CANCER
Chair: Rosalie C. Sears, Portland, OR

2:30 pm.  Introduction

2:35 p.m.  5749  Core transcriptional regulatory circuitry in a.m.L. Maxim Pimkin, Boston, MA

2:50 p.m.  5750  The mutational landscape of ultraconserved elements in human cancers. Recep Bayraktar, Houston, TX

3:05 p.m.  5751  Single-cell epigenomic analysis reveals an important role of the receptor kinase Ror2 in the erosion of cellular identity during pancreatic carcinogenesis. Simone Benitz, Detroit, MI

3:20 p.m.  5752  Enhancer amplification defines lineage addiction in human lung adenocarcinoma. John Louis Pulice, Boston, MA

3:35 p.m.  5753  RUNX3 disrupts MYC/MAX complex and promotes MYC degradation. Yoshiaki Ito, Singapore, Singapore

3:50 p.m.  5754  Determining the regulatory logic of breast cancer cells using single-cell multi-omics. Hector L. Franco, Chapel Hill, NC

4:05 p.m.  5755  TP63 fusions drive enhancer rewiring, lymphomagenesis, and dependence on EZH2. Gongwei Wu, Boston, MA

4:20 p.m.  Closing remarks
Room W307, Convention Center

**Population Sciences**

**SURVIVORSHIP AND BIOMARKERS OF PROGNOSIS**

**Cochairs:** Jennifer A. Doherty, Salt Lake City, UT; Lauren Cole Peres, Tampa, FL

2:30 pm. **Introduction**

2:35 p.m.  5757  Breast cancer diagnosis and treatment associated with acceleration of biological aging over time in a racially diverse cohort of women. Jacob K. Kresovich, Tampa, FL

2:50 p.m.  5758  Regular aspirin use, breast tumor characteristics and long-term breast cancer survival. Cheng Peng, Boston, MA

3:05 p.m.  5759  Accelerated cardiac aging in adolescent and young adult cancer survivors previously treated with cardiotoxic therapy. Michelle A. T. Hildebrandt, Houston, TX

3:20 p.m.  5760  Molecular, immune, and microbial profiles of early-onset, intermediate-onset, and later-onset CRCs. Tomotaka Ugai, Boston, MA

3:35 p.m.  5761  Bayesian estimation of a semi-parametric recurrent event model with competing outcomes for personalized risk prediction among cancer survivors. Nam H. Nguyen, Houston, TX

3:50 p.m.  5762  New perspective on racial disparities in prostate cancer: identification of new molecular subsets using whole-mount radical prostatectomy. Wei Zhao, Detroit, MI

4:05 p.m.  5763  Risk factors, trends, and disparities in HPV-associated subsequent malignant neoplasms among adolescent and young adult cancer survivors. Judy Y. Ou, Salt Lake City, UT

4:20 p.m. **Closing remarks**

Room W304 E-H, Convention Center

**Prevention / Early Detection / Interception**

**BEHAVIORAL AND BIOLOGICAL OPPORTUNITIES TO IMPROVE CANCER PREVENTION, EARLY DETECTION, AND DISPARITIES**

**Cochairs:** Timothy R. Rebbeck, Boston, MA; Andrew K. Godwin, Kansas City, KS

2:30 pm. **Introduction**

2:35 p.m.  5765  Promoter DNA methylation patterns in oral, laryngeal, and oropharyngeal anatomical regions are associated with tumor differentiation, nodal involvement, and survival in Latinos. Rafael E. Guerrero-Preston, Baltimore, MD

2:50 p.m.  5766  Prospective evaluation of cell-free DNA fragmentomes for lung cancer detection. Victor E. Velculescu, Baltimore, MD

3:05 p.m.  5767  Pan-viral response in African Americans and European Americans with hepatocellular carcinoma. Theressa Ewa, Bethesda, MD

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
3:20 p.m.  5768  Genetic screening in a tertiary medical center identifies carriers of cancer predisposition diseases that would be missed by clinical guidelines.  
Niloy Jewel Samadder, Phoenix, AZ

3:35 p.m.  5769  Disparities in uptake of levonorgestrel-releasing intrauterine system (LNG-IUS): implications for uterine cancer primary prevention.  
Paul G. Yeh, Houston, TX

3:50 p.m.  5770  Cardiorespiratory fitness and BMI in youth and five-year mortality after site-specific cancer in men: a population-based cohort study with register linkage.  
Aron Onerup, Memphis, TN

4:05 p.m.  5771  The vaginal microbiome as a mediator in the relationship between Black/White race and high grade cervical intraepithelial neoplasia.  
Katherine Y. Tossas, Richmond, VA

4:20 p.m.  Closing remarks

Room W304 A-D, Convention Center
Tumor Biology
NOVEL TARGETS, BIOMARKERS, AND MODELS FOR CANCER
Chair: Kwok-Kin Wong, New York, NY

2:30 pm.  Introduction

2:35 p.m.  5773  A forward genetic screen identifies SIRT1 as a driver of neuroendocrine prostate cancer.  
Francisca Nunes de Almeida, New York, NY

2:50 p.m.  5774  Small cell lung cancer subtype plasticity is regulated by KDM6A.  
Matthew G. Oser, Boston, MA

3:05 p.m.  5775  GLIS3 drives a neural-like malignant state enriched after neoadjuvant treatment in pancreatic cancer.  
Jimmy A. Guo, Cambridge, MA

3:20 p.m.  5776  Advancing a screening platform with panels of patient-derived organoid models for drug discovery and development.  
Annamaria Rapisarda, Frederick, MD

3:35 p.m.  5777  Race as a predictive confounder in the rate of transdifferentiation and drug response in human pancreatic acinar ductal metaplasia.  
Corey Melissa Perkins, Gainesville, FL

3:50 p.m.  5778  Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4/6-Cyclin D1 axis driving tumorigenesis and drug resistance.  
Xiaoqing Cheng, St. Louis, MO

4:05 p.m.  5779  A platform utilizing high-grade serous ovarian cancer organoids for prospective patient stratification in functional precision medicine.  
Wojciech Senkowski, Copenhagen, Denmark

4:20 p.m.  Closing remarks
Tangerine Ballroom 1 (WF1), Convention Center
Tumor Biology
SPATIAL CONSIDERATIONS OF THE 3D TUMOR MICROENVIRONMENT

**Cochairs:** Paolo P. Provenzano, Minneapolis, MN; Aaron M. Newman, San Mateo, CA

2:30 p.m. **Introduction**

2:35 p.m. **5782** The dynamic immune behavior of primary and metastatic tumors of ovarian cancer. Elaine Stur, Houston, TX

2:50 p.m. **5783** Integration of AI-powered digital pathology and imaging mass cytometry to identify relevant features of the tumor microenvironment. Federica Marchesi, Milan, Italy

3:05 p.m. **5784** Spatial clustering reveals immune hub interaction with reservoir of stem-like CD8 T cells and predicts immunotherapy response in lung cancer patients. Jonathan Chen, Cambridge, MA

3:20 p.m. **5785** A pan-cancer single-cell tumor micro-environment atlas predictive of immunotherapy response. Francesca Lodi, Leuven, Belgium

3:35 p.m. **5786** Spatial relationships in the tumor microenvironment predict response to immune checkpoint inhibitors in urothelial and head and neck cancer. Alberto Gil-Jimenez, Amsterdam, Netherlands

3:50 p.m. **5787** Modelling the spatial heterogeneity of CD45-positive tumor infiltrating lymphocytes in early-stage, estrogen receptor-positive breast cancer. Zak Kinsella, Dublin, Ireland

4:05 p.m. **5788** Single-cell and spatial transcriptomic mapping of human renal cell carcinoma brain metastases uncovers actionable immune-resistance targets. Elshad Hasanov, Houston, TX

4:20 p.m. **Closing remarks**

---

**Awards and Lectures • 3:45 p.m.–4:30 p.m.**

Room W311 E-H, Convention Center

**AACR AWARD FOR OUTSTANDING ACHIEVEMENT IN BLOOD CANCER RESEARCH**

**Chair:** Mignon L. Loh, Seattle, WA

3:45 p.m. **Introduction.** Mignon L. Loh, Seattle, WA

3:50 p.m. **Award Lecture.** Riccardo Dalla-Favera, New York, NY

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
NCI-NIH-Sponsored Session • 4:00 p.m.–5:00 p.m.
NOT ELIGIBLE FOR CME CREDIT

Room W314 A, Convention Center
OMICCIRCOS IN THE CANCER RESEARCH DATA COMMONS: A VISUALIZATION TOOL FOR BENCH BIOLOGISTS

Moderator: Erika Kim, Bethesda, MD

4:00 p.m. Cancer Research Data Commons overview. Erika Kim, Bethesda, MD
4:10 p.m. Seven Bridges' Cancer Genomics Cloud. Zelia Worman, Cambridge, MA
4:20 p.m. OmicCircos introduction and demonstration. Chunhua Yan, Bethesda, MD
4:50 p.m. Discussion

Awards and Lectures • 4:45 p.m.–5:30 p.m.
Room W331, Convention Center
AACR-IRVING WEINSTEIN FOUNDATION DISTINGUISHED LECTURESHIP

Chair: Lisa M. Coussens, Portland, OR

4:45 p.m. Introduction. Lisa M. Coussens, Portland, OR
4:50 p.m. Award Lecture. Andrea Schietinger, New York, NY

Awards and Lectures • 5:00 p.m.–5:45 p.m.
Room W304 E-H, Convention Center
AACR-ST. BALDRICK’S FOUNDATION AWARD FOR OUTSTANDING ACHIEVEMENT IN PEDIATRIC CANCER RESEARCH

Chair: Jason T. Yustein, Altanta, GA

5:00 p.m. Introduction. Jason T. Yustein, Altanta, GA
5:05 p.m. Ewing sarcoma, a paradigm for cell reprogramming in cancer. Olivier Delattre, Paris, France
**Forums • 5:00 p.m.–6:30 p.m.**

Room W311 E-H, Convention Center

**BEYOND PLATITUDES AND PROCLAMATIONS: MEANINGFUL ENGAGEMENT OF DIVERSE COMMUNITIES IN CANCER RESEARCH**

Moderator: Monica Baskin, Pittsburgh, PA

5:00 p.m.  **Moderator Introduction.** Monica Baskin, Pittsburgh, PA

5:10 p.m.  **Be trustworthy: Building Accessible and acceptable cancer research programs.** Erica T. Warner, Boston, MA

5:25 p.m.  **Asian American community engagement in cancer research.** Jiyoung Ahn, New York, NY

5:40 p.m.  **Panel Discussion**

Room W307, Convention Center

**BUILDING AND RETAINING THE CANCER WORKFORCE OF THE FUTURE: CHALLENGES, INNOVATION, AND DIVERSITY**

Moderator: Cornelia M. Ulrich, Salt Lake City, UT

5:00 p.m.  **Moderator Introduction.** Cornelia M. Ulrich, Salt Lake City, UT

5:10 p.m.  **Diversity pathways to training and workforce development.** Sanya A. Springfield, Rockville, MD

5:25 p.m.  **How can we retain valuable cancer center staff?** Leonidas C. Platanias, Chicago, IL

5:40 p.m.  **Panel Discussion**

Chapin Theater, Convention Center

**DRIVING TOWARDS RATIONAL COMBINATION ICT TRIALS**

Moderator: Padmanee Sharma, Houston, TX

5:00 p.m.  **Moderator Introduction.** Padmanee Sharma, Houston, TX

5:01 p.m.  **Investigating mechanisms of response and resistance for the development of ICT combinations.** Padmanee Sharma, Houston, TX

5:21 p.m.  **The contribution of agonists to combination immunotherapy for PD-1 resistant cancers.** Elizabeth M. Jaffee, Baltimore, MD

5:41 p.m.  **Rationally designing combination immunotherapy trials: Identifying biomarkers prior to Phase 3.** Thomas Urban Marron, New York, NY

6:01 p.m.  **Panel Discussion**

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
WHAT DOES A BIOSTATISTICIAN REALLY THINK OF YOUR STUDY AND WHY?

Moderator: Motomi Mori, Memphis, TN

5:00 p.m. Moderator Introduction. Motomi Mori, Memphis, TN
5:10 p.m. Designing a clinical trial: best practices and pitfalls to avoid. Christopher Cabanski, San Francisco, CA
5:25 p.m. Statistical considerations of optimal study design and novel data analysis for biomarker discovery research. Yu Shyr, Nashville, TN
5:40 p.m. Panel Discussion

WHAT IS THE FUTURE OF ANTIANGIOGENESIS IN THE ERA OF IMMUNOTHERAPY?

Moderator: Rakesh K. Jain, Boston, MA

5:00 p.m. Moderator Introduction. Rakesh K. Jain, Boston, MA
5:20 p.m. T cell therapy and tumor vasculature: Reciprocal modulation. George Coukos, Lausanne, Switzerland
5:35 p.m. Exploiting endothelial plasticity in promoting anti-tumor immunity: High endothelial venules and tertiary lymphoid-like structures. Gabriele Bergers, Leuven, Belgium
5:50 p.m. Panel Discussion

Career Development Forum • 5:00 p.m.–6:30 p.m.

NOT ELIGIBLE FOR CME CREDIT

Junior Ballroom G, Rosen Centre Hotel

MICR FORUM: HOW TO SUSTAIN EFFORTS PROMOTING DIVERSITY, EQUITY, AND INCLUSION (DEI) IN THE POST-COVID ERA

Cochairs: Gerardo Colon-Otero, Jacksonville, FL; Melissa B. Davis, Atlanta, GA

Awards and Lectures • 5:15 p.m.–6:00 p.m.

Tangerine Ballroom 2 (WF2), Convention Center

AACR JAMES S. EWING-THELMA B. DUNN AWARD FOR OUTSTANDING ACHIEVEMENT IN PATHOLOGY IN CANCER RESEARCH

Chair: Roy A. Jensen, Kansas City, KS
5:15 p.m. Introduction. Roy A. Jensen, Kansas City, KS
5:20 p.m. Award Lecture. Arul M. Chinnaiyan, Ann Arbor, MI
**Town Meetings • 6:00 p.m.–8:00 p.m.**

**NOT ELIGIBLE FOR CME CREDIT**

Windermere Y, Hyatt Regency

**BIOMARKERS AND EARLY DETECTION TESTS FOR CANCER PREVENTION: A CANCER PREVENTION WORKING GROUP TOWN HALL MEETING AND NETWORKING RECEPTION**

**Chair:** Adriana Albini, Milan, Italy

- **6:00 p.m.** Networking Reception
- **6:30 p.m.** CPWG Working Group Overview. Adriana Albini, Milan, Italy
- **6:40 p.m.** Title to be announced. Kala Visvanathan, Baltimore, MD
- **6:55 p.m.** Title to be announced. Klaus Pantel, Hamburg, Germany
- **7:10 p.m.** Title to be announced. Cornelia M. Ulrich, Salt Lake City, UT
- **7:25 p.m.** Panel Discussion
- **7:40 p.m.** Networking Reception

Windermere X, Hyatt Regency

**INTEGRATING EVOLUTIONARY PRINCIPLES INTO CANCER PATIENT CARE: A CANCER EVOLUTION WORKING GROUP TOWN HALL MEETING AND NETWORKING RECEPTION**

**Cochairs:** Frank H. Laukien, Billerica, MA; Charles Swanton, London, United Kingdom

- **6:00 p.m.** Networking Reception
- **6:40 p.m.** Speakers: Christina Curtis, Stanford University, Stanford, CA
  Louis Vermeulen, San Francisco, CA
  Additional speakers to be announced
- **7:10 p.m.** Panel Discussion
- **7:30 p.m.** Networking Reception

**Professional Advancement Session • 6:30 p.m.–8:00 p.m.**

**NOT ELIGIBLE FOR CME CREDIT**

Junior Ballroom F, Rosen Centre Hotel

**BUILDING AN EFFECTIVE MENTORSHIP TEAM: ESSENTIAL STRATEGIES AT EVERY STAGE IN YOUR CAREER**

**Cochairs:** Gerardo Colon-Otero, Jacksonville, FL; Sheila Kumari Singh, Dundas, ON, Canada; Kathleen W. Scotto, New Brunswick, NJ

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Meet-the-Expert Sessions • 7:00 a.m.–7:45 a.m.

Room W314 A, Convention Center
CANCER NEUROSCIENCE: EMERGING HALLMARK OF CANCER
Moran Amit, Houston, TX

Room W312, Convention Center
CELLULAR HIERARCHIES IN THE PANCREATIC TUMOR MICROENVIRONMENT
Mara H. Sherman, New York, NY

Room W315, Convention Center
DIET, METABOLISM, AND CANCER THERAPY
Karen H. Vousden, London, United Kingdom

Room W240, Convention Center
HISTONE MUTATIONS AND EPIGENETIC DEREGULATION IN CANCER: WHAT’S UP DOC?
Nada Jabado, Montréal, QC, Canada

Room W230, Convention Center
HOW TO MOVE THE NEEDLE FORWARD TO CURE: ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS
Mignon L. Loh, Seattle, WA

Room W330, Convention Center
UTILIZING GENOMIC TECHNOLOGIES TO STUDY PROSTATE CANCER AND PROSTATE CANCER DISPARITIES
Franklin W. Huang, San Francisco, CA

**Program as of March 9, 2022. Please check the Annual Meeting App for changes in rooms, times, or speakers.**
Plenary Session • 8:00 a.m.–10:00 a.m.

W Hall A2-3, Convention Center
NEW CONCEPTS IN DRUG DISCOVERY AND ENGINEERING

Chair: Sanjay V. Malhotra, Portland, OR

8:00 a.m.  Chair Introduction.  Sanjay V. Malhotra, Portland, OR

8:05 a.m.  Engineered proteins as innovative next-generation cancer therapeutics.  Jennifer R. Cochran, Stanford, CA

8:27 a.m.  To the tumor and beyond: Tales of a holistic miRNA delivery vehicle.  Andrea L. Kasinski, West Lafayette, IN

8:49 a.m.  What if all your favorite proteins are druggable?  Gregory R. Bowman, Philadelphia, PA

9:11 a.m.  Employing targeted nanocarriers for cell-selective cancer therapy.  Evan A. Scott, Evanston, IL

9:33 a.m.  The renaissance of antibody drug conjugates in oncology.  Puja Sapra, Gaithersburg, MD

9:55 a.m.  Wrap-up and opportunities for the future.  Sanjay V. Malhotra, Portland, OR

Poster Sessions • 9:00 a.m.-12:30 p.m.

W Halls B-E1, Convention Center

NOT ELIGIBLE FOR CME CREDIT

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

TUMOR BIOLOGY

Section 1  Cancer Stem Cells and Therapeutic Resistance
Section 2  Cell Adhesion and Cell Signaling in Cancer and Drug Resistance
Section 3  Crosstalk between Cancer Cells, Immune Cells, and Fibroblasts
Section 4  Immunotherapy and Cellular Interactions in the Tumor Microenvironment
Section 5  Interactions Between the Microbiome, Cancer Cells, and Tumor Stromal Components
Section 6  Methods to Measure Clonal Evolution
Section 7  Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.
MOLECULAR/CELLULAR BIOLOGY AND GENETICS
Section 9  Cyclin-dependent Kinases and Cyclin-dependent Kinase Inhibitors
Section 10 DNA Methylation Changes in Cancer
Section 11 Metabolism and Metabolomics of Cancer
Section 12 Multi-omics Tumor Profiling
Section 13 Targeting DNA Damage Response and Novel Pathways

EXPERIMENTAL AND MOLECULAR THERAPEUTICS
Section 15 Apoptosis and Growth Factor Receptors as Therapeutic Targets
Section 16 Cell Death Pathways and Treatment / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes
Section 17 DNA Damage Response
Section 18 DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes / Others
Section 19 DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents
Section 20 Epigenetics
Section 21 Growth Factor Receptors as Therapeutic Targets
Section 35 Late-Breaking Research: Experimental and Molecular Therapeutics 3

IMMUNOLOGY
Section 22 Anticancer Immunotherapeutics
Section 23 Immune Checkpoints
Section 24 Immune Mechanisms Mediated by Other Therapies
Section 25 Immunotherapy Strategies and Mechanisms
Section 36 Late-Breaking Research: Immunology 3

POPULATION SCIENCES
Section 26 Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors
Section 27 Novel Factors Associated with Cancer Mortality

PREVENTION / EARLY DETECTION / INTERCEPTION
Section 28 Early Detection and Molecular Markers of Prevention

BIOINFORMATICS / COMPUTATIONAL BIOLOGY / SYSTEMS BIOLOGY / CONVERGENT SCIENCE
Section 30 Bioinformatics Applications in Cancer Biology 3
Section 31 Databases, Platforms, and Tools
Section 32 Integrative Spatial and Temporal Multi-omics of Cancer
CLINICAL RESEARCH EXCLUDING TRIALS

Section 34 Late-Breaking Research: Clinical Research 3
Section 38 Immune Checkpoints
Section 39 Immune Monitoring and Responses to Therapy
Section 40 Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 5
Section 41 Preclinical Therapies and Clinical Observations in Pediatric Oncology
Section 42 Retrospective Clinical Analyses 2
Section 43 Spatial Proteomics and Transcriptomics 2
Section 44 Vaccines

**CME** Advances in Diagnostics and Therapeutics
10:15 a.m.–11:45 a.m.

Valencia D, Convention Center

TARGETING EPIGENETIC DYSREGULATION IN THE CLINIC

Chair: Katherine B. Chiappinelli, Washington, DC

10:15 a.m. **Chair Introduction.** Katherine B. Chiappinelli, Washington, DC

10:20 a.m. **Mechanisms of gene regulation by chromatin adaptor proteins in leukemia.**
Yadira Marie Soto-Feliciano, Cambridge, MA

10:45 a.m. **Epigenetic regulation of transposable elements to reverse immune evasion in cancer.**
Katherine B. Chiappinelli, Washington, DC

11:10 a.m. **Present challenges and opportunities for epigenetic therapy of thoracic malignancies.**
David S. Schrump, Bethesda, MD

11:35 a.m. **Panel Discussion**

Room W414, Convention Center

TECHNICAL ADVANCES IN LIQUID BIOPSY AND RARE EVENT DETECTION

Chair: Sunitha Nagrath, Ann Arbor, MI

10:15 a.m. **Chair Introduction.** Sunitha Nagrath, Ann Arbor, MI

10:45 a.m. **Novel technologies for highly efficient isolation and analysis of liquid biopsy markers for cancer disease management applications.**
Steven Soper, Lawrence, KS

11:10 a.m. **Title to be announced.** Chwee Teck Lim, Singapore, Singapore

10:20 a.m. **Advances in technologies for the study of extracellular vesicles and molecular profiling of circulating biomarkers.**
Sunitha Nagrath, Ann Arbor, MI

11:35 a.m. **Panel Discussion**

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Advances in Organ Site Research • 10:15 a.m.–11:45 a.m.

Valencia BC, Convention Center

Dharma Master Jiantai Advances in Lung Cancer Research
Session: Advances in NSCLC - More Targets, More Drugs, and More Cell States to Consider

Chair: Christine M. Lovly, Nashville, TN

10:15 a.m. Chair Introduction. Christine M. Lovly, Nashville, TN

10:20 a.m. Novel paradigms for oncogene directed therapies for NSCLC. Christine M. Lovly, Nashville, TN

11:10 a.m. Emerging therapeutic strategies for KRAS-mutant NSCLC. Ferdinandos Skoulidis, Houston, TX

10:45 a.m. Defining cells and cell states in non-small cell lung cancers. Purushothama Rao Tata, Durham, NC

11:35 a.m. Panel Discussion

Targeting Advanced Prostate Cancer: Identification of Evolving Tumor Vulnerabilities

Tangerine Ballroom 3-4 (WF3-4), Convention Center

Chair: Joaquin Mateo, Barcelona, Spain

10:15 a.m. Chair Introduction. Joaquin Mateo, Barcelona, Spain

10:17 a.m. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Duo Xu, New York, NY [AACR NextGen Star]

10:37 a.m. Lineage plasticity in prostate cancer: Therapeutic implications. Himisha Beltran, Boston, MA

10:53 a.m. Harnessing the immune system for prostate cancer treatment: Evolving strategies. Eugene Shenderov, Baltimore, MD

11:09 a.m. Defining homologous recombination repair deficient prostate cancer. Joaquin Mateo, Barcelona, Spain

11:25 a.m. Panel Discussion
**THE ROLE OF AGING, IMMUNITY, MICROBIOME, AND METABOLISM IN NEXT GENERATION MELANOMA THERAPEUTICS**

**Chair:** Patrick Hwu, Tampa, FL

10:20 a.m.  **Next generation TIL therapy for melanoma.** Patrick Hwu, Tampa, FL

10:45 a.m.  **The interplay of host, tumor, and microbial metabolic phenotypes.** Jennifer McQuade, Houston, TX

11:10 a.m.  **A race against time: How aging promotes tumor progression.** Ashani T. Weeraratna, Baltimore, MD

11:35 a.m.  Panel Discussion

---

**Advances in Prevention Research • 10:15 a.m.–11:45 a.m.**

**Room W224, Convention Center**

**STRATEGIES FOR CANCER INTERCEPTION**

**Chair:** Marcia R. Cruz-Correa, San Juan, PR

10:15 a.m.  **Introduction.** Marcia R. Cruz-Correa, San Juan, PR

10:20 a.m.  **Early detection and interception of lung cancer.** David Paul Carbone, Columbus, OH

10:45 a.m.  **Gastric cancer prevention and interception.** Marcia R. Cruz-Correa, San Juan, PR

11:10 a.m.  **Early detection and interception in multiple myeloma.** Irene M. Ghobrial, Boston, MA

11:35 a.m.  Panel Discussion

---

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Major Symposia • 10:15 a.m.–11:45 a.m.

Valencia A, Convention Center
CANCER ECOSYSTEM: MALIGNANT CELLS, MICROENVIRONMENT AND MORE

Chair: Benjamin Izar, New York, NY

10:15 a.m.  Chair Introduction. Benjamin Izar, New York, NY

10:18 a.m.  Dissecting the ecosystem of human brain metastasis. Benjamin Izar, New York, NY

10:38 a.m.  Contact Tracing the impact of chromosomal instability (CIN) on the tumor ecosystem. Ashley M. Laughney, New York, NY

10:58 a.m.  Autologous humanized PDX modeling for immuno- oncology recapitulates the human tumor microenvironment. Michael Chiorazzi, New Haven, CT [AACR NextGen Star]

11:18 a.m.  Intersection of type 2 immunity and microbiome in cancer. Prasenjit Dey, Buffalo, NY

11:38 a.m.  Panel Discussion

Tangerine Ballroom 2 (WF2), Convention Center
ENGINEERED T CELLS FOR SOLID TUMORS

Chair: Eric Tran, Portland, OR

10:15 a.m.  Chair Introduction. Eric Tran, Portland, OR

10:20 a.m.  Towards the development of synthetic immunity to cancer. Kole Roybal, San Francisco, CA

10:45 a.m.  Engineering a potent T-cell response against solid tumors. Cristina Puig Saus, Los Angeles, CA

11:10 a.m.  TCR-gene therapy targeting driver mutations. Eric Tran, Portland, OR

11:35 a.m.  Panel Discussion
GLOBAL CANCER BURDEN: CHALLENGES AND OPPORTUNITIES FOR INNOVATION

**Chair:** Sharmila Anandasabapathy, Houston, TX

**10:15 a.m.** *Chair Introduction.* Sharmila Anandasabapathy, Houston, TX

**10:20 a.m.** Global cancer in 2023: Innovation and approach to screening and early detection. Sharmila Anandasabapathy, Houston, TX

**10:35 a.m.** Feasibility of topical self-administered therapies to improve cervical precancer treatment outcomes among women living with HIV in low- and middle-income countries. Chemtai Mungo, Durham, NC [AACR NextGen Star]

**10:50 a.m.** Perspectives in radiation oncology: Gaps and opportunities. Surbhi Grover, Philadelphia, PA

**11:05 a.m.** Lessons from the field: Oncologic care in Africa. Fredrick C. Asirwa, Uasin Gishu County, Kenya

**11:20 a.m.** Panel Discussion

MODELING CANCER EVOLUTIONARY DYNAMICS: THE INTERFACE OF BIG DATA, SIMULATIONS AND AI

**Chair:** Paul Newton, Los Angeles, CA

**10:15 a.m.** *Chair Introduction.* Paul Newton, Los Angeles, CA

**10:20 a.m.** Integrating evolutionary dynamics into cancer therapy. Robert A. Gatenby, Tampa, FL

**10:45 a.m.** Mathematical models of evolutionary dynamics and reinforcement learning approaches to chemotherapy design. Paul Newton, Los Angeles, CA

**11:10 a.m.** Spatial computational modeling of tumor evolution to predict disease progression. Christina Curtis, Stanford, CA

**11:35 a.m.** Panel Discussion

*Program as of March 9, 2023. Please check the Annual Meeting App for changes in rooms, times, or speakers.*
Tangerine Ballroom 1 (WF1), Convention Center
SYSTEMIC EFFECTS OF CANCER

Chair: Tobias Janowitz, Cold Spring Harbor, NY

10:15 a.m.  Introduction

10:18 a.m.  Heterogeneous mechanisms of muscle wasting in cancer cachexia.
Erin Elizabeth Talbert, Iowa City, IA

10:41 a.m.  Altered calcium signaling in cancer: PTHrP-KRAS collateral amplification
governs pancreatic cancer metastasis, cachexia, and immunosuppression.
Jason Robert Pitarresi, Worcester, MA
[AACR NextGen Star]

10:59 a.m.  Tumor-directed inflammatory and metabolic alteration of the host.
Eileen P. White, New Brunswick, NJ

11:22 a.m.  Neuroendocrine and immunological consequences of cancer progression.
Tobias Janowitz, Cold Spring Harbor, NY

CME  Plenary Session • 12:00 p.m.–1:25 p.m.

Chapin Theater, Convention Center
AACR ANNUAL MEETING 2023 HIGHLIGHTS: VISION FOR THE FUTURE

Chair: Robert H. Vonderheide, Philadelphia, PA

12:00 p.m.  Introduction.  Robert H. Vonderheide, Philadelphia, PA

12:05 p.m.  Basic cancer science and translational research.  Sheila A. Stewart,
St. Louis, MO

12:30 p.m.  Prevention, early detection, population sciences, and disparities research.
Elizabeth A. Platz, Baltimore, MD

12:55 p.m.  Clinical research and clinical trials.  Shivaani Kummar, Portland, OR

1:20 p.m.  Wrap-up and opportunities for the future.  Robert H. Vonderheide,
Philadelphia, PA
**AACR Scholar-in-Training Awards**

**2023 AACR SCHOLAR-IN-TRAINING AWARDS SUPPORTED BY AN INDEPENDENT EDUCATIONAL GRANT FROM ABBVIE**

Early career investigators who will be presenting meritorious abstracts at the AACR Annual Meeting 2023 were generously supported by an independent educational grant from AbbVie.

**Mwangala Akamandisa, PhD,** Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. **Abstract 1183.** Mutation type and location in breast cancer susceptibility genes are associated with differential risk in the general population.

**Shankara K. Anand, MS,** Broad Institute of MIT and Harvard, Cambridge, MA. **Abstract 3132.** CLUMPS-PTM: Spatial clustering of post-translational modifications across cancer types.

**Jana Biermann, PhD,** Columbia University Irving Medical Center, New York, NY. **Abstract 109.** Multi-modal single-cell analysis of immunotherapy-experienced cutaneous and mucosal melanoma.

**Liang Chang, PhD,** Broad Institute of MIT and Harvard, Cambridge, MA. **Abstract 1175.** Systematic profiling of conditional pathway activation as a new class of cancer dependency.

**Taek-Chin Cheong, PhD,** Boston Children’s Hospital and Harvard Medical School, Boston, MA. **Abstract 313.** Mechanisms of oncogenic tyrosine kinase fusion formation and selection in human cancers.

**Janine M. DeBlasi, MS,** Moffitt Cancer Center, Tampa, FL. **Abstract 12.** Distinct Nrf2 signaling thresholds mediate lung tumor initiation and progression.

**Nathaniel Deboever, MD,** UT MD Anderson Cancer Center, Houston, TX. **Abstract 726.** Machine learning prediction of financial toxicity in patients with resected lung cancer.

**Francisco Exposito, PhD,** Center for Applied Medical Research (CIMA), University of Navarra/CIBERONC, ISCIII/Yale University School of Medicine, New Haven, CT. **Abstract 1124.** PTEN loss confers resistance to anti-PD-1 therapy in NSCLC by increasing tumor infiltration of T regulatory cells.

**Jimmy A. Guo, BA,** Broad Institute of MIT and Harvard, Cambridge, MA. **Abstract 5775.** GLIS3 drives a neural-like malignant state enriched after neoadjuvant treatment in pancreatic cancer.

**Deli Hong, PhD,** Dana-Farber Cancer Institute, Brookline, MA. **Abstract 5727.** Identification of synthetic lethal vulnerabilities in cancers with loss of function mutations in NOTCH.

**Lucas Zhongming Hu, PhD,** Columbia University Irving Medical Center, New York, NY. **Abstract 1119.** Systems pharmacology approaches to study tumor drug mechanism of action.

**Kelsey E. Huntington, BS,** Brown University, Providence, RI. **Abstract 5636.** Multiplex digital spatial profiling (DSP) of proteins in the tumor microenvironment in response to GSK-3 inhibition by 9-ING-41 (elraglusib) correlates with novel immunostimulatory effects observed in vivo.

**Neel Jasani, MS,** Moffitt Cancer Center, Tampa, FL. **Abstract 1159.** BRAF-mediated PHGDH induction establishes a metabolic vulnerability in melanoma.

**Jiexi Li, MS,** UT MD Anderson Cancer Center, Houston, TX. **Abstract 3515.** Histone demethylase KDM5D drives sex-specific differences in colorectal cancer.
Chang-Ching Lin, PhD, UT Southwestern Medical Center, Dallas, TX. Abstract 3934. PRMT5 is an actionable target in CDK4/6 inhibitor-resistant ER+/Rb-deficient breast cancer.

Runying Long, MS, The University of Hong Kong, Hong Kong, Hong Kong. Abstract 617. Oncogenic CXCL10 triggers CD8+ T cell exhaustion in ovarian cancer.


Aron Onerup, MD, PhD, St. Jude Children’s Research Hospital, Memphis, TN. Abstract 5770. Cardiorespiratory fitness and BMI in youth and five-year mortality after site-specific cancer in men: a population-based cohort study with register linkage.

Zahraa Rahal, MD, UT MD Anderson Cancer Center, Houston, TX. Abstract 2883. Gut microbiome dysbiosis promotes immune suppression and lung cancer development.

Ozge Saatci, MS, The Medical University of South Carolina (MUSC), Charleston, SC. Abstract 5728. Inhibition of TACC3 blocks the growth of highly aggressive breast cancers with centrosome amplification.

David T. Severson, MD, DPhil, Brigham and Women’s Hospital, Boston, MA. Abstract 95. Uncommitted cells and phenotypic plasticity elucidate the complexity of the epithelial-mesenchymal molecular gradient of pleural mesothelioma.

Mengyao Shi, MPH, Washington University School of Medicine, St. Louis, MO. Abstract 739. Alcohol consumption patterns among US cancer survivors: A cross-sectional study of the All of Us Research Program.

Rebecca Simpson, BS, Melanoma Institute Australia, The University of Sydney, Sydney, Australia. Abstract 3463. Longitudinal microbiome-immune dynamics in melanoma patients treated with immune checkpoint inhibitor immunotherapy.


Ankur Tiwari, MBBS, UT Health Science Center at San Antonio, San Antonio, TX. Abstract 2679. Combination of CDK 4/6 inhibitor palbociclib with rapamycin synergistically inhibits growth of hepatocellular carcinoma in preclinical models.

Tomotaka Ugai, MD, PhD, Brigham and Women’s Hospital, Boston, MA. Abstract 5760. Molecular, immune, and microbial profiles of early-onset, intermediate-onset, and later-onset CRCs.

Hanwen Wang, MS, Johns Hopkins University School of Medicine, Baltimore, MD. Abstract 5697. Predicting response to PD-L1 inhibition in NSCLC using a quantitative systems pharmacology model guided by immunogenomic data.

Jaroslav Zak, DPhil, PhD, The Scripps Research Institute, La Jolla, CA. Abstract 5743. Reprogramming myeloid cells by JAK inhibition to enhance checkpoint blockade immunotherapy.

Chao Zhang, PhD, Moffitt Cancer Center, Tampa, FL. Abstract 3465. HDAC8 regulates immune escape in melanoma through increased transcription of inhibitory cytokines that increase accumulation of myeloid-derived suppressor cells (MDSCs).
2023 AACR-AMERICAN BRAIN TUMOR ASSOCIATION SCHOLAR-IN-TRAINING AWARDS

The American Brain Tumor Association has graciously donated funds to support young investigators who will be presenting high-quality abstracts in brain cancer research for both primary and secondary (metastatic) brain tumors at the AACR Annual Meeting 2023.

Daniel Azorin, MS, Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg. Clinical Cooperation Unit Neuro oncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. Abstract 1084. AI-aided drug development for disconnecting glioma tumor microtube networks.

Anne-Florence Blandin, PhD, Dana-Farber Cancer Institute, Boston, MA. Abstract 1201. ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma.

Syed M. Faisal, PhD, University of Michigan Medical School, Ann Arbor, MI. Abstract 5835. Targeting discoid domain receptor 1 (DDR1) reverses glioma immune suppression by remodeling collagen fiber architecture.

Toshiro Hara, PhD, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA. Abstract 1246. Single-cell profiles of multiplexed in vivo models facilitate the characterization of phenotypic plasticity and invasion in glioblastoma.

Mariam Lotfy Khaled, PhD, H. Lee Moffitt Cancer Center, Tampa, FL. Abstract 1192. Branched-chain keto acids exert an immune-suppressive and neurodegenerative microenvironment in CNS leptomeningeal lymphoma.

Yamhilette Licon Munoz, PhD, University of New Mexico Health Sciences Center, Albuquerque, NM. Abstract 5802. The impact of tumor-treating fields on cancer stem-like cells isolated from the subventricular zone of glioblastoma patients.

Sandhya Prabhakaran, PhD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Abstract 6614. Spatial transcriptomic driven mechanistic model to investigate and predict pathogenesis of oligodendroglioma.

Uday Pratap, PhD, UT Health Science Center at San Antonio, San Antonio, TX. Abstract 1718. Development of potent estrogen receptor beta agonists for treating glioblastoma.

2023 AACR-BREAST CANCER RESEARCH FOUNDATION SCHOLAR-IN-TRAINING AWARDS in Memory of Rebecca Scheinkman

The Breast Cancer Research Foundation has graciously donated funds to support young investigators who will be presenting high quality abstracts in breast cancer research at the AACR Annual Meeting 2023. This year, this funding has been given by the Breast Cancer Research Foundation to honor the memory of Rebecca Scheinkman.

Pin-Ji Lei, PhD, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Abstract 1298. Single cell analysis of breast cancer progression and metastasis to lymph nodes reveals cancer cell plasticity and MHC class II-mediated immune regulation.

Praful R. Nair, PhD, Johns Hopkins University, Baltimore, MD. Abstract 3608. MLL1 regulates cytokine-driven cell migration and metastasis.
2023 AACR-BRISTOL MYERS SQUIBB SCHOLAR-IN-TRAINING AWARDS

Bristol Myers Squibb has graciously donated funds to support early career investigators who will be presenting meritorious abstracts at the AACR Annual Meeting 2023.

Majd Al Assaad, MD, New York Presbyterian Hospital Weill Cornell University Medical Center, New York, NY. Abstract 3437. Whole genome and transcriptome sequencing of a pan cancer cohort unearths novel therapeutic avenues.


Bina Desai, MS, H. Lee Moffitt Cancer Center, Tampa, FL. Abstract 552. Stromal facilitated multifactorial resistance to tumor cells against targeted therapies in ALK+ NSCLC.

Guochong Jia, PhD, Vanderbilt University Medical Center, Nashville, TN. Abstract 1180. Identification of target proteins for breast cancer genetic risk loci and blood risk biomarkers in a large study by integrating genomic and proteomic data.

Panagiotis Karras, PhD, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium. Abstract 103. Dissecting cell state diversity during melanoma growth and metastasis.

Guodong Lian, MD, PhD, Columbia University Medical Center, New York, NY. Abstract 3496. p53 mutation biases SCJ progenitor cells towards dysplasia rather than metaplasia in Barrett’s esophagus.

Anjali Mittal, MS, University of Michigan, Ann Arbor, MI. Abstract 1160. A machine learning based method for in-vivo metabolic flux analysis of patient tumors.

Béga Murray, MS, National Cancer Institute, Bethesda, MD. Abstract 3563. SWI/SNF-associated DPF1 is a unique transcriptional regulator of malignant peripheral nerve sheath tumors.

Anthony T. Nguyen, MD, PhD, Cedars-Sinai Medical Center, Los Angeles, CA. Abstract 6409. Non-redundant mechanisms of immune resistance to radiotherapy converge on innate immunity.

Jeffrey Patterson-Fortin, MD, PhD, Dana-Farber Cancer Institute, Boston, MA. Abstract 6190. Polymerase theta inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in BRCA-deficient cancers.

Gilbert J. Rahme, PhD, Dana-Farber Cancer Institute, Boston, MA. Abstract 3479. Modeling epigenetic lesions that cause gliomas.

Martin Rotbauer, BS, Princess Margaret Cancer Centre, Toronto, ON, Canada. Abstract 90. Exploring the role of common circulating tumor cell-associated genes in estrogen receptor-positive breast cancer recurrence.

Thinh N. Tran, MS, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 4259. Identification of antineoplastic therapy given before initial visit at a referral center using natural language processing applied to medical oncology initial consultation notes.

Danh D. Truong, PhD, UT MD Anderson Cancer Center, Houston, TX. Abstract 1196. The epigenetic impact and therapeutic opportunity of AR-directed therapy for DSRCT.
SCHOLAR AWARDS | Scholar-in-Training (cont’d)

Bogang Wu, PhD, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA. Abstract 1696. Systematic identification of pathways associated with antibody drug conjugate sensitivity in breast cancer.

Yiming Wu, PhD, City of Hope National Medical Center, Duarte, CA. Abstract 3482. METTL3-mediated m6A modification controls splicing factor abundance and contributes to CLL progression.

Xiaofei Zhi, MD, PhD, Irving Cancer Research Center, Columbia University Medical Center, New York, NY. Abstract 1193. Sensory innervation directly promotes gastric cancer and modulates the tumor microenvironment.

2023 AACR-SCHOLAR-IN-TRAINING AWARDS SUPPORTED BY AN INDEPENDENT EDUCATIONAL GRANT FROM DAIICHI SANKYO

Early career investigators who will be presenting meritorious abstracts at the AACR Annual Meeting 2023 were generously supported by an independent educational grant from Daiichi Sankyo.


Mohamed Gouda, MD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 1173. Landscape of 4,506 pan-cancer samples harboring BRAFV600E mutations, and NTRK/RET Fusions from 137,401 adult patients with cancer: Clinical implications for tissue agnostic therapies.

Christopher R. Grant, MS, University of California Irvine Medical Center, Orange, CA. Abstract 4404. Survival impact and trends of immunotherapy use in metastatic merkel cell carcinoma in the checkpoint era: analysis of a large database.

Justin Jee, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 5721. Automated annotation for large-scale clinicogenomic models of lung cancer treatment response and overall survival.


Sungsoo Kim, PhD, Columbia University Irving Medical Center, New York, NY. Abstract 3876. Kinetics of RTK activation determine ERK signaling dynamics and resistance to BRAF and MEK inhibitors.

Blair V. Landon, BS, Johns Hopkins University School of Medicine, Baltimore, MD. Abstract 3374. Circulating cell-free tumor DNA dynamics capture minimal residual disease with neoadjuvant immune checkpoint blockade plus chemoradiotherapy for patients with operable esophageal/gastroesophageal junction cancer.

Xuebing Leng, MS, MPH, University of Miami Miller School of Medicine, Miami, FL. Abstract 3807. MicroRNA-29a synergizes with PD-1 therapy to regulate anti-tumor immunity.

Benjamin B. Morris, PhD, UT MD Anderson Cancer Center, Houston, TX. Abstract 6115. Comprehensive DNA repair landscape analysis reveals novel small cell lung cancer biology.

Shengzhe Zhang, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 1714. CRACD/KIAA1211 loss drives cell plasticity and immune evasion of small cell lung cancer.

2023 AACR-DOREEN J. PUTRAH CANCER RESEARCH FOUNDATION SCHOLAR-IN-TRAINING AWARDS

These awards are presented to early career investigators of meritorious abstracts to be presented at the AACR Annual Meeting 2023. These awards are made possible through a gracious donation from the Doreen J. Putrah Cancer Research Foundation.

Ganesh Acharya, MS, Texas Tech University Health Sciences Center, Lubbock, TX. Abstract 2667. PARG inhibition augments CHK1 inhibitor-induced replication stress and synergistically kills ovarian cancer cells.

Vincent Bernard, MD, PhD, UT MD Anderson Cancer Center, Houston, TX. Abstract 1096. Single cell transcriptomic sequencing of pancreatic ductal adenocarcinoma reveals an enrichment of immunosuppressive pathways in patients at high risk for early local progression following stereotactic body radiation therapy.

Carla Bertulfo, MPhil, Columbia University Irving Medical Center, New York, NY. Abstract 3928. Therapeutic targeting of NOTCH1 and neddylation pathway in T cell acute lymphoblastic leukemia.

Nilanjana Chatterjee, PhD, UCSF - University of California San Francisco, San Francisco, CA. Abstract 3878. Targeting Hippo-YAP, BRD4 and RAS-MAPK interplay in lung cancer to forestall drug resistance.

Francesca Citron, PharmD, PhD, UT MD Anderson Cancer Center, Houston, TX. Abstract 303. DPY30 loss leads to DNA re-replication and immunoediting in pancreatic ductal adenocarcinoma.

Guangzheng Deng, MS, The Chinese University of Hong Kong, Hong Kong, Hong Kong. Abstract 2574. An exon-skipping HDAC1 novel isoform promotes colorectal carcinogenesis.

SeongJun (James) Han, PhD, Harvard University, Boston, MA. Abstract 5149. Age-associated remodeling of anti-tumor T cell immunity and metabolism.


Yoshinobu Konishi, MD, PhD, DFCI/Harvard Medical School, Brookline, MA. Abstract 796. Altered immune response to vaccination in patients with plasma cell premalignancy.

Felix Korell, MD, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA. Abstract 4098. Chimeric antigen receptor (CAR) T cells overexpressing Bcl-xL increase proliferation and antitumor activity alone and in combination with BH3 mimetics.

Jens Luebeck, PhD, UC San Diego, La Jolla, CA. Abstract 3130. Extrachromosomal DNA in the cancerous transformation of Barrett’s esophagus.
Claudia Manriquez Roman, MS, Mayo Clinic, Rochester, MN. Abstract 5074. Addition of MAPK inhibitors to prime and sensitize poorly differentiated thyroid cancers as a strategy to improve TSHR-CART cell therapy antitumor activity.

Katherine E. Masih, BS, National Institutes of Health (NIH), Bethesda, MD. Abstract 1199. Discovery of subtype-specific and therapy associated effects on the tumor immune microenvironment in pediatric neuroblastoma.

Nicole M. Mattson, BA, Beckman Research Institute of The City of Hope, Monrovia, CA. Abstract 6234. Targeting integrin alpha V beta 5 heterodimer stability using a novel small molecular inhibitor for tumor suppression.

Siddharth Mehra, PhD, University of Miami, Miami, FL. Abstract 653. Tumor cell-macrophage crosstalk drives immune suppression in pancreatic cancer.

Jayanta Mondal, BE, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 1294. Loss of bromodomain-7 (BRD7) promotes breast cancer lung metastasis by reprogramming the tumor immune microenvironment.

Nicole Peiris, PhD, Harvard Medical School, Massachusetts General Hospital, Boston, MA. Abstract 4353. Utilizing scRNA sequencing to understand biomarkers of response and resistance to Sacitizumab Govetican in localized TNBC.

Moeez Rathore, PhD, Case Western Reserve University School of Medicine, Cleveland, OH. Abstract 3636. Liver endothelium secreted LRG1 promotes metastatic colorectal cancer growth through the HER3/RSK/EIF4B AXIS.

David Requena, MS, Rockefeller University, New York, NY. Abstract 1516. Bulk and spatial single-cell transcriptomic characterization of fibrolamellar hepatocellular carcinoma.

Thomas Simon, PhD, USC - University of Southern California, Los Angeles, CA. Abstract 5842. Determining the tumor supportive and inhibitory capabilities of cancer associated fibroblast subpopulations in central nervous system metastasis.

Ian Sutton, BS, National Cancer Institute, Bethesda, MD. Abstract 2413. Glioblastoma stem-like cells are resistant to the negative effects of increased aneuploidy on in vitro survival and radiosensitivity.

Max M. Wang, MPH, Northwestern University, Evanston, IL. Abstract 2714. Inhibiting Myc using heterofunctional polymeric degrading chimeras (HYDRACs): a novel class of compounds capable of targeted protein degradation.

Nicholas K. Wang, MHS, UCLA - University of California Los Angeles, Los Angeles, CA. Abstract 4305. Germline structural variants shape prostate cancer clinical and molecular evolution.


Saigopalakrishna S. Yerneni, PhD, Carnegie Mellon University, Pittsburgh, PA. Abstract 836. Enabling mRNA Medicine for Brain Tumors.
2023 AACR-JUNE L. BIEDLER SCHOLAR-IN-TRAINING AWARDS

These awards are presented to authors of meritorious abstracts to be presented at the AACR Annual Meeting 2023. These awards are made possible through the Estate of Dr. June L. Biedler. The late Dr. Biedler was a dedicated member of AACR and a distinguished scientist at Memorial Sloan Kettering Cancer Center. Dr. Biedler believed that science communication is a cornerstone to the acceleration of progress.

Delia Friel, MS, DFCI/Harvard Medical School, Boston, MA. Abstract 3875. Evaluation of resistance mechanisms to ARV471, an ER-targeted PROTAC.

Sushanta Halder, MPharm, University of Nebraska Medical Center, Omaha, NE. Abstract 1756. Novel first-in-class oral small molecule inhibitor EC914 overcomes docetaxel-resistance by inhibiting LIFR/c-Myc axes in CRPC.

Chendi Li, PhD, Massachusetts General Hospital, Charlestown, MA. Abstract 3868. Aurora kinase A inhibition overcome adaptive resistance to KRAS G12C inhibitor by G1-checkpoint induced apoptosis in KRAS non-small cell lung cancer.

Pooja A. Shah, PhD, UT MD Anderson Cancer Center, Houston, TX. Abstract 2847. Concurrent inactivation of PI3K and PLK1 is synergistic and overcomes acquired resistance to PI3K inhibitors in NOTCH1MUTHNSCC.

David Alejandro Terrero, MD, University of Toledo, Toledo, OH. Abstract 2846. The mitochondrial dynamics of breast cancer regulate P-glycoprotein expression.

2023 AACR-LUDWIG INSTITUTE FOR CANCER RESEARCH SCHOLAR-IN-TRAINING AWARD

These awards were funded by a generous donation from Ludwig Institute for Cancer Research to early career scientist presenting exceptional research at the AACR Annual Meeting 2023.

Jonathan M. Downie, MD, PhD, Harvard Medical School/Massachusetts General Hospital, Somerville, MA. Abstract 5247. The effect of aspirin on the transcriptional landscape of the colon.

Alvaro Curiel Garcia, PhD, Columbia University Irving Medical Center, New York, NY. Abstract 4803. BMAL2 is a KRAS-dependent master regulator of hypoxic response in pancreatic ductal adenocarcinoma.


Susana Castro Pando, BS, UT MD Anderson Cancer Center, Houston, TX. Abstract 1188. IL-17/IL-17RA signaling in the pancreatic epithelium upregulates B7-H4 to promote tumorigenesis.

Jaime L. Schneider, MD, PhD, MGH/Harvard Medical School, Boston, MA. Abstract 1156. GUK1 is a novel metabolic liability in oncogene-driven lung cancer.

Carli M. Stewart, BS, Mayo Clinic, Rochester, MN. Abstract 1153. IL-4 depletion leads to the improvement of CART cell therapy.
SCHOLAR AWARDS | Scholar-in-Training (cont’d)

2023 AACR-MARGARET FOTI FOUNDATION SCHOLAR-IN-TRAINING AWARDS

Through a generous gift of The Margaret Foti Foundation, these awards recognize outstanding young investigators for their meritorious work in head and neck, lung, ovarian, pancreatic, prostate, and pediatric brain cancer research.

Naheed Arfin Borah, MTech, L V Prasad Eye Institute, Bhubaneswar, India. Abstract 1200. Aurora kinase A is a potential therapeutic target regulated by the MYCN oncogene in human retinoblastoma.

Pushpamali De Silva, PhD, Massachusetts General Hospital and Harvard Medical School, Boston, MA. Abstract 3228. Photodynamic priming enhances immunotherapy responses overcoming oncogenic drivers in pancreatic patient derived tumor organoids.

Soma Ghosh, PhD, UT MD Anderson Cancer Center, Houston, TX. Abstract 1564. Novel combination of TRIP13 and Aurora kinase A inhibition demonstrated extensive DNA damage and immunogenic cell death in RB-deficient cancers.


Mohammed L. Ibrahim, PhD, H. Lee Moffitt Cancer Center, Tampa, FL. Abstract 3264. Sotorasib, a selective G12C K-RAS inhibitor, modulates the tumor microenvironment to promote TNFα and IFNγ signaling and augment immunotherapy response.


Kinza Rizwan, PhD, Baylor College of Medicine, Houston, TX. Abstract 1705. SPOP: An essential gene for normal and prostate tumor cells.

Nilesh Prakash Talele, PhD, Harvard Medical School/Massachusetts General Hospital, Norwood, MA. Abstract 4416. IL-1 blockade prevents cardiac toxicity and improves immunotherapy efficacy.

Ignacio Vázquez-García, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 102. Transient chromosomal instability as a driver of ovarian cancer genome evolution.

Irene Y. Xie, MD, University of Toronto, Toronto, ON, Canada. Abstract 173. Genomic characterization of patient-derived pancreatic cancer organoids.

Wei Zhao, MD, PhD, Henry Ford Health System, Detroit, MI. Abstract 5762. New perspective on racial disparities in prostate cancer: Identification of new molecular subsets using whole-mount radical prostatectomy.

2023 AACR-PEZCOLLER FOUNDATION SCHOLAR-IN-TRAINING AWARDS

The Pezcoller Foundation supports these awards to enhance participation in the programs and activities of the AACR by early-career investigators residing in Europe and to provide these outstanding Scholar-in-Training Awardees with an opportunity to share their research findings with the international cancer research community at the AACR Annual Meeting.
**SCHOLAR AWARDS**


**Giulia Francescato, MS**, Italian Institute for Genomic Medicine (IIGM), Candiolo, Italy. **Abstract 3797.** Fecal miRNA profiles and gut metagenome composition in Lynch syndrome: results from a mouse model study and human subjects.

**Sia V. Lindskrog, MS**, Aarhus University Hospital, Aarhus N, Denmark. **Abstract 5600.** Utility of circulating tumor DNA and transcriptomic profiling in predicting outcome in muscle invasive bladder cancer patients.

**Alessia Potenza, PhD**, IRCCS San Raffaele Scientific Institute, Milan, Italy. **Abstract 902.** Harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.

**Simone Weiss, MS**, Aarhus University Hospital, Aarhus N, Denmark. **Abstract 3778.** Genome-Scale CRISPRa and CRISPRi screening for lncRNA drivers of prostate cancer progression.

**Anqi Wang, MBBS**, University of Southern California, Pasadena, CA. **Abstract 3508.** The Prostate Cancer Foundation has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious abstracts in prostate cancer research at the AACR Annual Meeting 2023.

**Ricardo A. Cordova, MS**, Indiana University School of Medicine, Indianapolis, IN. **Abstract 4818.** GCN2 eIF2 kinase and p53 coordinate amino acid homeostasis and metabolism in prostate cancer.

**Chui Yan Mah, PhD**, The University of Adelaide, Adelaide, Australia. **Abstract 1157.** Uncovering a novel role of peroxisomal β-oxidation in advanced, treatment-resistant prostate cancer.

**Jitender Monga, PhD**, Henry Ford Health System, Detroit, MI. **Abstract 1698.** Novel role of Tribbles 2 driving treatment-emergent neuroendocrine differentiation in prostate cancer.

**Anqi Wang, MBBS**, University of Southern California, Pasadena, CA. **Abstract 3508.** Association between clonal hematopoiesis and risk of prostate cancer in a large sample of African ancestry men.
2023 AACR-SANOFI SCHOLAR-IN-TRAINING AWARDS

Sanofi has graciously donated funds to support early career investigators who will be presenting meritorious work in cancer research at the AACR Annual Meeting 2023.


Jessica Ziyu Chen, MEng, Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 5931. Characterizing tumor heterogeneity through bulk and single cell analysis of patient derived bladder cancer models.


Elshad Hasanov, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 5788. Single-cell and spatial transcriptomic mapping of human renal cell carcinoma brain metastases uncovers actionable immune-resistance targets.

Jabril Johnson, PhD, Morehouse School of Medicine, Smyrna, GA. Abstract 3509. 1,25-dihydroxyvitamin D3-mediated suppression of genes associated with cell cycle regulation and actin organization in a non-malignant African American prostate cell line.

Aditi S. Khatpe, MS, Indiana University School of Medicine, Indianapolis, IN. Abstract 5458. TONSL is an immortalizing oncogene of the chromosome 8q24.3 amplicon and new therapeutic target in breast cancer.

Sieun Lee, BS, Ewha Womans University, Seoul, Korea, Republic of. Abstract 5860. ZEB1-driven reconstruction of the hyaluronan network establishes a pro-metastatic microenvironment in lung adenocarcinoma.

Jonathan T. Lei, PhD, Baylor College of Medicine, Houston, TX. Abstract 5726. Pan-cancer proteogenomics expands the landscape of therapeutic targets.

Chang In Moon, MS, Baylor College of Medicine, Houston, TX. Abstract 5717. Bridging the gap between clinical-omics and machine learning to improve cancer treatment.

Long Nguyen Chi, MD, PhD, University of Chicago, Chicago, IL. Abstract 4807. BACH1 proline hydroxylation regulates the hypoxia response and metastasis in triple negative breast cancer.

Jina Park, MS, Johns Hopkins University, Baltimore, MD. Abstract 6256. Inhibition of class Ila HDACs potentiates MYC inhibitor-driven cytotoxicity by inducing MYC depletion and oxidative stress in non-small cell lung cancer.

Ajinkya Patil, MS, Dana-Farber Cancer Institute/Harvard Medical School, Brookline, MA. Abstract 3485. Intrinsically disordered regions of the ARID1A/B tumor suppressors encode an interaction network within biomolecular condensates that directs mSWI/SNF chromatin remodeler complex activity.
Qizhi Qin, PhD, Johns Hopkins University School of Medicine, Baltimore, MD. **Abstract 3630.** TrkA+ sensory neurons modulate macrophage phenotype in osteosarcoma.

Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA. **Abstract 6629.** Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small cell lung cancer.

Alessandro Vasciaveo, PhD, Columbia University Irving Medical Center, New York, NY. **Abstract 1116.** Identifying neuroendocrine prostate cancer drivers using in vivo forward genetics.

Haochen Zhang, BS, Memorial Sloan Kettering Cancer Center, New York, NY. **Abstract 1169.** Genomic evolution of pancreatic cancer at single-cell resolution.

**2023 AACR-SYGNATURE DISCOVERY SCHOLAR-IN-TRAINING AWARDS IN ASSOCIATION WITH THE CICR WORKING GROUP**

Sygnature Discovery has graciously donated funds to the AACR to support an early-career investigator who will be presenting meritorious work in small molecular drug discovery research at the AACR Annual Meeting 2023.

Neelkanth M. Bardhan, PhD, Massachusetts Institute of Technology (MIT), Cambridge, MA. **Abstract 820.** Photo-activatable ON-OFF microparticles for on-demand pulsatile drug delivery in a breast cancer model.

DaeYong Lee, PhD, UT MD Anderson Cancer Center, Houston, TX. **Abstract 838.** Development of cationic polypeptide-based adjuvants for cancer immunotherapy.

**AACR-MARGARET FOTI FOUNDATION EARLY STAGE INVESTIGATOR SCHOLAR AWARD**

Funds were generously donated by The Margaret Foti Foundation for Early Stage Investigator (ESI) Scholars to present abstracts that were deemed to be of exceptional scientific merit by the scientific reviewers.

Eleonora Dondossola, PhD, UT MD Anderson Cancer Center, Houston, TX. **Abstract 3688.** Exploring metabolic vulnerabilities of metastatic prostate cancer to bone.

Matthew G. Oser, MD, PhD, Dana-Farber Cancer Institute, Boston, MA. **Abstract 5774.** Small cell lung cancer subtype plasticity is regulated by KDM6A.

Shervin Tabrizi, MD, Massachusetts General Hospital, Boston, MA. **Abstract 3371.** A DNA-binding priming agent protects cell-free DNA and improves the sensitivity of liquid biopsies.

**AACR Global Scholar-in-Training Awards**

The AACR is proud to offer 15 Global Scholar-in-Training Awards (GSITA) to support the participation of meritorious early-career scientists from countries building cancer research capacities who wish to participate in the AACR Annual Meeting 2023.

Ayodeji Adegoke, PhD, University of the Free State, Bloemfontein, South Africa. Abstract 3829. Antioxidant and antiproliferative activities of Ipomoea cairica (L) extracts on three breast cancer cell lines.

Anshika Chauhan, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Abstract 2311. Extensive molecular heterogeneity in circulating tumor cells: A key player in oral squamous cell carcinoma prognosis.

Montana Manselle Cocco, Instituto de Biología y Medicina Experimental (CONICET), Buenos Aires City, Argentina. Abstract 1265. Pan-cancer study of glycosylation-related gene expression: The emerging role of galectin-2 in tumor progression.

Andres Elia, Instituto de Biología y Medicina Experimental (CONICET), Buenos Aires City, Argentina. Abstract 5289. Proteomic profile of breast carcinomas with unbalanced levels of progesterone receptor isoforms.

Salma Fala, MD, Suez Canal University, Ismailia, Egypt. Abstract 4298. Machine learning-based model for survival prediction after ICIs in patients with solid tumors.

Vidit Gaur, Indian Institute of Technology Delhi (IIT Delhi), New Delhi, India. Abstract 4128. AJ17 potentiates agonist CD40 antibody efficacy and attenuates agonist CD40 induced PD-L1 expression and associated toxicity in murine tumor models.


Abram Kamiza, PhD, University of the Witwatersrand, Johannesburg, South Africa. Abstract 766. A genome-wide association study identifies the association of common variants in the major histocompatibility complex with cervical cancer in black South African women.


Aditi Patel, Ahmedabad University, Ahmedabad, India. Abstract 1743. miR-1307-5p reverses cisplatin resistance in oral squamous cell carcinomas (OSCC) by targeting EHF, a modulator of stemness genes.

Agustina Sabater, Institute of Biological Chemistry of the School of Sciences (IQUIBICEN), National Scientific and Technical Research Council (CONICET), Buenos Aires City, Argentina. Abstract 2437. HMOX1 modulates tumor stemness and metastatic properties in prostate cancer.

Juliana Siqueira, PhD, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil. Abstract 1216. Virome characterization in different types of non-Hodgkin lymphoma.

Kamonlapat Supimon, PhD, Mahidol University, Bangkok, Thailand. Abstract 1779. Fourth-generation chimeric antigen receptor T cells targeting mucin 1 against breast cancer.

AACR Minority and Minority-Serving Institution Faculty Scholar in Cancer Research Awards

The AACR is very pleased to administer this important program, which provides funds for the participation of full-time minority faculty members and faculty members of Minority-Serving Institutions (MSI) at the AACR Annual Meeting 2023. Recipients of this award are scientists who are working at the level of Assistant Professor or above who are engaged in meritorious basic, clinical, or translational cancer research.

Now in its 26th year, this award program has been supported by a generous grant provided by the National Cancer Institute’s Center to Reduce Cancer Health Disparities. The Center to Reduce Cancer Health Disparities (CRCHD) works to increase the number of underrepresented minorities participating as competitive NCI/NIH-funded cancer researchers. The Board of Directors of the AACR expresses its appreciation to the CRCHD for its long-term and generous support of faculty members and congratulations to the Minority and Minority Serving Institution Faculty Awardees.

The names and affiliations of the 2023 Minority and Minority-Serving Institution Faculty Scholars are listed below, along with the numbers and titles of their presentations.

Remi M. Adelaiye-Ogala, PhD, University at Buffalo, Buffalo, NY. Abstract 7111. Alterations in hormone receptors regulome following response to kinase inhibitors in lethal prostate cancer.

Matias A. Bustos, PhD, Saint John’s Cancer Institute, Santa Monica, CA. Abstract 7567. Transcriptomic signatures in melanoma lymph node metastasis that relate to immunotherapy.

Verline Justilien, PhD, Mayo Clinic, Jacksonville, FL. Abstract 5119. RAB27B drives a cancer stem cell phenotype in non-small cell lung cancer cells through enhanced extracellular vesicle secretion.

Francisco Sanchez-Vega, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 6337. Ultra-sensitive detection of circulating tumor DNA by whole-genome sequencing of blood samples from locally advanced rectal cancer patients receiving neoadjuvant therapy and enrolled in watch-and-wait strategies for organ preservation.

AACR Minority Scholar in Cancer Research Awards

The AACR is very pleased to administer this important program, which provides funds for the participation of early-career, meritorious minority scientists at the AACR Annual Meeting 2023. Scholars are chosen from both minority institutions and the larger bodies of universities, colleges, and research institutes. They are selected on the basis of their qualifications, references from mentors, and an estimation of the potential professional benefit to the awardees.

Since its founding in 1985, the Minority Scholar Awards in Cancer Research program has been supported by a generous grant of the National Cancer Institute's Center to Reduce Cancer Health Disparities. The Center to Reduce Cancer Health Disparities (CRCHD) works to increase the number of underrepresented minorities participating as competitive NCI/NIH-funded cancer researchers.

For 38 years, the AACR has endeavored through this program to reach out to minority predoctoral and postdoctoral students, trainees, and junior investigators as future cancer researchers. The program was created in an attempt to address the serious problem of lack of minority participation in cancer research by offering young minority students and trainees the opportunity to attend and participate in the Annual Meetings and Special Conferences of the AACR.

The names and affiliations of the 2023 Minority Scholar Award recipients are listed below, along with the numbers and titles of their presentations.

Salvador Alejo, BA, University of Texas Health Science Center at San Antonio, San Antonio, TX. Abstract 1732. Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments efficacy of temozolomide in glioblastoma.

Nelly A. Arroyo, MS, Ponce Health Sciences University, Ponce, PR. Abstract 7454. The functional role of promoter germline variants in breast cancer susceptibility genes.

Crystal Byrd, MS, Clark Atlanta University, Atlanta, GA. Abstract 2596. Infiltrating bruton’s tyrosine kinase expressed B cells effects on prostate cancer metastasis.

Alexis E. Carey, Johns Hopkins University, Baltimore, MD. Abstract 7643. Melanoma alters the bone marrow immune composition in an age-related manner.

Courtney D. Dill, PhD, National Cancer Institute, Rockville, MD. Abstract 3656. Association of genetic ancestry with all cancer risk in White and Black ever-smokers in the PLCO cohort.

Edward J. Evans Jr., PhD, University of Colorado, Anschutz Medical Campus, Aurora, CO. Abstract 4727. Clonal hematopoiesis in Down syndrome and its potential impact on hematopoietic lineages.


J. Alberto Maldonado, BA, National Cancer Institute, National Institutes of Health, Bethesda, MD. Abstract 1692. Racial and Ethnic Disparities in U.S. Clinical Trials in Liver Cancer in the last Nineteen Years.

Mauricio A. Marquez Palencia, BS, UT Southwestern Medical Center, Dallas, TX. Abstract 7956. AXL-WNIP1 mediated replication stress response aids metastatic latency and relapse.

Pedro T. Ochoa, BS, Loma Linda University, Loma Linda, CA. Abstract 8007. The glucocorticoid receptor-LEDGFp75 interaction in prostate cancer therapy cross-resistance.

Afia P. Ohemeng, MD, Florida A&M University, Tallahassee, FL. Abstract 6968. MDN1, a Novel Potential Early Biomarker for Endocrine Resistant Breast Cancer.

Dakota D. Okwuone, BS, University of Kansas Medical Center, Kansas City, KS. Abstract 3932. Tumor MK2 Signaling Regulates Cell Migration and Invasion in Head and Neck Squamous Cell Carcinoma.

Greisha L. Ortiz-Hernandez, PhD, City of Hope, Duarte, CA. Abstract 4975. CYR61, a member of the CCN protein family, regulates IGF-1 in metastatic prostate cancer.


Mabel G. Perez-Oquendo, BS, MD Anderson Cancer Center, Houston, TX. Abstract 5436. ZEB1 dimerization is regulated by acetylation and promotes protein stability, interactions, EMT, and NSCLC metastasis.

Adeiye Pilgrim, BS, Emory University School of Medicine, Atlanta, GA. Abstract 5557. The Yes-Associated Protein (YAP) regulates GD2 immunotherapy response in high-risk neuroblastoma.

Alexis R. Ramos, BS, University of Iowa, Iowa City, IA. Abstract 7490. Tumor Hypoxia Blocks the Induction of Antigen Processing Machinery.

Evelyn S. Sanchez Hernandez, BS, Loma Linda University, Loma Linda, CA. Abstract 8007. The glucocorticoid receptor-LEDGFp75 interaction in prostate cancer therapy cross-resistance.

Harmony I. Saunders, MS, University of Kansas, Kansas City, KS. Abstract 8038. Medical Center O-GlcNAcylation of progesterone receptor promotes mammary tumorigenesis.

SCHOLAR AWARDS (cont’d)

AACR Women in Cancer Research Scholar Awards

The AACR is very pleased to administer this important program, which provides funds for the participation of early-career, meritorious scientists at the AACR Annual Meeting 2023. Scholars are selected on the basis of their qualifications, references from mentors, and an estimation of the potential professional benefit to the awardees.

The names and affiliations of the 2023 Women in Cancer Research Scholars, along with the numbers and titles of their presentations, are listed below.

**Priya Alagesan, BS**, Duke University School of Medicine, Durham, NC. Abstract 5598. Biobanking of gastric organoid models from a racially diverse cohort for gastric cancer interception.

**Signe Caksa, BS**, Thomas Jefferson University, Philadelphia, PA. Abstract 5567. Transglutaminase-2 is elevated in the invasive cell state and modulates the tumor immune microenvironment in cutaneous melanoma.

**Kayla R. Getz, PhD**, Washington University School of Medicine in St. Louis, St. Louis, MO. Abstract 5380. Lipidome of mammographic breast density in premenopausal women.

**Tenna V. Henriksen, PhD**, Aarhus University Hospital, Aarhus, Region midtjylland, Denmark. Abstract 4398. Potential clinical utility of circulating tumor DNA detected by digital PCR in a nationwide Danish cohort of high-risk colorectal cancer patients.

**Deepi Mathur, PhD**, Memorial Sloan Kettering Cancer Center, New York, NY. Abstract 1883. The ratio of key metabolic transcripts is a predictive biomarker of breast cancer metastasis to the lung.

**Sonia A. Patel, BS**, University of Texas, MD Anderson Cancer Center, Houston, TX. Abstract 1891. Targeting IL-6/STAT3 signaling in EGFR-mutant drug-tolerant persister cells.


**Tejaswini P. Reddy, BA**, Houston Methodist Research Institute, Houston, TX. Abstract 1945. NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer.

**Virginia Turati, PhD**, Moffitt Cancer Center, Tampa, FL. Abstract 8040. Mathematical modelling of single-cell data reveals the key role of stochasticity - not fitness - in determining the clonal origins of relapse in childhood leukemia.

**Sidi Zhao, BS**, Washington University in St. Louis, St. Louis, MO. Abstract 4107. The landscape of circular RNAs in metastatic colorectal cancer.
AACR-Undergraduate Scholar Awards

The AACR is pleased to announce the recipients of 2023 AACR-Undergraduate Scholar Awards. The primary purpose of these awards is to inspire young science students at the undergraduate level to enter the field of cancer research. The AACR is committed to promoting the education and training of the next generation of dedicated scientists and to facilitating and nurturing their careers in cancer research or cancer related biomedical science. In 2023, the AACR is celebrating 26 years of this award program and continues to generously provide the funding for these awards. The Board of Directors would like to congratulate this year’s awardees.

2022-2023

Ritu Dave, Washington University in St. Louis, St. Louis, MO.

Anabella Maria D. Galang, Cornell University, Ithaca, NY.

Akshay Govindan, Washington University in St. Louis, St. Louis, MO.

Charlene Mansour, University of Alabama at Birmingham, Birmingham, AL.

Caitlin R. McCabe, Cornell University, Ithaca, NY.

Harrison Ngue, Harvard University, Cambridge, MA. Abstract 8016. Circular RNA expression is enriched in breast cancer extracellular vesicles and is associated with chemotherapy resistance.

Julia A. Pena, University of Texas at Austin, Austin, TX.

Melanie Perez, Florida International University, Miami, FL.

Eric G. Sun, Yale University, New Haven, CT.

Afi H. Tagnedji, University of Louisville, Louisville, KY.

2023-2024

Mariam O. Babajide, University of Houston, Houston, TX.

Aishani S. Gargapati, Rice University, Houston, TX. Abstract 7514. Fasting Induces Greater Expression of Mitochondrial Proteins Associated with Fatty Acid Metabolism and Non-Shivering Thermogenesis in Brown Adipose Tissue of Knock-in ACSS1K635Q Mice.

Iyana L. Gross, Morgan State University, Baltimore, MD.


Isabelle Harber, University of Michigan, Ann Arbor, MI. Abstract 8065. Early life liver proteomic signature and minerals mitigation of liver injury.

Kavya Harish, Saint Louis University, St Louis, MO. Abstract 2952. Targeting the elF6 and 60S ribosomal subunit interaction interface in cancers.

Daniel John, University of California in San Diego, San Diego, CA.

Rachel Kulchar, Princeton University, Princeton, NJ. Abstract 5527. Effects of radiation therapy on the hardness of enamel and dentin.

Hanjun Lee, Massachusetts Institute of Technology, Cambridge, MA. Abstract 6713. The non-canonical role of Rb in enhancers and insulators.
Thomas J. Li, The University of Chicago, Chicago, IL. Abstract 5647. BACH1 proline hydroxylation regulates the hypoxia response and metastasis in triple negative breast cancer.

George S. Morcos, University of Pennsylvania, Philadelphia PA.

Shrey Ramesh, University of Wisconsin-Madison, Madison, WI. Abstract 6883. MET inhibition enhances the effect of radiation in MET dysregulated non-small cell lung cancer models.


Carl Shirley, University of Wisconsin-Madison, Madison, WI. Abstract 6328. A potential pro-oncogenic role of SERPINB4 in melanoma.

Sophie R. Wu, Duke University, Durham, NC. Abstract 3660. Combining the RCAS/TVA retrovirus system and a conditional oncohistone H3.3K27M allele to investigate radiosensitization strategies in primary mouse models of diffuse midline glioma.
**EXHIBITORS** (Alphabetical)

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>10x Genomics</td>
<td>1419</td>
</tr>
<tr>
<td>3DHISTECH</td>
<td>1513</td>
</tr>
<tr>
<td>4Dcell</td>
<td>1354</td>
</tr>
<tr>
<td>A Cure in Sight</td>
<td>*AP19</td>
</tr>
<tr>
<td>AACR Central</td>
<td>443</td>
</tr>
<tr>
<td>AACR Publications</td>
<td>2743</td>
</tr>
<tr>
<td>Aadi Bioscience, Inc.</td>
<td>2072</td>
</tr>
<tr>
<td>AAT Bioquest, Inc.</td>
<td>603</td>
</tr>
<tr>
<td>AbbVie, Inc.</td>
<td>1951</td>
</tr>
<tr>
<td>Abcam</td>
<td>518</td>
</tr>
<tr>
<td>Abcepta</td>
<td>1474</td>
</tr>
<tr>
<td>Abiosciences, Inc.</td>
<td>3042</td>
</tr>
<tr>
<td>Absolute Biotech</td>
<td>2576</td>
</tr>
<tr>
<td>AcelaBio</td>
<td>3146</td>
</tr>
<tr>
<td>ACIR/UCIR</td>
<td>*AP15</td>
</tr>
<tr>
<td>ACROBiosystems</td>
<td>760</td>
</tr>
<tr>
<td>Active Motif, Inc.</td>
<td>714</td>
</tr>
<tr>
<td>Adaptive Biotechnologies</td>
<td>521</td>
</tr>
<tr>
<td>Adgyl Lifesiences Private Limited</td>
<td>459</td>
</tr>
<tr>
<td>Advanced Targeting Systems</td>
<td>2342</td>
</tr>
<tr>
<td>Agilent Technologies</td>
<td>2165</td>
</tr>
<tr>
<td>Aiforia, Inc.</td>
<td>2276</td>
</tr>
<tr>
<td>Aimed Bio, Inc.</td>
<td>3049</td>
</tr>
<tr>
<td>Akoya Biosciences, Inc.</td>
<td>1713</td>
</tr>
<tr>
<td>Alex’s Lemonade Stand Foundation</td>
<td>369</td>
</tr>
<tr>
<td>ALK Life Science Solutions</td>
<td>2949</td>
</tr>
<tr>
<td>Almac Group</td>
<td>853</td>
</tr>
<tr>
<td>Alpenglow Biosciences, Inc.</td>
<td>2775</td>
</tr>
<tr>
<td>AlphaThera</td>
<td>659</td>
</tr>
<tr>
<td>ALZET® Osmotic Pumps/ DURECT Corp.</td>
<td>442</td>
</tr>
<tr>
<td>American Brain Tumor Association (ABTA)</td>
<td>*AP14</td>
</tr>
<tr>
<td>American Cancer Society</td>
<td>2146</td>
</tr>
<tr>
<td>American Society of Clinical Oncology (ASCO)</td>
<td>446</td>
</tr>
<tr>
<td>Amgen Oncology</td>
<td>1965</td>
</tr>
<tr>
<td>Amoy Diagnostics Co., Ltd.</td>
<td>1220</td>
</tr>
<tr>
<td>AMSBIO</td>
<td>1826</td>
</tr>
<tr>
<td>Analytik Jena US LLC</td>
<td>1533</td>
</tr>
<tr>
<td>Apexbio Technology LLC</td>
<td>1060</td>
</tr>
<tr>
<td>Applied Biological Materials, Inc</td>
<td>406</td>
</tr>
<tr>
<td>Applied BioPhysics Inc.</td>
<td>2753</td>
</tr>
<tr>
<td>arigo Biolaboratories Corporation</td>
<td>1156</td>
</tr>
<tr>
<td>Arima Genomics</td>
<td>228</td>
</tr>
<tr>
<td>Arkana Laboratories</td>
<td>3077</td>
</tr>
<tr>
<td>ARRALYZE</td>
<td>3048</td>
</tr>
<tr>
<td>Arraystar, Inc.</td>
<td>1764</td>
</tr>
<tr>
<td>Arvinas, Inc.</td>
<td>201</td>
</tr>
<tr>
<td>Assay Genie</td>
<td>3443</td>
</tr>
<tr>
<td>ASTRAZENECA</td>
<td>225</td>
</tr>
<tr>
<td>ATCC</td>
<td>1633</td>
</tr>
<tr>
<td>AtlasXomics Inc.</td>
<td>703</td>
</tr>
<tr>
<td>ATOM Research Alliance</td>
<td>2045</td>
</tr>
<tr>
<td>ATUM</td>
<td>3271</td>
</tr>
<tr>
<td>Audubon Bioscience</td>
<td>2777</td>
</tr>
<tr>
<td>AUM BioTech, LLC</td>
<td>858</td>
</tr>
<tr>
<td>Aviva Systems Biology</td>
<td>263</td>
</tr>
<tr>
<td>Axion BioSystems</td>
<td>611</td>
</tr>
<tr>
<td>axiVEND, LLC</td>
<td>311</td>
</tr>
<tr>
<td>Azenta Life Sciences</td>
<td>1251</td>
</tr>
<tr>
<td>Azure Biosystems, Inc.</td>
<td>304</td>
</tr>
<tr>
<td>Basepair Inc.</td>
<td>1734</td>
</tr>
<tr>
<td>Bayer</td>
<td>1442</td>
</tr>
<tr>
<td>BeiGene USA, Inc.</td>
<td>1653</td>
</tr>
<tr>
<td>Beijing GenePlus Clinical Laboratory Co., Ltd.</td>
<td>1370</td>
</tr>
<tr>
<td>Belgian Volition srl</td>
<td>160</td>
</tr>
</tbody>
</table>
EXHIBITORS (Alphabetical)

*Advocacy Partners’ Pavilion located in the Front of Exhibit Hall B

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benchling</td>
<td>3465</td>
</tr>
<tr>
<td>Bentham Science Publishers</td>
<td>1271</td>
</tr>
<tr>
<td>Best Medical International/Best Cure Foundation</td>
<td>1173</td>
</tr>
<tr>
<td>BGI Americas Corporation</td>
<td>867</td>
</tr>
<tr>
<td>Binaree, Inc.</td>
<td>1467</td>
</tr>
<tr>
<td>Bio Molecular Systems</td>
<td>415</td>
</tr>
<tr>
<td>Bio SB, Inc.</td>
<td>1160</td>
</tr>
<tr>
<td>Bio Serv</td>
<td>3145</td>
</tr>
<tr>
<td>Bio X Cell</td>
<td>253</td>
</tr>
<tr>
<td>Biocare Medical, LLC</td>
<td>2572</td>
</tr>
<tr>
<td>BioChain Institute, Inc.</td>
<td>1656</td>
</tr>
<tr>
<td>Biocompare</td>
<td>1554</td>
</tr>
<tr>
<td>Biocytogen</td>
<td>723</td>
</tr>
<tr>
<td>Biodesix</td>
<td>1507</td>
</tr>
<tr>
<td>BioDuro-Sundia</td>
<td>2452</td>
</tr>
<tr>
<td>BioFluidica</td>
<td>410</td>
</tr>
<tr>
<td>Biognosys</td>
<td>319</td>
</tr>
<tr>
<td>Biointron Biological, Inc.</td>
<td>1350</td>
</tr>
<tr>
<td>BiolVT</td>
<td>307</td>
</tr>
<tr>
<td>Biological Dynamics</td>
<td>1368</td>
</tr>
<tr>
<td>Biomage LTD</td>
<td>205</td>
</tr>
<tr>
<td>biomodal</td>
<td>2172</td>
</tr>
<tr>
<td>Bionano</td>
<td>1319</td>
</tr>
<tr>
<td>BionLai</td>
<td>1563</td>
</tr>
<tr>
<td>BioOptions</td>
<td>1361</td>
</tr>
<tr>
<td>Bio-Rad Laboratories</td>
<td>1243</td>
</tr>
<tr>
<td>BioRender</td>
<td>1670</td>
</tr>
<tr>
<td>BioSkryb Genomics</td>
<td>401</td>
</tr>
<tr>
<td>Bioss Inc.</td>
<td>1066</td>
</tr>
<tr>
<td>Bio-Technne</td>
<td>1763</td>
</tr>
<tr>
<td>BioTechniques</td>
<td>2272</td>
</tr>
<tr>
<td>Biotium, Inc.</td>
<td>55</td>
</tr>
<tr>
<td>Biotrial International Ltd.</td>
<td>2771</td>
</tr>
<tr>
<td>BioVolume Ltd</td>
<td>2944</td>
</tr>
<tr>
<td>BIOZOL Diagnostica Vertrieb GmbH</td>
<td>605</td>
</tr>
<tr>
<td>BlueCatBio</td>
<td>163</td>
</tr>
<tr>
<td>Blueprint Medicines</td>
<td>3457</td>
</tr>
<tr>
<td>BMG LABTECH</td>
<td>1504</td>
</tr>
<tr>
<td>Boehringer Ingelheim Pharmaceuticals, Inc.</td>
<td>1331</td>
</tr>
<tr>
<td>Boster Biological Technology</td>
<td>2175</td>
</tr>
<tr>
<td>BostonGene</td>
<td>1358</td>
</tr>
<tr>
<td>BPS Bioscience</td>
<td>1305</td>
</tr>
<tr>
<td>BreakSight, Inc.</td>
<td>1664</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>743</td>
</tr>
<tr>
<td>Broad Institute of MIT and Harvard</td>
<td>1973</td>
</tr>
<tr>
<td>Bruker</td>
<td>1818</td>
</tr>
<tr>
<td>Burning Rock Dx, LLC</td>
<td>1658</td>
</tr>
<tr>
<td>C2i Genomics</td>
<td>1161</td>
</tr>
<tr>
<td>Cancer Grand Challenges</td>
<td>707</td>
</tr>
<tr>
<td>Cancer Research UK</td>
<td>1023</td>
</tr>
<tr>
<td>Cancer Science Institute of Singapore, National University of Singapore</td>
<td>2044</td>
</tr>
<tr>
<td>Cancer Today</td>
<td>*AP04</td>
</tr>
<tr>
<td>CancerLinQ</td>
<td>361</td>
</tr>
<tr>
<td>CancerModels.Org</td>
<td>1945</td>
</tr>
<tr>
<td>CancerTools.org</td>
<td>812</td>
</tr>
<tr>
<td>Canopy Biosciences</td>
<td>111</td>
</tr>
<tr>
<td>Caris Life Sciences</td>
<td>130</td>
</tr>
<tr>
<td>Carl Zeiss Microscopy, LLC</td>
<td>2655</td>
</tr>
<tr>
<td>Cayman Chemical Company</td>
<td>2765</td>
</tr>
<tr>
<td>cBioPortal for Cancer Genomics</td>
<td>1943</td>
</tr>
<tr>
<td>CBIS, Inc.</td>
<td>103</td>
</tr>
<tr>
<td>CDI Laboratories</td>
<td>1261</td>
</tr>
<tr>
<td>Cell Culture Company</td>
<td>2476</td>
</tr>
<tr>
<td>Cell Microsystems</td>
<td>1402</td>
</tr>
<tr>
<td>Cell Press</td>
<td>2645</td>
</tr>
<tr>
<td>Company Name</td>
<td>Page</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Cell Signaling Technology</td>
<td>713</td>
</tr>
<tr>
<td>Cellbox Solutions, Inc.</td>
<td>3073</td>
</tr>
<tr>
<td>CellCarta</td>
<td>216</td>
</tr>
<tr>
<td>Cellecta</td>
<td>1221</td>
</tr>
<tr>
<td>Celleonion</td>
<td>2843</td>
</tr>
<tr>
<td>Cellgentek Co., Ltd.</td>
<td>215</td>
</tr>
<tr>
<td>CELLINK</td>
<td>1158</td>
</tr>
<tr>
<td>CelVivo Inc.</td>
<td>706</td>
</tr>
<tr>
<td>Cerba Research</td>
<td>3148</td>
</tr>
<tr>
<td>Certara</td>
<td>2649</td>
</tr>
<tr>
<td>Certis Oncology Solutions</td>
<td>512</td>
</tr>
<tr>
<td>Champions Oncology</td>
<td>1551</td>
</tr>
<tr>
<td>Charles River</td>
<td>943</td>
</tr>
<tr>
<td>Chelatec</td>
<td>1502</td>
</tr>
<tr>
<td>ChemPartner</td>
<td>1155</td>
</tr>
<tr>
<td>Children's Brain Tumor Network</td>
<td>2143</td>
</tr>
<tr>
<td>Cholangiocarcinoma Foundation</td>
<td>*AP17</td>
</tr>
<tr>
<td>City of Hope</td>
<td>949</td>
</tr>
<tr>
<td>Comprehensive Cancer Center</td>
<td>949</td>
</tr>
<tr>
<td>ClearLight Biotech, Inc.</td>
<td>3257</td>
</tr>
<tr>
<td>Clinical Genome Resource (ClinGen)</td>
<td>2042</td>
</tr>
<tr>
<td>Somatic Cancer Clinical Domain Working Group</td>
<td>2042</td>
</tr>
<tr>
<td>CloudLIMS.com</td>
<td>200</td>
</tr>
<tr>
<td>Cogent Biosciences</td>
<td>3143</td>
</tr>
<tr>
<td>Cold Spring Harbor Laboratory Meetings &amp; Courses Program</td>
<td>2047</td>
</tr>
<tr>
<td>Colorectal Cancer Alliance</td>
<td>*AP18</td>
</tr>
<tr>
<td>Complete Genomics</td>
<td>1371</td>
</tr>
<tr>
<td>CONNEXT Co., Ltd.</td>
<td>1565</td>
</tr>
<tr>
<td>Cooperative Human Tissue Network (CHTN)</td>
<td>818</td>
</tr>
<tr>
<td>Corning Incorporated</td>
<td>1607</td>
</tr>
<tr>
<td>Covaris</td>
<td>2355</td>
</tr>
<tr>
<td>Creative Biomart, Inc.</td>
<td>1567</td>
</tr>
<tr>
<td>Crown Bioscience, Inc.</td>
<td>2865</td>
</tr>
<tr>
<td>Cureline, Inc.</td>
<td>1219</td>
</tr>
<tr>
<td>Curio Bioscience, Inc.</td>
<td>2770</td>
</tr>
<tr>
<td>CytoRecovery, Inc.</td>
<td>2544</td>
</tr>
<tr>
<td>Cytosurge AG</td>
<td>1772</td>
</tr>
<tr>
<td>Daiichi Sankyo, Inc.</td>
<td>1643</td>
</tr>
<tr>
<td>DAVA Oncology</td>
<td>1072</td>
</tr>
<tr>
<td>Deep Bio, Inc.</td>
<td>3445</td>
</tr>
<tr>
<td>Deepcell</td>
<td>460</td>
</tr>
<tr>
<td>Delfi Diagnostics</td>
<td>3355</td>
</tr>
<tr>
<td>DeNovix, Inc.</td>
<td>658</td>
</tr>
<tr>
<td>DiaCarta</td>
<td>1806</td>
</tr>
<tr>
<td>Diagenode</td>
<td>1200</td>
</tr>
<tr>
<td>Digital Science</td>
<td>2376</td>
</tr>
<tr>
<td>Discovery Life Sciences</td>
<td>243</td>
</tr>
<tr>
<td>Dragon Master Foundation</td>
<td>*AP22</td>
</tr>
<tr>
<td>Drug Discovery News</td>
<td>1101</td>
</tr>
<tr>
<td>Echelon Biosciences</td>
<td>1770</td>
</tr>
<tr>
<td>Eclipse BiInnovations</td>
<td>2274</td>
</tr>
<tr>
<td>Eisai Inc.</td>
<td>3155</td>
</tr>
<tr>
<td>Elabscience Biotechnology, Inc</td>
<td>661</td>
</tr>
<tr>
<td>Element Biosciences</td>
<td>559</td>
</tr>
<tr>
<td>Elephas</td>
<td>1766</td>
</tr>
<tr>
<td>Eli Lilly and Company</td>
<td>1043</td>
</tr>
<tr>
<td>Elsevier</td>
<td>2643</td>
</tr>
<tr>
<td>Emily Whitehead Foundation</td>
<td>*AP24</td>
</tr>
<tr>
<td>EMIT Imaging, Inc</td>
<td>259</td>
</tr>
<tr>
<td>Enable Medicine</td>
<td>1259</td>
</tr>
<tr>
<td>Enzo Life Sciences</td>
<td>514</td>
</tr>
<tr>
<td>EpiCypher, Inc.</td>
<td>159</td>
</tr>
<tr>
<td>EpigenDx Inc.</td>
<td>765</td>
</tr>
<tr>
<td>EpigenTek Group, Inc.</td>
<td>206</td>
</tr>
<tr>
<td>Epistem Ltd</td>
<td>2464</td>
</tr>
<tr>
<td>Eurofins Discovery</td>
<td>626</td>
</tr>
</tbody>
</table>
EXHIBITORS (Alphabetical)

• Advocacy Partners’ Pavilion located in the Front of Exhibit Hall B

European Association for Cancer Research ................................................................. 558
Evident Scientific ........................................................................................................... 1458
Evotec SE ..................................................................................................................... 966
Exact Sciences ............................................................................................................. 301, 302
Excellos ....................................................................................................................... 3345
Exelixis Medical Affairs .................................................................................................. 106
exonbio .......................................................................................................................... 300
Fidelis Research AD ..................................................................................................... 1557
Flagship Biosciences .................................................................................................... 2866
Florida Department of Health Office of Medical Marijuana Use ................................... 1172
Flywheel ....................................................................................................................... 2977
Focus Biomolecules, LLC ............................................................................................ 3242
FORMULATRIX ............................................................................................................ 1666
Fortis Life Sciences ...................................................................................................... 1625
Foundation Medicine, Inc ............................................................................................ 3053
Fraunhofer IIS .............................................................................................................. 1663
Frederick National Laboratory for Cancer Research ................................................. 2144
FroggaBio, Inc. ............................................................................................................. 1222
Fugene Transfection .................................................................................................... 2975
FUJIFILM Pharmaceuticals U.S.A., Inc ..................................................................... 1675
Fujifilm VisualSonics, Inc ............................................................................................ 1125
Fulgent Genetics .......................................................................................................... 872
Funakoshi Co., Ltd. ....................................................................................................... 173
GemPharmatech LLC ................................................................................................... 114
GeneCopoeia, Inc. ........................................................................................................ 2365
Genentech .................................................................................................................... 629
GeneTex, Inc. ................................................................................................................. 702
Genetic Engineering & Biotechnology News ................................................................. 261
Genmab ......................................................................................................................... 2555
GenomeWeb, a business unit of Crain Communications ............................................. 1218
Genomic Testing Cooperative ...................................................................................... 1775
GenScript USA, Inc. ..................................................................................................... 619
Gestalt Diagnostics ....................................................................................................... 368
Gilead and Kite Oncology ............................................................................................ 2265
Gold Biotechnology, Inc. ............................................................................................. 1631
Gradiant Bioconvergence ............................................................................................ 2174
Greiner Bio-One ........................................................................................................... 117
GSK ............................................................................................................................... 533
Guangzhou Dongsheng Biotech Co., Ltd. ................................................................... 666
Guardant Health ........................................................................................................... 2465
Haier Biomedical ......................................................................................................... 318
Hamamatsu Corporation .............................................................................................. 267
Hamilton Company ...................................................................................................... 1549
Hangzhou Allsheng Instruments Co., Ltd. ................................................................. 1167
Hangzhou Joying Biotechnology Co., Ltd. ................................................................. 3249
Hangzhou Tigermed Consulting Co., Ltd. ................................................................. 607
Haystack Oncology ...................................................................................................... 1403
Heidolph North America ............................................................................................. 2849
Hera BioLabs ............................................................................................................... 404
Hilltop Lab Animals, Inc. ............................................................................................. 1500
HistoWiz ....................................................................................................................... 260
Hope for Stomach Cancer ......................................................................................... *AP11
Hope4ATRT Foundation ............................................................................................ *AP01
HTG Molecular Diagnostics ....................................................................................... 2073
HUABIO ....................................................................................................................... 759
HUB Organoids ........................................................................................................... 2367
Human Metabolome Technologies ............................................................................. 511
Hypoxygen ................................................................................................................... 1601
ibidi USA, Inc. ............................................................................................................... 101
ICE Bioscience .............................................. 1162
IDeA National Resource for Quantitative Proteomics .......... 2277
IDEXX BioAnalytics ........................................ 466
IGM Biosciences, Inc. ..................................... 1702
Ignyte Bio, Inc. .............................................. 3350
Imagen Therapeutics ....................................... 314
Imagia Canexia Health .................................... 366
ImagenAb ........................................................ 2075
Immudex ........................................................... 400
Immunoculture ............................................ 1671
Immunocure Discovery Solutions ............................ 510
Impact Journals, LLC ....................................... 2642
Incyte Corporation ....................................... 1449
Indica Labs, Inc. .............................................. 710
Indivumed GmbH ........................................... 1351
Innopsys, Inc. ................................................ 1062
Inotiv .............................................................. 3354
INOVATION ........................................................... 230
InSphero, Inc. ................................................ 2446
INTEGRA ...................................................... 700, 2455
Integrated DNA Technologies .................................. 3043
Inteliquet, an IQVIA business ................................ 2377
intoDNA .......................................................... 2948
Inventia Life Science ....................................... 3275
Invicro ............................................................. 61
Invitae ............................................................. 2176
Ionpath ............................................................ 515
IPA (ImmunoPrecise Antibodies) ...................... 2352
iProcess Global Research Inc. ......................... 207
IQ Proteomics .................................................. 57
iRepertoire, Inc. ............................................ 1665
IsoPlexis .......................................................... 3444
iSpecimen .......................................................... 663
IVIM Technology ............................................. 1059
Izon Science US LLC ........................................ 3352
Jackson ImmunoResearch Laboratories, Inc. .............. 1105
JAMA Network ............................................. 2744
Janssen Oncology .......................................... 3164
Jiangsu Hillgene Biopharma Co., Ltd .................... 873
Keyence Corporation ....................................... 1254
Kibur Medical Inc. .......................................... 2242
Kindle Biosciences, LLC .................................. 1375
Kinnate Biopharma ......................................... 1725
Kiyatec Inc. ...................................................... 419
KML Vision GmbH ......................................... 3176
Korean Cancer Association ............................... 1947
KRAS Kickers ................................................ *AP20
KRISHGEN BIOSYSTEMS ................................ 1073
KUBTEC Scientific .......................................... 2543
Kyinno Biotechnology .................................... 1263
Lab To Pharmacy, LLC .................................... 358
Labcorp .......................................................... 2442
LabX Media Group ........................................ 1101
Lanterne Dx ................................................... 1808
LC Sciences .................................................... 1556
Leica Biosystems .......................................... 1824
Leica Microsystems ........................................ 1469
Leinco Technologies ....................................... 2755
LGC Clinical Diagnostics .................................. 133
Li Ka Shing Faculty of Medicine, The University of Hong Kong ........... 313
LifeOmic ............................................................ 3074
LKT Laboratories, Inc. .................................. 1762
Logos Biosystems, Inc. .................................. 359
LUMICKS .......................................................... 861
Luminex A DiaSorin Company ......................... 148
<table>
<thead>
<tr>
<th>Exhibitor</th>
<th>Booth No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lunaphore Technologies</td>
<td>1870</td>
</tr>
<tr>
<td>Lunit USA, Inc.</td>
<td>2671</td>
</tr>
<tr>
<td>M2GEN</td>
<td>1301</td>
</tr>
<tr>
<td>MABTECH</td>
<td>1272</td>
</tr>
<tr>
<td>MBL International</td>
<td>2864</td>
</tr>
<tr>
<td>MCRA, LLC</td>
<td>3243</td>
</tr>
<tr>
<td>MD Anderson Cancer Center</td>
<td>1501</td>
</tr>
<tr>
<td>MedGenome</td>
<td>2074</td>
</tr>
<tr>
<td>Medicilon, Inc.</td>
<td>3047</td>
</tr>
<tr>
<td>Menarini Silicon Biosystems</td>
<td>100</td>
</tr>
<tr>
<td>Merck &amp; Co.</td>
<td>1009</td>
</tr>
<tr>
<td>Mesoscale Discovery</td>
<td>465</td>
</tr>
<tr>
<td>Metabolon</td>
<td>2076</td>
</tr>
<tr>
<td>Metware Biotechnology, Inc.</td>
<td>258</td>
</tr>
<tr>
<td>MIB Agents</td>
<td>*AP06</td>
</tr>
<tr>
<td>MILabs B.V.</td>
<td>2847</td>
</tr>
<tr>
<td>MilliporeSigma</td>
<td>1543</td>
</tr>
<tr>
<td>Miltene Biotec B.V. &amp; Co. KG</td>
<td>1433</td>
</tr>
<tr>
<td>MIMETAS B.V</td>
<td>509</td>
</tr>
<tr>
<td>Minerva Biolabs, Inc.</td>
<td>213</td>
</tr>
<tr>
<td>Minerva Imaging</td>
<td>312</td>
</tr>
<tr>
<td>Mirati Therapeutics</td>
<td>1309</td>
</tr>
<tr>
<td>MiRXES</td>
<td>1204</td>
</tr>
<tr>
<td>Mispro Biotech Services</td>
<td>567</td>
</tr>
<tr>
<td>Moderna Tx, Inc.</td>
<td>2664</td>
</tr>
<tr>
<td>Moffitt Cancer Center</td>
<td>305</td>
</tr>
<tr>
<td>MOLECUBES</td>
<td>202</td>
</tr>
<tr>
<td>Molecular Devices</td>
<td>2946</td>
</tr>
<tr>
<td>Molecular Instruments, Inc.</td>
<td>2870</td>
</tr>
<tr>
<td>Molecular Loop Biosciences, Inc.</td>
<td>2472</td>
</tr>
<tr>
<td>Molecular Machines &amp; Industries</td>
<td>3144</td>
</tr>
<tr>
<td>Morphle Labs, Inc.</td>
<td>1575</td>
</tr>
<tr>
<td>Motic Digital Pathology</td>
<td>203</td>
</tr>
<tr>
<td>MP Biomedicals</td>
<td>2874</td>
</tr>
<tr>
<td>MS Validated Antibodies GmbH</td>
<td>204</td>
</tr>
<tr>
<td>MT Group</td>
<td>1727</td>
</tr>
<tr>
<td>Mucosal Melanoma</td>
<td></td>
</tr>
<tr>
<td>Warriors Foundation</td>
<td>*AP12</td>
</tr>
<tr>
<td>My Faulty Gene</td>
<td>*AP08</td>
</tr>
<tr>
<td>Myllia Biotechnology GmbH</td>
<td>3451</td>
</tr>
<tr>
<td>Nacalai USA, Inc.</td>
<td>2542</td>
</tr>
<tr>
<td>NanoCellect Biomedical, Inc.</td>
<td>462</td>
</tr>
<tr>
<td>Nanodigmbo (Nanjing) Biotechnology Co., LTD</td>
<td>3142</td>
</tr>
<tr>
<td>Nanolive SA</td>
<td>1470</td>
</tr>
<tr>
<td>NanoString Technologies, Inc.</td>
<td>1731</td>
</tr>
<tr>
<td>Natera, Inc.</td>
<td>3343</td>
</tr>
<tr>
<td>National Cancer Institute</td>
<td>809</td>
</tr>
<tr>
<td>Navigate Biopharma Services, Inc.</td>
<td>2776</td>
</tr>
<tr>
<td>Navinci Diagnostics AB</td>
<td>1771</td>
</tr>
<tr>
<td>Neobio US</td>
<td>1075</td>
</tr>
<tr>
<td>NeoGenomics</td>
<td>2153</td>
</tr>
<tr>
<td>NeoSome Life Sciences, LLC</td>
<td>963</td>
</tr>
<tr>
<td>NET Research Foundation</td>
<td>*AP13</td>
</tr>
<tr>
<td>Nilogen Oncosystems</td>
<td>1700</td>
</tr>
<tr>
<td>Noble Life Sciences</td>
<td>569</td>
</tr>
<tr>
<td>Nona Biosciences</td>
<td>2344</td>
</tr>
<tr>
<td>Novadiscovers</td>
<td>1667</td>
</tr>
<tr>
<td>Novartis Pharmaceuticals</td>
<td>1001</td>
</tr>
<tr>
<td>Novocure, Inc.</td>
<td>142</td>
</tr>
<tr>
<td>Novogene Corporation, Inc.</td>
<td>527</td>
</tr>
<tr>
<td>nRichDX, Inc.</td>
<td>3044</td>
</tr>
<tr>
<td>NuAire, Inc.</td>
<td>816</td>
</tr>
<tr>
<td>NuChem Sciences</td>
<td>362</td>
</tr>
<tr>
<td>Nuclai</td>
<td>3455</td>
</tr>
<tr>
<td>Nucleus Biologics</td>
<td>411</td>
</tr>
<tr>
<td>NuProbe USA, Inc.</td>
<td>610</td>
</tr>
<tr>
<td>Nuvisan ICB GmbH</td>
<td>1622</td>
</tr>
</tbody>
</table>
Olink Proteomics, Inc. .................................... 2549
Omega Bio-tek ............................................ 608
OncLive .................................................... 2677
Oncodesign Services ................................. 1055
Oncohost .................................................... 168
OncoKB ...................................................... 519
Oncolines B.V. ............................................ 758
OrganaBio ................................................... 461
ORGANOIDSCIENCES Co., Ltd. .................. 272
OriGene Technologies, Inc. ....................... 529
Owkin ......................................................... 154
Owlstone Medical ....................................... 3076
Oxford Nanopore Technologies ............... 801
PacBio .......................................................... 958
Paige .............................................................. 2942
PamGene Int. ............................................... 75
Panome Bio .................................................. 363
Paraza Pharma, Inc. .................................. 367
Parhelia Biosciences .................................. 1709
Parse Biosciences ...................................... 1202
Partek Incorporated .................................... 1473
PathAI .......................................................... 315
PCR Biosystems ........................................ 662
Pear Bio ..................................................... 1730
PEPperPRINT GmbH ................................ 1269
PeproTech, Inc., part of Thermo Fisher Scientific .................. 343
PerkinElmer, Inc. ....................................... 1130
Personalis, Inc. .......................................... 1365
Pfizer Oncology ........................................... 831
PharmaLegacy Laboratories ...................... 71
Pharmatest Services ................................. 347
Phase Genomics ........................................ 561
PHC Corporation of North America .............. 2474
Pillar Biosciences ....................................... 2343
Polycarbin, Inc. ......................................... 1457
PolyPeptide Group .................................... 1154
Porsolt SAS ................................................ 3244
Porvair Sciences ....................................... 563
PreAnalytix ................................................. 868
PreciGenome LLC ...................................... 2466
Precision Biosystems ............................... 69
Precision for Medicine ............................. 2853
Precision NanoSystems ............................ 1774
Precision X-Ray, Inc. ................................. 1400
Predicine, Inc. ............................................ 501
PredxBio (Formerly SpIntellx) ..................... 974
Prior Scientific .......................................... 1571
ProImmune, Inc. ....................................... 969
ProMab Biotechnologies, Inc. ..................... 859
Promega Corporation ............................... 3173
ProSci - A Genesee
Scientific Company .................................. 1174
Proscia ....................................................... 2173
Protein Fluidics, Inc. ................................. 2774
Proteintech Group ..................................... 1119
ProteoGenix, Inc./DX Biosamples .............. 513
ProteoGenix .............................................. 1019, 1118
Psomagen, Inc. ........................................... 2468
Q Squared Solutions .................................. 1418
QIAGEN, Inc. ............................................. 753
Quantum-Si .............................................. 1707
Rain Oncology, Inc. .................................. 219
RapID Lab ............................................... 560
Rapid Novor ............................................... 3045
RareCyte, Inc. .......................................... 955
RayBiotech ............................................... 1067
Reaction Biology ....................................... 1527
## EXHIBITORS (Alphabetical)

- Advocacy Partners’ Pavilion located in the Front of Exhibit Hall B

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reddot Biotech, Inc.</td>
<td>1359</td>
</tr>
<tr>
<td>Regeneron Commercial</td>
<td>2475</td>
</tr>
<tr>
<td>Regeneron Medical</td>
<td>303</td>
</tr>
<tr>
<td>REPROCELL/BioServe</td>
<td>961</td>
</tr>
<tr>
<td>Research Diets, Inc.</td>
<td>3348</td>
</tr>
<tr>
<td>Rho</td>
<td>1559</td>
</tr>
<tr>
<td>Roche Sequencing &amp; Life Science</td>
<td>232</td>
</tr>
<tr>
<td>Rockefeller University Press</td>
<td>2742</td>
</tr>
<tr>
<td>Rockland Immunochemicals, Inc.</td>
<td>1662</td>
</tr>
<tr>
<td>RockStep Solutions</td>
<td>2346</td>
</tr>
<tr>
<td>Rosalind</td>
<td>1719</td>
</tr>
<tr>
<td>Roswell Park Comprehensive Cancer Center</td>
<td>1275</td>
</tr>
<tr>
<td>S2 Genomics</td>
<td>973</td>
</tr>
<tr>
<td>Samba Scientific</td>
<td>2443</td>
</tr>
<tr>
<td>Sampled</td>
<td>2872</td>
</tr>
<tr>
<td>Sanofi</td>
<td>3365</td>
</tr>
<tr>
<td>Sanyou Biopharmaceuticals Co., Ltd</td>
<td>866</td>
</tr>
<tr>
<td>Sapio Sciences</td>
<td>1573</td>
</tr>
<tr>
<td>SARSTEDT</td>
<td>1648</td>
</tr>
<tr>
<td>Sarotorus</td>
<td>412</td>
</tr>
<tr>
<td>Say YES to Hope</td>
<td>*AP02</td>
</tr>
<tr>
<td>Science/AAAS</td>
<td>800</td>
</tr>
<tr>
<td>ScienCell Research Laboratories</td>
<td>1401</td>
</tr>
<tr>
<td>Scientist.com</td>
<td>2347</td>
</tr>
<tr>
<td>SCIEX</td>
<td>2547</td>
</tr>
<tr>
<td>SciLeads</td>
<td>3374</td>
</tr>
<tr>
<td>Scintica</td>
<td>1061</td>
</tr>
<tr>
<td>Seagen</td>
<td>1318</td>
</tr>
<tr>
<td>Selvita, Inc.</td>
<td>158</td>
</tr>
<tr>
<td>Shanghai Haoyuan</td>
<td>2177</td>
</tr>
<tr>
<td>MedChemExpress Co., Ltd</td>
<td>105</td>
</tr>
<tr>
<td>Shanghai LIDE Biotech</td>
<td>972</td>
</tr>
<tr>
<td>Signalchem Biotech, Inc.</td>
<td>761</td>
</tr>
<tr>
<td>Simport Scientific Inc.</td>
<td>1373</td>
</tr>
<tr>
<td>Singular Scientific Inc.</td>
<td>1613</td>
</tr>
<tr>
<td>Sino Genomics</td>
<td>952</td>
</tr>
<tr>
<td>Sirona Dx</td>
<td>3442</td>
</tr>
<tr>
<td>SMOBIO Technology, Inc.</td>
<td>1455</td>
</tr>
<tr>
<td>Society for Immunotherapy of Cancer</td>
<td>767</td>
</tr>
<tr>
<td>SoftMouse.NET</td>
<td>2545</td>
</tr>
<tr>
<td>SomaLogic</td>
<td>1618</td>
</tr>
<tr>
<td>SOMARK Innovations</td>
<td>2246</td>
</tr>
<tr>
<td>Sony Biotechnology, Inc.</td>
<td>1566</td>
</tr>
<tr>
<td>SOPHIA GENETICS</td>
<td>123</td>
</tr>
<tr>
<td>Southern Research</td>
<td>3273</td>
</tr>
<tr>
<td>Spectral Instruments Imaging, LLC</td>
<td>153</td>
</tr>
<tr>
<td>SpectronRx</td>
<td>2473</td>
</tr>
<tr>
<td>Springer Nature</td>
<td>2648</td>
</tr>
<tr>
<td>St. Jude Children’s Research Hospital</td>
<td>2046</td>
</tr>
<tr>
<td>Standard BioTools</td>
<td>1224</td>
</tr>
<tr>
<td>STEMCELL Technologies</td>
<td>802</td>
</tr>
<tr>
<td>Stemline, A Menarini Group Company</td>
<td>701</td>
</tr>
<tr>
<td>STILLA TECHNOLOGIES</td>
<td>3172</td>
</tr>
<tr>
<td>Streck</td>
<td>402</td>
</tr>
<tr>
<td>Studylog Systems, Inc.</td>
<td>51, 2456</td>
</tr>
<tr>
<td>Stupid Cancer, Inc.</td>
<td>*AP16</td>
</tr>
<tr>
<td>Synthego</td>
<td>1977</td>
</tr>
<tr>
<td>Symsmex Inostics</td>
<td>1325</td>
</tr>
<tr>
<td>Taconic Inostics</td>
<td>2854</td>
</tr>
<tr>
<td>Takeda</td>
<td>3265</td>
</tr>
<tr>
<td>Targeted Bioscience</td>
<td>1800</td>
</tr>
</tbody>
</table>

222 AACR ANNUAL MEETING 2023
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targetmol Chemicals, Inc.</td>
<td>1674</td>
</tr>
<tr>
<td>Teiko Bio</td>
<td>73</td>
</tr>
<tr>
<td>Teledyne Lumenera</td>
<td>1570</td>
</tr>
<tr>
<td>Telesis Bio</td>
<td>3370</td>
</tr>
<tr>
<td>Tempus</td>
<td>922</td>
</tr>
<tr>
<td>The Bioinformatics CRO</td>
<td>1303</td>
</tr>
<tr>
<td>The Brain Tumor Network</td>
<td>*AP23</td>
</tr>
<tr>
<td>The Cancer Epitope Database and Analysis Resource (CEDAR)</td>
<td>2043</td>
</tr>
<tr>
<td>The ComedyCures Foundation</td>
<td>*AP10</td>
</tr>
<tr>
<td>The Hormel Institute</td>
<td>2142</td>
</tr>
<tr>
<td>The Jackson Laboratory</td>
<td>351</td>
</tr>
<tr>
<td>The Leukemia &amp; Lymphoma Society</td>
<td>2147</td>
</tr>
<tr>
<td>The Sontag Foundation</td>
<td>*AP09</td>
</tr>
<tr>
<td>Theradex Oncology</td>
<td>1032</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>2665</td>
</tr>
<tr>
<td>TheWell Bioscience, Inc.</td>
<td>444</td>
</tr>
<tr>
<td>ThinkCyte Inc.</td>
<td>962</td>
</tr>
<tr>
<td>Tigerlily Foundation</td>
<td>*AP05</td>
</tr>
<tr>
<td>Tokyo Ohka Kogyo Co., Ltd.</td>
<td>1574</td>
</tr>
<tr>
<td>TOUCH, The Black Breast Cancer Alliance</td>
<td>*AP03</td>
</tr>
<tr>
<td>TRANSGENE</td>
<td>310</td>
</tr>
<tr>
<td>Translational Drug Development (TD2)</td>
<td>3149</td>
</tr>
<tr>
<td>Transomic Technologies</td>
<td>1472</td>
</tr>
<tr>
<td>Triage Cancer</td>
<td>*AP21</td>
</tr>
<tr>
<td>TriSalus Life Sciences</td>
<td>2149</td>
</tr>
<tr>
<td>TriStar Technology Group, LLC</td>
<td>2373</td>
</tr>
<tr>
<td>TubeWriter</td>
<td>2852</td>
</tr>
<tr>
<td>Twist Bioscience</td>
<td>2754</td>
</tr>
<tr>
<td>Unified Information Devices</td>
<td>2353</td>
</tr>
<tr>
<td>Union Biometrica, Inc.</td>
<td>458</td>
</tr>
<tr>
<td>US Biolab</td>
<td>864</td>
</tr>
<tr>
<td>VectorBuilder, Inc.</td>
<td>601</td>
</tr>
<tr>
<td>Velsera</td>
<td>768</td>
</tr>
<tr>
<td>Veracyte</td>
<td>1701</td>
</tr>
<tr>
<td>Veranome Biosystems</td>
<td>2943</td>
</tr>
<tr>
<td>Vieworks</td>
<td>1519</td>
</tr>
<tr>
<td>Visciopharm Corporation</td>
<td>612</td>
</tr>
<tr>
<td>Viva Biotech</td>
<td>2773</td>
</tr>
<tr>
<td>vivoPharm Global</td>
<td>2248</td>
</tr>
<tr>
<td>Vizgen</td>
<td>1619</td>
</tr>
<tr>
<td>Watchmaker Genomics</td>
<td>211</td>
</tr>
<tr>
<td>Watson Bio Lab</td>
<td>2372</td>
</tr>
<tr>
<td>World Precision Instruments</td>
<td>2244</td>
</tr>
<tr>
<td>WuXi AppTec</td>
<td>1427</td>
</tr>
<tr>
<td>X-Chem</td>
<td>669</td>
</tr>
<tr>
<td>XEN TECH SAS</td>
<td>618</td>
</tr>
<tr>
<td>Xilio Therapeutics</td>
<td>1374</td>
</tr>
<tr>
<td>XpressBio</td>
<td>1404</td>
</tr>
<tr>
<td>Zaber Technologies</td>
<td>3248</td>
</tr>
<tr>
<td>ZenBio, Inc.</td>
<td>615</td>
</tr>
<tr>
<td>Zoefia Alexandria Foundation, Inc.</td>
<td>*AP07</td>
</tr>
<tr>
<td>ZoomRx, Inc.</td>
<td>1475</td>
</tr>
<tr>
<td>Zymo Research Corp.</td>
<td>2273</td>
</tr>
</tbody>
</table>
EXHIBITORS (Booth Number)

• Advocacy Partners’ Pavilion located in the Front of Exhibit Hall B

51.............Studylog Systems, Inc.
55.............Biotium, Inc.
57.............IQ Proteomics
61.............Invicro
69.............Precision Biosystems
71.............PharmaLegacy Laboratories
73.............Teiko Bio
75.............PamGene Int.
100..........Menarini Silicon Biosystems
101..........ibidi USA, Inc.
103..........CBiS, Inc.
105..........Shanghai LIDE Biotech
106..........Exelxis Medical Affairs
111..........Canopy Biosciences
114..........GemPharmatech LLC
117..........Greiner Bio-One
123..........SOPHiA GENETICS
129..........Syncell Inc.
130..........Caris Life Sciences
133..........LGC Clinical Diagnostics
142..........Novocure, Inc.
148..........Luminex A DiaSorin Company
153..........Spectral Instruments Imaging, LLC
154..........Owkin
158..........Selvita, Inc.
159..........EpiCypher, Inc.
160..........Belgian Volition srl
163..........BlueCatBio
168..........Oncohost
173..........Funakoshi Co., Ltd.
200..........CloudLIMS.com
201..........Arvinas, Inc.
202..........MOLECUBES
203..........Motic Digital Pathology
204..........MS Validated Antibodies GmbH
205..........Biomage LTD
206..........EpigenTek Group, Inc.
207..........iProcess Global Research Inc.
211..........Watchmaker Genomics
213..........Minerva Biolabs, Inc.
215..........Cellgentek Co., Ltd
216..........CellCarta
219..........Rain Oncology, Inc.
225..........ASTRAZENECA
228..........Arima Genomics
230..........INOVOTION
232..........Roche Sequencing & Life Science
243..........Discovery Life Sciences
253..........Bio X Cell
258..........Metware Biotechnology, Inc.
259..........EMIT Imaging, Inc.
260..........HistoWiz
261..........Genetic Engineering & Biotechnology News
263..........Aviva Systems Biology
267..........Hamamatsu Corporation
272..........ORGANOIDSCIENCES Co., Ltd.
300..........exonbio
301..........Exact Sciences
302..........Exact Sciences
303..........Regeneron Medical
304..........Azure Biosystems, Inc.
305..........Moffitt Cancer Center
307..........BiolVT
310..........TRANSGENE
311..........axiVEND, LLC
312..........Minerva Imaging
313 ........... Li Ka Shing Faculty of Medicine, The University of Hong Kong
314 ........... Imagen Therapeutics
315 ........... PathAI
318 ........... Haier Biomedical
319 ........... Biognosys
343 ........... PeproTech, Inc., part of Thermo Fisher Scientific
347 ........... Pharmatest Services
351 ........... The Jackson Laboratory
358 ........... Lab To Pharmacy, LLC
359 ........... Logos Biosystems, Inc.
361 ........... CancerLinQ
362 ........... NuChem Sciences
363 ........... Panome Bio
366 ........... Imagia Canexia Health
367 ........... Paraza Pharma, Inc.
368 ........... Gestalt Diagnostics
369 ........... Alex’s Lemonade Stand Foundation
400 ........... Immudex
401 ........... BioSkryb Genomics
402 ........... Streck
404 ........... Hera BioLabs
406 ........... Applied Biological Materials, Inc.
410 ........... BioFluidica
411 ........... Nucleus Biologics
412 ........... Sartorius
415 ........... Bio Molecular Systems
419 ........... Kiyatec Inc.
442 ........... ALZET® Osmotic Pumps/DURECT Corp.
443 ........... ACR Central
444 ........... TheWell Bioscience, Inc.
446 ........... American Society of Clinical Oncology (ASCO)
458 ........... Union Biometrica, Inc.
459 ........... Adgyl Lifesciences Private Limited
460 ........... Deepcell
461 ........... OrganaBio
462 ........... NanoCellect Biomedical, Inc.
465 ........... Meso Scale Discovery
466 ........... IDEXX BioAnalytics
501 ........... Predicine, Inc.
509 ........... MIMETAS B.V.
510 ........... Immunocure, Inc.
511 ........... Human Metabolome Technologies
512 ........... Certis Oncology Solutions
513 ........... ProteoGenix, Inc./DX Biosamples
514 ........... Enzo Life Sciences
515 ........... Ionpath
518 ........... abcam
519 ........... OncoKB
521 ........... Adaptive Biotechnologies
527 ........... Novogene Corporation, Inc.
529 ........... OriGene Technologies, Inc.
533 ........... GSK
558 ........... European Association for Cancer Research
559 ........... Element Biosciences
560 ........... RapID Lab
561 ........... Phase Genomics
563 ........... Porvair Sciences
567 ........... Misprou Biotech Services
569 ........... Noble Life Sciences
601 ........... VectorBuilder, Inc.
603 ........... AAT Bioquest, Inc.
EXHIBITORS

• Advocacy Partners’ Pavilion located in the Front of Exhibit Hall B

605..........BIOZOL Diagnostica Vertrieb GmbH
607..........Hangzhou Tigermed Consulting Co., Ltd
608..........Omega Bio-tek
610..........NuProbe USA, Inc.
611..........Axion BioSystems
612..........Visiopharm Corporation
615..........ZenBio, Inc.
618..........XENTECH SAS
619..........GenScript USA, Inc.
626..........Eurofins Discovery
629..........Genentech
658..........DeNovix, Inc.
659..........AlphaThera
661..........Elabscience Biotechnology, Inc.
662..........PCR Biosystems
663..........iSpecimen
666..........Guangzhou Dongsheng Biotech Co., Ltd
669..........X-Chem
700..........INTEGRA
701..........Stemline, A Menarini Group Company
702..........GeneTex, Inc.
703..........AtlasXomics Inc.
706..........CelVivo Inc
707..........Cancer Grand Challenges
710..........Indica Labs, Inc.
713..........Cell Signaling Technology
714..........Active Motif, Inc.
723..........Biocytogen
743..........Bristol Myers Squibb
753..........QIAGEN, Inc.
758..........Oncolines B.V.
759..........HUABIO
760..........ACROBiosystems
761..........Signalchem Biotech, Inc.
765..........EpigenDx Inc
767..........Society for Immunotherapy of Cancer
768..........Velsera
800..........Science/AAAS
801..........Oxford Nanopore Technologies
802..........STEMCELL Technologies
809..........National Cancer Institute
812..........CancerTools.org
816..........NuAire, Inc.
818..........Cooperative Human Tissue Network (CHTN)
831..........Pfizer Oncology
853..........Almac Group
858..........AUM BioTech, LLC.
859..........ProMab Biotechnologies, Inc.
861..........LUMICKS
864..........US Biolab
866..........Sanyou Biopharmaceuticals Co., Ltd.
867..........BGI Americas Corporation
868..........PreAnalytix
872..........Fulgent Genetics
873..........Jiangsu Hillgene Biopharma Co., Ltd
922..........Tempus
943..........Charles River
949..........City of Hope Comprehensive Cancer Center
952..........Sino Biological
955..........RareCyte, Inc.
958..........PacBio
<table>
<thead>
<tr>
<th>Booth Number</th>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>961</td>
<td>REPROCELL/BioServe</td>
</tr>
<tr>
<td>962</td>
<td>ThinkCyte Inc.</td>
</tr>
<tr>
<td>963</td>
<td>NeoSome Life Sciences, LLC.</td>
</tr>
<tr>
<td>966</td>
<td>Evotec SE</td>
</tr>
<tr>
<td>969</td>
<td>ProImmune, Inc.</td>
</tr>
<tr>
<td>972</td>
<td>Shuimu BioSciences</td>
</tr>
<tr>
<td>973</td>
<td>S2 Genomics</td>
</tr>
<tr>
<td>974</td>
<td>PredxBio (Formerly SpIntellx)</td>
</tr>
<tr>
<td>1001</td>
<td>Novartis Pharmaceuticals</td>
</tr>
<tr>
<td>1009</td>
<td>Merck &amp; Co.</td>
</tr>
<tr>
<td>1019</td>
<td>ProteoGenix</td>
</tr>
<tr>
<td>1023</td>
<td>Cancer Research UK</td>
</tr>
<tr>
<td>1032</td>
<td>Theradex Oncology</td>
</tr>
<tr>
<td>1043</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>1055</td>
<td>Oncodesign Services</td>
</tr>
<tr>
<td>1059</td>
<td>IVIM Technology</td>
</tr>
<tr>
<td>1060</td>
<td>Apexbio Technology LLC</td>
</tr>
<tr>
<td>1061</td>
<td>Scintica</td>
</tr>
<tr>
<td>1062</td>
<td>Innopsys, Inc.</td>
</tr>
<tr>
<td>1066</td>
<td>Bioss Inc.</td>
</tr>
<tr>
<td>1067</td>
<td>RayBiotech</td>
</tr>
<tr>
<td>1072</td>
<td>DAVA Oncology</td>
</tr>
<tr>
<td>1073</td>
<td>KRISHGEN BIOSYSTEMS</td>
</tr>
<tr>
<td>1075</td>
<td>Neobio US</td>
</tr>
<tr>
<td>1101</td>
<td>Drug Discovery News</td>
</tr>
<tr>
<td>1101</td>
<td>LabX Media Group</td>
</tr>
<tr>
<td>1105</td>
<td>Jackson ImmunoResearch Laboratories, Inc.</td>
</tr>
<tr>
<td>1118</td>
<td>ProteoGenix</td>
</tr>
<tr>
<td>1119</td>
<td>Proteintech Group</td>
</tr>
<tr>
<td>1125</td>
<td>FujiFilm VisualSonics, Inc.</td>
</tr>
<tr>
<td>1130</td>
<td>PerkinElmer, Inc.</td>
</tr>
<tr>
<td>1154</td>
<td>PolyPeptide Group</td>
</tr>
<tr>
<td>1155</td>
<td>ChemPartner</td>
</tr>
<tr>
<td>1156</td>
<td>arigo Biolaboratories Corporation</td>
</tr>
<tr>
<td>1158</td>
<td>CELLINK</td>
</tr>
<tr>
<td>1160</td>
<td>Bio SB, Inc.</td>
</tr>
<tr>
<td>1161</td>
<td>C2i Genomics</td>
</tr>
<tr>
<td>1162</td>
<td>ICE Bioscience</td>
</tr>
<tr>
<td>1167</td>
<td>Hangzhou Allsheng Instruments Co., Ltd.</td>
</tr>
<tr>
<td>1172</td>
<td>Florida Department of Health Office of Medical Marijuana Use</td>
</tr>
<tr>
<td>1173</td>
<td>Best Medical International/ Best Cure Foundation</td>
</tr>
<tr>
<td>1174</td>
<td>ProSci - A Genesee Scientific Company</td>
</tr>
<tr>
<td>1200</td>
<td>Diagenode</td>
</tr>
<tr>
<td>1202</td>
<td>Parse Biosciences</td>
</tr>
<tr>
<td>1204</td>
<td>MiRXES</td>
</tr>
<tr>
<td>1218</td>
<td>GenomeWeb, a business unit of Crain Communications</td>
</tr>
<tr>
<td>1219</td>
<td>Cureline, Inc.</td>
</tr>
<tr>
<td>1220</td>
<td>Amoy Diagnostics Co., Ltd.</td>
</tr>
<tr>
<td>1221</td>
<td>Collecta</td>
</tr>
<tr>
<td>1222</td>
<td>FroggaBio, Inc.</td>
</tr>
<tr>
<td>1224</td>
<td>Standard BioTools</td>
</tr>
<tr>
<td>1243</td>
<td>Bio-Rad Laboratories</td>
</tr>
<tr>
<td>1251</td>
<td>Azenta Life Sciences</td>
</tr>
<tr>
<td>1254</td>
<td>Keyence Corporation</td>
</tr>
<tr>
<td>1259</td>
<td>Enable Medicine</td>
</tr>
<tr>
<td>1261</td>
<td>CDI Laboratories</td>
</tr>
<tr>
<td>1263</td>
<td>Kyinno Biotechnology</td>
</tr>
<tr>
<td>1269</td>
<td>PEPperPRINT GmbH</td>
</tr>
<tr>
<td>1271</td>
<td>Bentham Science Publishers</td>
</tr>
<tr>
<td>1272</td>
<td>MABTECH</td>
</tr>
<tr>
<td>1275</td>
<td>Roswell Park Comprehensive Cancer Center</td>
</tr>
<tr>
<td>1301</td>
<td>M2GEN</td>
</tr>
</tbody>
</table>
EXHIBITORS (Booth Number)

• Advocacy Partners’ Pavilion located in the Front of Exhibit Hall B

1303..........The Bioinformatics CRO
1305..........BPS Bioscience
1309..........Mirati Therapeutics
1318..........Seagen
1319..........Bionano
1325..........Sysmex Inostics
1331..........Boehringer Ingelheim Pharmaceuticals, Inc.
1350..........Indiviron Biological, Inc
1351..........Indivummed GmbH
1354..........4Dcell
1358..........BostonGene
1359..........Reddot Biotech, Inc.
1361..........BioOptions
1365..........Personalis, Inc.
1368..........Biological Dynamics
1370..........Beijing GenePlus Clinical Laboratory Co., Ltd.
1371..........Complete Genomics
1373..........Simport Scientific Inc.
1374..........Xilio Therapeutics
1375..........Kindle Biosciences, LLC
1400..........Precision X-Ray, Inc.
1401..........ScienCell Research Laboratories
1402..........Cell Microsystems
1403..........Haystack Oncology
1404..........XpressBio
1418..........Q Squared Solutions
1419..........10x Genomics
1427..........WuXi AppTec
1433..........Miltenyi Biotec B.V. & Co. KG
1442..........Bayer
1449..........Incyte Corporation
1455..........SMOBIO Technology, Inc.
1457..........Polycarbin, Inc.
1458..........Evident Scientific
1467..........Binaree, Inc.
1469..........Leica Microsystems
1470..........Nanolive SA
1472..........Transomic Technologies
1473..........Partek Incorporated
1474..........Abcepta
1475..........ZoomRx, Inc.
1500..........Hilltop Lab Animals, Inc.
1501..........MD Anderson Cancer Center
1502..........Chelatec
1504..........BMG LABTECH
1507..........Biodex
1513..........3DHISTECH
1519..........Vieworks
1527..........Reaction Biology
1533..........Analytik Jena US LLC
1543..........MilliporeSigma
1549..........Hamilton Company
1551..........Champions Oncology
1554..........Biocompare
1556..........LC Sciences
1557..........Fidelis Research AD
1559..........Rho
1563..........Bionl.ai
1565..........CONNEXT Co., Ltd.
1566..........Sony Biotechnology, Inc.
1567..........Creative Biomart, Inc.
1570..........Teledyne Lumenera
1571..........Prior Scientific
1573..........Sapios Sciences
1574..........Tokyo Ohka Kogyo Co., Ltd.
1575..........Morphle Labs, Inc.
1601......Hypoxygen
1607......Corning Incorporated
1613......Singular Genomics
1618......SomaLogic
1619......Vizgen
1622......Nuvisan ICB GmbH
1625......Fortis Life Sciences
1631......Gold Biotechnology, Inc.
1633......ATCC
1643......Daiichi Sankyo, Inc.
1648......SARSTEDT
1653......BeiGene USA, Inc.
1656......BioChain Institute, Inc.
1658......Burning Rock Dx, LLC
1662......Rockland Immunochemicals, Inc.
1663......Fraunhofer IIS
1664......BreakSight, Inc.
1665......iRepertoire, Inc.
1666......FORMULATRIX
1667......Novadiscovery
1670......BioRender
1671......Immunochemistry Technologies
1674......Targetmol Chemicals, Inc.
1675......FUJIFILM Pharmaceuticals U.S.A., Inc.
1700......Nilogen Oncosystems
1701......Veracyte
1702......IGM Biosciences, Inc.
1707......Quantum-Si
1709......Parhelia Biosciences
1713......Akoya Biosciences, Inc.
1719......Rosalind
1725......Kinnate Biopharma
1727......MT Group
1730......Pear Bio
1731......NanoString Technologies, Inc.
1734......Basepair Inc
1762......LKT Laboratories, Inc.
1763......Bio-Technne
1764......Arraystar, Inc.
1766......Elephas
1770......Echelon Biosciences
1771......Navinci Diagnostics AB
1772......Cytosurge AG
1773......Syd Labs, Inc.
1774......Precision NanoSystems
1775......Genomic Testing Cooperative
1800......Targeted Bioscience
1806......DiaCarta
1808......Lanterne Dx
1818......Bruker
1824......Leica Biosystems
1826......AMSBIO
1870......Lunaphore Technologies
1943......cBioPortal for Cancer Genomics
1945......CancerModels.Org
1947......Korean Cancer Association
1951......AbbVie, Inc.
1965......Amgen Oncology
1973......Broad Institute of MIT and Harvard
1977......Synthego
2042......Clinical Genome Resource (ClinGen) Somatic Cancer Clinical Domain Working Group
2043......The Cancer Epitope Database and Analysis Resource (CEDAR)
EXHIBITORS (Booth Number)

• Advocacy Partners’ Pavilion located in the Front of Exhibit Hall B

2044........Cancer Science Institute of Singapore, National University of Singapore
2045........ATOM Research Alliance
2046........St. Jude Children’s Research Hospital
2047........Cold Spring Harbor Laboratory Meetings & Courses Program
2072........Aadi Bioscience, Inc.
2073........HTG Molecular Diagnostics
2074........MedGenome
2075........ImaginAb
2076........Metabolon
2142........The Hormel Institute
2143........Children’s Brain Tumor Network
2144........Frederick National Laboratory for Cancer Research
2146........American Cancer Society
2147........The Leukemia & Lymphoma Society
2149........TriSalus Life Sciences
2153........NeoGenomics
2165........Agilent Technologies
2172........ biomodal
2173........Proscia
2174........Gradient Bioconvergence
2175........Boster Biological Technology
2176........Invitae
2177........Shanghai Haoyuan MedChemExpress Co., Ltd
2242........Kibur Medical Inc.
2244........World Precision Instruments
2246........SOMARK Innovations
2248........vivoPharm Global
2265........Gilead and Kite Oncology
2272........BioTechniques
2273........Zymo Research Corp.
2274........Eclipse Biollnovations
2276........Aiforia, Inc.
2277........IDeA National Resource for Quantitative Proteomics
2342........Advanced Targeting Systems
2343........Pillar Biosciences
2344........Nona Biosciences
2346........RockStep Solutions
2347........Scientist.com
2352........IPA (ImmunoPrecise Antibodies)
2353........Unified Information Devices
2355........Covaris
2365........GeneCopoeia, Inc.
2367........HUB Organoids
2372........Watson Bio Lab
2373........TriStar Technology Group, LLC
2376........Digital Science
2377........Inteliqeut, an IQVIA business
2442........Labcorp
2443........Samba Scientific
2446........InSphero, Inc.
2452........BioDuro-Sundia
2455........INTEGRA
2456........Studylog Systems, Inc.
2464........Epistem Ltd
2465........Guardant Health
2466........PreciGenome LLC
2468........Psomagen, Inc.
2472........Molecular Loop Biosciences, Inc.
2473........SpectronRx
2474........PHC Corporation of North America
2475........Regeneron Commercial
2476........Cell Culture Company
2542........Nacalai USA, Inc.
2543........KUBTEC Scientific
2544........CytoRecovery, Inc.
2545........SoftMouse.NET
2547........SCIEX
2549........Olink Proteomics, Inc.
2555........Genmab
2572........Biocare Medical, LLC
2576........Absolute Biotech
2642........Impact Journals, LLC.
2643........Elsevier
2645........Cell Press
2648........Springer Nature
2649........Certara
2655........Carl Zeiss Microscopy, LLC
2664........Moderna Tx, Inc.
2665........Thermo Fisher Scientific
2671........Lunit USA, Inc.
2677........Onclive
2742........Rockefeller University Press
2743........AACC Publications
2744........JAMA Network
2753........Applied BioPhysics Inc.
2754........Twist Bioscience
2755........Leinco Technologies
2765........Cayman Chemical Company
2770........Curio Bioscience, Inc.
2771........Biotrial International Ltd
2773........Viva Biotech
2774........Protein Fluidics, Inc.
2775........Alpenglow Biosciences, Inc.
2776........Navigate Biopharma Services, Inc.
2777........Audubon Bioscience
2843........Cellenion
2847........MiLabs B.V.
2849........Heidolph North America
2852........TubeWriter
2853........Precision for Medicine
2854........Taconic Biosciences
2864........MBL International
2865........Crown Bioscience, Inc.
2866........Flagship Biosciences
2870........Molecular Instruments, Inc.
2872........Sampled
2874........MP Biomedicals
2942........Paige
2943........Veranome Biosystems
2944........BioVolume Ltd
2946........Molecular Devices
2948........intoDNA
2949........ALK Life Science Solutions
2975........Fugene Transfection
2977........FlyWheel
3042........Abiosciences, Inc.
3043........Integrated DNA Technologies
3044........nRichDX, Inc.
3045........Rapid Novor
3047........Medicilon, Inc.
3048........ARRALYZE
3049........Aimed Bio, Inc.
3053........Foundation Medicine, Inc.
3073........Cellbox Solutions, Inc.
3074........LifeOmic
3076........Owlstone Medical
3077........Arkana Laboratories
3142........NanodigmBio (Nanjing) Biotechnology Co., LTD
EXHIBITORS (Booth Number)

• Advocacy Partners’ Pavilion located in the Front of Exhibit Hall B

3143.......... Cogent Biosciences
3144.......... Molecular Machines & Industries
3145.......... Bio Serv
3146.......... AcelaBio
3148.......... Cerba Research
3149.......... Translational Drug Development (TD2)
3155.......... Eisai Inc.
3164.......... Janssen Oncology
3172.......... STILLA TECHNOLOGIES
3173.......... Promega Corporation
3176.......... KML Vision GmbH
3242.......... Focus Biomolecules, LLC
3243.......... MCRA, LLC
3244.......... Porsolt SAS
3248.......... Zaber Technologies
3249.......... Hangzhou Joying Biotechnology Co., Ltd.
3257.......... ClearLight Biotech, Inc.
3265.......... Takeda
3271.......... ATUM
3273.......... Southern Research
3275.......... Inventia Life Science
3343.......... Natera, Inc.
3345.......... Excellos
3348.......... Research Diets, Inc.
3350.......... Ignyte Bio, Inc.
3352.......... Izon Science US LLC.
3354.......... Inotiv
3355.......... Delfi Diagnostics
3365.......... Sanofi
3370.......... Telesis Bio
3374.......... SciLeads
3442.......... Sirona Dx
3443.......... Assay Genie
3444.......... IsoPlexis
3445.......... Deep Bio, Inc.
3451.......... Myliia Biotechnology GmbH
3455.......... Nucleai
3457.......... Blueprint Medicines
3465.......... Benchling
*AP01...... Hope4ATRT Foundation
*AP02...... Say YES to Hope
*AP03...... TOUCH, The Black Breast Cancer Alliance
*AP04...... Cancer Today
*AP05...... Tigerlily Foundation
*AP06...... MIB Agents
*AP07...... Zoefia Alexandria Foundation, Inc.
*AP08...... My Faulty Gene
*AP09...... The Sontag Foundation
*AP10...... The ComedyCures Foundation
*AP11...... Hope for Stomach Cancer
*AP12...... Mucosal Melanoma Warriors Foundation
*AP13...... NET Research Foundation
*AP14...... American Brain Tumor Association (ABTA)
*AP15...... ACIR/UCIR
*AP16...... Stupid Cancer, Inc.
*AP17...... Cholangiocarcinoma Foundation
*AP18...... Colorectal Cancer Alliance
*AP19...... A Cure In Sight
*AP20...... KRAS Kickers
*AP21...... Triage Cancer
*AP22...... Dragon Master Foundation
*AP23...... The Brain Tumor Network
*AP24...... Emily Whitehead Foundation
JOIN US IN SAN DIEGO
AACR ANNUAL MEETING 2024
APRIL 5-10, 2024

SAVE THE DATE!

PROGRAM COMMITTEE CHAIRS

Christina Curtis, PhD, MSc
Professor of Medicine and Genetics
Stanford University School of Medicine
Director, Breast Cancer Translational Research
Co-director, Molecular Tumor Board
Stanford Cancer Institute

Keith T. Flaherty, MD
Professor of Medicine
Harvard Medical School
Director, Termeer Center for Targeted Therapy
Director, Clinical Research and Richard Saltonstall Endowed Chair in Oncology
Massachusetts General Hospital Cancer Center
Editor-in-Chief, Clinical Cancer Research
Your Trusted Supplier of *in vivo* MAbs

Accelerate your research from pilot to pre-clinical phases.

- Rely on us to deliver the largest catalog of monoclonal antibodies formulated specifically for *in vivo* use and provide customizable antibody production services - backed by over 25 years of experience.

- Immune Checkpoint Inhibitors
- Mouse Immune Cell Depletion Antibodies
- Cytokine Neutralizing Antibodies
- Biosimilar Antibodies
- Recombinant Antibodies
- Antibody Production
  & Conjugation Services

VISIT US AT AACR23
BOOTH #253

[SPIN TO WIN](bioxcell.com)